{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:13:44Z","timestamp":1792253624361,"version":"4.4.0"},"reference-count":1559,"publisher":"Japan Atherosclerosis Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2024,6,1]]},"DOI":"10.5551\/jat.gl2022","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T17:11:05Z","timestamp":1702919465000},"page":"641-853","source":"Crossref","is-referenced-by-count":262,"title":["Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022"],"prefix":"10.5551","volume":"31","author":[{"given":"Tomonori","family":"Okamura","sequence":"first","affiliation":[{"name":"Preventive Medicine and Public Health, Keio University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Tsukamoto","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Teikyo University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Arai","sequence":"additional","affiliation":[{"name":"National Center for Geriatrics and Gerontology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Fujioka","sequence":"additional","affiliation":[{"name":"Faculty of Nutrition, Division of Clinical Nutrition, Kobe Gakuin University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Ishigaki","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Iwate Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Koba","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Showa University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Ohmura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Shoji","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Osaka Metropolitan University Graduate school of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koutaro","family":"Yokote","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Jikei University Kashiwa Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Bioethics Research Center, Tokyo Medical and Dental University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juno","family":"Deguchi","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Saitama Medical Center, Saitama Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Dobashi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, University of Yamanashi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Fujiyoshi","sequence":"additional","affiliation":[{"name":"Department of Hygiene, Wakayama Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Hamaguchi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kita-Harima Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masumi","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mizonokuchi Hospital, Teikyo University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Harada-Shiba","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Osaka Medical and Pharmaceutical University"},{"name":"Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Hirata","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Translational Science, Nara Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Iida","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Cardiology, Gifu Prefectural General Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine and Hypertension, Graduate School of Medical and Dental Sciences, Kagoshima University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Ishibashi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Jichi Medical University, School of Medicine"},{"name":"Current affiliation: Ishibashi Diabetes and Endocrine Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Kanda","sequence":"additional","affiliation":[{"name":"Department of Public Health, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Kihara","sequence":"additional","affiliation":[{"name":"Medical Laboratory Science and Technology, Division of Health Sciences, Osaka University graduate School of medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kodama","sequence":"additional","affiliation":[{"name":"Department of Prevention of Noncommunicable Diseases and Promotion of Health Checkup, Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Koseki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Maezawa","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisaku","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Center for Innovative Medicine and Therapeutics, Dementia Care Center, Doctor\u2019s Support Center, Health Care Center, Rinku General Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Miida","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Open Innovation Center, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimei","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Metabolism and Endocrinology, The Jikei University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Saga University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Noguchi","sequence":"additional","affiliation":[{"name":"Division of Public Health, Department of Social Medicine, Graduate School of Medicine, Osaka University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Ohishi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine and Hypertension, Graduate School of Medical and Dental Sciences, Kagoshima University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Public Health and Epidemiology, Faculty of Medicine, Oita University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shojiro","family":"Sawada","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Diabetes, Faculty of Medicine, Tohoku Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Sone","sequence":"additional","affiliation":[{"name":"Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Takemoto","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Metabolism and Endocrinology, International University of Health and Welfare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Wakatsuki","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Aichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekatsu","family":"Yanai","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine Kohnodai Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","unstructured":"1) Subcommittee for preparing guidelines for ultrasound diagnosis of carotid artery: Standard method for ultrasound evaluation of carotid artery lesions 2017. Jpn J Med Ultrasonics, 2018. https:\/\/www.jsum.or.jp\/committee\/diagnostic\/pdf\/jsum0515_guideline.pdf; 2018 (in Japanese)"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Homma S, Hirose N, Ishida H, Ishii T, Araki G: Carotid plaque and intima-media thickness assessed by b-mode ultrasonography in subjects ranging from young adults to centenarians. Stroke, 2001; 32: 830-835","DOI":"10.1161\/01.STR.32.4.830"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Nezu T, Hosomi N, Aoki S, Matsumoto M: Carotid Intima-Media Thickness for Atherosclerosis. J Atheroscler Thromb, 2016; 23: 18-31","DOI":"10.5551\/jat.31989"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) O\u2019Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK, Jr.: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med, 1999; 340: 14-22","DOI":"10.1056\/NEJM199901073400103"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) del Sol AI, Moons KG, Hollander M, Hofman A, Koudstaal PJ, Grobbee DE, Breteler MM, Witteman JC, Bots ML: Is carotid intima-media thickness useful in cardiovascular disease risk assessment? The Rotterdam Study. Stroke, 2001; 32: 1532-1538","DOI":"10.1161\/01.STR.32.7.1532"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M: Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation, 2007; 115: 459-467","DOI":"10.1161\/CIRCULATIONAHA.106.628875"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, Csiba L, Desvarieux M, Ebrahim S, Hernandez Hernandez R, Jaff M, Kownator S, Naqvi T, Prati P, Rundek T, Sitzer M, Schminke U, Tardif JC, Taylor A, Vicaut E, Woo KS: Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis, 2012; 34: 290-296","DOI":"10.1159\/000343145"},{"key":"8","unstructured":"8) Koga M, Kimura K, Minematsu K, Yamaguchi T: Diagnosis of internal carotid artery stenosis greater than 70% with power Doppler duplex sonography. AJNR Am J Neuroradiol, 2001; 22: 413-417"},{"key":"9","unstructured":"9) Subcommittee for preparing guidelines for ultrasound diagnosis of peripheral artery: Standard method for ultrasound evaluation of peripheral artery lesions. Jpn J Med Ultrasonics, 2023 submitting (in Japanese)"},{"key":"10","unstructured":"10) Aboyans V, Ricco JB, Bartelink MEL, Bj\u00f6rck M, Brodmann M, Cohnert T, Collet JP, Czerny M, De Carlo M, Debus S, Espinola-Klein C, Kahan T, Kownator S, Mazzolai L, Naylor AR, Roffi M, R\u00f6ther J, Sprynger M, Tendera M, Tepe G, Venermo M, Vlachopoulos C, Desormais I: 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J, 2018; 39: 763-816"},{"key":"11","unstructured":"11) Mizuta R, Kubota Y, Takeshita S, Akutsu K, Nakamoto F, Tanaka N, Sano M, Okajima T, Tsutsumi Y: Transit Time of Vessel Flow in Below-knee is Useful for Screening of Vessel in Below-knee Lesions. Jpn J Med Ultrasound Technology, 2009; 34: 543-547"},{"key":"12","unstructured":"12) Subcommittee for preparing guidelines for ultrasound diagnosis of aortic lesions: Standard method for ultrasound evaluation of aortic lesions 2020. Jpn J Med Ultrasonics, 2021 https:\/\/www.jsum.or.jp\/committee\/diagnostic\/pdf\/aorticlesion2020.pdf;2021. (in Japanese)"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Japanese Society of Nephrology: Essential points from Evidence-based Clinical Practice Guidelines for Chronic Kidney Disease 2018. Clin Exp Nephrol, 2019; 23: 1-15","DOI":"10.1007\/s10157-018-1648-1"},{"key":"14","unstructured":"14) Subcommittee for preparing guidelines on ultrasound diagnosis of renal arteries. Guidelines on methods of standard assessment of ultradound diagnosis of renal arterial lesions. Jpn J Med Ultrasonics, 2015;42:185-200 (in Japanese)"},{"key":"15","unstructured":"15) Diagnosis, Prevention, and Treatment of Cardiovascular Diseases in People with Type 2 Diabetesand Pre-Diabetes: A Consensus Statement Jointed from The Japanese Circulation Society and The Japan Diabetes Society. 2020: 11-18 (in Japanese)"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Vanhoenacker PK, Heijenbrok-Kal MH, Van Heste R, Decramer I, Van Hoe LR, Wijns W, Hunink MG: Diagnostic performance of multidetector CT angiography for assessment of coronary artery disease: meta-analysis. Radiology, 2007; 244: 419-428","DOI":"10.1148\/radiol.2442061218"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Schroeder S, Achenbach S, Bengel F, Burgstahler C, Cademartiri F, de Feyter P, George R, Kaufmann P, Kopp AF, Knuuti J, Ropers D, Schuijf J, Tops LF, Bax JJ: Cardiac computed tomography: indications, applications, limitations, and training requirements: report of a Writing Group deployed by the Working Group Nuclear Cardiology and Cardiac CT of the European Society of Cardiology and the European Council of Nuclear Cardiology. Eur Heart J, 2008; 29: 531-556","DOI":"10.1093\/eurheartj\/ehm544"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Budoff MJ, Dowe D, Jollis JG, Gitter M, Sutherland J, Halamert E, Scherer M, Bellinger R, Martin A, Benton R, Delago A, Min JK: Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial. J Am Coll Cardiol, 2008; 52: 1724-1732","DOI":"10.1016\/j.jacc.2008.07.031"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Miller JM, Rochitte CE, Dewey M, Arbab-Zadeh A, Niinuma H, Gottlieb I, Paul N, Clouse ME, Shapiro EP, Hoe J, Lardo AC, Bush DE, de Roos A, Cox C, Brinker J, Lima JA: Diagnostic performance of coronary angiography by 64-row CT. N Engl J Med, 2008; 359: 2324-2336","DOI":"10.1056\/NEJMoa0806576"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Celeng C, Leiner T, Maurovich-Horvat P, Merkely B, de Jong P, Dankbaar JW, van Es HW, Ghoshhajra BB, Hoffmann U, Takx RAP: Anatomical and Functional Computed Tomography for Diagnosing Hemodynamically Significant Coronary Artery Disease: A Meta-Analysis. JACC Cardiovasc Imaging, 2019; 12: 1316-1325","DOI":"10.1016\/j.jcmg.2018.07.022"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Siontis GC, Mavridis D, Greenwood JP, Coles B, Nikolakopoulou A, J\u00fcni P, Salanti G, Windecker S: Outcomes of non-invasive diagnostic modalities for the detection of coronary artery disease: network meta-analysis of diagnostic randomised controlled trials. BMJ, 2018; 360: k504","DOI":"10.1136\/bmj.k504"},{"key":"22","unstructured":"22) The Japanese Circulation Society. Guidelines for non-invasive vascular function test(JCS 2013). 2013 http:\/\/www.j-circ.or.jp\/guideline\/pdf\/JCS2013_yamashina_h.pdf (in Japanese)"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Tanaka A, Tomiyama H, Maruhashi T, Matsuzawa Y, Miyoshi T, Kabutoya T, Kario K, Sugiyama S, Munakata M, Ito H, Ueda S, Vlachopoulos C, Higashi Y, Inoue T, Node K: Physiological Diagnostic Criteria for Vascular Failure. Hypertension, 2018; 72: 1060-1071","DOI":"10.1161\/HYPERTENSIONAHA.118.11554"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FG, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RA, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME: 2016 AHA\/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2017; 135: e686-e725","DOI":"10.1161\/CIR.0000000000000470"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Tomiyama H, Matsumoto C, Shiina K, Yamashina A: Brachial-Ankle PWV: Current Status and Future Directions as a Useful Marker in the Management of Cardiovascular Disease and\/or Cardiovascular Risk Factors. J Atheroscler Thromb, 2016; 23: 128-146","DOI":"10.5551\/jat.32979"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Tomiyama H, Yamashina A, Arai T, Hirose K, Koji Y, Chikamori T, Hori S, Yamamoto Y, Doba N, Hinohara S: Influences of age and gender on results of noninvasive brachial-ankle pulse wave velocity measurement--a survey of 12517 subjects. Atherosclerosis, 2003; 166: 303-309","DOI":"10.1016\/S0021-9150(02)00332-5"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Yamashina A, Tomiyama H, Arai T, Koji Y, Yambe M, Motobe H, Glunizia Z, Yamamoto Y, Hori S: Nomogram of the relation of brachial-ankle pulse wave velocity with blood pressure. Hypertens Res, 2003; 26: 801-806","DOI":"10.1291\/hypres.26.801"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Ohnishi H, Saitoh S, Takagi S, Ohata J, Isobe T, Kikuchi Y, Takeuchi H, Shimamoto K: Pulse wave velocity as an indicator of atherosclerosis in impaired fasting glucose: the Tanno and Sobetsu study. Diabetes Care, 2003; 26: 437-440","DOI":"10.2337\/diacare.26.2.437"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Ohkuma T, Ninomiya T, Tomiyama H, Kario K, Hoshide S, Kita Y, Inoguchi T, Maeda Y, Kohara K, Tabara Y, Nakamura M, Ohkubo T, Watada H, Munakata M, Ohishi M, Ito N, Nakamura M, Shoji T, Vlachopoulos C, Yamashina A: Brachial-Ankle Pulse Wave Velocity and the Risk Prediction of Cardiovascular Disease: An Individual Participant Data Meta-Analysis. Hypertension, 2017; 69: 1045-1052","DOI":"10.1161\/HYPERTENSIONAHA.117.09097"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Saiki A, Sato Y, Watanabe R, Watanabe Y, Imamura H, Yamaguchi T, Ban N, Kawana H, Nagumo A, Nagayama D, Ohira M, Endo K, Tatsuno I: The Role of a Novel Arterial Stiffness Parameter, Cardio-Ankle Vascular Index (CAVI), as a Surrogate Marker for Cardiovascular Diseases. J Atheroscler Thromb, 2016; 23: 155-168","DOI":"10.5551\/jat.32797"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Ogawa T, Shimada M, Ishida H, Matsuda N, Fujiu A, Ando Y, Nitta K: Relation of stiffness parameter beta to carotid arteriosclerosis and silent cerebral infarction in patients on chronic hemodialysis. Int Urol Nephrol, 2009; 41: 739-745","DOI":"10.1007\/s11255-009-9526-0"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Hayashi K, Yamamoto T, Takahara A, Shirai K: Clinical assessment of arterial stiffness with cardio-ankle vascular index: theory and applications. J Hypertens, 2015; 33: 1742-1757; discussion 1757","DOI":"10.1097\/HJH.0000000000000651"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Shirai K, Hiruta N, Song M, Kurosu T, Suzuki J, Tomaru T, Miyashita Y, Saiki A, Takahashi M, Suzuki K, Takata M: Cardio-ankle vascular index (CAVI) as a novel indicator of arterial stiffness: theory, evidence and perspectives. J Atheroscler Thromb, 2011; 18: 924-938","DOI":"10.5551\/jat.7716"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Takenaka T, Hoshi H, Kato N, Kobayashi K, Takane H, Shoda J, Suzuki H: Cardio-ankle vascular index to screen cardiovascular diseases in patients with end-stage renal diseases. J Atheroscler Thromb, 2008; 15: 339-344","DOI":"10.5551\/jat.E584"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Sato Y, Nagayama D, Saiki A, Watanabe R, Watanabe Y, Imamura H, Yamaguchi T, Ban N, Kawana H, Nagumo A, Ohira M, Endo K, Kurosu T, Tomaru T, Shirai K, Tatsuno I: Cardio-Ankle Vascular Index is Independently Associated with Future Cardiovascular Events in Outpatients with Metabolic Disorders. J Atheroscler Thromb, 2016; 23: 596-605","DOI":"10.5551\/jat.31385"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Miyoshi T, Ito H, Shirai K, Horinaka S, Higaki J, Yamamura S, Saiki A, Takahashi M, Masaki M, Okura T, Kotani K, Kubozono T, Yoshioka R, Kihara H, Hasegawa K, Satoh-Asahara N, Orimo H: Predictive Value of the Cardio-Ankle Vascular Index for Cardiovascular Events in Patients at Cardiovascular Risk. J Am Heart Assoc, 2021; 10: e020103","DOI":"10.1161\/JAHA.120.020103"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol, 2002; 39: 257-265","DOI":"10.1016\/S0735-1097(01)01746-6"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE: Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol, 1994; 24: 1468-1474","DOI":"10.1016\/0735-1097(94)90141-4"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Den Ruijter HM, Peters SA, Anderson TJ, Britton AR, Dekker JM, Eijkemans MJ, Engstr\u00f6m G, Evans GW, de Graaf J, Grobbee DE, Hedblad B, Hofman A, Holewijn S, Ikeda A, Kavousi M, Kitagawa K, Kitamura A, Koffijberg H, Lonn EM, Lorenz MW, Mathiesen EB, Nijpels G, Okazaki S, O\u2019Leary DH, Polak JF, Price JF, Robertson C, Rembold CM, Rosvall M, Rundek T, Salonen JT, Sitzer M, Stehouwer CD, Witteman JC, Moons KG, Bots ML: Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA, 2012; 308: 796-803","DOI":"10.1001\/jama.2012.9630"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Kadota A, Miura K, Okamura T, Fujiyoshi A, Ohkubo T, Kadowaki T, Takashima N, Hisamatsu T, Nakamura Y, Kasagi F, Maegawa H, Kashiwagi A, Ueshima H: Carotid intima-media thickness and plaque in apparently healthy Japanese individuals with an estimated 10-year absolute risk of CAD death according to the Japan Atherosclerosis Society (JAS) guidelines 2012: the Shiga Epidemiological Study of Subclinical Atherosclerosis (SESSA). J Atheroscler Thromb, 2013; 20: 755-766","DOI":"10.5551\/jat.17244"},{"key":"41","unstructured":"41) Subcommittee for preparing guidelines for ultrasound measurement of Achilles tendon thickness. Standard method for ultrasound evaluation of Achilles tendon thickness used for adult familial hypercholesterolemia screening. https:\/\/www.jsum.or.jp\/committee\/diagnostic\/pdf\/measurement_achilles.pdf, 2018 (in Japanese)"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Imamura T, Doi Y, Arima H, Yonemoto K, Hata J, Kubo M, Tanizaki Y, Ibayashi S, Iida M, Kiyohara Y: LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hisayama study. Stroke, 2009; 40: 382-388","DOI":"10.1161\/STROKEAHA.108.529537"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Imano H, Noda H, Kitamura A, Sato S, Kiyama M, Sankai T, Ohira T, Nakamura M, Yamagishi K, Ikeda A, Shimamoto T, Iso H: Low-density lipoprotein cholesterol and risk of coronary heart disease among Japanese men and women: the Circulatory Risk in Communities Study (CIRCS). Prev Med, 2011; 52: 381-386","DOI":"10.1016\/j.ypmed.2011.02.019"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Noda H, Iso H, Irie F, Sairenchi T, Ohtaka E, Ohta H: Gender difference of association between LDL cholesterol concentrations and mortality from coronary heart disease amongst Japanese: the Ibaraki Prefectural Health Study. J Intern Med, 2010; 267: 576-587","DOI":"10.1111\/j.1365-2796.2009.02183.x"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Yokokawa H, Yasumura S, Tanno K, Ohsawa M, Onoda T, Itai K, Sakata K, Kawamura K, Tanaka F, Yoshida Y, Nakamura M, Terayama Y, Ogawa A, Okayama A: Serum low-density lipoprotein to high-density lipoprotein ratio as a predictor of future acute myocardial infarction among men in a 2.7-year cohort study of a Japanese northern rural population. J Atheroscler Thromb, 2011; 18: 89-98","DOI":"10.5551\/jat.5215"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Noda H, Iso H, Irie F, Sairenchi T, Ohtaka E, Doi M, Izumi Y, Ohta H: Low-density lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage: the Ibaraki Prefectural Health Study. Circulation, 2009; 119: 2136-2145","DOI":"10.1161\/CIRCULATIONAHA.108.795666"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Okamura T, Kokubo Y, Watanabe M, Higashiyama A, Miyamoto Y, Yoshimasa Y, Okayama A: Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol and the incidence of cardiovascular disease in an urban Japanese cohort study: The Suita study. Atherosclerosis, 2009; 203: 587-592","DOI":"10.1016\/j.atherosclerosis.2008.07.020"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Sugiyama D, Turin TC, Yeasmin F, Rumana N, Watanabe M, Higashiyama A, Takegami M, Kokubo Y, Okamura T, Miyamoto Y: Hypercholesterolemia and Lifetime Risk of Coronary Heart Disease in the General Japanese Population: Results from the Suita Cohort Study. J Atheroscler Thromb, 2020; 27: 60-70","DOI":"10.5551\/jat.49098"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y: Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet, 2006; 368: 1155-1163","DOI":"10.1016\/S0140-6736(06)69472-5"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Pravastatin use and risk of coronary events and cerebral infarction in japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study. J Atheroscler Thromb, 2000; 7: 110-121","DOI":"10.5551\/jat1994.7.110"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Ito H, Ouchi Y, Ohashi Y, Saito Y, Ishikawa T, Nakamura H, Orimo H: A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the pravastatin anti-atherosclerosis trial in the elderly (PATE). J Atheroscler Thromb, 2001; 8: 33-44","DOI":"10.5551\/jat1994.8.33"},{"key":"52","unstructured":"52) Chikamori T, Sugimoto K, Hamada T, Kitaoka H, Furuno T, Seo H, Doi Y: Efficacy of cholesterol-lowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. J Cardiol, 2000; 35: 95-101"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Saito I, Iso H, Kokubo Y, Inoue M, Tsugane S: Metabolic syndrome and all-cause and cardiovascular disease mortality: Japan Public Health Center-based Prospective (JPHC) Study. Circ J, 2009; 73: 878-884","DOI":"10.1253\/circj.CJ-08-1025"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Noda H, Iso H, Saito I, Konishi M, Inoue M, Tsugane S: The impact of the metabolic syndrome and its components on the incidence of ischemic heart disease and stroke: the Japan public health center-based study. Hypertens Res, 2009; 32: 289-298","DOI":"10.1038\/hr.2009.14"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Tsukinoki R, Okamura T, Watanabe M, Kokubo Y, Higashiyama A, Nishimura K, Takegami M, Murakami Y, Okayama A, Miyamoto Y: Blood pressure, low-density lipoprotein cholesterol, and incidences of coronary artery disease and ischemic stroke in Japanese: the Suita study. Am J Hypertens, 2014; 27: 1362-1369","DOI":"10.1093\/ajh\/hpu059"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Kodama K, Sasaki H, Shimizu Y: Trend of coronary heart disease and its relationship to risk factors in a Japanese population: a 26-year follow-up, Hiroshima\/Nagasaki study. Jpn Circ J, 1990; 54: 414-421","DOI":"10.1253\/jcj.54.414"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Konishi M, Iso H, Iida M, Naito Y, Sato S, Komachi Y, Shimamoto T, Doi M, Ito M: Trends for coronary heart disease and its risk factors in Japan: epidemiologic and pathologic studies. Jpn Circ J, 1990; 54: 428-435","DOI":"10.1253\/jcj.54.428"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Okamura T, Tanaka H, Miyamatsu N, Hayakawa T, Kadowaki T, Kita Y, Nakamura Y, Okayama A, Ueshima H: The relationship between serum total cholesterol and all-cause or cause-specific mortality in a 17.3-year study of a Japanese cohort. Atherosclerosis, 2007; 190: 216-223","DOI":"10.1016\/j.atherosclerosis.2006.01.024"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Tanabe N, Iso H, Okada K, Nakamura Y, Harada A, Ohashi Y, Ando T, Ueshima H: Serum total and non-high-density lipoprotein cholesterol and the risk prediction of cardiovascular events - the JALS-ECC. Circ J, 2010; 74: 1346-1356","DOI":"10.1253\/circj.CJ-09-0861"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Wakugami K, Iseki K, Kimura Y, Okumura K, Ikemiya Y, Muratani H, Fukiyama K: Relationship between serum cholesterol and the risk of acute myocardial infarction in a screened cohort in Okinawa, Japan. Jpn Circ J, 1998; 62: 7-14","DOI":"10.1253\/jcj.62.7"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Kitamura A, Iso H, Naito Y, Iida M, Konishi M, Folsom AR, Sato S, Kiyama M, Nakamura M, Sankai T, et al.: High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. Circulation, 1994; 89: 2533-2539","DOI":"10.1161\/01.CIR.89.6.2533"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Sugiyama D, Okamura T, Watanabe M, Higashiyama A, Okuda N, Nakamura Y, Hozawa A, Kita Y, Kadota A, Murakami Y, Miyamatsu N, Ohkubo T, Hayakawa T, Miyamoto Y, Miura K, Okayama A, Ueshima H: Risk of hypercholesterolemia for cardiovascular disease and the population attributable fraction in a 24-year Japanese cohort study. J Atheroscler Thromb, 2015; 22: 95-107","DOI":"10.5551\/jat.25908"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Nagasawa SY, Okamura T, Iso H, Tamakoshi A, Yamada M, Watanabe M, Murakami Y, Miura K, Ueshima H: Relation between serum total cholesterol level and cardiovascular disease stratified by sex and age group: a pooled analysis of 65 594 individuals from 10 cohort studies in Japan. J Am Heart Assoc, 2012; 1: e001974","DOI":"10.1161\/JAHA.112.001974"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Okumura K, Iseki K, Wakugami K, Kimura Y, Muratani H, Ikemiya Y, Fukiyama K: Low serum cholesterol as a risk factor for hemorrhagic stroke in men: a community-based mass screening in Okinawa, Japan. Jpn Circ J, 1999; 63: 53-58","DOI":"10.1253\/jcj.63.53"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Cui R, Iso H, Toyoshima H, Date C, Yamamoto A, Kikuchi S, Kondo T, Watanabe Y, Koizumi A, Inaba Y, Tamakoshi A: Serum total cholesterol levels and risk of mortality from stroke and coronary heart disease in Japanese: the JACC study. Atherosclerosis, 2007; 194: 415-420","DOI":"10.1016\/j.atherosclerosis.2006.08.022"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Tanizaki Y, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Shinohara N, Arima H, Tanaka K, Ibayashi S, Fujishima M: Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayama study. Stroke, 2000; 31: 2616-2622","DOI":"10.1161\/01.STR.31.11.2616"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Cui R, Iso H, Yamagishi K, Saito I, Kokubo Y, Inoue M, Tsugane S: High serum total cholesterol levels is a risk factor of ischemic stroke for general Japanese population: the JPHC study. Atherosclerosis, 2012; 221: 565-569","DOI":"10.1016\/j.atherosclerosis.2012.01.013"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Satoh M, Ohkubo T, Asayama K, Murakami Y, Sakurai M, Nakagawa H, Iso H, Okayama A, Miura K, Imai Y, Ueshima H, Okamura T: Combined effect of blood pressure and total cholesterol levels on long-term risks of subtypes of cardiovascular death: Evidence for Cardiovascular Prevention from Observational Cohorts in Japan. Hypertension, 2015; 65: 517-524","DOI":"10.1161\/HYPERTENSIONAHA.114.04639"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Satoh M, Ohkubo T, Asayama K, Murakami Y, Sugiyama D, Waki T, Tanaka-Mizuno S, Yamada M, Saitoh S, Sakata K, Irie F, Sairenchi T, Ishikawa S, Kiyama M, Okayama A, Miura K, Imai Y, Ueshima H, Okamura T: A Combination of Blood Pressure and Total Cholesterol Increases the Lifetime Risk of Coronary Heart Disease Mortality: EPOCH-JAPAN. J Atheroscler Thromb, 2021; 28: 6-24","DOI":"10.5551\/jat.52613"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL: Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med, 2001; 161: 1413-1419","DOI":"10.1001\/archinte.161.11.1413"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB: Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation, 2005; 112: 3375-3383","DOI":"10.1161\/CIRCULATIONAHA.104.532499"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Kitamura A, Noda H, Nakamura M, Kiyama M, Okada T, Imano H, Ohira T, Sato S, Yamagishi K, Iso H: Association between non-high-density lipoprotein cholesterol levels and the incidence of coronary heart disease among Japanese: the Circulatory Risk in Communities Study (CIRCS). J Atheroscler Thromb, 2011; 18: 454-463","DOI":"10.5551\/jat.7237"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Okamura T, Kokubo Y, Watanabe M, Higashiyama A, Ono Y, Miyamoto Y, Yoshimasa Y, Okayama A: Triglycerides and non-high-density lipoprotein cholesterol and the incidence of cardiovascular disease in an urban Japanese cohort: the Suita study. Atherosclerosis, 2010; 209: 290-294","DOI":"10.1016\/j.atherosclerosis.2009.09.012"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Noda H, Iso H, Irie F, Sairenchi T, Ohtaka E, Ohta H: Association between non-high-density lipoprotein cholesterol concentrations and mortality from coronary heart disease among Japanese men and women: the Ibaraki Prefectural Health Study. J Atheroscler Thromb, 2010; 17: 30-36","DOI":"10.5551\/jat.1016"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Imamura T, Doi Y, Ninomiya T, Hata J, Nagata M, Ikeda F, Mukai N, Hirakawa Y, Yoshida D, Fukuhara M, Kitazono T, Kiyohara Y: Non-high-density lipoprotein cholesterol and the development of coronary heart disease and stroke subtypes in a general Japanese population: the Hisayama Study. Atherosclerosis, 2014; 233: 343-348","DOI":"10.1016\/j.atherosclerosis.2014.01.005"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Takeuchi T, Nemoto K, Takahashi O, Urayama KY, Deshpande GA, Izumo H: Comparison of cardiovascular disease risk associated with 3 lipid measures in Japanese adults. J Clin Lipidol, 2014; 8: 501-509","DOI":"10.1016\/j.jacl.2014.06.005"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Tanaka F, Makita S, Onoda T, Tanno K, Ohsawa M, Itai K, Sakata K, Omama S, Yoshida Y, Ogasawara K, Ogawa A, Ishibashi Y, Kuribayashi T, Okayama A, Nakamura M: Predictive value of lipoprotein indices for residual risk of acute myocardial infarction and sudden death in men with low-density lipoprotein cholesterol levels &lt;120 mg\/dl. Am J Cardiol, 2013; 112: 1063-1068","DOI":"10.1016\/j.amjcard.2013.05.049"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Kakehi E, Kotani K, Ishikawa S, Gotoh T, Kayaba K, Nakamura Y, Kajii E: Serum non-high-density lipoprotein cholesterol levels and the incidence of ischemic stroke in a Japanese population: the Jichi Medical School cohort study. Asia Pac J Public Health, 2015; 27: Np535-543","DOI":"10.1177\/1010539513475649"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79) Saito I, Yamagishi K, Kokubo Y, Yatsuya H, Iso H, Sawada N, Inoue M, Tsugane S: Non-High-Density Lipoprotein Cholesterol and Risk of Stroke Subtypes and Coronary Heart Disease: The Japan Public Health Center-Based Prospective (JPHC) Study. J Atheroscler Thromb, 2020; 27: 363-374","DOI":"10.5551\/jat.50385"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) Usui T, Nagata M, Hata J, Mukai N, Hirakawa Y, Yoshida D, Kishimoto H, Kitazono T, Kiyohara Y, Ninomiya T: Serum Non-High-Density Lipoprotein Cholesterol and Risk of Cardiovascular Disease in Community Dwellers with Chronic Kidney Disease: the Hisayama Study. J Atheroscler Thromb, 2017; 24: 706-715","DOI":"10.5551\/jat.37044"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81) Shimano H, Arai H, Harada-Shiba M, Ueshima H, Ohta T, Yamashita S, Gotoda T, Kiyohara Y, Hayashi T, Kobayashi J, Shimamoto K, Bujo H, Ishibashi S, Shirai K, Oikawa S, Saito Y, Yamada N: Proposed guidelines for hypertriglyceridemia in Japan with non-HDL cholesterol as the second target. J Atheroscler Thromb, 2008; 15: 116-121","DOI":"10.5551\/jat.E560"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Sugimoto K, Isobe K, Kawakami Y, Yamada N: The relationship between non-HDL cholesterol and other lipid parameters in Japanese subjects. J Atheroscler Thromb, 2005; 12: 107-110","DOI":"10.5551\/jat.12.107"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Chei CL, Yamagishi K, Kitamura A, Kiyama M, Imano H, Ohira T, Cui R, Tanigawa T, Sankai T, Ishikawa Y, Sato S, Hitsumoto S, Iso H: High-density lipoprotein subclasses and risk of stroke and its subtypes in Japanese population: the Circulatory Risk in Communities Study. Stroke, 2013; 44: 327-333","DOI":"10.1161\/STROKEAHA.112.674812"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84) Soyama Y, Miura K, Morikawa Y, Nishijo M, Nakanishi Y, Naruse Y, Kagamimori S, Nakagawa H: High-density lipoprotein cholesterol and risk of stroke in Japanese men and women: the Oyabe Study. Stroke, 2003; 34: 863-868","DOI":"10.1161\/01.STR.0000060869.34009.38"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85) Iso H, Sato S, Kitamura A, Imano H, Kiyama M, Yamagishi K, Cui R, Tanigawa T, Shimamoto T: Metabolic syndrome and the risk of ischemic heart disease and stroke among Japanese men and women. Stroke, 2007; 38: 1744-1751","DOI":"10.1161\/STROKEAHA.106.469072"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86) Satoh H, Tomita K, Fujii S, Kishi R, Tsutsui H: Lower high-density lipoprotein cholesterol is a significant and independent risk for coronary artery disease in Japanese men. J Atheroscler Thromb, 2009; 16: 792-798","DOI":"10.5551\/jat.1644"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87) Saito I, Yamagishi K, Kokubo Y, Yatsuya H, Iso H, Sawada N, Inoue M, Tsugane S: Association of high-density lipoprotein cholesterol concentration with different types of stroke and coronary heart disease: The Japan Public Health Center-based prospective (JPHC) study. Atherosclerosis, 2017; 265: 147-154","DOI":"10.1016\/j.atherosclerosis.2017.08.032"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88) Okamura T, Hayakawa T, Kadowaki T, Kita Y, Okayama A, Ueshima H: The inverse relationship between serum high-density lipoprotein cholesterol level and all-cause mortality in a 9.6-year follow-up study in the Japanese general population. Atherosclerosis, 2006; 184: 143-150","DOI":"10.1016\/j.atherosclerosis.2005.03.042"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89) Matsuzaki M, Kita T, Mabuchi H, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H: Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J, 2002; 66: 1087-1095","DOI":"10.1253\/circj.66.1087"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90) Mabuchi H, Kita T, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H: Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J, 2002; 66: 1096-1100","DOI":"10.1253\/circj.66.1096"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91) Huxley RR, Barzi F, Lam TH, Czernichow S, Fang X, Welborn T, Shaw J, Ueshima H, Zimmet P, Jee SH, Patel JV, Caterson I, Perkovic V, Woodward M: Isolated low levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease: an individual participant data meta-analysis of 23 studies in the Asia-Pacific region. Circulation, 2011; 124: 2056-2064","DOI":"10.1161\/CIRCULATIONAHA.111.028373"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92) Hirata T, Sugiyama D, Nagasawa SY, Murakami Y, Saitoh S, Okayama A, Iso H, Irie F, Sairenchi T, Miyamoto Y, Yamada M, Ishikawa S, Miura K, Ueshima H, Okamura T: A pooled analysis of the association of isolated low levels of high-density lipoprotein cholesterol with cardiovascular mortality in Japan. Eur J Epidemiol, 2017; 32: 547-557","DOI":"10.1007\/s10654-016-0203-1"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93) Watanabe J, Kakehi E, Kotani K, Kayaba K, Nakamura Y, Ishikawa S: Isolated low levels of high-density lipoprotein cholesterol and stroke incidence: JMS Cohort Study. J Clin Lab Anal, 2020; 34: e23087","DOI":"10.1002\/jcla.23087"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94) Hirata A, Sugiyama D, Watanabe M, Tamakoshi A, Iso H, Kotani K, Kiyama M, Yamada M, Ishikawa S, Murakami Y, Miura K, Ueshima H, Okamura T: Association of extremely high levels of high-density lipoprotein cholesterol with cardiovascular mortality in a pooled analysis of 9 cohort studies including 43,407 individuals: The EPOCH-JAPAN study. J Clin Lipidol, 2018; 12: 674-684.e675","DOI":"10.1016\/j.jacl.2018.01.014"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95) Arai H, Yamamoto A, Matsuzawa Y, Saito Y, Yamada N, Oikawa S, Mabuchi H, Teramoto T, Sasaki J, Nakaya N, Itakura H, Ishikawa Y, Ouchi Y, Horibe H, Kita T: Serum lipid survey and its recent trend in the general Japanese population in 2000. J Atheroscler Thromb, 2005; 12: 98-106","DOI":"10.5551\/jat.12.98"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96) Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V: Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation, 2007; 115: 450-458","DOI":"10.1161\/CIRCULATIONAHA.106.637793"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97) Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G, Woodward M: Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation, 2004; 110: 2678-2686","DOI":"10.1161\/01.CIR.0000145615.33955.83"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98) Iso H, Naito Y, Sato S, Kitamura A, Okamura T, Sankai T, Shimamoto T, Iida M, Komachi Y: Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol, 2001; 153: 490-499","DOI":"10.1093\/aje\/153.5.490"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99) Satoh H, Nishino T, Tomita K, Tsutsui H: Fasting triglyceride is a significant risk factor for coronary artery disease in middle-aged Japanese men. Circ J, 2006; 70: 227-231","DOI":"10.1253\/circj.70.227"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100) Okamura T, Kokubo Y, Watanabe M, Higashiyama A, Ono Y, Nishimura K, Okayama A, Miyamoto Y: A revised definition of the metabolic syndrome predicts coronary artery disease and ischemic stroke after adjusting for low density lipoprotein cholesterol in a 13-year cohort study of Japanese: the Suita study. Atherosclerosis, 2011; 217: 201-206","DOI":"10.1016\/j.atherosclerosis.2011.03.010"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101) Iso H, Imano H, Yamagishi K, Ohira T, Cui R, Noda H, Sato S, Kiyama M, Okada T, Hitsumoto S, Tanigawa T, Kitamura A: Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women: the Circulatory Risk in Communities Study (CIRCS). Atherosclerosis, 2014; 237: 361-368","DOI":"10.1016\/j.atherosclerosis.2014.08.028"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102) Higashiyama A, Wakabayashi I, Okamura T, Kokubo Y, Watanabe M, Takegami M, Honda-Kohmo K, Okayama A, Miyamoto Y: The Risk of Fasting Triglycerides and its Related Indices for Ischemic Cardiovascular Diseases in Japanese Community Dwellers: the Suita Study. J Atheroscler Thromb, 2021","DOI":"10.5551\/jat.62730"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103) Castelli WP: Lipids, risk factors and ischaemic heart disease. Atherosclerosis, 1996; 124 Suppl: S1-9","DOI":"10.1016\/S0021-9150(96)90500-6"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104) Higashiyama A, Wakabayashi I, Okamura T, Kokubo Y, Watanabe M, Takegami M, Honda-Kohmo K, Okayama A, Miyamoto Y: The Risk of Fasting Triglycerides and its Related Indices for Ischemic Cardiovascular Diseases in Japanese Community Dwellers: the Suita Study. J Atheroscler Thromb, 2021; 28: 1275-1288","DOI":"10.5551\/jat.62730"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105) Labreuche J, Touboul PJ, Amarenco P: Plasma triglyceride levels and risk of stroke and carotid atherosclerosis: a systematic review of the epidemiological studies. Atherosclerosis, 2009; 203: 331-345","DOI":"10.1016\/j.atherosclerosis.2008.08.040"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106) Antonios N, Angiolillo DJ, Silliman S: Hypertriglyceridemia and ischemic stroke. Eur Neurol, 2008; 60: 269-278","DOI":"10.1159\/000157880"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107) Hirata A, Okamura T, Hirata T, Sugiyama D, Ohkubo T, Okuda N, Kita Y, Hayakawa T, Kadota A, Kondo K, Miura K, Okayama A, Ueshima H: Relationship Between Non-fasting Triglycerides and Cardiovascular Disease Mortality in a 20-year Follow-up Study of a Japanese General Population: NIPPON DATA90. J Epidemiol, 2022; 32: 303-313","DOI":"10.2188\/jea.JE20200399"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108) Saito I, Folsom AR, Aono H, Ozawa H, Ikebe T, Yamashita T: Comparison of fatal coronary heart disease occurrence based on population surveys in Japan and the USA. Int J Epidemiol, 2000; 29: 837-844","DOI":"10.1093\/ije\/29.5.837"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109) Sekikawa A, Miyamoto Y, Miura K, Nishimura K, Willcox BJ, Masaki KH, Rodriguez B, Tracy RP, Okamura T, Kuller LH: Continuous decline in mortality from coronary heart disease in Japan despite a continuous and marked rise in total cholesterol: Japanese experience after the Seven Countries Study. Int J Epidemiol, 2015; 44: 1614-1624","DOI":"10.1093\/ije\/dyv143"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110) Kitamura A, Sato S, Kiyama M, Imano H, Iso H, Okada T, Ohira T, Tanigawa T, Yamagishi K, Nakamura M, Konishi M, Shimamoto T, Iida M, Komachi Y: Trends in the incidence of coronary heart disease and stroke and their risk factors in Japan, 1964 to 2003: the Akita-Osaka study. J Am Coll Cardiol, 2008; 52: 71-79","DOI":"10.1016\/j.jacc.2008.02.075"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111) Takii T, Yasuda S, Takahashi J, Ito K, Shiba N, Shirato K, Shimokawa H: Trends in acute myocardial infarction incidence and mortality over 30 years in Japan: report from the MIYAGI-AMI Registry Study. Circ J, 2010; 74: 93-100","DOI":"10.1253\/circj.CJ-09-0619"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112) Kitamura A, Iso H, Iida M, Naito Y, Sato S, Jacobs DR, Nakamura M, Shimamoto T, Komachi Y: Trends in the incidence of coronary heart disease and stroke and the prevalence of cardiovascular risk factors among Japanese men from 1963 to 1994. Am J Med, 2002; 112: 104-109","DOI":"10.1016\/S0002-9343(01)01053-1"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113) Miida T, Nishimura K, Okamura T, Hirayama S, Ohmura H, Yoshida H, Miyashita Y, Ai M, Tanaka A, Sumino H, Murakami M, Inoue I, Kayamori Y, Nakamura M, Nobori T, Miyazawa Y, Teramoto T, Yokoyama S: A multicenter study on the precision and accuracy of homogeneous assays for LDL-cholesterol: comparison with a beta-quantification method using fresh serum obtained from non-diseased and diseased subjects. Atherosclerosis, 2012; 225: 208-215","DOI":"10.1016\/j.atherosclerosis.2012.08.022"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114) Miida T, Nishimura K, Hirayama S, Miyamoto Y, Nakamura M, Masuda D, Yamashita S, Ushiyama M, Komori T, Fujita N, Yokoyama S, Teramoto T: Homogeneous Assays for LDL-C and HDL-C are Reliable in Both the Postprandial and Fasting State. J Atheroscler Thromb, 2017; 24: 583-599","DOI":"10.5551\/jat.40006"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115) Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18: 499-502","DOI":"10.1093\/clinchem\/18.6.499"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116) Pownall HJ: Dietary ethanol is associated with reduced lipolysis of intestinally derived lipoproteins. J Lipid Res, 1994; 35: 2105-2113","DOI":"10.1016\/S0022-2275(20)39917-X"},{"key":"117","doi-asserted-by":"crossref","unstructured":"117) Miida T, Nakamura Y, Mezaki T, Hanyu O, Maruyama S, Horikawa Y, Izawa S, Yamada Y, Matsui H, Okada M: LDL-cholesterol and HDL-cholesterol concentrations decrease during the day. Ann Clin Biochem, 2002; 39: 241-249","DOI":"10.1258\/0004563021901946"},{"key":"118","doi-asserted-by":"crossref","unstructured":"118) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 2002; 106: 3143-3421","DOI":"10.1161\/circ.106.25.3143"},{"key":"119","doi-asserted-by":"crossref","unstructured":"119) Miida T, Otsuka H, Tsuchiya A, Okada M: Plasma lipoprotein profiles change significantly during cardiac catheterization. Clin Chem, 1998; 44: 517-521","DOI":"10.1093\/clinchem\/44.3.517"},{"key":"120","doi-asserted-by":"crossref","unstructured":"120) Nordestgaard BG: A Test in Context: Lipid Profile, Fasting Versus Nonfasting. J Am Coll Cardiol, 2017; 70: 1637-1646","DOI":"10.1016\/j.jacc.2017.08.006"},{"key":"121","doi-asserted-by":"crossref","unstructured":"121) Nakagawa T, Hirayama S, Watanabe T, Yokomura M, Kohno M, Sato T, Bujo H, Sato A, Murata M, Miida T: Triglyceride concentrations should be measured after elimination of free glycerol to exclude interindividual variations due to adiposity and fasting status. Clin Chem Lab Med, 2017; 55: e191-e194","DOI":"10.1515\/cclm-2016-0710"},{"key":"122","doi-asserted-by":"crossref","unstructured":"122) Sniderman A, Williams K, Cobbaert C: ApoB versus non-HDL-C: what to do when they disagree. Curr Atheroscler Rep, 2009; 11: 358-363","DOI":"10.1007\/s11883-009-0054-2"},{"key":"123","doi-asserted-by":"crossref","unstructured":"123) Kosuge K, Miida T, Takahashi A, Obayashi K, Ito M, Ito T, Soda S, Ozaki K, Hirayama S, Hanyu O, Aizawa Y, Nakamura Y: Estimating the fasting triglyceride concentration from the postprandial HDL-cholesterol and apolipoprotein CIII concentrations. Atherosclerosis, 2006; 184: 413-419","DOI":"10.1016\/j.atherosclerosis.2005.05.037"},{"key":"124","doi-asserted-by":"crossref","unstructured":"124) Todo Y, Kobayashi J, Higashikata T, Kawashiri M, Nohara A, Inazu A, Koizumi J, Mabuchi H: Detailed analysis of serum lipids and lipoproteins from Japanese type III hyperlipoproteinemia with apolipoprotein E2\/2 phenotype. Clin Chim Acta, 2004; 348: 35-40","DOI":"10.1016\/j.cccn.2004.04.018"},{"key":"125","doi-asserted-by":"crossref","unstructured":"125) Hirowatari Y, Yoshida H, Kurosawa H, Doumitu KI, Tada N: Measurement of cholesterol of major serum lipoprotein classes by anion-exchange HPLC with perchlorate ion-containing eluent. J Lipid Res, 2003; 44: 1404-1412","DOI":"10.1194\/jlr.D300003-JLR200"},{"key":"126","doi-asserted-by":"crossref","unstructured":"126) Manita D, Hirowatari Y, Yoshida H: A rapid anion-exchange chromatography for measurement of cholesterol concentrations in five lipoprotein classes and estimation of lipoprotein profiles in male volunteers without overt diseases. Ann Clin Biochem, 2015; 52: 638-646","DOI":"10.1177\/0004563215584405"},{"key":"127","doi-asserted-by":"crossref","unstructured":"127) Nordestgaard BG: Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. Circ Res, 2016; 118: 547-563","DOI":"10.1161\/CIRCRESAHA.115.306249"},{"key":"128","doi-asserted-by":"crossref","unstructured":"128) Yoshida H, Kurosawa H, Hirowatari Y, Ogura Y, Ikewaki K, Abe I, Saikawa S, Domitsu K, Ito K, Yanai H, Tada N: Characteristic comparison of triglyceride-rich remnant lipoprotein measurement between a new homogenous assay (RemL-C) and a conventional immunoseparation method (RLP-C). Lipids Health Dis, 2008; 7: 18","DOI":"10.1186\/1476-511X-7-18"},{"key":"129","doi-asserted-by":"crossref","unstructured":"129) Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, Moriarty PM, Rader DJ, Remaley AT, Reyes-Soffer G, Santos RD, Thanassoulis G, Witztum JL, Danthi S, Olive M, Liu L: NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. J Am Coll Cardiol, 2018; 71: 177-192","DOI":"10.1016\/j.jacc.2017.11.014"},{"key":"130","doi-asserted-by":"crossref","unstructured":"130) Tsimikas S: A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol, 2017; 69: 692-711","DOI":"10.1016\/j.jacc.2016.11.042"},{"key":"131","doi-asserted-by":"crossref","unstructured":"131) Marcovina SM, Albers JJ: Lipoprotein (a) measurements for clinical application. J Lipid Res, 2016; 57: 526-537","DOI":"10.1194\/jlr.R061648"},{"key":"132","doi-asserted-by":"crossref","unstructured":"132) Yoshida H: Clinical Impact and Significance of Serum Lipoprotein (a) Levels on Cardiovascular Risk in Patients With Coronary Artery Disease. Circ J, 2019; 83: 967-968","DOI":"10.1253\/circj.CJ-19-0221"},{"key":"133","doi-asserted-by":"crossref","unstructured":"133) Scharnagl H, Stojakovic T, Dieplinger B, Dieplinger H, Erhart G, Kostner GM, Herrmann M, M\u00e4rz W, Grammer TB: Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays. Atherosclerosis, 2019; 289: 206-213","DOI":"10.1016\/j.atherosclerosis.2019.08.015"},{"key":"134","doi-asserted-by":"crossref","unstructured":"134) Nelson JR, Raskin S: The eicosapentaenoic acid:arachidonic acid ratio and its clinical utility in cardiovascular disease. Postgrad Med, 2019; 131: 268-277","DOI":"10.1080\/00325481.2019.1607414"},{"key":"135","doi-asserted-by":"crossref","unstructured":"135) Ninomiya T, Nagata M, Hata J, Hirakawa Y, Ozawa M, Yoshida D, Ohara T, Kishimoto H, Mukai N, Fukuhara M, Kitazono T, Kiyohara Y: Association between ratio of serum eicosapentaenoic acid to arachidonic acid and risk of cardiovascular disease: the Hisayama Study. Atherosclerosis, 2013; 231: 261-267","DOI":"10.1016\/j.atherosclerosis.2013.09.023"},{"key":"136","doi-asserted-by":"crossref","unstructured":"136) Yoshida H, Ito K, Sato R, Kurosawa H, Tomono Y, Hirowatari Y, Shimizu M, Tada N: Clinical relevance of decreased ratios of serum eicosapentaenoic acid\/arachidonic acid (AA) and docosahexaenoic acid\/AA to impaired arterial stiffness. Int J Cardiol, 2014; 177: 517-519","DOI":"10.1016\/j.ijcard.2014.08.093"},{"key":"137","doi-asserted-by":"crossref","unstructured":"137) Wu SA, Kersten S, Qi L: Lipoprotein Lipase and Its Regulators: An Unfolding Story. Trends Endocrinol Metab, 2021; 32: 48-61","DOI":"10.1016\/j.tem.2020.11.005"},{"key":"138","doi-asserted-by":"crossref","unstructured":"138) Hanyu O, Miida T, Obayashi K, Ikarashi T, Soda S, Kaneko S, Hirayama S, Suzuki K, Nakamura Y, Yamatani K, Aizawa Y: Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity. Atherosclerosis, 2004; 174: 385-390","DOI":"10.1016\/j.atherosclerosis.2004.01.034"},{"key":"139","doi-asserted-by":"crossref","unstructured":"139) Hanyu O, Miida T, Kosuge K, Ito T, Soda S, Hirayama S, Wardaningsih E, Fueki Y, Obayashi K, Aizawa Y: Preheparin lipoprotein lipase mass is a practical marker of insulin resistance in ambulatory type 2 diabetic patients treated with oral hypoglycemic agents. Clin Chim Acta, 2007; 384: 118-123","DOI":"10.1016\/j.cca.2007.06.015"},{"key":"140","doi-asserted-by":"crossref","unstructured":"140) Ishibashi R, Takemoto M, Tsurutani Y, Kuroda M, Ogawa M, Wakabayashi H, Uesugi N, Nagata M, Imai N, Hattori A, Sakamoto K, Kitamoto T, Maezawa Y, Narita I, Hiroi S, Furuta A, Miida T, Yokote K: Immune-mediated acquired lecithin-cholesterol acyltransferase deficiency: A case report and literature review. J Clin Lipidol, 2018; 12: 888-897.e882","DOI":"10.1016\/j.jacl.2018.05.002"},{"key":"141","doi-asserted-by":"crossref","unstructured":"141) Oldoni F, Baldassarre D, Castelnuovo S, Ossoli A, Amato M, van Capelleveen J, Hovingh GK, De Groot E, Bochem A, Simonelli S, Barbieri S, Veglia F, Franceschini G, Kuivenhoven JA, Holleboom AG, Calabresi L: Complete and Partial Lecithin:Cholesterol Acyltransferase Deficiency Is Differentially Associated With Atherosclerosis. Circulation, 2018; 138: 1000-1007","DOI":"10.1161\/CIRCULATIONAHA.118.034706"},{"key":"142","doi-asserted-by":"crossref","unstructured":"142) Miida T, Hirayama S: Controversy over the atherogenicity of lipoprotein-X. Curr Opin Endocrinol Diabetes Obes, 2019; 26: 117-123","DOI":"10.1097\/MED.0000000000000466"},{"key":"143","doi-asserted-by":"crossref","unstructured":"143) Nagano M, Nakamura M, Kobayashi N, Kamata J, Hiramori K: Effort angina in a middle-aged woman with abnormally high levels of serum high-density lipoprotein cholesterol: a case of cholesteryl-ester transfer protein deficiency. Circ J, 2005; 69: 609-612","DOI":"10.1253\/circj.69.609"},{"key":"144","doi-asserted-by":"crossref","unstructured":"144) Steinberg D, Witztum JL: Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol, 2010; 30: 2311-2316","DOI":"10.1161\/ATVBAHA.108.179697"},{"key":"145","doi-asserted-by":"crossref","unstructured":"145) Yoshida H, Kisugi R: Mechanisms of LDL oxidation. Clin Chim Acta, 2010; 411: 1875-1882","DOI":"10.1016\/j.cca.2010.08.038"},{"key":"146","doi-asserted-by":"crossref","unstructured":"146) Kotani K, Tashiro J, Yamazaki K, Nakamura Y, Miyazaki A, Bujo H, Saito Y, Kanno T, Maekawa M: Investigation of MDA-LDL (malondialdehyde-modified low-density lipoprotein) as a prognostic marker for coronary artery disease in patients with type 2 diabetes mellitus. Clin Chim Acta, 2015; 450: 145-150","DOI":"10.1016\/j.cca.2015.08.003"},{"key":"147","doi-asserted-by":"crossref","unstructured":"147) Krauss RM: Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol, 2010; 21: 305-311","DOI":"10.1097\/MOL.0b013e32833b7756"},{"key":"148","doi-asserted-by":"crossref","unstructured":"148) Hirano T: Pathophysiology of Diabetic Dyslipidemia. J Atheroscler Thromb, 2018; 25: 771-782","DOI":"10.5551\/jat.RV17023"},{"key":"149","doi-asserted-by":"crossref","unstructured":"149) Koba S, Hirano T, Ito Y, Tsunoda F, Yokota Y, Ban Y, Iso Y, Suzuki H, Katagiri T: Significance of small dense low-density lipoprotein-cholesterol concentrations in relation to the severity of coronary heart diseases. Atherosclerosis, 2006; 189: 206-214","DOI":"10.1016\/j.atherosclerosis.2005.12.002"},{"key":"150","doi-asserted-by":"crossref","unstructured":"150) Yoshida H, Tada H, Ito K, Kishimoto Y, Yanai H, Okamura T, Ikewaki K, Inagaki K, Shoji T, Bujo H, Miida T, Yoshida M, Kuzuya M, Yamashita S: Reference Intervals of Serum Non-Cholesterol Sterols by Gender in Healthy Japanese Individuals. J Atheroscler Thromb, 2020; 27: 409-417","DOI":"10.5551\/jat.50187"},{"key":"151","doi-asserted-by":"crossref","unstructured":"151) Tada H, Nohara A, Inazu A, Sakuma N, Mabuchi H, Kawashiri MA: Sitosterolemia, Hypercholesterolemia, and Coronary Artery Disease. J Atheroscler Thromb, 2018; 25: 783-789","DOI":"10.5551\/jat.RV17024"},{"key":"152","doi-asserted-by":"crossref","unstructured":"152) Miettinen TA, Tilvis RS, Kes\u00e4niemi YA: Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol, 1990; 131: 20-31","DOI":"10.1093\/oxfordjournals.aje.a115479"},{"key":"153","doi-asserted-by":"crossref","unstructured":"153) Simonen P, Gylling H, Miettinen TA: The validity of serum squalene and non-cholesterol sterols as surrogate markers of cholesterol synthesis and absorption in type 2 diabetes. Atherosclerosis, 2008; 197: 883-888","DOI":"10.1016\/j.atherosclerosis.2007.08.003"},{"key":"154","doi-asserted-by":"crossref","unstructured":"154) Harada-Shiba M, Arai H, Ishigaki Y, Ishibashi S, Okamura T, Ogura M, Dobashi K, Nohara A, Bujo H, Miyauchi K, Yamashita S, Yokote K: Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017. J Atheroscler Thromb, 2018; 25: 751-770","DOI":"10.5551\/jat.CR003"},{"key":"155","doi-asserted-by":"crossref","unstructured":"155) Cao YX, Jin JL, Sun D, Liu HH, Guo YL, Wu NQ, Xu RX, Zhu CG, Dong Q, Sun J, Li JJ: Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy. J Transl Med, 2019; 17: 367","DOI":"10.1186\/s12967-019-2123-9"},{"key":"156","doi-asserted-by":"crossref","unstructured":"156) Cohen JC, Boerwinkle E, Mosley TH, Jr., Hobbs HH: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med, 2006; 354: 1264-1272","DOI":"10.1056\/NEJMoa054013"},{"key":"157","doi-asserted-by":"crossref","unstructured":"157) Kono S, Ikeda M, Tokudome S, Nishizumi M, Kuratsune M: Smoking and mortalities from cancer, coronary heart disease and stroke in male Japanese physicians. J Cancer Res Clin Oncol, 1985; 110: 161-164","DOI":"10.1007\/BF00402732"},{"key":"158","unstructured":"158) Irie F ST, Iso H, Shimamoto T.: Prediction of mortality from findings of annual health checkups utility for health care programs. Nihon Koshu Eisei Zasshi, 2001; 48: 95-108"},{"key":"159","doi-asserted-by":"crossref","unstructured":"159) Yamagishi K, Iso H, Kitamura A, Sankai T, Tanigawa T, Naito Y, Sato S, Imano H, Ohira T, Shimamoto T: Smoking raises the risk of total and ischemic strokes in hypertensive men. Hypertens Res, 2003; 26: 209-217","DOI":"10.1291\/hypres.26.209"},{"key":"160","doi-asserted-by":"crossref","unstructured":"160) Ueshima H, Choudhury SR, Okayama A, Hayakawa T, Kita Y, Kadowaki T, Okamura T, Minowa M, Iimura O: Cigarette smoking as a risk factor for stroke death in Japan: NIPPON DATA80. Stroke, 2004; 35: 1836-1841","DOI":"10.1161\/01.STR.0000131747.84423.74"},{"key":"161","doi-asserted-by":"crossref","unstructured":"161) Iso H, Date C, Yamamoto A, Toyoshima H, Watanabe Y, Kikuchi S, Koizumi A, Wada Y, Kondo T, Inaba Y, Tamakoshi A: Smoking cessation and mortality from cardiovascular disease among Japanese men and women: the JACC Study. Am J Epidemiol, 2005; 161: 170-179","DOI":"10.1093\/aje\/kwi027"},{"key":"162","doi-asserted-by":"crossref","unstructured":"162) Higashiyama A, Okamura T, Ono Y, Watanabe M, Kokubo Y, Okayama A: Risk of smoking and metabolic syndrome for incidence of cardiovascular disease--comparison of relative contribution in urban Japanese population: the Suita study. Circ J, 2009; 73: 2258-2263","DOI":"10.1253\/circj.CJ-09-0264"},{"key":"163","doi-asserted-by":"crossref","unstructured":"163) Hata J, Doi Y, Ninomiya T, Fukuhara M, Ikeda F, Mukai N, Hirakawa Y, Kitazono T, Kiyohara Y: Combined effects of smoking and hypercholesterolemia on the risk of stroke and coronary heart disease in Japanese: the Hisayama study. Cerebrovasc Dis, 2011; 31: 477-484","DOI":"10.1159\/000324392"},{"key":"164","doi-asserted-by":"crossref","unstructured":"164) Kondo T, Osugi S, Shimokata K, Honjo H, Morita Y, Maeda K, Yamashita K, Muramatsu T, Shintani S, Matsushita K, Murohara T: Smoking and smoking cessation in relation to all-cause mortality and cardiovascular events in 25,464 healthy male Japanese workers. Circ J, 2011; 75: 2885-2892","DOI":"10.1253\/circj.CJ-11-0416"},{"key":"165","unstructured":"165) Eshak ES, Iso H, Yamagishi K, Kokubo Y, Saito I, Yatsuya H, Sawada N, Inoue M, Tsugane S: Modification of the excess risk of coronary heart disease due to smoking by seafood\/fish intake. Am J Epidemiol, 2014; 179: 1173-1181"},{"key":"166","unstructured":"166) National Center for Chronic Disease P, Health Promotion Office on S, Health: Reports of the Surgeon General.In: Reports of the Surgeon General, Centers for Disease Control and Prevention (US), Atlanta (GA), 2014"},{"key":"167","doi-asserted-by":"crossref","unstructured":"167) Hackshaw A, Morris JK, Boniface S, Tang JL, Milenkovi\u0107 D: Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. BMJ, 2018; 360: j5855","DOI":"10.1136\/bmj.j5855"},{"key":"168","doi-asserted-by":"crossref","unstructured":"168) Aune D, Schlesinger S, Norat T, Riboli E: Tobacco smoking and the risk of abdominal aortic aneurysm: a systematic review and meta-analysis of prospective studies. Sci Rep, 2018; 8: 14786","DOI":"10.1038\/s41598-018-32100-2"},{"key":"169","doi-asserted-by":"crossref","unstructured":"169) Lu L, Mackay DF, Pell JP: Meta-analysis of the association between cigarette smoking and peripheral arterial disease. Heart, 2014; 100: 414-423","DOI":"10.1136\/heartjnl-2013-304082"},{"key":"170","doi-asserted-by":"crossref","unstructured":"170) Lv X, Sun J, Bi Y, Xu M, Lu J, Zhao L, Xu Y: Risk of all-cause mortality and cardiovascular disease associated with secondhand smoke exposure: a systematic review and meta-analysis. Int J Cardiol, 2015; 199: 106-115","DOI":"10.1016\/j.ijcard.2015.07.011"},{"key":"171","doi-asserted-by":"crossref","unstructured":"171) Oono IP, Mackay DF, Pell JP: Meta-analysis of the association between secondhand smoke exposure and stroke. J Public Health (Oxf), 2011; 33: 496-502","DOI":"10.1093\/pubmed\/fdr025"},{"key":"172","doi-asserted-by":"crossref","unstructured":"172) Pan A, Wang Y, Talaei M, Hu FB, Wu T: Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol, 2015; 3: 958-967","DOI":"10.1016\/S2213-8587(15)00316-2"},{"key":"173","doi-asserted-by":"crossref","unstructured":"173) Ishizaka N, Ishizaka Y, Toda E, Hashimoto H, Nagai R, Yamakado M: Association between cigarette smoking, metabolic syndrome, and carotid arteriosclerosis in Japanese individuals. Atherosclerosis, 2005; 181: 381-388","DOI":"10.1016\/j.atherosclerosis.2005.01.026"},{"key":"174","doi-asserted-by":"crossref","unstructured":"174) Craig WY, Palomaki GE, Haddow JE: Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. BMJ, 1989; 298: 784-788","DOI":"10.1136\/bmj.298.6676.784"},{"key":"175","doi-asserted-by":"crossref","unstructured":"175) Simonavicius E, McNeill A, Shahab L, Brose LS: Heat-not-burn tobacco products: a systematic literature review. Tob Control, 2019; 28: 582-594","DOI":"10.1136\/tobaccocontrol-2018-054419"},{"key":"176","doi-asserted-by":"crossref","unstructured":"176) Biondi-Zoccai G, Sciarretta S, Bullen C, Nocella C, Violi F, Loffredo L, Pignatelli P, Perri L, Peruzzi M, Marullo AGM, De Falco E, Chimenti I, Cammisotto V, Valenti V, Coluzzi F, Cavarretta E, Carrizzo A, Prati F, Carnevale R, Frati G: Acute Effects of Heat-Not-Burn, Electronic Vaping, and Traditional Tobacco Combustion Cigarettes: The Sapienza University of Rome-Vascular Assessment of Proatherosclerotic Effects of Smoking ( SUR - VAPES ) 2 Randomized Trial. J Am Heart Assoc, 2019; 8: e010455","DOI":"10.1161\/JAHA.118.010455"},{"key":"177","doi-asserted-by":"crossref","unstructured":"177) Uchiyama S, Senoo Y, Hayashida H, Inaba Y, Nakagome H, Kunugita N: Determination of Chemical Compounds Generated from Second-generation E-cigarettes Using a Sorbent Cartridge Followed by a Two-step Elution Method. Anal Sci, 2016; 32: 549-555","DOI":"10.2116\/analsci.32.549"},{"key":"178","doi-asserted-by":"crossref","unstructured":"178) Kiernan E, Click ES, Melstrom P, Evans ME, Layer MR, Weissman DN, Reagan-Steiner S, Wiltz JL, Hocevar S, Goodman AB, Twentyman E: A Brief Overview of the National Outbreak of e-Cigarette, or Vaping, Product Use-Associated Lung Injury and the Primary Causes. Chest, 2021; 159: 426-431","DOI":"10.1016\/j.chest.2020.07.068"},{"key":"179","doi-asserted-by":"crossref","unstructured":"179) Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, Horio T, Hoshide S, Ikeda S, Ishimitsu T, Ito M, Ito S, Iwashima Y, Kai H, Kamide K, Kanno Y, Kashihara N, Kawano Y, Kikuchi T, Kitamura K, Kitazono T, Kohara K, Kudo M, Kumagai H, Matsumura K, Matsuura H, Miura K, Mukoyama M, Nakamura S, Ohkubo T, Ohya Y, Okura T, Rakugi H, Saitoh S, Shibata H, Shimosawa T, Suzuki H, Takahashi S, Tamura K, Tomiyama H, Tsuchihashi T, Ueda S, Uehara Y, Urata H, Hirawa N: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res, 2019; 42: 1235-1481","DOI":"10.1038\/s41440-019-0284-9"},{"key":"180","doi-asserted-by":"crossref","unstructured":"180) Fujiyoshi A, Ohkubo T, Miura K, Murakami Y, Nagasawa SY, Okamura T, Ueshima H: Blood pressure categories and long-term risk of cardiovascular disease according to age group in Japanese men and women. Hypertens Res, 2012; 35: 947-953","DOI":"10.1038\/hr.2012.87"},{"key":"181","doi-asserted-by":"crossref","unstructured":"181) Sasaki J, Kita T, Mabuchi H, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Shimamoto K, Kono S, Itakura H: Gender difference in coronary events in relation to risk factors in Japanese hypercholesterolemic patients treated with low-dose simvastatin. Circ J, 2006; 70: 810-814","DOI":"10.1253\/circj.70.810"},{"key":"182","doi-asserted-by":"crossref","unstructured":"182) Kadowaki S, Okamura T, Hozawa A, Kadowaki T, Kadota A, Murakami Y, Nakamura K, Saitoh S, Nakamura Y, Hayakawa T, Kita Y, Okayama A, Ueshima H: Relationship of elevated casual blood glucose level with coronary heart disease, cardiovascular disease and all-cause mortality in a representative sample of the Japanese population. NIPPON DATA80. Diabetologia, 2008; 51: 575-582","DOI":"10.1007\/s00125-007-0915-6"},{"key":"183","doi-asserted-by":"crossref","unstructured":"183) Sakurai M, Saitoh S, Miura K, Nakagawa H, Ohnishi H, Akasaka H, Kadota A, Kita Y, Hayakawa T, Ohkubo T, Okayama A, Okamura T, Ueshima H: HbA1c and the risks for all-cause and cardiovascular mortality in the general Japanese population: NIPPON DATA90. Diabetes Care, 2013; 36: 3759-3765","DOI":"10.2337\/dc12-2412"},{"key":"184","doi-asserted-by":"crossref","unstructured":"184) Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care, 1999; 22: 920-924","DOI":"10.2337\/diacare.22.6.920"},{"key":"185","doi-asserted-by":"crossref","unstructured":"185) Islam Z, Akter S, Inoue Y, Hu H, Kuwahara K, Nakagawa T, Honda T, Yamamoto S, Okazaki H, Miyamoto T, Ogasawara T, Sasaki N, Uehara A, Yamamoto M, Kochi T, Eguchi M, Shirasaka T, Shimizu M, Nagahama S, Hori A, Imai T, Nishihara A, Tomita K, Sone T, Konishi M, Kabe I, Mizoue T, Dohi S: Prediabetes, Diabetes, and the Risk of All-Cause and Cause-Specific Mortality in a Japanese Working Population: Japan Epidemiology Collaboration on Occupational Health Study. Diabetes Care, 2021; 44: 757-764","DOI":"10.2337\/dc20-1213"},{"key":"186","doi-asserted-by":"crossref","unstructured":"186) Kokubo Y, Okamura T, Watanabe M, Higashiyama A, Ono Y, Miyamoto Y, Furukawa Y, Kamide K, Kawanishi K, Okayama A, Yoshimasa Y: The combined impact of blood pressure category and glucose abnormality on the incidence of cardiovascular diseases in a Japanese urban cohort: the Suita Study. Hypertens Res, 2010; 33: 1238-1243","DOI":"10.1038\/hr.2010.174"},{"key":"187","doi-asserted-by":"crossref","unstructured":"187) Hu H, Mizoue T, Sasaki N, Ogasawara T, Tomita K, Nagahama S, Hori A, Nishihara A, Imai T, Yamamoto M, Eguchi M, Kochi T, Miyamoto T, Honda T, Nakagawa T, Yamamoto S, Okazaki H, Uehara A, Shimizu M, Murakami T, Kuwahara K, Nanri A, Konishi M, Kabe I, Dohi S: Prediabetes and cardiovascular disease risk: A nested case-control study. Atherosclerosis, 2018; 278: 1-6","DOI":"10.1016\/j.atherosclerosis.2018.09.004"},{"key":"188","doi-asserted-by":"crossref","unstructured":"188) Hirokawa W, Nakamura K, Sakurai M, Morikawa Y, Miura K, Ishizaki M, Yoshita K, Kido T, Naruse Y, Nakagawa H: Mild metabolic abnormalities, abdominal obesity and the risk of cardiovascular diseases in middle-aged Japanese men. J Atheroscler Thromb, 2010; 17: 934-943","DOI":"10.5551\/jat.4549"},{"key":"189","doi-asserted-by":"crossref","unstructured":"189) Nakanishi N, Takatorige T, Fukuda H, Shirai K, Li W, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K: Components of the metabolic syndrome as predictors of cardiovascular disease and type 2 diabetes in middle-aged Japanese men. Diabetes Res Clin Pract, 2004; 64: 59-70","DOI":"10.1016\/j.diabres.2003.10.001"},{"key":"190","doi-asserted-by":"crossref","unstructured":"190) Ikeda F, Doi Y, Ninomiya T, Hirakawa Y, Mukai N, Hata J, Shikata K, Yoshida D, Matsumoto T, Kitazono T, Kiyohara Y: Haemoglobin A1c even within non-diabetic level is a predictor of cardiovascular disease in a general Japanese population: the Hisayama Study. Cardiovasc Diabetol, 2013; 12: 164","DOI":"10.1186\/1475-2840-12-164"},{"key":"191","doi-asserted-by":"crossref","unstructured":"191) Goto A, Noda M, Matsushita Y, Goto M, Kato M, Isogawa A, Takahashi Y, Kurotani K, Oba S, Nanri A, Mizoue T, Yamagishi K, Yatsuya H, Saito I, Kokubo Y, Sawada N, Inoue M, Iso H, Kadowaki T, Tsugane S: Hemoglobin a1c levels and the risk of cardiovascular disease in people without known diabetes: a population-based cohort study in Japan. Medicine (Baltimore), 2015; 94: e785","DOI":"10.1097\/MD.0000000000000785"},{"key":"192","doi-asserted-by":"crossref","unstructured":"192) Nishimura R, Nakagami T, Sone H, Ohashi Y, Tajima N: Relationship between hemoglobin A1c and cardiovascular disease in mild-to-moderate hypercholesterolemic Japanese individuals: subanalysis of a large-scale randomized controlled trial. Cardiovasc Diabetol, 2011; 10: 58","DOI":"10.1186\/1475-2840-10-58"},{"key":"193","doi-asserted-by":"crossref","unstructured":"193) Watanabe M, Kokubo Y, Higashiyama A, Ono Y, Okayama A, Okamura T: New diagnosis criteria for diabetes with hemoglobin A1c and risks of macro-vascular complications in an urban Japanese cohort: the Suita study. Diabetes Res Clin Pract, 2010; 88: e20-23","DOI":"10.1016\/j.diabres.2010.01.019"},{"key":"194","doi-asserted-by":"crossref","unstructured":"194) Satoh H, Nishino T, Tomita K, Saijo Y, Kishi R, Tsutsui H: Risk factors and the incidence of coronary artery disease in young middle-aged Japanese men: results from a 10-year cohort study. Intern Med, 2006; 45: 235-239","DOI":"10.2169\/internalmedicine.45.1532"},{"key":"195","doi-asserted-by":"crossref","unstructured":"195) Doi Y, Ninomiya T, Hata J, Fukuhara M, Yonemoto K, Iwase M, Iida M, Kiyohara Y: Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population: the Hisayama study. Stroke, 2010; 41: 203-209","DOI":"10.1161\/STROKEAHA.109.564708"},{"key":"196","doi-asserted-by":"crossref","unstructured":"196) Kannel WB, McGee DL: Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care, 1979; 2: 120-126","DOI":"10.2337\/diacare.2.2.120"},{"key":"197","doi-asserted-by":"crossref","unstructured":"197) Vaccaro O, Stamler J, Neaton JD: Sixteen-year coronary mortality in black and white men with diabetes screened for the Multiple Risk Factor Intervention Trial (MRFIT). Int J Epidemiol, 1998; 27: 636-641","DOI":"10.1093\/ije\/27.4.636"},{"key":"198","doi-asserted-by":"crossref","unstructured":"198) Fujishima M, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, Ohmori S, Yoshitake T: Diabetes and cardiovascular disease in a prospective population survey in Japan: The Hisayama Study. Diabetes, 1996; 45 Suppl 3: S14-16","DOI":"10.2337\/diab.45.3.S14"},{"key":"199","doi-asserted-by":"crossref","unstructured":"199) Iso H, Imano H, Kitamura A, Sato S, Naito Y, Tanigawa T, Ohira T, Yamagishi K, Iida M, Shimamoto T: Type 2 diabetes and risk of non-embolic ischaemic stroke in Japanese men and women. Diabetologia, 2004; 47: 2137-2144","DOI":"10.1007\/s00125-004-1587-0"},{"key":"200","doi-asserted-by":"crossref","unstructured":"200) Haffner SM, Lehto S, R\u00f6nnemaa T, Py\u00f6r\u00e4l\u00e4 K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998; 339: 229-234","DOI":"10.1056\/NEJM199807233390404"},{"key":"201","doi-asserted-by":"crossref","unstructured":"201) Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG: Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg, 2007; 45 Suppl S: S5-67","DOI":"10.1016\/j.jvs.2006.12.037"},{"key":"202","doi-asserted-by":"crossref","unstructured":"202) Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH: Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med, 2004; 141: 421-431","DOI":"10.7326\/0003-4819-141-6-200409210-00007"},{"key":"203","doi-asserted-by":"crossref","unstructured":"203) Nesto RW, Phillips RT, Kett KG, Hill T, Perper E, Young E, Leland OS, Jr.: Angina and exertional myocardial ischemia in diabetic and nondiabetic patients: assessment by exercise thallium scintigraphy. Ann Intern Med, 1988; 108: 170-175","DOI":"10.7326\/0003-4819-108-2-170"},{"key":"204","doi-asserted-by":"crossref","unstructured":"204) Goraya TY, Leibson CL, Palumbo PJ, Weston SA, Killian JM, Pfeifer EA, Jacobsen SJ, Frye RL, Roger VL: Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol, 2002; 40: 946-953","DOI":"10.1016\/S0735-1097(02)02065-X"},{"key":"205","doi-asserted-by":"crossref","unstructured":"205) Kataoka Y, Yasuda S, Morii I, Otsuka Y, Kawamura A, Miyazaki S: Quantitative coronary angiographic studies of patients with angina pectoris and impaired glucose tolerance. Diabetes Care, 2005; 28: 2217-2222","DOI":"10.2337\/diacare.28.9.2217"},{"key":"206","doi-asserted-by":"crossref","unstructured":"206) Hoff JA, Quinn L, Sevrukov A, Lipton RB, Daviglus M, Garside DB, Ajmere NK, Gandhi S, Kondos GT: The prevalence of coronary artery calcium among diabetic individuals without known coronary artery disease. J Am Coll Cardiol, 2003; 41: 1008-1012","DOI":"10.1016\/S0735-1097(02)02975-3"},{"key":"207","doi-asserted-by":"crossref","unstructured":"207) Cui R, Iso H, Yamagishi K, Saito I, Kokubo Y, Inoue M, Tsugane S: Diabetes mellitus and risk of stroke and its subtypes among Japanese: the Japan public health center study. Stroke, 2011; 42: 2611-2614","DOI":"10.1161\/STROKEAHA.111.614313"},{"key":"208","doi-asserted-by":"crossref","unstructured":"208) Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM: Diabetes and mortality following acute coronary syndromes. JAMA, 2007; 298: 765-775","DOI":"10.1001\/jama.298.7.765"},{"key":"209","doi-asserted-by":"crossref","unstructured":"209) Takara A, Ogawa H, Endoh Y, Mori F, Yamaguchi J, Takagi A, Koyanagi R, Shiga T, Kasanuki H, Hagiwara N: Long-term prognosis of diabetic patients with acute myocardial infarction in the era of acute revascularization. Cardiovasc Diabetol, 2010; 9: 1","DOI":"10.1186\/1475-2840-9-1"},{"key":"210","doi-asserted-by":"crossref","unstructured":"210) Kuramitsu S, Yokoi H, Domei T, Nomura A, Watanabe H, Yamaji K, Soga Y, Arita T, Kondo K, Shirai S, Ando K, Sakai K, Iwabuchi M, Nosaka H, Nobuyoshi M: Impact of post-challenge hyperglycemia on clinical outcomes in Japanese patients with stable angina undergoing percutaneous coronary intervention. Cardiovasc Diabetol, 2013; 12: 74","DOI":"10.1186\/1475-2840-12-74"},{"key":"211","doi-asserted-by":"crossref","unstructured":"211) Hillen T, Coshall C, Tilling K, Rudd AG, McGovern R, Wolfe CD: Cause of stroke recurrence is multifactorial: patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register. Stroke, 2003; 34: 1457-1463","DOI":"10.1161\/01.STR.0000072985.24967.7F"},{"key":"212","doi-asserted-by":"crossref","unstructured":"212) Shinohara Y, Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Itoh E, Matsuda T, Sawada T, Yamaguchi T, Nishimaru K, Ohashi Y: Antiplatelet cilostazol is beneficial in diabetic and\/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. Cerebrovasc Dis, 2008; 26: 63-70","DOI":"10.1159\/000135654"},{"key":"213","doi-asserted-by":"crossref","unstructured":"213) Paquette M, Bernard S, Ruel I, Blank DW, Genest J, Baass A: Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia. J Clin Lipidol, 2019; 13: 123-128","DOI":"10.1016\/j.jacl.2018.09.008"},{"key":"214","doi-asserted-by":"crossref","unstructured":"214) Sun D, Cao YX, You XD, Zhou BY, Li S, Guo YL, Zhang Y, Wu NQ, Zhu CG, Gao Y, Dong QT, Liu G, Dong Q, Li JJ: Clinical and genetic characteristics of familial hypercholesterolemia patients with type 2 diabetes. J Endocrinol Invest, 2019; 42: 591-598","DOI":"10.1007\/s40618-018-0959-0"},{"key":"215","doi-asserted-by":"crossref","unstructured":"215) Yanagi K, Yamashita S, Kihara S, Nakamura T, Nozaki S, Nagai Y, Funahashi T, Kameda-Takemura K, Ueyama Y, Jiao S, Kubo M, Tokunaga K, Matsuzawa Y: Characteristics of coronary artery disease and lipoprotein abnormalities in patients with heterozygous familial hypercholesterolemia associated with diabetes mellitus or impaired glucose tolerance. Atherosclerosis, 1997; 132: 43-51","DOI":"10.1016\/S0021-9150(97)00076-2"},{"key":"216","doi-asserted-by":"crossref","unstructured":"216) Uchiyama S, Goto S, Matsumoto M, Nagai R, Origasa H, Yamazaki T, Shigematsu H, Shimada K, Yamada N, Bhatt DL, Steg PG, Ikeda Y: Cardiovascular event rates in patients with cerebrovascular disease and atherothrombosis at other vascular locations: results from 1-year outcomes in the Japanese REACH Registry. J Neurol Sci, 2009; 287: 45-51","DOI":"10.1016\/j.jns.2009.09.011"},{"key":"217","doi-asserted-by":"crossref","unstructured":"217) Goto S, Ikeda Y, Shimada K, Uchiyama S, Origasa H, Kobayashi H: One-year cardiovascular event rates in Japanese outpatients with myocardial infarction, stroke, and atrial fibrillation. -Results From the Japan Thrombosis Registry for Atrial Fibrillation, Coronary, or Cerebrovascular Events (J-TRACE). Circ J, 2011; 75: 2598-2604","DOI":"10.1253\/circj.CJ-11-0378"},{"key":"218","doi-asserted-by":"crossref","unstructured":"218) Birkeland KI, Bodegard J, Eriksson JW, Norhammar A, Haller H, Linssen GCM, Banerjee A, Thuresson M, Okami S, Garal-Pantaler E, Overbeek J, Mamza JB, Zhang R, Yajima T, Komuro I, Kadowaki T: Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. Diabetes Obes Metab, 2020; 22: 1607-1618","DOI":"10.1111\/dom.14074"},{"key":"219","doi-asserted-by":"crossref","unstructured":"219) Krempf M, Parhofer KG, Steg PG, Bhatt DL, Ohman EM, R\u00f6ther J, Goto S, Pasquet B, Wilson PW: Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am J Cardiol, 2010; 105: 667-671","DOI":"10.1016\/j.amjcard.2009.10.048"},{"key":"220","doi-asserted-by":"crossref","unstructured":"220) Bund\u00f3 M, Mu\u00f1oz L, P\u00e9rez C, Montero JJ, Montell\u00e0 N, Tor\u00e1n P, Pera G: Asymptomatic peripheral arterial disease in type 2 diabetes patients: a 10-year follow-up study of the utility of the ankle brachial index as a prognostic marker of cardiovascular disease. Ann Vasc Surg, 2010; 24: 985-993","DOI":"10.1016\/j.avsg.2010.06.001"},{"key":"221","doi-asserted-by":"crossref","unstructured":"221) Chang LH, Lin HD, Kwok CF, Won JG, Chen HS, Chu CH, Hwu CM, Kuo CS, Jap TS, Shih KC, Lin LY: The combination of the ankle brachial index and brachial ankle pulse wave velocity exhibits a superior association with outcomes in diabetic patients. Intern Med, 2014; 53: 2425-2431","DOI":"10.2169\/internalmedicine.53.2999"},{"key":"222","doi-asserted-by":"crossref","unstructured":"222) Hosaka A, Miyata T, Onishi Y, Liao L, Zhang Q: Clinical and economic burden in patients with diagnosis of peripheral arterial disease in a claims database in Japan. Clin Ther, 2014; 36: 1223-1230, 1230.e1221-1224","DOI":"10.1016\/j.clinthera.2014.06.013"},{"key":"223","doi-asserted-by":"crossref","unstructured":"223) Leibson CL, Ransom JE, Olson W, Zimmerman BR, O\u2019Fallon W M, Palumbo PJ: Peripheral arterial disease, diabetes, and mortality. Diabetes Care, 2004; 27: 2843-2849","DOI":"10.2337\/diacare.27.12.2843"},{"key":"224","doi-asserted-by":"crossref","unstructured":"224) Mohammedi K, Woodward M, Hirakawa Y, Zoungas S, Colagiuri S, Hamet P, Harrap S, Poulter N, Matthews DR, Marre M, Chalmers J: Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study. Cardiovasc Diabetol, 2016; 15: 129","DOI":"10.1186\/s12933-016-0446-x"},{"key":"225","doi-asserted-by":"crossref","unstructured":"225) Norman PE, Davis WA, Bruce DG, Davis TM: Peripheral arterial disease and risk of cardiac death in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care, 2006; 29: 575-580","DOI":"10.2337\/diacare.29.03.06.dc05-1567"},{"key":"226","doi-asserted-by":"crossref","unstructured":"226) Ogren M, Hedblad B, Engstr\u00f6m G, Janzon L: Prevalence and prognostic significance of asymptomatic peripheral arterial disease in 68-year-old men with diabetes. Results from the population study \u2018Men born in 1914\u2019 from Malm\u00f6, Sweden. Eur J Vasc Endovasc Surg, 2005; 29: 182-189","DOI":"10.1016\/j.ejvs.2004.11.013"},{"key":"227","doi-asserted-by":"crossref","unstructured":"227) Saely CH, Schindewolf M, Zanolin D, Heinzle CF, Vonbank A, Silbernagel G, Leiherer A, Drexel H, Baumgartner I: Single and combined effects of peripheral artery disease and of type 2 diabetes mellitus on the risk of cardiovascular events: A prospective cohort study. Atherosclerosis, 2018; 279: 32-37","DOI":"10.1016\/j.atherosclerosis.2018.09.031"},{"key":"228","doi-asserted-by":"crossref","unstructured":"228) Cheung N, Wang JJ, Klein R, Couper DJ, Sharrett AR, Wong TY: Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Diabetes Care, 2007; 30: 1742-1746","DOI":"10.2337\/dc07-0264"},{"key":"229","doi-asserted-by":"crossref","unstructured":"229) Cusick M, Meleth AD, Agr\u00f3n E, Fisher MR, Reed GF, Knatterud GL, Barton FB, Davis MD, Ferris FL, 3rd, Chew EY: Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27. Diabetes Care, 2005; 28: 617-625","DOI":"10.2337\/diacare.28.3.617"},{"key":"230","doi-asserted-by":"crossref","unstructured":"230) Gerstein HC, Ambrosius WT, Danis R, Ismail-Beigi F, Cushman W, Calles J, Banerji M, Schubart U, Chew EY: Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care, 2013; 36: 1266-1271","DOI":"10.2337\/dc12-1311"},{"key":"231","doi-asserted-by":"crossref","unstructured":"231) Juutilainen A, Lehto S, R\u00f6nnemaa T, Py\u00f6r\u00e4l\u00e4 K, Laakso M: Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women. Diabetes Care, 2007; 30: 292-299","DOI":"10.2337\/dc06-1747"},{"key":"232","doi-asserted-by":"crossref","unstructured":"232) Kawasaki R, Tanaka S, Tanaka S, Abe S, Sone H, Yokote K, Ishibashi S, Katayama S, Ohashi Y, Akanuma Y, Yamada N, Yamashita H: Risk of cardiovascular diseases is increased even with mild diabetic retinopathy: the Japan Diabetes Complications Study. Ophthalmology, 2013; 120: 574-582","DOI":"10.1016\/j.ophtha.2012.08.029"},{"key":"233","doi-asserted-by":"crossref","unstructured":"233) Kawasaki S, Misawa H, Tamura Y, Kondo Y, Satoh S, Hasegawa O, Kato S, Terauchi Y: Relationship between coronary artery disease and retinopathy in patients with type 2 diabetes mellitus. Intern Med, 2013; 52: 2483-2487","DOI":"10.2169\/internalmedicine.52.9444"},{"key":"234","doi-asserted-by":"crossref","unstructured":"234) Miettinen H, Haffner SM, Lehto S, R\u00f6nnemaa T, Py\u00f6r\u00e4l\u00e0 K, Laakso M: Retinopathy predicts coronary heart disease events in NIDDM patients. Diabetes Care, 1996; 19: 1445-1448","DOI":"10.2337\/diacare.19.12.1445"},{"key":"235","doi-asserted-by":"crossref","unstructured":"235) Ono T, Kobayashi J, Sasako Y, Bando K, Tagusari O, Niwaya K, Imanaka H, Nakatani T, Kitamura S: The impact of diabetic retinopathy on long-term outcome following coronary artery bypass graft surgery. J Am Coll Cardiol, 2002; 40: 428-436","DOI":"10.1016\/S0735-1097(02)01983-6"},{"key":"236","doi-asserted-by":"crossref","unstructured":"236) Rajala U, Pajunp\u00e4\u00e4 H, Koskela P, Kein\u00e4nen-Kiukaanniemi S: High cardiovascular disease mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care, 2000; 23: 957-961","DOI":"10.2337\/diacare.23.7.957"},{"key":"237","doi-asserted-by":"crossref","unstructured":"237) Seferovic JP, Bentley-Lewis R, Claggett B, Diaz R, Gerstein HC, K\u00f8ber LV, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Pfeffer MA: Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration. J Diabetes Res, 2018; 2018: 1631263","DOI":"10.1155\/2018\/1631263"},{"key":"238","doi-asserted-by":"crossref","unstructured":"238) Targher G, Bertolini L, Zenari L, Lippi G, Pichiri I, Zoppini G, Muggeo M, Arcaro G: Diabetic retinopathy is associated with an increased incidence of cardiovascular events in Type 2 diabetic patients. Diabet Med, 2008; 25: 45-50","DOI":"10.1111\/j.1464-5491.2007.02327.x"},{"key":"239","doi-asserted-by":"crossref","unstructured":"239) Yamada T, Itoi T, Kiuchi Y, Nemoto M, Yamashita S: Proliferative diabetic retinopathy is a predictor of coronary artery disease in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract, 2012; 96: e4-6","DOI":"10.1016\/j.diabres.2011.12.007"},{"key":"240","doi-asserted-by":"crossref","unstructured":"240) Xie J, Ikram MK, Cotch MF, Klein B, Varma R, Shaw JE, Klein R, Mitchell P, Lamoureux EL, Wong TY: Association of Diabetic Macular Edema and Proliferative Diabetic Retinopathy With Cardiovascular Disease: A Systematic Review and Meta-analysis. JAMA Ophthalmol, 2017; 135: 586-593","DOI":"10.1001\/jamaophthalmol.2017.0988"},{"key":"241","doi-asserted-by":"crossref","unstructured":"241) Pearce I, Sim\u00f3 R, L\u00f6vestam-Adrian M, Wong DT, Evans M: Association between diabetic eye disease and other complications of diabetes: Implications for care. A systematic review. Diabetes Obes Metab, 2019; 21: 467-478","DOI":"10.1111\/dom.13550"},{"key":"242","doi-asserted-by":"crossref","unstructured":"242) Kim JJ, Hwang BH, Choi IJ, Choo EH, Lim S, Koh YS, Lee JM, Kim PJ, Seung KB, Lee SH, Cho JH, Jung JI, Chang K: A prospective two-center study on the associations between microalbuminuria, coronary atherosclerosis and long-term clinical outcome in asymptomatic patients with type 2 diabetes mellitus: evaluation by coronary CT angiography. Int J Cardiovasc Imaging, 2015; 31: 193-203","DOI":"10.1007\/s10554-014-0541-6"},{"key":"243","doi-asserted-by":"crossref","unstructured":"243) Wang Y, Katzmarzyk PT, Horswell R, Zhao W, Johnson J, Hu G: Kidney function and the risk of cardiovascular disease in patients with type 2 diabetes. Kidney Int, 2014; 85: 1192-1199","DOI":"10.1038\/ki.2013.396"},{"key":"244","doi-asserted-by":"crossref","unstructured":"244) Hsieh MC, Hsiao JY, Tien KJ, Chang SJ, Hsu SC, Liang HT, Chen HC, Lin SR, Tu ST: Chronic kidney disease as a risk factor for coronary artery disease in Chinese with type 2 diabetes. Am J Nephrol, 2008; 28: 317-323","DOI":"10.1159\/000111388"},{"key":"245","doi-asserted-by":"crossref","unstructured":"245) Tanaka K, Hara S, Kushiyama A, Ubara Y, Yoshida Y, Mizuiri S, Aikawa A, Kawatzu S: Risk of macrovascular disease stratified by stage of chronic kidney disease in type 2 diabetic patients: critical level of the estimated glomerular filtration rate and the significance of hyperuricemia. Clin Exp Nephrol, 2011; 15: 391-397","DOI":"10.1007\/s10157-011-0420-6"},{"key":"246","doi-asserted-by":"crossref","unstructured":"246) Bo S, Ciccone G, Rosato R, Gancia R, Grassi G, Merletti F, Pagano GF: Renal damage in patients with Type 2 diabetes: a strong predictor of mortality. Diabet Med, 2005; 22: 258-265","DOI":"10.1111\/j.1464-5491.2004.01394.x"},{"key":"247","doi-asserted-by":"crossref","unstructured":"247) Asakawa H, Tokunaga K, Kawakami F: Comparison of risk factors of macrovascular complications. Peripheral vascular disease, cerebral vascular disease, and coronary heart disease in Japanese type 2 diabetes mellitus patients. J Diabetes Complications, 2000; 14: 307-313","DOI":"10.1016\/S1056-8727(00)00092-1"},{"key":"248","doi-asserted-by":"crossref","unstructured":"248) Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int, 2003; 63: 225-232","DOI":"10.1046\/j.1523-1755.2003.00712.x"},{"key":"249","doi-asserted-by":"crossref","unstructured":"249) Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, de Boer IH: Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol, 2013; 24: 302-308","DOI":"10.1681\/ASN.2012070718"},{"key":"250","doi-asserted-by":"crossref","unstructured":"250) de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation, 2004; 110: 921-927","DOI":"10.1161\/01.CIR.0000139860.33974.28"},{"key":"251","doi-asserted-by":"crossref","unstructured":"251) Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Macmahon S, Chalmers J: Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol, 2009; 20: 1813-1821","DOI":"10.1681\/ASN.2008121270"},{"key":"252","doi-asserted-by":"crossref","unstructured":"252) Ito H, Antoku S, Izutsu T, Kusano E, Matsumoto S, Yamasaki T, Mori T, Togane M: The prognosis of subjects showing a reduced estimated glomerular filtration rate without albuminuria in Japanese patients with type 2 diabetes: a cohort study for diabetic kidney disease. Clin Exp Nephrol, 2020; 24: 1033-1043","DOI":"10.1007\/s10157-020-01935-3"},{"key":"253","doi-asserted-by":"crossref","unstructured":"253) Pop-Busui R, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ, Genuth S, Grimm RH, Corson MA, Prineas R: Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care, 2010; 33: 1578-1584","DOI":"10.2337\/dc10-0125"},{"key":"254","doi-asserted-by":"crossref","unstructured":"254) Yun JS, Park YM, Cha SA, Ahn YB, Ko SH: Progression of cardiovascular autonomic neuropathy and cardiovascular disease in type 2 diabetes. Cardiovasc Diabetol, 2018; 17: 109","DOI":"10.1186\/s12933-018-0752-6"},{"key":"255","doi-asserted-by":"crossref","unstructured":"255) Lee KH, Jang HJ, Kim YH, Lee EJ, Choe YS, Choi Y, Lee MG, Lee SH, Kim BT: Prognostic value of cardiac autonomic neuropathy independent and incremental to perfusion defects in patients with diabetes and suspected coronary artery disease. Am J Cardiol, 2003; 92: 1458-1461","DOI":"10.1016\/j.amjcard.2003.08.060"},{"key":"256","doi-asserted-by":"crossref","unstructured":"256) Baltzis D, Roustit M, Grammatikopoulou MG, Katsaboukas D, Athanasiou V, Iakovou I, Veves A, Manes C, Trakatelli MC: Diabetic Peripheral Neuropathy as a Predictor of Asymptomatic Myocardial Ischemia in Type 2 Diabetes Mellitus: A Cross-Sectional Study. Adv Ther, 2016; 33: 1840-1847","DOI":"10.1007\/s12325-016-0399-1"},{"key":"257","doi-asserted-by":"crossref","unstructured":"257) Brownrigg JR, de Lusignan S, McGovern A, Hughes C, Thompson MM, Ray KK, Hinchliffe RJ: Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus. Heart, 2014; 100: 1837-1843","DOI":"10.1136\/heartjnl-2014-305657"},{"key":"258","doi-asserted-by":"crossref","unstructured":"258) Brownrigg JR, Davey J, Holt PJ, Davis WA, Thompson MM, Ray KK, Hinchliffe RJ: The association of ulceration of the foot with cardiovascular and all-cause mortality in patients with diabetes: a meta-analysis. Diabetologia, 2012; 55: 2906-2912","DOI":"10.1007\/s00125-012-2673-3"},{"key":"259","doi-asserted-by":"crossref","unstructured":"259) Pinto A, Tuttolomondo A, Di Raimondo D, Fernandez P, La Placa S, Di Gati M, Licata G: Cardiovascular risk profile and morbidity in subjects affected by type 2 diabetes mellitus with and without diabetic foot. Metabolism, 2008; 57: 676-682","DOI":"10.1016\/j.metabol.2008.01.004"},{"key":"260","doi-asserted-by":"crossref","unstructured":"260) Seghieri G, Policardo L, Gualdani E, Anichini R, Francesconi P: Gender difference in the risk for cardiovascular events or mortality of patients with diabetic foot syndrome. Acta Diabetol, 2019; 56: 561-567","DOI":"10.1007\/s00592-019-01292-y"},{"key":"261","doi-asserted-by":"crossref","unstructured":"261) Hamada S, Gulliford MC: Multiple risk factor control, mortality and cardiovascular events in type 2 diabetes and chronic kidney disease: a population-based cohort study. BMJ Open, 2018; 8: e019950","DOI":"10.1136\/bmjopen-2017-019950"},{"key":"262","doi-asserted-by":"crossref","unstructured":"262) Blomster JI, Woodward M, Zoungas S, Hillis GS, Harrap S, Neal B, Poulter N, Mancia G, Chalmers J, Huxley R: The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial. BMJ Open, 2016; 6: e009668","DOI":"10.1136\/bmjopen-2015-009668"},{"key":"263","doi-asserted-by":"crossref","unstructured":"263) Stevens RJ, Kothari V, Adler AI, Stratton IM: The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond), 2001; 101: 671-679","DOI":"10.1042\/cs1010671"},{"key":"264","doi-asserted-by":"crossref","unstructured":"264) Rosengren A, Welin L, Tsipogianni A, Wilhelmsen L: Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study. BMJ, 1989; 299: 1127-1131","DOI":"10.1136\/bmj.299.6708.1127"},{"key":"265","doi-asserted-by":"crossref","unstructured":"265) Hadaegh F, Derakhshan A, Mozaffary A, Hasheminia M, Khalili D, Azizi F: Twelve-Year Cardiovascular and Mortality Risk in Relation to Smoking Habits in Type 2 Diabetic and Non-Diabetic Men: Tehran Lipid and Glucose Study. PLoS One, 2016; 11: e0149780","DOI":"10.1371\/journal.pone.0149780"},{"key":"266","doi-asserted-by":"crossref","unstructured":"266) Pan A, Wang Y, Talaei M, Hu FB: Relation of Smoking With Total Mortality and Cardiovascular Events Among Patients With Diabetes Mellitus: A Meta-Analysis and Systematic Review. Circulation, 2015; 132: 1795-1804","DOI":"10.1161\/CIRCULATIONAHA.115.017926"},{"key":"267","doi-asserted-by":"crossref","unstructured":"267) Rawshani A, Rawshani A, Franz\u00e9n S, Sattar N, Eliasson B, Svensson AM, Zethelius B, Miftaraj M, McGuire DK, Rosengren A, Gudbj\u00f6rnsdottir S: Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med, 2018; 379: 633-644","DOI":"10.1056\/NEJMoa1800256"},{"key":"268","doi-asserted-by":"crossref","unstructured":"268) Sone H, Tanaka S, Tanaka S, Iimuro S, Oida K, Yamasaki Y, Oikawa S, Ishibashi S, Katayama S, Ohashi Y, Akanuma Y, Yamada N: Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab, 2011; 96: 3448-3456","DOI":"10.1210\/jc.2011-0622"},{"key":"269","doi-asserted-by":"crossref","unstructured":"269) Roussel R, Steg PG, Mohammedi K, Marre M, Potier L: Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose-lowering interventions. Diabetes Obes Metab, 2018; 20: 238-244","DOI":"10.1111\/dom.13033"},{"key":"270","doi-asserted-by":"crossref","unstructured":"270) Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 2000; 321: 405-412","DOI":"10.1136\/bmj.321.7258.405"},{"key":"271","doi-asserted-by":"crossref","unstructured":"271) Harada M, Fujihara K, Osawa T, Yamamoto M, Kaneko M, Ishizawa M, Matsubayashi Y, Yamada T, Yamanaka N, Seida H, Kodama S, Ogawa W, Sone H: Association of treatment-achieved HbA(1c) with incidence of coronary artery disease and severe eye disease in diabetes patients. Diabetes Metab, 2020; 46: 331-334","DOI":"10.1016\/j.diabet.2018.08.009"},{"key":"272","unstructured":"272) Subcommittee for Renal Health Examination, Committee on Renal Disease Control, Japanese Society of Nephrology: Health guidance for the examinees of kidney medical checkup and suggestions to the referral criteria to medical institutions, Jpn J Nephrol 2017;59:38-42 (in Japanese)"},{"key":"273","doi-asserted-by":"crossref","unstructured":"273) Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension, 2003; 42: 1050-1065","DOI":"10.1161\/01.HYP.0000102971.85504.7c"},{"key":"274","doi-asserted-by":"crossref","unstructured":"274) Shoji T, Abe T, Matsuo H, Egusa G, Yamasaki Y, Kashihara N, Shirai K, Kashiwagi A: Chronic kidney disease, dyslipidemia, and atherosclerosis. J Atheroscler Thromb, 2012; 19: 299-315","DOI":"10.5551\/jat.10454"},{"key":"275","doi-asserted-by":"crossref","unstructured":"275) Kokubo Y, Nakamura S, Okamura T, Yoshimasa Y, Makino H, Watanabe M, Higashiyama A, Kamide K, Kawanishi K, Okayama A, Kawano Y: Relationship between blood pressure category and incidence of stroke and myocardial infarction in an urban Japanese population with and without chronic kidney disease: the Suita Study. Stroke, 2009; 40: 2674-2679","DOI":"10.1161\/STROKEAHA.109.550707"},{"key":"276","doi-asserted-by":"crossref","unstructured":"276) Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, Wakugawa Y, Hata J, Oishi Y, Shikata K, Yonemoto K, Hirakata H, Iida M: Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int, 2005; 68: 228-236","DOI":"10.1111\/j.1523-1755.2005.00397.x"},{"key":"277","doi-asserted-by":"crossref","unstructured":"277) Ninomiya T, Kiyohara Y, Tokuda Y, Doi Y, Arima H, Harada A, Ohashi Y, Ueshima H: Impact of kidney disease and blood pressure on the development of cardiovascular disease: an overview from the Japan Arteriosclerosis Longitudinal Study. Circulation, 2008; 118: 2694-2701","DOI":"10.1161\/CIRCULATIONAHA.108.792903"},{"key":"278","doi-asserted-by":"crossref","unstructured":"278) Yasuno S, Ueshima K, Oba K, Fujimoto A, Ogihara T, Saruta T, Nakao K: Clinical significance of left ventricular hypertrophy and changes in left ventricular mass in high-risk hypertensive patients: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan trial. J Hypertens, 2009; 27: 1705-1712","DOI":"10.1097\/HJH.0b013e32832c6968"},{"key":"279","doi-asserted-by":"crossref","unstructured":"279) Wanner C, Amann K, Shoji T: The heart and vascular system in dialysis. Lancet, 2016; 388: 276-284","DOI":"10.1016\/S0140-6736(16)30508-6"},{"key":"280","doi-asserted-by":"crossref","unstructured":"280) Tonelli M, Muntner P, Lloyd A, Manns B, Klarenbach S, Pannu N, James M, Hemmelgarn B: Association between LDL-C and risk of myocardial infarction in CKD. J Am Soc Nephrol, 2013; 24: 979-986","DOI":"10.1681\/ASN.2012080870"},{"key":"281","doi-asserted-by":"crossref","unstructured":"281) Wanner C, Krane V, M\u00e4rz W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med, 2005; 353: 238-248","DOI":"10.1056\/NEJMoa043545"},{"key":"282","doi-asserted-by":"crossref","unstructured":"282) Fellstr\u00f6m BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gr\u00f6nhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, S\u00fcleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, W\u00fcthrich RP, Gottlow M, Johnsson E, Zannad F: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med, 2009; 360: 1395-1407","DOI":"10.1056\/NEJMoa0810177"},{"key":"283","doi-asserted-by":"crossref","unstructured":"283) Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, Ura N, Kiyohara Y, Moriyama T, Ando Y, Fujimoto S, Konta T, Yokoyama H, Makino H, Hishida A, Matsuo S: Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol, 2009; 13: 621-630","DOI":"10.1007\/s10157-009-0199-x"},{"key":"284","doi-asserted-by":"crossref","unstructured":"284) The Japanese Counsil on Cerebro-Cardiovascular Disease: Comprehensive risk management chart for cerebro-cardiovascular disease 2019. Nihon Naika Gakkai Zasshi, 2019; 108: 1024-1074 (in Japanese)","DOI":"10.2169\/naika.108.1024"},{"key":"285","doi-asserted-by":"crossref","unstructured":"285) Wilson PW, D\u2019Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation, 1998; 97: 1837-1847","DOI":"10.1161\/01.CIR.97.18.1837"},{"key":"286","doi-asserted-by":"crossref","unstructured":"286) Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population. Circ J, 2006; 70: 1249-1255","DOI":"10.1253\/circj.70.1249"},{"key":"287","doi-asserted-by":"crossref","unstructured":"287) Nakai M, Watanabe M, Kokubo Y, Nishimura K, Higashiyama A, Takegami M, Nakao YM, Okamura T, Miyamoto Y: Development of a Cardiovascular Disease Risk Prediction Model Using the Suita Study, a Population-Based Prospective Cohort Study in Japan. J Atheroscler Thromb, 2020; 27: 1160-1175","DOI":"10.5551\/jat.48843"},{"key":"288","doi-asserted-by":"crossref","unstructured":"288) Rumana N, Kita Y, Turin TC, Murakami Y, Sugihara H, Morita Y, Tomioka N, Okayama A, Nakamura Y, Abbott RD, Ueshima H: Trend of increase in the incidence of acute myocardial infarction in a Japanese population: Takashima AMI Registry, 1990-2001. Am J Epidemiol, 2008; 167: 1358-1364","DOI":"10.1093\/aje\/kwn064"},{"key":"289","unstructured":"289) Ministry of Health LaW: Vital Statistics in Japan, 2020"},{"key":"290","doi-asserted-by":"crossref","unstructured":"290) Silberberg JS, Wlodarczyk J, Fryer J, Robertson R, Hensley MJ: Risk associated with various definitions of family history of coronary heart disease. The Newcastle Family History Study II. Am J Epidemiol, 1998; 147: 1133-1139","DOI":"10.1093\/oxfordjournals.aje.a009411"},{"key":"291","doi-asserted-by":"crossref","unstructured":"291) Li R, Bensen JT, Hutchinson RG, Province MA, Hertz-Picciotto I, Sprafka JM, Tyroler HA: Family risk score of coronary heart disease (CHD) as a predictor of CHD: the Atherosclerosis Risk in Communities (ARIC) study and the NHLBI family heart study. Genet Epidemiol, 2000; 18: 236-250","DOI":"10.1002\/(SICI)1098-2272(200003)18:3<236::AID-GEPI4>3.0.CO;2-0"},{"key":"292","doi-asserted-by":"crossref","unstructured":"292) Williams RR, Hunt SC, Heiss G, Province MA, Bensen JT, Higgins M, Chamberlain RM, Ware J, Hopkins PN: Usefulness of cardiovascular family history data for population-based preventive medicine and medical research (the Health Family Tree Study and the NHLBI Family Heart Study). Am J Cardiol, 2001; 87: 129-135","DOI":"10.1016\/S0002-9149(00)01303-5"},{"key":"293","doi-asserted-by":"crossref","unstructured":"293) Lloyd-Jones DM, Nam BH, D\u2019Agostino RB, Sr., Levy D, Murabito JM, Wang TJ, Wilson PW, O\u2019Donnell CJ: Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA, 2004; 291: 2204-2211","DOI":"10.1001\/jama.291.18.2204"},{"key":"294","doi-asserted-by":"crossref","unstructured":"294) Myers RH, Kiely DK, Cupples LA, Kannel WB: Parental history is an independent risk factor for coronary artery disease: the Framingham Study. Am Heart J, 1990; 120: 963-969","DOI":"10.1016\/0002-8703(90)90216-K"},{"key":"295","doi-asserted-by":"crossref","unstructured":"295) Watkins H, Farrall M: Genetic susceptibility to coronary artery disease: from promise to progress. Nat Rev Genet, 2006; 7: 163-173","DOI":"10.1038\/nrg1805"},{"key":"296","doi-asserted-by":"crossref","unstructured":"296) Nasir K, Budoff MJ, Wong ND, Scheuner M, Herrington D, Arnett DK, Szklo M, Greenland P, Blumenthal RS: Family history of premature coronary heart disease and coronary artery calcification: Multi-Ethnic Study of Atherosclerosis (MESA). Circulation, 2007; 116: 619-626","DOI":"10.1161\/CIRCULATIONAHA.107.688739"},{"key":"297","doi-asserted-by":"crossref","unstructured":"297) Furukawa Y, Ehara N, Taniguchi R, Haruna Y, Ozasa N, Saito N, Doi T, Hoshino K, Tamura T, Shizuta S, Abe M, Toma M, Morimoto T, Teramukai S, Fukushima M, Kita T, Kimura T: Coronary risk factor profile and prognostic factors for young Japanese patients undergoing coronary revascularization. Circ J, 2009; 73: 1459-1465","DOI":"10.1253\/circj.CJ-08-1083"},{"key":"298","doi-asserted-by":"crossref","unstructured":"298) Wahrenberg A, Kuja-Halkola R, Magnusson PKE, H\u00e4bel H, Warnqvist A, Hambraeus K, Jernberg T, Svensson P: Cardiovascular Family History Increases the Risk of Disease Recurrence After a First Myocardial Infarction. J Am Heart Assoc, 2021; 10: e022264","DOI":"10.1161\/JAHA.121.022264"},{"key":"299","doi-asserted-by":"crossref","unstructured":"299) Timmerman N, de Kleijn DPV, de Borst GJ, den Ruijter HM, Asselbergs FW, Pasterkamp G, Haitjema S, van der Laan SW: Family history and polygenic risk of cardiovascular disease: Independent factors associated with secondary cardiovascular events in patients undergoing carotid endarterectomy. Atherosclerosis, 2020; 307: 121-129","DOI":"10.1016\/j.atherosclerosis.2020.04.013"},{"key":"300","doi-asserted-by":"crossref","unstructured":"300) Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O\u2019Leary D, Carr JJ, Goff DC, Greenland P, Herrington DM: Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA, 2012; 308: 788-795","DOI":"10.1001\/jama.2012.9624"},{"key":"301","doi-asserted-by":"crossref","unstructured":"301) Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, Natarajan P, Lander ES, Lubitz SA, Ellinor PT, Kathiresan S: Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet, 2018; 50: 1219-1224","DOI":"10.1038\/s41588-018-0183-z"},{"key":"302","doi-asserted-by":"crossref","unstructured":"302) Koyama S, Ito K, Terao C, Akiyama M, Horikoshi M, Momozawa Y, Matsunaga H, Ieki H, Ozaki K, Onouchi Y, Takahashi A, Nomura S, Morita H, Akazawa H, Kim C, Seo JS, Higasa K, Iwasaki M, Yamaji T, Sawada N, Tsugane S, Koyama T, Ikezaki H, Takashima N, Tanaka K, Arisawa K, Kuriki K, Naito M, Wakai K, Suna S, Sakata Y, Sato H, Hori M, Sakata Y, Matsuda K, Murakami Y, Aburatani H, Kubo M, Matsuda F, Kamatani Y, Komuro I: Population-specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci for coronary artery disease. Nat Genet, 2020; 52: 1169-1177","DOI":"10.1038\/s41588-020-0705-3"},{"key":"303","doi-asserted-by":"crossref","unstructured":"303) Elliott J, Bodinier B, Bond TA, Chadeau-Hyam M, Evangelou E, Moons KGM, Dehghan A, Muller DC, Elliott P, Tzoulaki I: Predictive Accuracy of a Polygenic Risk Score-Enhanced Prediction Model vs a Clinical Risk Score for Coronary Artery Disease. JAMA, 2020; 323: 636-645","DOI":"10.1001\/jama.2019.22241"},{"key":"304","doi-asserted-by":"crossref","unstructured":"304) Roerecke M, Rehm J: Chronic heavy drinking and ischaemic heart disease: a systematic review and meta-analysis. Open Heart, 2014; 1: e000135","DOI":"10.1136\/openhrt-2014-000135"},{"key":"305","doi-asserted-by":"crossref","unstructured":"305) Patra J, Taylor B, Irving H, Roerecke M, Baliunas D, Mohapatra S, Rehm J: Alcohol consumption and the risk of morbidity and mortality for different stroke types--a systematic review and meta-analysis. BMC Public Health, 2010; 10: 258","DOI":"10.1186\/1471-2458-10-258"},{"key":"306","doi-asserted-by":"crossref","unstructured":"306) Higashiyama A, Wakabayashi I, Ono Y, Watanabe M, Kokubo Y, Okayama A, Miyamoto Y, Okamura T: Association with serum gamma-glutamyltransferase levels and alcohol consumption on stroke and coronary artery disease: the Suita study. Stroke, 2011; 42: 1764-1767","DOI":"10.1161\/STROKEAHA.110.608307"},{"key":"307","doi-asserted-by":"crossref","unstructured":"307) Camargo CA, Jr.: Moderate alcohol consumption and stroke. The epidemiologic evidence. Stroke, 1989; 20: 1611-1626","DOI":"10.1161\/01.STR.20.12.1611"},{"key":"308","doi-asserted-by":"crossref","unstructured":"308) Reynolds K, Lewis B, Nolen JD, Kinney GL, Sathya B, He J: Alcohol consumption and risk of stroke: a meta-analysis. JAMA, 2003; 289: 579-588","DOI":"10.1001\/jama.289.5.579"},{"key":"309","doi-asserted-by":"crossref","unstructured":"309) Ikehara S, Iso H, Toyoshima H, Date C, Yamamoto A, Kikuchi S, Kondo T, Watanabe Y, Koizumi A, Wada Y, Inaba Y, Tamakoshi A: Alcohol consumption and mortality from stroke and coronary heart disease among Japanese men and women: the Japan collaborative cohort study. Stroke, 2008; 39: 2936-2942","DOI":"10.1161\/STROKEAHA.108.520288"},{"key":"310","doi-asserted-by":"crossref","unstructured":"310) Iso H, Baba S, Mannami T, Sasaki S, Okada K, Konishi M, Tsugane S: Alcohol consumption and risk of stroke among middle-aged men: the JPHC Study Cohort I. Stroke, 2004; 35: 1124-1129","DOI":"10.1161\/01.STR.0000124459.33597.00"},{"key":"311","doi-asserted-by":"crossref","unstructured":"311) Kawano Y: Physio-pathological effects of alcohol on the cardiovascular system: its role in hypertension and cardiovascular disease. Hypertens Res, 2010; 33: 181-191","DOI":"10.1038\/hr.2009.226"},{"key":"312","doi-asserted-by":"crossref","unstructured":"312) Higashiyama A, Okamura T, Watanabe M, Kokubo Y, Wakabayashi I, Okayama A, Miyamoto Y: Alcohol consumption and cardiovascular disease incidence in men with and without hypertension: the Suita study. Hypertens Res, 2013; 36: 58-64","DOI":"10.1038\/hr.2012.133"},{"key":"313","doi-asserted-by":"crossref","unstructured":"313) Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA: Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ, 2011; 342: d671","DOI":"10.1136\/bmj.d671"},{"key":"314","doi-asserted-by":"crossref","unstructured":"314) Bell S, Daskalopoulou M, Rapsomaniki E, George J, Britton A, Bobak M, Casas JP, Dale CE, Denaxas S, Shah AD, Hemingway H: Association between clinically recorded alcohol consumption and initial presentation of 12 cardiovascular diseases: population based cohort study using linked health records. BMJ, 2017; 356: j909","DOI":"10.1136\/bmj.j909"},{"key":"315","doi-asserted-by":"crossref","unstructured":"315) GBD2016Alcohol-Collaborators.: Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, 2018; 392: 1015-1035","DOI":"10.1016\/S0140-6736(18)31310-2"},{"key":"316","doi-asserted-by":"crossref","unstructured":"316) Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, Paige E, Paul DS, Sweeting M, Burgess S, Bell S, Astle W, Stevens D, Koulman A, Selmer RM, Verschuren WMM, Sato S, Nj\u00f8lstad I, Woodward M, Salomaa V, Nordestgaard BG, Yeap BB, Fletcher A, Melander O, Kuller LH, Balkau B, Marmot M, Koenig W, Casiglia E, Cooper C, Arndt V, Franco OH, Wennberg P, Gallacher J, de la C\u00e1mara AG, V\u00f6lzke H, Dahm CC, Dale CE, Bergmann MM, Crespo CJ, van der Schouw YT, Kaaks R, Simons LA, Lagiou P, Schoufour JD, Boer JMA, Key TJ, Rodriguez B, Moreno-Iribas C, Davidson KW, Taylor JO, Sacerdote C, Wallace RB, Quiros JR, Tumino R, Blazer DG, 2nd, Linneberg A, Daimon M, Panico S, Howard B, Skeie G, Strandberg T, Weiderpass E, Nietert PJ, Psaty BM, Kromhout D, Salamanca-Fernandez E, Kiechl S, Krumholz HM, Grioni S, Palli D, Huerta JM, Price J, Sundstr\u00f6m J, Arriola L, Arima H, Travis RC, Panagiotakos DB, Karakatsani A, Trichopoulou A, K\u00fchn T, Grobbee DE, Barrett-Connor E, van Schoor N, Boeing H, Overvad K, Kauhanen J, Wareham N, Langenberg C, Forouhi N, Wennberg M, Despr\u00e9s JP, Cushman M, Cooper JA, Rodriguez CJ, Sakurai M, Shaw JE, Knuiman M, Voortman T, Meisinger C, Tj\u00f8nneland A, Brenner H, Palmieri L, Dallongeville J, Brunner EJ, Assmann G, Trevisan M, Gillum RF, Ford I, Sattar N, Lazo M, Thompson SG, Ferrari P, Leon DA, Smith GD, Peto R, Jackson R, Banks E, Di Angelantonio E, Danesh J: Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet, 2018; 391: 1513-1523","DOI":"10.1016\/S0140-6736(18)30134-X"},{"key":"317","doi-asserted-by":"crossref","unstructured":"317) Kitamura A, Iso H, Sankai T, Naito Y, Sato S, Kiyama M, Okamura T, Nakagawa Y, Iida M, Shimamoto T, Komachi Y: Alcohol intake and premature coronary heart disease in urban Japanese men. Am J Epidemiol, 1998; 147: 59-65","DOI":"10.1093\/oxfordjournals.aje.a009367"},{"key":"318","doi-asserted-by":"crossref","unstructured":"318) Saito E, Inoue M, Sawada N, Charvat H, Shimazu T, Yamaji T, Iwasaki M, Sasazuki S, Mizoue T, Iso H, Tsugane S: Impact of Alcohol Intake and Drinking Patterns on Mortality From All Causes and Major Causes of Death in a Japanese Population. J Epidemiol, 2018; 28: 140-148","DOI":"10.2188\/jea.JE20160200"},{"key":"319","doi-asserted-by":"crossref","unstructured":"319) Langer RD, Criqui MH, Reed DM: Lipoproteins and blood pressure as biological pathways for effect of moderate alcohol consumption on coronary heart disease. Circulation, 1992; 85: 910-915","DOI":"10.1161\/01.CIR.85.3.910"},{"key":"320","doi-asserted-by":"crossref","unstructured":"320) Mukamal KJ, Jensen MK, Gr\u00f8nbaek M, Stampfer MJ, Manson JE, Pischon T, Rimm EB: Drinking frequency, mediating biomarkers, and risk of myocardial infarction in women and men. Circulation, 2005; 112: 1406-1413","DOI":"10.1161\/CIRCULATIONAHA.105.537704"},{"key":"321","doi-asserted-by":"crossref","unstructured":"321) Hirata A, Okamura T, Sugiyama D, Kuwabara K, Kadota A, Fujiyoshi A, Miura K, Okuda N, Ohkubo T, Okayama A, Ueshima H: The Relationship between Very High Levels of Serum High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in a 20-Year Follow-Up Study of Japanese General Population. J Atheroscler Thromb, 2016; 23: 800-809","DOI":"10.5551\/jat.33449"},{"key":"322","doi-asserted-by":"crossref","unstructured":"322) Madsen CM, Varbo A, Nordestgaard BG: Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J, 2017; 38: 2478-2486","DOI":"10.1093\/eurheartj\/ehx163"},{"key":"323","doi-asserted-by":"crossref","unstructured":"323) Roerecke M, Rehm J: Irregular heavy drinking occasions and risk of ischemic heart disease: a systematic review and meta-analysis. Am J Epidemiol, 2010; 171: 633-644","DOI":"10.1093\/aje\/kwp451"},{"key":"324","doi-asserted-by":"crossref","unstructured":"324) O\u2019Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, Rao-Melacini P, Zhang X, Pais P, Agapay S, Lopez-Jaramillo P, Damasceno A, Langhorne P, McQueen MJ, Rosengren A, Dehghan M, Hankey GJ, Dans AL, Elsayed A, Avezum A, Mondo C, Diener HC, Ryglewicz D, Czlonkowska A, Pogosova N, Weimar C, Iqbal R, Diaz R, Yusoff K, Yusufali A, Oguz A, Wang X, Penaherrera E, Lanas F, Ogah OS, Ogunniyi A, Iversen HK, Malaga G, Rumboldt Z, Oveisgharan S, Al Hussain F, Magazi D, Nilanont Y, Ferguson J, Pare G, Yusuf S: Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet, 2016; 388: 761-775","DOI":"10.1016\/S0140-6736(16)30506-2"},{"key":"325","doi-asserted-by":"crossref","unstructured":"325) Mostofsky E, Chahal HS, Mukamal KJ, Rimm EB, Mittleman MA: Alcohol and Immediate Risk of Cardiovascular Events: A Systematic Review and Dose-Response Meta-Analysis. Circulation, 2016; 133: 979-987","DOI":"10.1161\/CIRCULATIONAHA.115.019743"},{"key":"326","doi-asserted-by":"crossref","unstructured":"326) Leong DP, Smyth A, Teo KK, McKee M, Rangarajan S, Pais P, Liu L, Anand SS, Yusuf S: Patterns of alcohol consumption and myocardial infarction risk: observations from 52 countries in the INTERHEART case-control study. Circulation, 2014; 130: 390-398","DOI":"10.1161\/CIRCULATIONAHA.113.007627"},{"key":"327","unstructured":"327) National Institute of Alcohol Abuse and Alcoholism: NIAAA council approves definition of binge drinking., 2004;3:3"},{"key":"328","unstructured":"328) Higuchi S: Promotion of Terms and Research, Alcohol and Health Impairment Countermeasures Conference Materials, Ministry of Health, Labour and Welfare, 2015 (in Japanese)"},{"key":"329","doi-asserted-by":"crossref","unstructured":"329) Di Castelnuovo A, Costanzo S, Bagnardi V, Donati MB, Iacoviello L, de Gaetano G: Alcohol dosing and total mortality in men and women: an updated meta-analysis of 34 prospective studies. Arch Intern Med, 2006; 166: 2437-2445","DOI":"10.1001\/archinte.166.22.2437"},{"key":"330","doi-asserted-by":"crossref","unstructured":"330) Tsugane S, Fahey MT, Sasaki S, Baba S: Alcohol consumption and all-cause and cancer mortality among middle-aged Japanese men: seven-year follow-up of the JPHC study Cohort I. Japan Public Health Center. Am J Epidemiol, 1999; 150: 1201-1207","DOI":"10.1093\/oxfordjournals.aje.a009946"},{"key":"331","doi-asserted-by":"crossref","unstructured":"331) Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376: 1670-1681","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"332","doi-asserted-by":"crossref","unstructured":"332) Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C: The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet, 2012; 380: 581-590","DOI":"10.1016\/S0140-6736(12)60367-5"},{"key":"333","doi-asserted-by":"crossref","unstructured":"333) Fulcher J, O\u2019Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A: Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet, 2015; 385: 1397-1405","DOI":"10.1016\/S0140-6736(14)61368-4"},{"key":"334","doi-asserted-by":"crossref","unstructured":"334) Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y: Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J, 2009; 73: 1283-1290","DOI":"10.1253\/circj.CJ-08-1197"},{"key":"335","doi-asserted-by":"crossref","unstructured":"335) Current status of the background of patients with coronary artery disease in Japan. Circ J, 2006; 70: 1256-1262","DOI":"10.1253\/circj.70.1256"},{"key":"336","doi-asserted-by":"crossref","unstructured":"336) Furukawa Y, Taniguchi R, Ehara N, Ozasa N, Haruna Y, Saito N, Doi T, Hoshino K, Shizuta S, Morimoto T, Imai Y, Teramukai S, Fukushima M, Kita T, Kimura T: Better survival with statin administration after revascularization therapy in Japanese patients with coronary artery disease: perspectives from the CREDO-Kyoto registry. Circ J, 2008; 72: 1937-1945","DOI":"10.1253\/circj.CJ-08-0293"},{"key":"337","doi-asserted-by":"crossref","unstructured":"337) Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, Sakaino N, Kitagawa A: Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol, 2006; 97: 1165-1171","DOI":"10.1016\/j.amjcard.2005.11.031"},{"key":"338","doi-asserted-by":"crossref","unstructured":"338) Sato H, Kinjo K, Ito H, Hirayama A, Nanto S, Fukunami M, Nishino M, Lim YJ, Kijima Y, Koretsune Y, Nakatani D, Mizuno H, Shimizu M, Hori M: Effect of early use of low-dose pravastatin on major adverse cardiac events in patients with acute myocardial infarction: the OACIS-LIPID Study. Circ J, 2008; 72: 17-22","DOI":"10.1253\/circj.72.17"},{"key":"339","doi-asserted-by":"crossref","unstructured":"339) Miura T, Izawa A, Motoki H, Miyashita Y, Kashima Y, Ebisawa S, Tomita T, Koyama J, Ikeda U: Clinical Impact of Rapid Reduction of Low-Density Lipoprotein Cholesterol Level on Long-Term Outcome of Acute Myocardial Infarction in the Statin Era: Subanalysis of the ALPS-AMI Study. PLoS One, 2015; 10: e0127835","DOI":"10.1371\/journal.pone.0127835"},{"key":"340","doi-asserted-by":"crossref","unstructured":"340) Daida H, Miyauchi K, Ogawa H, Yokoi H, Matsumoto M, Kitakaze M, Kimura T, Matsubara T, Ikari Y, Kimura K, Tsukahara K, Origasa H, Morino Y, Tsutsui H, Kobayashi M, Isshiki T: Management and two-year long-term clinical outcome of acute coronary syndrome in Japan: prevention of atherothrombotic incidents following ischemic coronary attack (PACIFIC) registry. Circ J, 2013; 77: 934-943","DOI":"10.1253\/circj.CJ-13-0174"},{"key":"341","doi-asserted-by":"crossref","unstructured":"341) Hagiwara N, Kawada-Watanabe E, Koyanagi R, Arashi H, Yamaguchi J, Nakao K, Tobaru T, Tanaka H, Oka T, Endoh Y, Saito K, Uchida T, Matsui K, Ogawa H: Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J, 2017; 38: 2264-2276","DOI":"10.1093\/eurheartj\/ehx162"},{"key":"342","doi-asserted-by":"crossref","unstructured":"342) Nakamura M, Ako J, Arai H, Hirayama A, Nohara A, Murakami Y, Ozaki A, Harada-Shiba M: Lipid Management and 2-Year Clinical Outcomes in Japanese Patients with Acute Coronary Syndrome: EXPLORE-J. J Atheroscler Thromb, 2021; 28: 1307-1322","DOI":"10.5551\/jat.59543"},{"key":"343","doi-asserted-by":"crossref","unstructured":"343) Amarenco P, Lavall\u00e9e PC, Labreuche J, Albers GW, Bornstein NM, Canh\u00e3o P, Caplan LR, Donnan GA, Ferro JM, Hennerici MG, Molina C, Rothwell PM, Sissani L, \u0160koloud\u00edk D, Steg PG, Touboul PJ, Uchiyama S, Vicaut \u00c9, Wong LK: One-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke. N Engl J Med, 2016; 374: 1533-1542","DOI":"10.1056\/NEJMoa1412981"},{"key":"344","doi-asserted-by":"crossref","unstructured":"344) Amarenco P, Lavall\u00e9e PC, Monteiro Tavares L, Labreuche J, Albers GW, Abboud H, Anticoli S, Audebert H, Bornstein NM, Caplan LR, Correia M, Donnan GA, Ferro JM, Gongora-Rivera F, Heide W, Hennerici MG, Kelly PJ, Kr\u00e1l M, Lin HF, Molina C, Park JM, Purroy F, Rothwell PM, Segura T, \u0160koloud\u00edk D, Steg PG, Touboul PJ, Uchiyama S, Vicaut \u00c9, Wang Y, Wong LKS: Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke. N Engl J Med, 2018; 378: 2182-2190","DOI":"10.1056\/NEJMoa1802712"},{"key":"345","doi-asserted-by":"crossref","unstructured":"345) Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X, Cui L, Jia J, Dong Q, Xu A, Zeng J, Li Y, Wang Z, Xia H, Johnston SC: Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med, 2013; 369: 11-19","DOI":"10.1056\/NEJMoa1215340"},{"key":"346","doi-asserted-by":"crossref","unstructured":"346) Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY: Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med, 2018; 379: 215-225","DOI":"10.1056\/NEJMoa1800410"},{"key":"347","doi-asserted-by":"crossref","unstructured":"347) Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong KS: Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. N Engl J Med, 2016; 375: 35-43","DOI":"10.1056\/NEJMoa1603060"},{"key":"348","doi-asserted-by":"crossref","unstructured":"348) Hosomi N, Nagai Y, Kohriyama T, Ohtsuki T, Aoki S, Nezu T, Maruyama H, Sunami N, Yokota C, Kitagawa K, Terayama Y, Takagi M, Ibayashi S, Nakamura M, Origasa H, Fukushima M, Mori E, Minematsu K, Uchiyama S, Shinohara Y, Yamaguchi T, Matsumoto M: The Japan Statin Treatment Against Recurrent Stroke (J-STARS): A Multicenter, Randomized, Open-label, Parallel-group Study. EBioMedicine, 2015; 2: 1071-1078","DOI":"10.1016\/j.ebiom.2015.08.006"},{"key":"349","doi-asserted-by":"crossref","unstructured":"349) Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C: Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol, 2010; 9: 959-968","DOI":"10.1016\/S1474-4422(10)70198-8"},{"key":"350","doi-asserted-by":"crossref","unstructured":"350) Ogawa A, Toyoda K, Kitagawa K, Kitazono T, Nagao T, Yamagami H, Uchiyama S, Tanahashi N, Matsumoto M, Minematsu K, Nagata I, Nishikawa M, Nanto S, Abe K, Ikeda Y: Comparison of prasugrel and clopidogrel in patients with non-cardioembolic ischaemic stroke: a phase 3, randomised, non-inferiority trial (PRASTRO-I). Lancet Neurol, 2019; 18: 238-247","DOI":"10.1016\/S1474-4422(18)30449-6"},{"key":"351","doi-asserted-by":"crossref","unstructured":"351) Toyoda K, Uchiyama S, Yamaguchi T, Easton JD, Kimura K, Hoshino H, Sakai N, Okada Y, Tanaka K, Origasa H, Naritomi H, Houkin K, Yamaguchi K, Isobe M, Minematsu K: Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. Lancet Neurol, 2019; 18: 539-548","DOI":"10.1016\/S1474-4422(19)30148-6"},{"key":"352","doi-asserted-by":"crossref","unstructured":"352) Kitagawa K, Yamamoto Y, Arima H, Maeda T, Sunami N, Kanzawa T, Eguchi K, Kamiyama K, Minematsu K, Ueda S, Rakugi H, Ohya Y, Kohro T, Yonemoto K, Okada Y, Higaki J, Tanahashi N, Kimura G, Umemura S, Matsumoto M, Shimamoto K, Ito S, Saruta T, Shimada K: Effect of Standard vs Intensive Blood Pressure Control on the Risk of Recurrent Stroke: A Randomized Clinical Trial and Meta-analysis. JAMA Neurol, 2019; 76: 1309-1318","DOI":"10.1001\/jamaneurol.2019.2167"},{"key":"353","doi-asserted-by":"crossref","unstructured":"353) Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, B\u00e9jot Y, Cabrejo L, Cha JK, Ducrocq G, Giroud M, Guidoux C, Hobeanu C, Kim YJ, Lapergue B, Lavall\u00e9e PC, Lee BC, Lee KB, Leys D, Mahagne MH, Meseguer E, Nighoghossian N, Pico F, Samson Y, Sibon I, Steg PG, Sung SM, Touboul PJ, Touz\u00e9 E, Varenne O, Vicaut \u00c9, Yelles N, Bruckert E: A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. N Engl J Med, 2020; 382: 9","DOI":"10.1056\/NEJMoa1910355"},{"key":"354","doi-asserted-by":"crossref","unstructured":"354) Kitagawa K, Hougaku H, Yamagami H, Hashimoto H, Itoh T, Shimizu Y, Takahashi D, Murata S, Seike Y, Kondo K, Hoshi T, Furukado S, Abe Y, Yagita Y, Sakaguchi M, Tagaya M, Etani H, Fukunaga R, Nagai Y, Matsumoto M, Hori M: Carotid intima-media thickness and risk of cardiovascular events in high-risk patients. Results of the Osaka Follow-Up Study for Carotid Atherosclerosis 2 (OSACA2 Study). Cerebrovasc Dis, 2007; 24: 35-42","DOI":"10.1159\/000103114"},{"key":"355","doi-asserted-by":"crossref","unstructured":"355) Irie Y, Katakami N, Kaneto H, Kasami R, Sumitsuji S, Yamasaki K, Tachibana K, Kuroda T, Sakamoto K, Umayahara Y, Ueda Y, Kosugi K, Shimomura I: Maximum carotid intima-media thickness improves the prediction ability of coronary artery stenosis in type 2 diabetic patients without history of coronary artery disease. Atherosclerosis, 2012; 221: 438-444","DOI":"10.1016\/j.atherosclerosis.2012.01.022"},{"key":"356","doi-asserted-by":"crossref","unstructured":"356) Hirano M, Nakamura T, Kitta Y, Takishima I, Deyama J, Kobayashi T, Fujioka D, Saito Y, Watanabe K, Watanabe Y, Kawabata K, Obata JE, Kugiyama K: Short-term progression of maximum intima-media thickness of carotid plaque is associated with future coronary events in patients with coronary artery disease. Atherosclerosis, 2011; 215: 507-512","DOI":"10.1016\/j.atherosclerosis.2011.01.014"},{"key":"357","doi-asserted-by":"crossref","unstructured":"357) Lorenz MW, Polak JF, Kavousi M, Mathiesen EB, V\u00f6lzke H, Tuomainen TP, Sander D, Plichart M, Catapano AL, Robertson CM, Kiechl S, Rundek T, Desvarieux M, Lind L, Schmid C, DasMahapatra P, Gao L, Ziegelbauer K, Bots ML, Thompson SG: Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet, 2012; 379: 2053-2062","DOI":"10.1016\/S0140-6736(12)60441-3"},{"key":"358","unstructured":"358) JCS Joint research group: Guidelines for the management of peripheral arterial occlusive diseases (JCS 2015) https:\/\/plaza.umin.ac.jp\/~jscvs\/wordpress\/wp-content\/uploads\/2020\/06\/JCS2015_miyata_h.pdf (in Japanese)"},{"key":"359","doi-asserted-by":"crossref","unstructured":"359) Kojima I, Ninomiya T, Hata J, Fukuhara M, Hirakawa Y, Mukai N, Yoshida D, Kitazono T, Kiyohara Y: A low ankle brachial index is associated with an increased risk of cardiovascular disease: the Hisayama study. J Atheroscler Thromb, 2014; 21: 966-973","DOI":"10.5551\/jat.22608"},{"key":"360","doi-asserted-by":"crossref","unstructured":"360) Cui R, Yamagishi K, Imano H, Ohira T, Tanigawa T, Hitsumoto S, Kiyama M, Okada T, Kitamura A, Iso H: Relationship between the ankle-brachial index and the risk of coronary heart disease and stroke: the circulatory risk in communities study. J Atheroscler Thromb, 2014; 21: 1283-1289","DOI":"10.5551\/jat.24133"},{"key":"361","doi-asserted-by":"crossref","unstructured":"361) Ohkuma T, Ninomiya T, Tomiyama H, Kario K, Hoshide S, Kita Y, Inoguchi T, Maeda Y, Kohara K, Tabara Y, Nakamura M, Ohkubo T, Watada H, Munakata M, Ohishi M, Ito N, Nakamura M, Shoji T, Vlachopoulos C, Aboyans V, Yamashina A: Ankle-brachial index measured by oscillometry is predictive for cardiovascular disease and premature death in the Japanese population: An individual participant data meta-analysis. Atherosclerosis, 2018; 275: 141-148","DOI":"10.1016\/j.atherosclerosis.2018.05.048"},{"key":"362","unstructured":"362) Shigematsu H, Nishibe T, Obitsu Y, Matsuzaki K, Ishida A, Miyata T, Shindo S, Hida K, Ohta T, Ando M, Kawasaki T, Yasugi T, Matsumoto T: Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD). Int Angiol, 2010; 29: 2-13"},{"key":"363","doi-asserted-by":"crossref","unstructured":"363) Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FG, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RA, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME: 2016 AHA\/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2017; 135: e726-e779","DOI":"10.1161\/CIR.0000000000000471"},{"key":"364","doi-asserted-by":"crossref","unstructured":"364) Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC: Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev, 2007; 2007: Cd000123","DOI":"10.1002\/14651858.CD000123.pub2"},{"key":"365","doi-asserted-by":"crossref","unstructured":"365) Antoniou GA, Fisher RK, Georgiadis GS, Antoniou SA, Torella F: Statin therapy in lower limb peripheral arterial disease: Systematic review and meta-analysis. Vascul Pharmacol, 2014; 63: 79-87","DOI":"10.1016\/j.vph.2014.09.001"},{"key":"366","doi-asserted-by":"crossref","unstructured":"366) Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg, 2007; 45: 645-654; discussion 653-644","DOI":"10.1016\/j.jvs.2006.12.054"},{"key":"367","doi-asserted-by":"crossref","unstructured":"367) Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Jr., Goto S, Ohman EM, Elbez Y, Sritara P, Baumgartner I, Banerjee S, Creager MA, Bhatt DL: Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J, 2014; 35: 2864-2872","DOI":"10.1093\/eurheartj\/ehu080"},{"key":"368","doi-asserted-by":"crossref","unstructured":"368) Ramos R, Garc\u00eda-Gil M, Comas-Cuf\u00ed M, Quesada M, Marrugat J, Elosua R, Sala J, Grau M, Mart\u00ed R, Ponjoan A, Alves-Cabratosa L, Blanch J, Bol\u00edbar B: Statins for Prevention of Cardiovascular Events in a Low-Risk Population With Low Ankle Brachial Index. J Am Coll Cardiol, 2016; 67: 630-640","DOI":"10.1016\/j.jacc.2015.11.052"},{"key":"369","doi-asserted-by":"crossref","unstructured":"369) Vogel TR, Dombrovskiy VY, Gali\u00f1anes EL, Kruse RL: Preoperative statins and limb salvage after lower extremity revascularization in the Medicare population. Circ Cardiovasc Interv, 2013; 6: 694-700","DOI":"10.1161\/CIRCINTERVENTIONS.113.000274"},{"key":"370","doi-asserted-by":"crossref","unstructured":"370) Bonaca MP, Gutierrez JA, Cannon C, Giugliano R, Blazing M, Park JG, White J, Tershakovec A, Braunwald E: Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol, 2018; 6: 934-943","DOI":"10.1016\/S2213-8587(18)30290-0"},{"key":"371","doi-asserted-by":"crossref","unstructured":"371) Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS: Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation, 2018; 137: 338-350","DOI":"10.1161\/CIRCULATIONAHA.117.032235"},{"key":"372","doi-asserted-by":"crossref","unstructured":"372) Ishikawa Y, Yokoyama M, Saito Y, Matsuzaki M, Origasa H, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y: Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease. Circ J, 2010; 74: 1451-1457","DOI":"10.1253\/circj.CJ-09-0520"},{"key":"373","doi-asserted-by":"crossref","unstructured":"373) Mohler ER, 3rd, Hiatt WR, Creager MA: Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation, 2003; 108: 1481-1486","DOI":"10.1161\/01.CIR.0000090686.57897.F5"},{"key":"374","doi-asserted-by":"crossref","unstructured":"374) Bath MF, Gokani VJ, Sidloff DA, Jones LR, Choke E, Sayers RD, Bown MJ: Systematic review of cardiovascular disease and cardiovascular death in patients with a small abdominal aortic aneurysm. Br J Surg, 2015; 102: 866-872","DOI":"10.1002\/bjs.9837"},{"key":"375","doi-asserted-by":"crossref","unstructured":"375) Chaikof EL, Dalman RL, Eskandari MK, Jackson BM, Lee WA, Mansour MA, Mastracci TM, Mell M, Murad MH, Nguyen LL, Oderich GS, Patel MS, Schermerhorn ML, Starnes BW: The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. J Vasc Surg, 2018; 67: 2-77.e72","DOI":"10.1016\/j.jvs.2017.10.044"},{"key":"376","doi-asserted-by":"crossref","unstructured":"376) Kioka Y, Tanabe A, Kotani Y, Yamada N, Nakahama M, Ueda T, Seitou T, Maruyama M: Review of coronary artery disease in patients with infrarenal abdominal aortic aneurysm. Circ J, 2002; 66: 1110-1112","DOI":"10.1253\/circj.66.1110"},{"key":"377","doi-asserted-by":"crossref","unstructured":"377) Hirose K, Chikamori T, Hida S, Tanaka H, Igarashi Y, Watanabe Y, Koizumi N, Kawaguchi S, Obitsu Y, Shigematsu H, Yamashina A: Prevalence of coronary heart disease in patients with aortic aneurysm and\/or peripheral artery disease. Am J Cardiol, 2009; 103: 1215-1220","DOI":"10.1016\/j.amjcard.2009.01.033"},{"key":"378","doi-asserted-by":"crossref","unstructured":"378) Elkalioubie A, Haulon S, Duhamel A, Rosa M, Rauch A, Staels B, Susen S, Van Belle E, Dupont A: Meta-Analysis of Abdominal Aortic Aneurysm in Patients With Coronary Artery Disease. Am J Cardiol, 2015; 116: 1451-1456","DOI":"10.1016\/j.amjcard.2015.07.074"},{"key":"379","doi-asserted-by":"crossref","unstructured":"379) Hobbs SD, Claridge MW, Quick CR, Day NE, Bradbury AW, Wilmink AB: LDL cholesterol is associated with small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg, 2003; 26: 618-622","DOI":"10.1016\/S1078-5884(03)00412-X"},{"key":"380","doi-asserted-by":"crossref","unstructured":"380) T\u00f6rnwall ME, Virtamo J, Haukka JK, Albanes D, Huttunen JK: Life-style factors and risk for abdominal aortic aneurysm in a cohort of Finnish male smokers. Epidemiology, 2001; 12: 94-100","DOI":"10.1097\/00001648-200101000-00016"},{"key":"381","doi-asserted-by":"crossref","unstructured":"381) Bhak RH, Wininger M, Johnson GR, Lederle FA, Messina LM, Ballard DJ, Wilson SE: Factors associated with small abdominal aortic aneurysm expansion rate. JAMA Surg, 2015; 150: 44-50","DOI":"10.1001\/jamasurg.2014.2025"},{"key":"382","doi-asserted-by":"crossref","unstructured":"382) Akai A, Watanabe Y, Hoshina K, Obitsu Y, Deguchi J, Sato O, Shigematsu K, Miyata T: Family history of aortic aneurysm is an independent risk factor for more rapid growth of small abdominal aortic aneurysms in Japan. J Vasc Surg, 2015; 61: 287-290","DOI":"10.1016\/j.jvs.2014.07.007"},{"key":"383","doi-asserted-by":"crossref","unstructured":"383) Bahia SS, Vidal-Diez A, Seshasai SR, Shpitser I, Brownrigg JR, Patterson BO, Ray KK, Holt PJ, Thompson MM, Karthikesalingam A: Cardiovascular risk prevention and all-cause mortality in primary care patients with an abdominal aortic aneurysm. Br J Surg, 2016; 103: 1626-1633","DOI":"10.1002\/bjs.10269"},{"key":"384","doi-asserted-by":"crossref","unstructured":"384) Wanhainen A, Verzini F, Van Herzeele I, Allaire E, Bown M, Cohnert T, Dick F, van Herwaarden J, Karkos C, Koelemay M, K\u00f6lbel T, Loftus I, Mani K, Melissano G, Powell J, Szeberin Z, Esvs Guidelines C, de Borst GJ, Chakfe N, Debus S, Hinchliffe R, Kakkos S, Koncar I, Kolh P, Lindholt JS, de Vega M, Vermassen F, Document R, Bj\u00f6rck M, Cheng S, Dalman R, Davidovic L, Donas K, Earnshaw J, Eckstein HH, Golledge J, Haulon S, Mastracci T, Naylor R, Ricco JB, Verhagen H: Editor\u2019s Choice - European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms. Eur J Vasc Endovasc Surg, 2019; 57: 8-93","DOI":"10.1016\/j.ejvs.2018.09.020"},{"key":"385","doi-asserted-by":"crossref","unstructured":"385) Tanemoto M, Saitoh H, Satoh F, Satoh H, Abe T, Ito S: Predictors of undiagnosed renal artery stenosis among Japanese patients with risk factors of atherosclerosis. Hypertens Res, 2005; 28: 237-242","DOI":"10.1291\/hypres.28.237"},{"key":"386","doi-asserted-by":"crossref","unstructured":"386) Tollefson DF, Ernst CB: Natural history of atherosclerotic renal artery stenosis associated with aortic disease. J Vasc Surg, 1991; 14: 327-331","DOI":"10.1016\/0741-5214(91)90084-8"},{"key":"387","doi-asserted-by":"crossref","unstructured":"387) Zierler RE, Bergelin RO, Davidson RC, Cantwell-Gab K, Polissar NL, Strandness DE, Jr.: A prospective study of disease progression in patients with atherosclerotic renal artery stenosis. Am J Hypertens, 1996; 9: 1055-1061","DOI":"10.1016\/0895-7061(96)00196-3"},{"key":"388","doi-asserted-by":"crossref","unstructured":"388) White CJ, Jaff MR, Haskal ZJ, Jones DJ, Olin JW, Rocha-Singh KJ, Rosenfield KA, Rundback JH, Linas SL: Indications for renal arteriography at the time of coronary arteriography: a science advisory from the American Heart Association Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology, and the Councils on Cardiovascular Radiology and Intervention and on Kidney in Cardiovascular Disease. Circulation, 2006; 114: 1892-1895","DOI":"10.1161\/CIRCULATIONAHA.106.178777"},{"key":"389","doi-asserted-by":"crossref","unstructured":"389) Conlon PJ, Athirakul K, Kovalik E, Schwab SJ, Crowley J, Stack R, McCants CB, Jr., Mark DB, Bashore TM, Albers F: Survival in renal vascular disease. J Am Soc Nephrol, 1998; 9: 252-256","DOI":"10.1681\/ASN.V92252"},{"key":"390","doi-asserted-by":"crossref","unstructured":"390) Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, Cohen DJ, Matsumoto AH, Steffes M, Jaff MR, Prince MR, Lewis EF, Tuttle KR, Shapiro JI, Rundback JH, Massaro JM, D\u2019Agostino RB, Sr., Dworkin LD: Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med, 2014; 370: 13-22","DOI":"10.1056\/NEJMoa1310753"},{"key":"391","doi-asserted-by":"crossref","unstructured":"391) Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C, Carr S, Chalmers N, Eadington D, Hamilton G, Lipkin G, Nicholson A, Scoble J: Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med, 2009; 361: 1953-1962","DOI":"10.1056\/NEJMoa0905368"},{"key":"392","doi-asserted-by":"crossref","unstructured":"392) Bax L, Woittiez AJ, Kouwenberg HJ, Mali WP, Buskens E, Beek FJ, Braam B, Huysmans FT, Schultze Kool LJ, Rutten MJ, Doorenbos CJ, Aarts JC, Rabelink TJ, Plouin PF, Raynaud A, van Montfrans GA, Reekers JA, van den Meiracker AH, Pattynama PM, van de Ven PJ, Vroegindeweij D, Kroon AA, de Haan MW, Postma CT, Beutler JJ: Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann Intern Med, 2009; 150: 840-848, w150-841","DOI":"10.7326\/0003-4819-150-12-200906160-00119"},{"key":"393","doi-asserted-by":"crossref","unstructured":"393) Riaz IB, Husnain M, Riaz H, Asawaeer M, Bilal J, Pandit A, Shetty R, Lee KS: Meta-analysis of revascularization versus medical therapy for atherosclerotic renal artery stenosis. Am J Cardiol, 2014; 114: 1116-1123","DOI":"10.1016\/j.amjcard.2014.06.033"},{"key":"394","doi-asserted-by":"crossref","unstructured":"394) Raman G, Adam GP, Halladay CW, Langberg VN, Azodo IA, Balk EM: Comparative Effectiveness of Management Strategies for Renal Artery Stenosis: An Updated Systematic Review. Ann Intern Med, 2016; 165: 635-649","DOI":"10.7326\/M16-1053"},{"key":"395","doi-asserted-by":"crossref","unstructured":"395) Fujihara M, Yokoi Y, Abe T, Soga Y, Yamashita T, Miyashita Y, Nakamura M, Yokoi H, Ito S: Clinical outcome of renal artery stenting for hypertension and chronic kidney disease up to 12 months in the J-RAS Study \u2013 prospective, single-arm, multicenter clinical study. Circ J, 2015; 79: 351-359","DOI":"10.1253\/circj.CJ-14-0908"},{"key":"396","doi-asserted-by":"crossref","unstructured":"396) Prince M, Tafur JD, White CJ: When and How Should We Revascularize Patients With Atherosclerotic Renal Artery Stenosis? JACC Cardiovasc Interv, 2019; 12: 505-517","DOI":"10.1016\/j.jcin.2018.10.023"},{"key":"397","doi-asserted-by":"crossref","unstructured":"397) Bovet P, Perret F, Cornuz J, Quilindo J, Paccaud F: Improved smoking cessation in smokers given ultrasound photographs of their own atherosclerotic plaques. Prev Med, 2002; 34: 215-220","DOI":"10.1006\/pmed.2001.0976"},{"key":"398","doi-asserted-by":"crossref","unstructured":"398) Taylor AJ, Bindeman J, Feuerstein I, Le T, Bauer K, Byrd C, Wu H, O\u2019Malley PG: Community-based provision of statin and aspirin after the detection of coronary artery calcium within a community-based screening cohort. J Am Coll Cardiol, 2008; 51: 1337-1341","DOI":"10.1016\/j.jacc.2007.11.069"},{"key":"399","doi-asserted-by":"crossref","unstructured":"399) Bokura H, Kobayashi S, Yamaguchi S, Iijima K, Nagai A, Toyoda G, Oguro H, Takahashi K: Silent brain infarction and subcortical white matter lesions increase the risk of stroke and mortality: a prospective cohort study. J Stroke Cerebrovasc Dis, 2006; 15: 57-63","DOI":"10.1016\/j.jstrokecerebrovasdis.2005.11.001"},{"key":"400","doi-asserted-by":"crossref","unstructured":"400) Matsui R, Nakagawa T, Takayoshi H, Onoda K, Oguro H, Nagai A, Yamaguchi S: A Prospective Study of Asymptomatic Intracranial Atherosclerotic Stenosis in Neurologically Normal Volunteers in a Japanese Cohort. Front Neurol, 2016; 7: 39","DOI":"10.3389\/fneur.2016.00039"},{"key":"401","unstructured":"401) The Japan Stroke Society,: Japanese Guidelines for the Management of Stroke 2015 [addendum 2019], 2019 (in Japanese)"},{"key":"402","doi-asserted-by":"crossref","unstructured":"402) Kokubo Y, Watanabe M, Higashiyama A, Nakao YM, Nakamura F, Miyamoto Y: Impact of Intima-Media Thickness Progression in the Common Carotid Arteries on the Risk of Incident Cardiovascular Disease in the Suita Study. J Am Heart Assoc, 2018; 7","DOI":"10.1161\/JAHA.117.007720"},{"key":"403","doi-asserted-by":"crossref","unstructured":"403) Yoshida M, Mita T, Yamamoto R, Shimizu T, Ikeda F, Ohmura C, Kanazawa A, Hirose T, Kawamori R, Watada H: Combination of the Framingham risk score and carotid intima-media thickness improves the prediction of cardiovascular events in patients with type 2 diabetes. Diabetes Care, 2012; 35: 178-180","DOI":"10.2337\/dc11-1333"},{"key":"404","doi-asserted-by":"crossref","unstructured":"404) Yang CW, Guo YC, Li CI, Liu CS, Lin CH, Liu CH, Wang MC, Yang SY, Li TC, Lin CC: Subclinical Atherosclerosis Markers of Carotid Intima-Media Thickness, Carotid Plaques, Carotid Stenosis, and Mortality in Community-Dwelling Adults. Int J Environ Res Public Health, 2020; 17","DOI":"10.3390\/ijerph17134745"},{"key":"405","doi-asserted-by":"crossref","unstructured":"405) Xie W, Wu Y, Wang W, Zhao D, Liang L, Wang M, Yang Y, Sun J, Shi P, Huo Y: A longitudinal study of carotid plaque and risk of ischemic cardiovascular disease in the Chinese population. J Am Soc Echocardiogr, 2011; 24: 729-737","DOI":"10.1016\/j.echo.2011.02.011"},{"key":"406","doi-asserted-by":"crossref","unstructured":"406) Chien KL, Su TC, Jeng JS, Hsu HC, Chang WT, Chen MF, Lee YT, Hu FB: Carotid artery intima-media thickness, carotid plaque and coronary heart disease and stroke in Chinese. PLoS One, 2008; 3: e3435","DOI":"10.1371\/journal.pone.0003435"},{"key":"407","doi-asserted-by":"crossref","unstructured":"407) Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Mu\u00f1oz D, Smith SC, Jr., Virani SS, Williams KA, Sr., Yeboah J, Ziaeian B: 2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019; 140: e596-e646","DOI":"10.1161\/CIR.0000000000000677"},{"key":"408","doi-asserted-by":"crossref","unstructured":"408) Ninomiya T, Kojima I, Doi Y, Fukuhara M, Hirakawa Y, Hata J, Kitazono T, Kiyohara Y: Brachial-ankle pulse wave velocity predicts the development of cardiovascular disease in a general Japanese population: the Hisayama Study. J Hypertens, 2013; 31: 477-483; discussion 483","DOI":"10.1097\/HJH.0b013e32835c5c23"},{"key":"409","doi-asserted-by":"crossref","unstructured":"409) Ohkuma T, Tomiyama H, Ninomiya T, Kario K, Hoshide S, Kita Y, Inoguchi T, Maeda Y, Kohara K, Tabara Y, Nakamura M, Ohkubo T, Watada H, Munakata M, Ohishi M, Ito N, Nakamura M, Shoji T, Vlachopoulos C, Yamashina A: Proposed Cutoff Value of Brachial-Ankle Pulse Wave Velocity for the Management of Hypertension. Circ J, 2017; 81: 1540-1542","DOI":"10.1253\/circj.CJ-17-0636"},{"key":"410","doi-asserted-by":"crossref","unstructured":"410) Satoh-Asahara N, Kotani K, Yamakage H, Yamada T, Araki R, Okajima T, Adachi M, Oishi M, Shimatsu A: Cardio-ankle vascular index predicts for the incidence of cardiovascular events in obese patients: a multicenter prospective cohort study (Japan Obesity and Metabolic Syndrome Study: JOMS). Atherosclerosis, 2015; 242: 461-468","DOI":"10.1016\/j.atherosclerosis.2015.08.003"},{"key":"411","doi-asserted-by":"crossref","unstructured":"411) Woo J, Leung J: Does measurement of ankle-brachial index contribute to prediction of adverse health outcomes in older Chinese people? Intern Med J, 2013; 43: 1017-1023","DOI":"10.1111\/imj.12101"},{"key":"412","doi-asserted-by":"crossref","unstructured":"412) Wang Y, Guo X, Li J, Hu D, Zhao D, Ma H, Mou Q, Liu J, Xu Y: Predictive value of ankle-brachial index to all-cause mortality and cardiovascular mortality in Chinese patients with chronic kidney disease. Vasa, 2012; 41: 205-213","DOI":"10.1024\/0301-1526\/a000187"},{"key":"413","unstructured":"413) Wang Y, Mou Q, Zhao D, Xu Y, Hu D, Ma H, Liu J, Guo X, Li J: Predictive value of ankle-brachial index and blood glucose on the outcomes of six-year all-cause mortality and cardiovascular mortality in a Chinese population of type 2 diabetes patients. Int Angiol, 2012; 31: 586-594"},{"key":"414","unstructured":"414) The Japanese Society of Gastroenterology, Hepatology TJSo: NAFLD\/NASH Clinical Practice Guidelines 2020, Nankodo, 2020"},{"key":"415","doi-asserted-by":"crossref","unstructured":"415) Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K: The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med, 2005; 143: 722-728","DOI":"10.7326\/0003-4819-143-10-200511150-00009"},{"key":"416","doi-asserted-by":"crossref","unstructured":"416) Nakahara T, Hyogo H, Yoneda M, Sumida Y, Eguchi Y, Fujii H, Ono M, Kawaguchi T, Imajo K, Aikata H, Tanaka S, Kanemasa K, Fujimoto K, Anzai K, Saibara T, Sata M, Nakajima A, Itoh Y, Chayama K, Okanoue T: Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol, 2014; 49: 1477-1484","DOI":"10.1007\/s00535-013-0911-1"},{"key":"417","doi-asserted-by":"crossref","unstructured":"417) Imajo K, Hyogo H, Yoneda M, Honda Y, Kessoku T, Tomeno W, Ogawa Y, Taguri M, Mawatari H, Nozaki Y, Fujita K, Kirikoshi H, Saito S, Sumida Y, Ono M, Wada K, Nakajima A, Eguchi Y: LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study. PLoS One, 2014; 9: e115403","DOI":"10.1371\/journal.pone.0115403"},{"key":"418","doi-asserted-by":"crossref","unstructured":"418) Campanella A, Iacovazzi PA, Misciagna G, Bonfiglio C, Mirizzi A, Franco I, Bianco A, Sorino P, Caruso MG, Cisternino AM, Buongiorno C, Liuzzi R, Osella AR: The Effect of Three Mediterranean Diets on Remnant Cholesterol and Non-Alcoholic Fatty Liver Disease: A Secondary Analysis. Nutrients, 2020; 12","DOI":"10.3390\/nu12061674"},{"key":"419","doi-asserted-by":"crossref","unstructured":"419) Musso G, Gambino R, Cassader M, Pagano G: Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med, 2011; 43: 617-649","DOI":"10.3109\/07853890.2010.518623"},{"key":"420","doi-asserted-by":"crossref","unstructured":"420) Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C: Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol, 2016; 65: 589-600","DOI":"10.1016\/j.jhep.2016.05.013"},{"key":"421","doi-asserted-by":"crossref","unstructured":"421) Simon TG, Roelstraete B, Khalili H, Hagstr\u00f6m H, Ludvigsson JF: Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut, 2021; 70: 1375-1382","DOI":"10.1136\/gutjnl-2020-322786"},{"key":"422","doi-asserted-by":"crossref","unstructured":"422) Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z: Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis. Sci Rep, 2016; 6: 33386","DOI":"10.1038\/srep33386"},{"key":"423","doi-asserted-by":"crossref","unstructured":"423) Puchner SB, Lu MT, Mayrhofer T, Liu T, Pursnani A, Ghoshhajra BB, Truong QA, Wiviott SD, Fleg JL, Hoffmann U, Ferencik M: High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial. Radiology, 2015; 274: 693-701","DOI":"10.1148\/radiol.14140933"},{"key":"424","doi-asserted-by":"crossref","unstructured":"424) Zhou YY, Zhou XD, Wu SJ, Fan DH, Van Poucke S, Chen YP, Fu SW, Zheng MH: Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta-analysis. Hepatol Commun, 2018; 2: 376-392","DOI":"10.1002\/hep4.1155"},{"key":"425","doi-asserted-by":"crossref","unstructured":"425) Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S, Bendtsen F: Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2015; 149: 389-397.e310","DOI":"10.1053\/j.gastro.2015.04.043"},{"key":"426","doi-asserted-by":"crossref","unstructured":"426) McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM: cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature, 1987; 330: 132-137","DOI":"10.1038\/330132a0"},{"key":"427","doi-asserted-by":"crossref","unstructured":"427) Kronenberg F, Utermann G: Lipoprotein(a): resurrected by genetics. J Intern Med, 2013; 273: 6-30","DOI":"10.1111\/j.1365-2796.2012.02592.x"},{"key":"428","doi-asserted-by":"crossref","unstructured":"428) Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG: Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA, 2009; 301: 2331-2339","DOI":"10.1001\/jama.2009.801"},{"key":"429","doi-asserted-by":"crossref","unstructured":"429) Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, Abolafia JM, Lippel K, Levy RI: Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. JAMA, 1994; 271: 999-1003","DOI":"10.1001\/jama.271.13.999"},{"key":"430","doi-asserted-by":"crossref","unstructured":"430) Bennet A, Di Angelantonio E, Erqou S, Eiriksdottir G, Sigurdsson G, Woodward M, Rumley A, Lowe GD, Danesh J, Gudnason V: Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med, 2008; 168: 598-608","DOI":"10.1001\/archinte.168.6.598"},{"key":"431","doi-asserted-by":"crossref","unstructured":"431) Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J: Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA, 2009; 302: 412-423","DOI":"10.1001\/jama.2009.1063"},{"key":"432","doi-asserted-by":"crossref","unstructured":"432) Marcovina SM, Koschinsky ML: Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol, 2003; 14: 361-366","DOI":"10.1097\/00041433-200308000-00004"},{"key":"433","doi-asserted-by":"crossref","unstructured":"433) Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R, Watkins H, Farrall M: Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med, 2009; 361: 2518-2528","DOI":"10.1056\/NEJMoa0902604"},{"key":"434","doi-asserted-by":"crossref","unstructured":"434) Kyriakou T, Seedorf U, Goel A, Hopewell JC, Clarke R, Watkins H, Farrall M: A common LPA null allele associates with lower lipoprotein(a) levels and coronary artery disease risk. Arterioscler Thromb Vasc Biol, 2014; 34: 2095-2099","DOI":"10.1161\/ATVBAHA.114.303462"},{"key":"435","doi-asserted-by":"crossref","unstructured":"435) Saleheen D, Haycock PC, Zhao W, Rasheed A, Taleb A, Imran A, Abbas S, Majeed F, Akhtar S, Qamar N, Zaman KS, Yaqoob Z, Saghir T, Rizvi SNH, Memon A, Mallick NH, Ishaq M, Rasheed SZ, Memon FU, Mahmood K, Ahmed N, Frossard P, Tsimikas S, Witztum JL, Marcovina S, Sandhu M, Rader DJ, Danesh J: Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis. Lancet Diabetes Endocrinol, 2017; 5: 524-533","DOI":"10.1016\/S2213-8587(17)30088-8"},{"key":"436","doi-asserted-by":"crossref","unstructured":"436) Jansen H, Samani NJ, Schunkert H: Mendelian randomization studies in coronary artery disease. Eur Heart J, 2014; 35: 1917-1924","DOI":"10.1093\/eurheartj\/ehu208"},{"key":"437","doi-asserted-by":"crossref","unstructured":"437) Langsted A, Kamstrup PR, Nordestgaard BG: High lipoprotein(a) and high risk of mortality. Eur Heart J, 2019; 40: 2760-2770","DOI":"10.1093\/eurheartj\/ehy902"},{"key":"438","doi-asserted-by":"crossref","unstructured":"438) Boffa MB, Koschinsky ML: Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? J Lipid Res, 2016; 57: 745-757","DOI":"10.1194\/jlr.R060582"},{"key":"439","doi-asserted-by":"crossref","unstructured":"439) Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB: Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med, 2005; 353: 46-57","DOI":"10.1056\/NEJMoa043175"},{"key":"440","doi-asserted-by":"crossref","unstructured":"440) Tsimikas S, Witztum JL: The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr Opin Lipidol, 2008; 19: 369-377","DOI":"10.1097\/MOL.0b013e328308b622"},{"key":"441","doi-asserted-by":"crossref","unstructured":"441) Nielsen LB: Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux. Atherosclerosis, 1999; 143: 229-243","DOI":"10.1016\/S0021-9150(99)00064-7"},{"key":"442","doi-asserted-by":"crossref","unstructured":"442) Pavanello C, Pirazzi C, Bjorkman K, Sandstedt J, Tarlarini C, Mosca L, Romeo S, Calabresi L, Mancina RM: Individuals with familial hypercholesterolemia and cardiovascular events have higher circulating Lp(a) levels. J Clin Lipidol, 2019; 13: 778-787.e776","DOI":"10.1016\/j.jacl.2019.06.011"},{"key":"443","doi-asserted-by":"crossref","unstructured":"443) Alonso R, Andres E, Mata N, Fuentes-Jim\u00e9nez F, Badim\u00f3n L, L\u00f3pez-Miranda J, Padr\u00f3 T, Mu\u00f1iz O, D\u00edaz-D\u00edaz JL, Mauri M, Ordov\u00e1s JM, Mata P: Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol, 2014; 63: 1982-1989","DOI":"10.1016\/j.jacc.2014.01.063"},{"key":"444","doi-asserted-by":"crossref","unstructured":"444) Shah NP, Pajidipati NJ, McGarrah RW, Navar AM, Vemulapalli S, Blazing MA, Shah SH, Hernandez AF, Patel MR: Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. Am J Cardiol, 2020; 126: 94-102","DOI":"10.1016\/j.amjcard.2020.03.043"},{"key":"445","doi-asserted-by":"crossref","unstructured":"445) Cook NR, Mora S, Ridker PM: Lipoprotein(a) and Cardiovascular Risk Prediction Among Women. J Am Coll Cardiol, 2018; 72: 287-296","DOI":"10.1016\/j.jacc.2018.04.060"},{"key":"446","doi-asserted-by":"crossref","unstructured":"446) Kouvari M, Panagiotakos DB, Chrysohoou C, Georgousopoulou EN, Yannakoulia M, Tousoulis D, Pitsavos C: Lipoprotein (a) and 10-year Cardiovascular Disease Incidence in Apparently Healthy Individuals: A Sex-based Sensitivity Analysis from ATTICA Cohort Study. Angiology, 2019; 70: 819-829","DOI":"10.1177\/0003319719854872"},{"key":"447","doi-asserted-by":"crossref","unstructured":"447) Agarwala A, Pokharel Y, Saeed A, Sun W, Virani SS, Nambi V, Ndumele C, Shahar E, Heiss G, Boerwinkle E, Konety S, Hoogeveen RC, Ballantyne CM: The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study. Atherosclerosis, 2017; 262: 131-137","DOI":"10.1016\/j.atherosclerosis.2017.05.014"},{"key":"448","doi-asserted-by":"crossref","unstructured":"448) Aronis KN, Zhao D, Hoogeveen RC, Alonso A, Ballantyne CM, Guallar E, Jones SR, Martin SS, Nazarian S, Steffen BT, Virani SS, Michos ED: Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Atherosclerosis Risk in Communities) Study. J Am Heart Assoc, 2017; 6","DOI":"10.1161\/JAHA.117.007372"},{"key":"449","doi-asserted-by":"crossref","unstructured":"449) Verbeek R, Hoogeveen RM, Langsted A, Stiekema LCA, Verweij SL, Hovingh GK, Wareham NJ, Khaw KT, Boekholdt SM, Nordestgaard BG, Stroes ESG: Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. Eur Heart J, 2018; 39: 2589-2596","DOI":"10.1093\/eurheartj\/ehy334"},{"key":"450","doi-asserted-by":"crossref","unstructured":"450) Albers JJ, Slee A, O\u2019Brien KD, Robinson JG, Kashyap ML, Kwiterovich PO, Jr., Xu P, Marcovina SM: Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL\/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol, 2013; 62: 1575-1579","DOI":"10.1016\/j.jacc.2013.06.051"},{"key":"451","doi-asserted-by":"crossref","unstructured":"451) Nestel PJ, Barnes EH, Tonkin AM, Simes J, Fournier M, White HD, Colquhoun DM, Blankenberg S, Sullivan DR: Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. Arterioscler Thromb Vasc Biol, 2013; 33: 2902-2908","DOI":"10.1161\/ATVBAHA.113.302479"},{"key":"452","doi-asserted-by":"crossref","unstructured":"452) Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE: Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med, 2017; 376: 1933-1942","DOI":"10.1056\/NEJMoa1609581"},{"key":"453","doi-asserted-by":"crossref","unstructured":"453) O\u2019Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, \u010ce\u0161ka R, Ezhov MV, Jukema JW, Jensen HK, Tokg\u00f6zo\u011flu SL, Mach F, Huber K, Sever PS, Keech AC, Pedersen TR, Sabatine MS: Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation, 2019; 139: 1483-1492","DOI":"10.1161\/CIRCULATIONAHA.118.037184"},{"key":"454","doi-asserted-by":"crossref","unstructured":"454) Gaudet D, Watts GF, Robinson JG, Minini P, Sasiela WJ, Edelberg J, Louie MJ, Raal FJ: Effect of Alirocumab on Lipoprotein(a) Over \u22651.5 Years (from the Phase 3 ODYSSEY Program). Am J Cardiol, 2017; 119: 40-46","DOI":"10.1016\/j.amjcard.2016.09.010"},{"key":"455","doi-asserted-by":"crossref","unstructured":"455) Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, Schwartz GG, Olsson AG, Colhoun HM, Kronenberg F, Drechsler C, Wanner C, Mora S, Lesogor A, Tsimikas S: Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet, 2018; 392: 1311-1320","DOI":"10.1016\/S0140-6736(18)31652-0"},{"key":"456","doi-asserted-by":"crossref","unstructured":"456) Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Jr., Sperling L, Virani SS, Yeboah J: 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019; 139: e1082-e1143","DOI":"10.1161\/CIR.0000000000000624"},{"key":"457","doi-asserted-by":"crossref","unstructured":"457) Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O: 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 2020; 41: 111-188","DOI":"10.15829\/1560-4071-2020-3826"},{"key":"458","doi-asserted-by":"crossref","unstructured":"458) Mehta A, Virani SS, Ayers CR, Sun W, Hoogeveen RC, Rohatgi A, Berry JD, Joshi PH, Ballantyne CM, Khera A: Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk. J Am Coll Cardiol, 2020; 76: 781-793","DOI":"10.1016\/j.jacc.2020.06.040"},{"key":"459","doi-asserted-by":"crossref","unstructured":"459) Ito T, Fujita H, Tani T, Ohte N: Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous coronary intervention using drug-eluting stent. Atherosclerosis, 2015; 239: 311-317","DOI":"10.1016\/j.atherosclerosis.2015.01.026"},{"key":"460","doi-asserted-by":"crossref","unstructured":"460) Amioka N, Miyoshi T, Otsuka H, Yamada D, Takaishi A, Ueeda M, Hirohata S, Ito H: Serum malondialdehyde-modified low-density lipoprotein levels on admission predict prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention. J Cardiol, 2019; 74: 258-266","DOI":"10.1016\/j.jjcc.2019.02.012"},{"key":"461","doi-asserted-by":"crossref","unstructured":"461) Ikenaga H, Kurisu S, Kono S, Sumimoto Y, Watanabe N, Shimonaga T, Higaki T, Iwasaki T, Mitsuba N, Ishibashi K, Dohi Y, Fukuda Y, Kihara Y: Impact of Malondialdehyde-Modified Low-Density Lipoprotein on Tissue Characteristics in Patients With Stable Coronary Artery Disease - Integrated Backscatter-Intravascular Ultrasound Study. Circ J, 2016; 80: 2173-2182","DOI":"10.1253\/circj.CJ-16-0451"},{"key":"462","doi-asserted-by":"crossref","unstructured":"462) Ito T, Ichihashi T, Fujita H, Sugiura T, Ohte N: Impact of malondialdehyde-modified low-density lipoprotein on coronary plaque vulnerability in patients not receiving lipid-lowering therapy: a whole coronary analysis with multislice-computed tomography. Heart Vessels, 2018; 33: 351-357","DOI":"10.1007\/s00380-017-1074-4"},{"key":"463","doi-asserted-by":"crossref","unstructured":"463) Kugiyama K, Doi H, Takazoe K, Kawano H, Soejima H, Mizuno Y, Tsunoda R, Sakamoto T, Nakano T, Nakajima K, Ogawa H, Sugiyama S, Yoshimura M, Yasue H: Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation, 1999; 99: 2858-2860","DOI":"10.1161\/01.CIR.99.22.2858"},{"key":"464","doi-asserted-by":"crossref","unstructured":"464) Nakamura T, Obata JE, Hirano M, Kitta Y, Fujioka D, Saito Y, Kawabata K, Watanabe K, Watanabe Y, Mishina H, Kugiyama K: Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals. Atherosclerosis, 2011; 218: 163-167","DOI":"10.1016\/j.atherosclerosis.2011.04.040"},{"key":"465","doi-asserted-by":"crossref","unstructured":"465) Nguyen SV, Nakamura T, Kugiyama K: High remnant lipoprotein predicts recurrent cardiovascular events on statin treatment after acute coronary syndrome. Circ J, 2014; 78: 2492-2500","DOI":"10.1253\/circj.CJ-14-0380"},{"key":"466","doi-asserted-by":"crossref","unstructured":"466) Nguyen SV, Nakamura T, Uematsu M, Fujioka D, Watanabe K, Watanabe Y, Obata JE, Nakamura K, Kugiyama K: Remnant lipoproteinemia predicts cardiovascular events in patients with type 2 diabetes and chronic kidney disease. J Cardiol, 2017; 69: 529-535","DOI":"10.1016\/j.jjcc.2016.04.011"},{"key":"467","doi-asserted-by":"crossref","unstructured":"467) Fujihara Y, Nakamura T, Horikoshi T, Obata JE, Fujioka D, Watanabe Y, Watanabe K, Kugiyama K: Remnant Lipoproteins Are Residual Risk Factor for Future Cardiovascular Events in Patients With Stable Coronary Artery Disease and On-Statin Low-Density Lipoprotein Cholesterol Levels &lt;70 mg\/dL. Circ J, 2019; 83: 1302-1308","DOI":"10.1253\/circj.CJ-19-0047"},{"key":"468","doi-asserted-by":"crossref","unstructured":"468) Salinas CAA, Chapman MJ: Remnant lipoproteins: are they equal to or more atherogenic than LDL? Curr Opin Lipidol, 2020; 31: 132-139","DOI":"10.1097\/MOL.0000000000000682"},{"key":"469","doi-asserted-by":"crossref","unstructured":"469) Bor\u00e9n J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, Daemen MJ, Demer LL, Hegele RA, Nicholls SJ, Nordestgaard BG, Watts GF, Bruckert E, Fazio S, Ference BA, Graham I, Horton JD, Landmesser U, Laufs U, Masana L, Pasterkamp G, Raal FJ, Ray KK, Schunkert H, Taskinen MR, van de Sluis B, Wiklund O, Tokgozoglu L, Catapano AL, Ginsberg HN: Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J, 2020; 41: 2313-2330","DOI":"10.1093\/eurheartj\/ehz962"},{"key":"470","doi-asserted-by":"crossref","unstructured":"470) McNamara JR, Shah PK, Nakajima K, Cupples LA, Wilson PW, Ordovas JM, Schaefer EJ: Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis, 2001; 154: 229-236","DOI":"10.1016\/S0021-9150(00)00484-6"},{"key":"471","doi-asserted-by":"crossref","unstructured":"471) Jepsen AM, Langsted A, Varbo A, Bang LE, Kamstrup PR, Nordestgaard BG: Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortality in 5414 Patients with Ischemic Heart Disease. Clin Chem, 2016; 62: 593-604","DOI":"10.1373\/clinchem.2015.253757"},{"key":"472","doi-asserted-by":"crossref","unstructured":"472) Ginsberg HN, Packard CJ, Chapman MJ, Bor\u00e9n J, Aguilar-Salinas CA, Averna M, Ference BA, Gaudet D, Hegele RA, Kersten S, Lewis GF, Lichtenstein AH, Moulin P, Nordestgaard BG, Remaley AT, Staels B, Stroes ESG, Taskinen MR, Tokg\u00f6zo\u011flu LS, Tybjaerg-Hansen A, Stock JK, Catapano AL: Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J, 2021; 42: 4791-4806","DOI":"10.1093\/eurheartj\/ehab551"},{"key":"473","doi-asserted-by":"crossref","unstructured":"473) Masuda D, Sugimoto T, Tsujii K, Inagaki M, Nakatani K, Yuasa-Kawase M, Tsubakio-Yamamoto K, Ohama T, Nishida M, Ishigami M, Kawamoto T, Matsuyama A, Sakai N, Komuro I, Yamashita S: Correlation of fasting serum apolipoprotein B-48 with coronary artery disease prevalence. Eur J Clin Invest, 2012; 42: 992-999","DOI":"10.1111\/j.1365-2362.2012.02687.x"},{"key":"474","doi-asserted-by":"crossref","unstructured":"474) Tian J, Chen H, Liu P, Wang C, Chen Y: Fasting apolipoprotein B48 is associated with large artery atherosclerotic stroke: a case-control study. Sci Rep, 2019; 9: 3729","DOI":"10.1038\/s41598-019-40385-0"},{"key":"475","doi-asserted-by":"crossref","unstructured":"475) Nordestgaard BG, Varbo A: Triglycerides and cardiovascular disease. Lancet, 2014; 384: 626-635","DOI":"10.1016\/S0140-6736(14)61177-6"},{"key":"476","doi-asserted-by":"crossref","unstructured":"476) Zilversmit DB: Atherogenesis: a postprandial phenomenon. Circulation, 1979; 60: 473-485","DOI":"10.1161\/01.CIR.60.3.473"},{"key":"477","doi-asserted-by":"crossref","unstructured":"477) Havel RJ: Remnant lipoproteins as therapeutic targets. Curr Opin Lipidol, 2000; 11: 615-620","DOI":"10.1097\/00041433-200012000-00008"},{"key":"478","doi-asserted-by":"crossref","unstructured":"478) Eberly LE, Stamler J, Neaton JD: Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med, 2003; 163: 1077-1083","DOI":"10.1001\/archinte.163.9.1077"},{"key":"479","doi-asserted-by":"crossref","unstructured":"479) Driver SL, Martin SS, Gluckman TJ, Clary JM, Blumenthal RS, Stone NJ: Fasting or Nonfasting Lipid Measurements: It Depends on the Question. J Am Coll Cardiol, 2016; 67: 1227-1234","DOI":"10.1016\/j.jacc.2015.12.047"},{"key":"480","doi-asserted-by":"crossref","unstructured":"480) Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, Watts GF, Sypniewska G, Wiklund O, Bor\u00e9n J, Chapman MJ, Cobbaert C, Descamps OS, von Eckardstein A, Kamstrup PR, Pulkki K, Kronenberg F, Remaley AT, Rifai N, Ros E, Langlois M: Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J, 2016; 37: 1944-1958","DOI":"10.1093\/eurheartj\/ehw152"},{"key":"481","doi-asserted-by":"crossref","unstructured":"481) Masuda D, Sakai N, Sugimoto T, Kitazume-Taneike R, Yamashita T, Kawase R, Nakaoka H, Inagaki M, Nakatani K, Yuasa-Kawase M, Tsubakio-Yamamoto K, Ohama T, Nakagawa-Toyama Y, Nishida M, Ishigami M, Masuda Y, Matsuyama A, Komuro I, Yamashita S: Fasting serum apolipoprotein B-48 can be a marker of postprandial hyperlipidemia. J Atheroscler Thromb, 2011; 18: 1062-1070","DOI":"10.5551\/jat.10470"},{"key":"482","doi-asserted-by":"crossref","unstructured":"482) Yamashita S, Arai H, Yokote K, Araki E, Suganami H, Ishibashi S: Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia. J Clin Lipidol, 2018; 12: 1267-1279.e1264","DOI":"10.1016\/j.jacl.2018.06.010"},{"key":"483","doi-asserted-by":"crossref","unstructured":"483) Ohno Y, Miyoshi T, Noda Y, Oe H, Toh N, Nakamura K, Kohno K, Morita H, Ito H: Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study. Cardiovasc Diabetol, 2014; 13: 71","DOI":"10.1186\/1475-2840-13-71"},{"key":"484","doi-asserted-by":"crossref","unstructured":"484) Kurozumi A, Okada Y, Mori H, Kobayashi T, Masuda D, Yamashita S, Tanaka Y: Detrimental effects of high-fat diet loading on vascular endothelial function and therapeutic efficacy of ezetimibe and statins in patients with type 2 diabetes. Endocr J, 2016; 63: 431-440","DOI":"10.1507\/endocrj.EJ15-0623"},{"key":"485","doi-asserted-by":"crossref","unstructured":"485) Nakamura A, Sato K, Kanazawa M, Kondo M, Endo H, Takahashi T, Nozaki E: Impact of decreased insulin resistance by ezetimibe on postprandial lipid profiles and endothelial functions in obese, non-diabetic-metabolic syndrome patients with coronary artery disease. Heart Vessels, 2019; 34: 916-925","DOI":"10.1007\/s00380-018-1319-x"},{"key":"486","doi-asserted-by":"crossref","unstructured":"486) Sawada T, Tsubata H, Hashimoto N, Takabe M, Miyata T, Aoki K, Yamashita S, Oishi S, Osue T, Yokoi K, Tsukishiro Y, Onishi T, Shimane A, Taniguchi Y, Yasaka Y, Ohara T, Kawai H, Yokoyama M: Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial. Cardiovasc Diabetol, 2016; 15: 121","DOI":"10.1186\/s12933-016-0437-y"},{"key":"487","doi-asserted-by":"crossref","unstructured":"487) Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA, 1988; 260: 1917-1921","DOI":"10.1001\/jama.260.13.1917"},{"key":"488","doi-asserted-by":"crossref","unstructured":"488) Krauss R: Low-density lipoprotein subclasses and risk of coronary artery disease. Curr Opin Lipidol, 1991; 2: 248-242","DOI":"10.1097\/00041433-199108000-00005"},{"key":"489","doi-asserted-by":"crossref","unstructured":"489) St-Pierre AC, Cantin B, Dagenais GR, Mauri\u00e8ge P, Bernard PM, Despr\u00e9s JP, Lamarche B: Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Qu\u00e9bec Cardiovascular Study. Arterioscler Thromb Vasc Biol, 2005; 25: 553-559","DOI":"10.1161\/01.ATV.0000154144.73236.f4"},{"key":"490","doi-asserted-by":"crossref","unstructured":"490) Arsenault BJ, Lemieux I, Despr\u00e9s JP, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM: Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study. Eur Heart J, 2007; 28: 2770-2777","DOI":"10.1093\/eurheartj\/ehm390"},{"key":"491","doi-asserted-by":"crossref","unstructured":"491) El Harchaoui K, van der Steeg WA, Stroes ES, Kuivenhoven JA, Otvos JD, Wareham NJ, Hutten BA, Kastelein JJ, Khaw KT, Boekholdt SM: Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol, 2007; 49: 547-553","DOI":"10.1016\/j.jacc.2006.09.043"},{"key":"492","doi-asserted-by":"crossref","unstructured":"492) Austin MA, Rodriguez BL, McKnight B, McNeely MJ, Edwards KL, Curb JD, Sharp DS: Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. Am J Cardiol, 2000; 86: 412-416","DOI":"10.1016\/S0002-9149(00)00956-5"},{"key":"493","doi-asserted-by":"crossref","unstructured":"493) Rizzo M, Pernice V, Frasheri A, Berneis K: Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease. Atherosclerosis, 2008; 197: 237-241","DOI":"10.1016\/j.atherosclerosis.2007.03.034"},{"key":"494","doi-asserted-by":"crossref","unstructured":"494) Rizzo M, Krayenb\u00fchl PA, Pernice V, Frasheri A, Battista Rini G, Berneis K: LDL size and subclasses in patients with abdominal aortic aneurysm. Int J Cardiol, 2009; 134: 406-408","DOI":"10.1016\/j.ijcard.2007.12.082"},{"key":"495","doi-asserted-by":"crossref","unstructured":"495) Hirano T, Ito Y, Koba S, Toyoda M, Ikejiri A, Saegusa H, Yamazaki J, Yoshino G: Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol, 2004; 24: 558-563","DOI":"10.1161\/01.ATV.0000117179.92263.08"},{"key":"496","doi-asserted-by":"crossref","unstructured":"496) Koba S, Yokota Y, Hirano T, Ito Y, Ban Y, Tsunoda F, Sato T, Shoji M, Suzuki H, Geshi E, Kobayashi Y, Katagiri T: Small LDL-cholesterol is superior to LDL-cholesterol for determining severe coronary atherosclerosis. J Atheroscler Thromb, 2008; 15: 250-260","DOI":"10.5551\/jat.E572"},{"key":"497","doi-asserted-by":"crossref","unstructured":"497) Nishikura T, Koba S, Yokota Y, Hirano T, Tsunoda F, Shoji M, Hamazaki Y, Suzuki H, Itoh Y, Katagiri T, Kobayashi Y: Elevated small dense low-density lipoprotein cholesterol as a predictor for future cardiovascular events in patients with stable coronary artery disease. J Atheroscler Thromb, 2014; 21: 755-767","DOI":"10.5551\/jat.23465"},{"key":"498","doi-asserted-by":"crossref","unstructured":"498) de Graaf J, Hak-Lemmers HL, Hectors MP, Demacker PN, Hendriks JC, Stalenhoef AF: Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb, 1991; 11: 298-306","DOI":"10.1161\/01.ATV.11.2.298"},{"key":"499","doi-asserted-by":"crossref","unstructured":"499) Galeano NF, Al-Haideri M, Keyserman F, Rumsey SC, Deckelbaum RJ: Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J Lipid Res, 1998; 39: 1263-1273","DOI":"10.1016\/S0022-2275(20)32551-7"},{"key":"500","doi-asserted-by":"crossref","unstructured":"500) Ip S, Lichtenstein AH, Chung M, Lau J, Balk EM: Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes. Ann Intern Med, 2009; 150: 474-484","DOI":"10.7326\/0003-4819-150-7-200904070-00007"},{"key":"501","doi-asserted-by":"crossref","unstructured":"501) Berneis KK, Krauss RM: Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res, 2002; 43: 1363-1379","DOI":"10.1194\/jlr.R200004-JLR200"},{"key":"502","doi-asserted-by":"crossref","unstructured":"502) Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM: Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest, 1993; 92: 141-146","DOI":"10.1172\/JCI116541"},{"key":"503","doi-asserted-by":"crossref","unstructured":"503) Austin MA, Edwards KL: Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol, 1996; 7: 167-171","DOI":"10.1097\/00041433-199606000-00010"},{"key":"504","doi-asserted-by":"crossref","unstructured":"504) Arai H, Kokubo Y, Watanabe M, Sawamura T, Ito Y, Minagawa A, Okamura T, Miyamato Y: Small dense low-density lipoproteins cholesterol can predict incident cardiovascular disease in an urban Japanese cohort: the Suita study. J Atheroscler Thromb, 2013; 20: 195-203","DOI":"10.5551\/jat.14936"},{"key":"505","doi-asserted-by":"crossref","unstructured":"505) Higashioka M, Sakata S, Honda T, Hata J, Yoshida D, Hirakawa Y, Shibata M, Goto K, Kitazono T, Osawa H, Ninomiya T: Small Dense Low-Density Lipoprotein Cholesterol and the Risk of Coronary Heart Disease in a Japanese Community. J Atheroscler Thromb, 2020; 27: 669-682","DOI":"10.5551\/jat.51961"},{"key":"506","doi-asserted-by":"crossref","unstructured":"506) Higashioka M, Sakata S, Honda T, Hata J, Shibata M, Yoshida D, Goto K, Kitazono T, Osawa H, Ninomiya T: The Association of Small Dense Low-Density Lipoprotein Cholesterol and Coronary Heart Disease in Subjects at High Cardiovascular Risk. J Atheroscler Thromb, 2021; 28: 79-89","DOI":"10.5551\/jat.55350"},{"key":"507","doi-asserted-by":"crossref","unstructured":"507) Hoogeveen RC, Gaubatz JW, Sun W, Dodge RC, Crosby JR, Jiang J, Couper D, Virani SS, Kathiresan S, Boerwinkle E, Ballantyne CM: Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol, 2014; 34: 1069-1077","DOI":"10.1161\/ATVBAHA.114.303284"},{"key":"508","doi-asserted-by":"crossref","unstructured":"508) Tsai MY, Steffen BT, Guan W, McClelland RL, Warnick R, McConnell J, Hoefner DM, Remaley AT: New automated assay of small dense low-density lipoprotein cholesterol identifies risk of coronary heart disease: the Multi-ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol, 2014; 34: 196-201","DOI":"10.1161\/ATVBAHA.113.302401"},{"key":"509","doi-asserted-by":"crossref","unstructured":"509) Duran EK, Aday AW, Cook NR, Buring JE, Ridker PM, Pradhan AD: Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease. J Am Coll Cardiol, 2020; 75: 2122-2135","DOI":"10.1016\/j.jacc.2020.02.059"},{"key":"510","doi-asserted-by":"crossref","unstructured":"510) Balling M, Nordestgaard BG, Langsted A, Varbo A, Kamstrup PR, Afzal S: Small Dense Low-Density Lipoprotein Cholesterol Predicts Atherosclerotic Cardiovascular Disease in the Copenhagen General Population Study. J Am Coll Cardiol, 2020; 75: 2873-2875","DOI":"10.1016\/j.jacc.2020.03.072"},{"key":"511","doi-asserted-by":"crossref","unstructured":"511) Jin JL, Zhang HW, Cao YX, Liu HH, Hua Q, Li YF, Zhang Y, Wu NQ, Zhu CG, Xu RX, Gao Y, Li XL, Cui CJ, Liu G, Sun J, Dong Q, Guo YL, Li JJ: Association of small dense low-density lipoprotein with cardiovascular outcome in patients with coronary artery disease and diabetes: a prospective, observational cohort study. Cardiovasc Diabetol, 2020; 19: 45","DOI":"10.1186\/s12933-020-01015-6"},{"key":"512","doi-asserted-by":"crossref","unstructured":"512) Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE: Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA, 2005; 294: 326-333","DOI":"10.1001\/jama.294.3.326"},{"key":"513","doi-asserted-by":"crossref","unstructured":"513) Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD: A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes, 2011; 4: 337-345","DOI":"10.1161\/CIRCOUTCOMES.110.959247"},{"key":"514","doi-asserted-by":"crossref","unstructured":"514) Pencina MJ, D\u2019Agostino RB, Zdrojewski T, Williams K, Thanassoulis G, Furberg CD, Peterson ED, Vasan RS, Sniderman AD: Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. Eur J Prev Cardiol, 2015; 22: 1321-1327","DOI":"10.1177\/2047487315569411"},{"key":"515","doi-asserted-by":"crossref","unstructured":"515) Thanassoulis G, Williams K, Ye K, Brook R, Couture P, Lawler PR, de Graaf J, Furberg CD, Sniderman A: Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials. J Am Heart Assoc, 2014; 3: e000759","DOI":"10.1161\/JAHA.113.000759"},{"key":"516","doi-asserted-by":"crossref","unstructured":"516) Robinson JG, Wang S, Jacobson TA: Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. Am J Cardiol, 2012; 110: 1468-1476","DOI":"10.1016\/j.amjcard.2012.07.007"},{"key":"517","doi-asserted-by":"crossref","unstructured":"517) Khan SU, Khan MU, Valavoor S, Khan MS, Okunrintemi V, Mamas MA, Leucker TM, Blaha MJ, Michos ED: Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials. Eur J Prev Cardiol, 2020; 27: 1255-1268","DOI":"10.1177\/2047487319871733"},{"key":"518","doi-asserted-by":"crossref","unstructured":"518) Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, Laufs U, Oliver-Williams C, Wood AM, Butterworth AS, Di Angelantonio E, Danesh J, Nicholls SJ, Bhatt DL, Sabatine MS, Catapano AL: Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. JAMA, 2019; 321: 364-373","DOI":"10.1001\/jama.2018.20045"},{"key":"519","doi-asserted-by":"crossref","unstructured":"519) Ling Y, Jiang J, Wu B, Gao X: Serum triglyceride, high-density lipoprotein cholesterol, apolipoprotein B, and coronary heart disease in a Chinese population undergoing coronary angiography. J Clin Lipidol, 2017; 11: 646-656","DOI":"10.1016\/j.jacl.2017.02.017"},{"key":"520","doi-asserted-by":"crossref","unstructured":"520) Nordestgaard BG, Langlois MR, Langsted A, Chapman MJ, Aakre KM, Baum H, Bor\u00e9n J, Bruckert E, Catapano A, Cobbaert C, Collinson P, Descamps OS, Duff CJ, von Eckardstein A, Hammerer-Lercher A, Kamstrup PR, Kolovou G, Kronenberg F, Mora S, Pulkki K, Remaley AT, Rifai N, Ros E, Stankovic S, Stavljenic-Rukavina A, Sypniewska G, Watts GF, Wiklund O, Laitinen P: Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. Atherosclerosis, 2020; 294: 46-61","DOI":"10.1016\/j.atherosclerosis.2019.12.005"},{"key":"521","doi-asserted-by":"crossref","unstructured":"521) Welsh C, Celis-Morales CA, Brown R, Mackay DF, Lewsey J, Mark PB, Gray SR, Ferguson LD, Anderson JJ, Lyall DM, Cleland JG, Jhund PS, Gill JMR, Pell JP, Sattar N, Welsh P: Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease. Circulation, 2019; 140: 542-552","DOI":"10.1161\/CIRCULATIONAHA.119.041149"},{"key":"522","doi-asserted-by":"crossref","unstructured":"522) McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, Kazmi K, Yusuf S: Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet, 2008; 372: 224-233","DOI":"10.1016\/S0140-6736(08)61076-4"},{"key":"523","doi-asserted-by":"crossref","unstructured":"523) Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, Deedwania P, Olsson AG, Boekholdt SM, Demicco DA, Szarek M, LaRosa JC, Pedersen TR, Grundy SM: Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation, 2008; 117: 3002-3009","DOI":"10.1161\/CIRCULATIONAHA.107.713438"},{"key":"524","doi-asserted-by":"crossref","unstructured":"524) Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E: Prognostic utility of apoB\/AI, total cholesterol\/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol, 2009; 29: 424-430","DOI":"10.1161\/ATVBAHA.108.181735"},{"key":"525","doi-asserted-by":"crossref","unstructured":"525) Sung KC, Ryu S, Wild SH, Byrne CD: An increased high-density lipoprotein cholesterol\/apolipoprotein A-I ratio is associated with increased cardiovascular and all-cause mortality. Heart, 2015; 101: 553-558","DOI":"10.1136\/heartjnl-2014-306784"},{"key":"526","doi-asserted-by":"crossref","unstructured":"526) Chang TI, Streja E, Soohoo M, Kim TW, Rhee CM, Kovesdy CP, Kashyap ML, Vaziri ND, Kalantar-Zadeh K, Moradi H: Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients. Clin J Am Soc Nephrol, 2017; 12: 591-602","DOI":"10.2215\/CJN.08730816"},{"key":"527","doi-asserted-by":"crossref","unstructured":"527) Tian M, Li R, Shan Z, Wang DW, Jiang J, Cui G: Comparison of Apolipoprotein B\/A1 ratio, Framingham risk score and TC\/HDL-c for predicting clinical outcomes in patients undergoing percutaneous coronary intervention. Lipids Health Dis, 2019; 18: 202","DOI":"10.1186\/s12944-019-1144-y"},{"key":"528","unstructured":"528) Hong LF, Yan XN, Fan Y, Wu Q, Luo SH, Yang B, Li JJ: Is the ratio of apoB\/apoA-1 the best predictor for the severity of coronary artery lesions in Chinese diabetics with stable angina pectoris? An assessment based on Gensini scores. J Geriatr Cardiol, 2015; 12: 402-409"},{"key":"529","doi-asserted-by":"crossref","unstructured":"529) Boot CS, Middling E, Allen J, Neely RDG: Evaluation of the Non-HDL Cholesterol to Apolipoprotein B Ratio as a Screening Test for Dysbetalipoproteinemia. Clin Chem, 2019; 65: 313-320","DOI":"10.1373\/clinchem.2018.292425"},{"key":"530","doi-asserted-by":"crossref","unstructured":"530) Hisamatsu T, Fujiyoshi A, Miura K, Ohkubo T, Kadota A, Kadowaki S, Kadowaki T, Yamamoto T, Miyagawa N, Zaid M, Torii S, Takashima N, Murakami Y, Okamura T, Horie M, Ueshima H: Lipoprotein particle profiles compared with standard lipids in association with coronary artery calcification in the general Japanese population. Atherosclerosis, 2014; 236: 237-243","DOI":"10.1016\/j.atherosclerosis.2014.07.019"},{"key":"531","doi-asserted-by":"crossref","unstructured":"531) Li Y, Yatsuya H, Tanaka S, Iso H, Okayama A, Tsuji I, Sakata K, Miyamoto Y, Ueshima H, Miura K, Murakami Y, Okamura T: Estimation of 10-Year Risk of Death from Coronary Heart Disease, Stroke, and Cardiovascular Disease in a Pooled Analysis of Japanese Cohorts: EPOCH-JAPAN. J Atheroscler Thromb, 2021; 28: 816-825","DOI":"10.5551\/jat.58958"},{"key":"532","doi-asserted-by":"crossref","unstructured":"532) Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, Butterworth AS, Amouyel P, Assmann G, Bakker SJ, Barr EL, Barrett-Connor E, Benjamin EJ, Bj\u00f6rkelund C, Brenner H, Brunner E, Clarke R, Cooper JA, Cremer P, Cushman M, Dagenais GR, D\u2019Agostino RB, Sr., Dankner R, Davey-Smith G, Deeg D, Dekker JM, Engstr\u00f6m G, Folsom AR, Fowkes FG, Gallacher J, Gaziano JM, Giampaoli S, Gillum RF, Hofman A, Howard BV, Ingelsson E, Iso H, J\u00f8rgensen T, Kiechl S, Kitamura A, Kiyohara Y, Koenig W, Kromhout D, Kuller LH, Lawlor DA, Meade TW, Nissinen A, Nordestgaard BG, Onat A, Panagiotakos DB, Psaty BM, Rodriguez B, Rosengren A, Salomaa V, Kauhanen J, Salonen JT, Shaffer JA, Shea S, Ford I, Stehouwer CD, Strandberg TE, Tipping RW, Tosetto A, Wassertheil-Smoller S, Wennberg P, Westendorp RG, Whincup PH, Wilhelmsen L, Woodward M, Lowe GD, Wareham NJ, Khaw KT, Sattar N, Packard CJ, Gudnason V, Ridker PM, Pepys MB, Thompson SG, Danesh J: C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med, 2012; 367: 1310-1320","DOI":"10.1056\/NEJMoa1107477"},{"key":"533","doi-asserted-by":"crossref","unstructured":"533) Kawase Ishihara K, Kokubo Y, Yokota C, Hida E, Miyata T, Toyoda K, Matsumoto M, Minematsu K, Miyamoto Y: Effect of Plasma Fibrinogen, High-Sensitive C-Reactive Protein, and Cigarette Smoking on Carotid Atherosclerosis: The Suita Study. J Stroke Cerebrovasc Dis, 2015; 24: 2385-2389","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.06.039"},{"key":"534","doi-asserted-by":"crossref","unstructured":"534) Chei CL, Yamagishi K, Kitamura A, Kiyama M, Imano H, Ohira T, Cui R, Tanigawa T, Sankai T, Ishikawa Y, Sato S, Iso H: C-reactive protein levels and risk of stroke and its subtype in Japanese: The Circulatory Risk in Communities Study (CIRCS). Atherosclerosis, 2011; 217: 187-193","DOI":"10.1016\/j.atherosclerosis.2011.03.001"},{"key":"535","doi-asserted-by":"crossref","unstructured":"535) Iso H, Noda H, Ikeda A, Yamagishi K, Inoue M, Iwasaki M, Tsugane S: The impact of C-reactive protein on risk of stroke, stroke subtypes, and ischemic heart disease in middle-aged Japanese: the Japan public health center-based study. J Atheroscler Thromb, 2012; 19: 756-766","DOI":"10.5551\/jat.11999"},{"key":"536","doi-asserted-by":"crossref","unstructured":"536) Tian R, Tian M, Wang L, Qian H, Zhang S, Pang H, Liu Z, Fang L, Shen Z: C-reactive protein for predicting cardiovascular and all-cause mortality in type 2 diabetic patients: A meta-analysis. Cytokine, 2019; 117: 59-64","DOI":"10.1016\/j.cyto.2019.02.005"},{"key":"537","doi-asserted-by":"crossref","unstructured":"537) Tabrizi R, Tamtaji OR, Mirhosseini N, Lankarani KB, Akbari M, Dadgostar E, Borhani-Haghighi A, Peymani P, Ahmadizar F, Asemi Z: The effects of statin use on inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res, 2019; 141: 85-103","DOI":"10.1016\/j.phrs.2018.12.010"},{"key":"538","doi-asserted-by":"crossref","unstructured":"538) Zhang XL, Lan RF, Zhang XW, Xu W, Wang L, Kang LN, Xu B: Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta-Analysis. J Am Heart Assoc, 2019; 8: e012428","DOI":"10.1161\/JAHA.119.012428"},{"key":"539","doi-asserted-by":"crossref","unstructured":"539) Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T, Engert JC, Clarke R, Davey-Smith G, Nordestgaard BG, Saleheen D, Samani NJ, Sandhu M, Anand S, Pepys MB, Smeeth L, Whittaker J, Casas JP, Thompson SG, Hingorani AD, Danesh J: Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ, 2011; 342: d548","DOI":"10.1136\/bmj.d548"},{"key":"540","doi-asserted-by":"crossref","unstructured":"540) Matsuura Y, Hatakeyama K, Imamura T, Tsuruda T, Shibata Y, Kodama T, Kitamura K, Asada Y: Different distribution of pentraxin 3 and C-reactive protein in coronary atherosclerotic plaques. J Atheroscler Thromb, 2012; 19: 837-845","DOI":"10.5551\/jat.12526"},{"key":"541","doi-asserted-by":"crossref","unstructured":"541) Iwata A, Miura S, Tanaka T, Ike A, Sugihara M, Nishikawa H, Kawamura A, Saku K: Plasma pentraxin-3 levels are associated with coronary plaque vulnerability and are decreased by statin. Coron Artery Dis, 2012; 23: 315-321","DOI":"10.1097\/MCA.0b013e328352ffec"},{"key":"542","doi-asserted-by":"crossref","unstructured":"542) Yasunaga T, Ikeda S, Koga S, Nakata T, Yoshida T, Masuda N, Kohno S, Maemura K: Plasma pentraxin 3 is a more potent predictor of endothelial dysfunction than high-sensitive C-reactive protein. Int Heart J, 2014; 55: 160-164","DOI":"10.1536\/ihj.13-253"},{"key":"543","doi-asserted-by":"crossref","unstructured":"543) Li H, Liu W, Xie J: Circulating interleukin-6 levels and cardiovascular and all-cause mortality in the elderly population: A meta-analysis. Arch Gerontol Geriatr, 2017; 73: 257-262","DOI":"10.1016\/j.archger.2017.08.007"},{"key":"544","doi-asserted-by":"crossref","unstructured":"544) Zhang B, Li XL, Zhao CR, Pan CL, Zhang Z: Interleukin-6 as a Predictor of the Risk of Cardiovascular Disease: A Meta-Analysis of Prospective Epidemiological Studies. Immunol Invest, 2018; 47: 689-699","DOI":"10.1080\/08820139.2018.1480034"},{"key":"545","unstructured":"545) Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ: Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet, 2017; 390: 1833-1842"},{"key":"546","doi-asserted-by":"crossref","unstructured":"546) Gerhard GT, Duell PB: Homocysteine and atherosclerosis. Curr Opin Lipidol, 1999; 10: 417-428","DOI":"10.1097\/00041433-199910000-00006"},{"key":"547","doi-asserted-by":"crossref","unstructured":"547) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA, 2002; 288: 2015-2022","DOI":"10.1001\/jama.288.16.2015"},{"key":"548","doi-asserted-by":"crossref","unstructured":"548) Verhoef P, Stampfer MJ: Prospective studies of homocysteine and cardiovascular disease. Nutr Rev, 1995; 53: 283-288","DOI":"10.1111\/j.1753-4887.1995.tb01478.x"},{"key":"549","doi-asserted-by":"crossref","unstructured":"549) Peng HY, Man CF, Xu J, Fan Y: Elevated homocysteine levels and risk of cardiovascular and all-cause mortality: a meta-analysis of prospective studies. J Zhejiang Univ Sci B, 2015; 16: 78-86","DOI":"10.1631\/jzus.B1400183"},{"key":"550","doi-asserted-by":"crossref","unstructured":"550) de Ruijter W, Westendorp RG, Assendelft WJ, den Elzen WP, de Craen AJ, le Cessie S, Gussekloo J: Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ, 2009; 338: a3083","DOI":"10.1136\/bmj.a3083"},{"key":"551","doi-asserted-by":"crossref","unstructured":"551) Lewis SJ, Ebrahim S, Davey Smith G: Meta-analysis of MTHFR 677C-&gt;T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ, 2005; 331: 1053","DOI":"10.1136\/bmj.38611.658947.55"},{"key":"552","doi-asserted-by":"crossref","unstructured":"552) Mart\u00ed-Carvajal AJ, Sol\u00e0 I, Lathyris D, Dayer M: Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev, 2017; 8: Cd006612","DOI":"10.1002\/14651858.CD006612.pub5"},{"key":"553","doi-asserted-by":"crossref","unstructured":"553) Li Y, Huang T, Zheng Y, Muka T, Troup J, Hu FB: Folic Acid Supplementation and the Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc, 2016; 5","DOI":"10.1161\/JAHA.116.003768"},{"key":"554","doi-asserted-by":"crossref","unstructured":"554) Zeng R, Xu CH, Xu YN, Wang YL, Wang M: The effect of folate fortification on folic acid-based homocysteine-lowering intervention and stroke risk: a meta-analysis. Public Health Nutr, 2015; 18: 1514-1521","DOI":"10.1017\/S1368980014002134"},{"key":"555","doi-asserted-by":"crossref","unstructured":"555) Hou X, Chen X, Shi J: Genetic polymorphism of MTHFR C677T and premature coronary artery disease susceptibility: A meta-analysis. Gene, 2015; 565: 39-44","DOI":"10.1016\/j.gene.2015.03.062"},{"key":"556","doi-asserted-by":"crossref","unstructured":"556) van Meurs JB, Pare G, Schwartz SM, Hazra A, Tanaka T, Vermeulen SH, Cotlarciuc I, Yuan X, M\u00e4larstig A, Bandinelli S, Bis JC, Blom H, Brown MJ, Chen C, Chen YD, Clarke RJ, Dehghan A, Erdmann J, Ferrucci L, Hamsten A, Hofman A, Hunter DJ, Goel A, Johnson AD, Kathiresan S, Kampman E, Kiel DP, Kiemeney LA, Chambers JC, Kraft P, Lindemans J, McKnight B, Nelson CP, O\u2019Donnell CJ, Psaty BM, Ridker PM, Rivadeneira F, Rose LM, Seedorf U, Siscovick DS, Schunkert H, Selhub J, Ueland PM, Vollenweider P, Waeber G, Waterworth DM, Watkins H, Witteman JC, den Heijer M, Jacques P, Uitterlinden AG, Kooner JS, Rader DJ, Reilly MP, Mooser V, Chasman DI, Samani NJ, Ahmadi KR: Common genetic loci influencing plasma homocysteine concentrations and their effect on risk of coronary artery disease. Am J Clin Nutr, 2013; 98: 668-676","DOI":"10.3945\/ajcn.112.044545"},{"key":"557","doi-asserted-by":"crossref","unstructured":"557) Fuster V: Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation, 1994; 90: 2126-2146","DOI":"10.1161\/01.CIR.90.4.2126"},{"key":"558","doi-asserted-by":"crossref","unstructured":"558) Zhu M, Mao M, Lou X: Elevated homocysteine level and prognosis in patients with acute coronary syndrome: a meta-analysis. Biomarkers, 2019; 24: 309-316","DOI":"10.1080\/1354750X.2019.1589577"},{"key":"559","doi-asserted-by":"crossref","unstructured":"559) Zhang Z, Xiao S, Yang C, Ye R, Hu X, Chen X: Association of Elevated Plasma Homocysteine Level with Restenosis and Clinical Outcomes After Percutaneous Coronary Interventions: a Systemic Review and Meta-analysis. Cardiovasc Drugs Ther, 2019; 33: 353-361","DOI":"10.1007\/s10557-019-06866-0"},{"key":"560","doi-asserted-by":"crossref","unstructured":"560) Yeh JK, Chen CC, Hsieh MJ, Tsai ML, Yang CH, Chen DY, Chang SH, Wang CY, Lee CH, Hsieh IC: Impact of Homocysteine Level on Long-term Cardiovascular Outcomes in Patients after Coronary Artery Stenting. J Atheroscler Thromb, 2017; 24: 696-705","DOI":"10.5551\/jat.36434"},{"key":"561","doi-asserted-by":"crossref","unstructured":"561) Zhang T, Jiang Y, Zhang S, Tie T, Cheng Y, Su X, Man Z, Hou J, Sun L, Tian M, Zhang Y, Li J, Ma Y: The association between homocysteine and ischemic stroke subtypes in Chinese: A meta-analysis. Medicine (Baltimore), 2020; 99: e19467","DOI":"10.1097\/MD.0000000000019467"},{"key":"562","doi-asserted-by":"crossref","unstructured":"562) Piao X, Wu G, Yang P, Shen J, De A, Wu J, Qu Q: Association between Homocysteine and Cerebral Small Vessel Disease: A Meta-Analysis. J Stroke Cerebrovasc Dis, 2018; 27: 2423-2430","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.04.035"},{"key":"563","unstructured":"563) Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M, Goldbourt U, Willeit J, Kiechl S, Yarnell JW, Sweetnam PM, Elwood PC, Cushman M, Psaty BM, Tracy RP, Tybjaerg-Hansen A, Haverkate F, de Maat MP, Fowkes FG, Lee AJ, Smith FB, Salomaa V, Harald K, Rasi R, Vahtera E, Jousilahti P, Pekkanen J, D\u2019Agostino R, Kannel WB, Wilson PW, Tofler G, Arocha-Pi\u00f1ango CL, Rodriguez-Larralde A, Nagy E, Mijares M, Espinosa R, Rodriquez-Roa E, Ryder E, Diez-Ewald MP, Campos G, Fernandez V, Torres E, Marchioli R, Valagussa F, Rosengren A, Wilhelmsen L, Lappas G, Eriksson H, Cremer P, Nagel D, Curb JD, Rodriguez B, Yano K, Salonen JT, Nyyss\u00f6nen K, Tuomainen TP, Hedblad B, Lind P, Loewel H, Koenig W, Meade TW, Cooper JA, De Stavola B, Knottenbelt C, Miller GJ, Cooper JA, Bauer KA, Rosenberg RD, Sato S, Kitamura A, Naito Y, Palosuo T, Ducimetiere P, Amouyel P, Arveiler D, Evans AE, Ferrieres J, Juhan-Vague I, Bingham A, Schulte H, Assmann G, Cantin B, Lamarche B, Despr\u00e9s JP, Dagenais GR, Tunstall-Pedoe H, Woodward M, Ben-Shlomo Y, Davey Smith G, Palmieri V, Yeh JL, Rudnicka A, Ridker P, Rodeghiero F, Tosetto A, Shepherd J, Ford I, Robertson M, Brunner E, Shipley M, Feskens EJ, Kromhout D, Dickinson A, Ireland B, Juzwishin K, Kaptoge S, Lewington S, Memon A, Sarwar N, Walker M, Wheeler J, White I, Wood A: Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA, 2005; 294: 1799-1809"},{"key":"564","doi-asserted-by":"crossref","unstructured":"564) Kunutsor SK, Kurl S, Zaccardi F, Laukkanen JA: Baseline and long-term fibrinogen levels and risk of sudden cardiac death: A new prospective study and meta-analysis. Atherosclerosis, 2016; 245: 171-180","DOI":"10.1016\/j.atherosclerosis.2015.12.020"},{"key":"565","doi-asserted-by":"crossref","unstructured":"565) Ward-Caviness CK, de Vries PS, Wiggins KL, Huffman JE, Yanek LR, Bielak LF, Giulianini F, Guo X, Kleber ME, Kacprowski T, Gro\u00df S, Petersman A, Davey Smith G, Hartwig FP, Bowden J, Hemani G, M\u00fcller-Nuraysid M, Strauch K, Koenig W, Waldenberger M, Meitinger T, Pankratz N, Boerwinkle E, Tang W, Fu YP, Johnson AD, Song C, de Maat MPM, Uitterlinden AG, Franco OH, Brody JA, McKnight B, Chen YI, Psaty BM, Mathias RA, Becker DM, Peyser PA, Smith JA, Bielinski SJ, Ridker PM, Taylor KD, Yao J, Tracy R, Delgado G, Trompet S, Sattar N, Jukema JW, Becker LC, Kardia SLR, Rotter JI, M\u00e4rz W, D\u00f6rr M, Chasman DI, Dehghan A, O\u2019Donnell CJ, Smith NL, Peters A, Morrison AC: Mendelian randomization evaluation of causal effects of fibrinogen on incident coronary heart disease. PLoS One, 2019; 14: e0216222","DOI":"10.1371\/journal.pone.0216222"},{"key":"566","doi-asserted-by":"crossref","unstructured":"566) Tabakc\u0131 MM, Gerin F, Sunbul M, Toprak C, Durmu\u015f H, Demir S, Arslanta\u015f U, Cer\u015fit S, Batgerel U, Karg\u0131n R: Relation of Plasma Fibrinogen Level With the Presence, Severity, and Complexity of Coronary Artery Disease. Clin Appl Thromb Hemost, 2017; 23: 638-644","DOI":"10.1177\/1076029616629210"},{"key":"567","doi-asserted-by":"crossref","unstructured":"567) Nagasawa SY, Ohkubo T, Masaki K, Barinas-Mitchell E, Miura K, Seto T, El-Saed A, Kadowaki T, Willcox BJ, Edmundowicz D, Kadota A, Evans RW, Kadowaki S, Fujiyoshi A, Hisamatsu T, Bertolet MH, Okamura T, Nakamura Y, Kuller LH, Ueshima H, Sekikawa A: Associations between Inflammatory Markers and Subclinical Atherosclerosis in Middle-aged White, Japanese-American and Japanese Men: The ERA-JUMP Study. J Atheroscler Thromb, 2015; 22: 590-598","DOI":"10.5551\/jat.23580"},{"key":"568","doi-asserted-by":"crossref","unstructured":"568) Sakamoto T, Yasue H, Ogawa H, Misumi I, Masuda T: Association of patency of the infarct-related coronary artery with plasma levels of plasminogen activator inhibitor activity in acute myocardial infarction. Am J Cardiol, 1992; 70: 271-276","DOI":"10.1016\/0002-9149(92)90603-V"},{"key":"569","doi-asserted-by":"crossref","unstructured":"569) Sahebkar A, Catena C, Ray KK, Vallejo-Vaz AJ, Reiner \u017d, Sechi LA, Colussi G: Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. A systematic review and meta-analysis of randomised controlled trials. Thromb Haemost, 2016; 116: 162-171","DOI":"10.1160\/TH15-10-0770"},{"key":"570","doi-asserted-by":"crossref","unstructured":"570) Wang NC, Matthews KA, Barinas-Mitchell EJ, Chang CC, El Khoudary SR: Inflammatory\/Hemostatic Biomarkers and Coronary Artery Calcium Progression in Women at Midlife (from the Study of Women\u2019s Health Across the Nation, Heart Study). Am J Cardiol, 2016; 118: 311-318","DOI":"10.1016\/j.amjcard.2016.05.009"},{"key":"571","doi-asserted-by":"crossref","unstructured":"571) Jung RG, Motazedian P, Ramirez FD, Simard T, Di Santo P, Visintini S, Faraz MA, Labinaz A, Jung Y, Hibbert B: Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis. Thromb J, 2018; 16: 12","DOI":"10.1186\/s12959-018-0166-4"},{"key":"572","doi-asserted-by":"crossref","unstructured":"572) Neeland IJ, Ross R, Despr\u00e9s JP, Matsuzawa Y, Yamashita S, Shai I, Seidell J, Magni P, Santos RD, Arsenault B, Cuevas A, Hu FB, Griffin B, Zambon A, Barter P, Fruchart JC, Eckel RH: Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol, 2019; 7: 715-725","DOI":"10.1016\/S2213-8587(19)30084-1"},{"key":"573","doi-asserted-by":"crossref","unstructured":"573) Ross R, Neeland IJ, Yamashita S, Shai I, Seidell J, Magni P, Santos RD, Arsenault B, Cuevas A, Hu FB, Griffin BA, Zambon A, Barter P, Fruchart JC, Eckel RH, Matsuzawa Y, Despr\u00e9s JP: Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat Rev Endocrinol, 2020; 16: 177-189","DOI":"10.1038\/s41574-019-0310-7"},{"key":"574","unstructured":"574) Ministry of Health, Labour and Welfare: National health and nutrition survey in Japan, 2019., 2020 (in Japanese)"},{"key":"575","unstructured":"575) Committee to Evaluate Diagnostic Standards for Metabolic Syndrome: Definition and the diagnostic standard for metabolic syndrome. J Jpn Soc Intern Med, 2005; 94: 794-809 (in Japanese)"},{"key":"576","doi-asserted-by":"crossref","unstructured":"576) Alberti KG, Zimmet P, Shaw J: The metabolic syndrome--a new worldwide definition. Lancet, 2005; 366: 1059-1062","DOI":"10.1016\/S0140-6736(05)67402-8"},{"key":"577","doi-asserted-by":"crossref","unstructured":"577) Nakamura T, Tsubono Y, Kameda-Takemura K, Funahashi T, Yamashita S, Hisamichi S, Kita T, Yamamura T, Matsuzawa Y: Magnitude of sustained multiple risk factors for ischemic heart disease in Japanese employees: a case-control study. Jpn Circ J, 2001; 65: 11-17","DOI":"10.1253\/jcj.65.11"},{"key":"578","unstructured":"578) The 1994 Report of the Group of the Research for the Association between Host Origin and Atherosclerotic Diseases under the Preventive Measure for Work-related Diseases of the Japanese Labor Ministry Significance of host factors contributing to the development of atherosclerosis, 1994 (in Japanese)"},{"key":"579","doi-asserted-by":"crossref","unstructured":"579) Nakamura Y, Yamamoto T, Okamura T, Kadowaki T, Hayakawa T, Kita Y, Saitoh S, Okayama A, Ueshima H: Combined cardiovascular risk factors and outcome: NIPPON DATA80, 1980-1994. Circ J, 2006; 70: 960-964","DOI":"10.1253\/circj.70.960"},{"key":"580","unstructured":"580) Okubo K, Kiyohara Y.: Frequency of the metabolic syndrome in the general inhabitant. Rinsho to Kenkyu, 2004; 81: 1736-1740"},{"key":"581","unstructured":"581) Matsuzawa Y.: Multicenter follow-up study of insulin resistance and the lifestyle basis in patients at high risk of diabetes mellitus-establishment of significance of abdominal obesity for Intervention. Health Science Research Project, Ministry of Health, Labour and Welfare,2001, in Japanese"},{"key":"582","unstructured":"582) Matsuzawa Y, Inoue S, Ikeda Y, Sakata T, Saitou Y,Satoh H, Shirai A, Oono J, Miyazaki S, Tokunaga M,Fukagawa H, Yamanouchi K, Nakamura M.: New evaluation of obesity and diagnostic criteria of obesity. J Jpn Soc Study of Obesity, 2000; 6: 18-28, in Japanese"},{"key":"583","unstructured":"583) Japan Society for the Study of Obesity: Guidelines for the management of obesity disease 2016. 2016 (in Japanese)"},{"key":"584","unstructured":"584) Saito Y, Shirai K, Nakamura T: Diagnostic criteria for obesity. J Jpn Soc Study of Obesity, 2011; 17: 1-78 (in Japanese)"},{"key":"585","doi-asserted-by":"crossref","unstructured":"585) The Examination Committee of Criteria for Obesity Disease in Japan (2002) Japan Society for the Study of Obesity:New criteria for \u2018obesity disease\u2019 in Japan. Circ J, 2002; 66: 987-992","DOI":"10.1253\/circj.66.987"},{"key":"586","doi-asserted-by":"crossref","unstructured":"586) Klein S, Burke LE, Bray GA, Blair S, Allison DB, Pi-Sunyer X, Hong Y, Eckel RH: Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation, 2004; 110: 2952-2967","DOI":"10.1161\/01.CIR.0000145546.97738.1E"},{"key":"587","doi-asserted-by":"crossref","unstructured":"587) Nakamura T, Tokunaga K, Shimomura I, Nishida M, Yoshida S, Kotani K, Islam AH, Keno Y, Kobatake T, Nagai Y, et al.: Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis, 1994; 107: 239-246","DOI":"10.1016\/0021-9150(94)90025-6"},{"key":"588","doi-asserted-by":"crossref","unstructured":"588) Fujimoto WY, Bergstrom RW, Boyko EJ, Chen KW, Leonetti DL, Newell-Morris L, Shofer JB, Wahl PW: Visceral adiposity and incident coronary heart disease in Japanese-American men. The 10-year follow-up results of the Seattle Japanese-American Community Diabetes Study. Diabetes Care, 1999; 22: 1808-1812","DOI":"10.2337\/diacare.22.11.1808"},{"key":"589","doi-asserted-by":"crossref","unstructured":"589) Malik S, Wong ND, Franklin SS, Kamath TV, L\u2019Italien GJ, Pio JR, Williams GR: Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation, 2004; 110: 1245-1250","DOI":"10.1161\/01.CIR.0000140677.20606.0E"},{"key":"590","doi-asserted-by":"crossref","unstructured":"590) Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP: National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation, 2004; 110: 1251-1257","DOI":"10.1161\/01.CIR.0000140762.04598.F9"},{"key":"591","doi-asserted-by":"crossref","unstructured":"591) Isomaa B, Almgren P, Tuomi T, Fors\u00e9n B, Lahti K, Niss\u00e9n M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 2001; 24: 683-689","DOI":"10.2337\/diacare.24.4.683"},{"key":"592","doi-asserted-by":"crossref","unstructured":"592) Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA, 2002; 288: 2709-2716","DOI":"10.1001\/jama.288.21.2709"},{"key":"593","doi-asserted-by":"crossref","unstructured":"593) Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ: The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol, 2010; 56: 1113-1132","DOI":"10.1016\/j.jacc.2010.05.034"},{"key":"594","doi-asserted-by":"crossref","unstructured":"594) Takeuchi H, Saitoh S, Takagi S, Ohnishi H, Ohhata J, Isobe T, Shimamoto K: Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program-Adult Treatment Panel III to Japanese men--the Tanno and Sobetsu Study. Hypertens Res, 2005; 28: 203-208","DOI":"10.1291\/hypres.28.203"},{"key":"595","doi-asserted-by":"crossref","unstructured":"595) Iso H, Cui R, Takamoto I, Kiyama M, Saito I, Okamura T, Miyamoto Y, Higashiyama A, Kiyohara Y, Ninomiya T, Yamada M, Nakagawa H, Sakurai M, Shimabukuro M, Higa M, Shimamoto K, Saito S, Daimon M, Kayama T, Noda M, Ito S, Yokote K, Ito C, Nakao K, Yamauchi T, Kadowaki T: Risk Classification for Metabolic Syndrome and the Incidence of Cardiovascular Disease in Japan With Low Prevalence of Obesity: A Pooled Analysis of 10 Prospective Cohort Studies. J Am Heart Assoc, 2021: e020760","DOI":"10.1161\/JAHA.121.020760"},{"key":"596","doi-asserted-by":"crossref","unstructured":"596) Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC, Jr.: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 2009; 120: 1640-1645","DOI":"10.1161\/CIRCULATIONAHA.109.192644"},{"key":"597","doi-asserted-by":"crossref","unstructured":"597) Hiuge-Shimizu A, Kishida K, Funahashi T, Ishizaka Y, Oka R, Okada M, Suzuki S, Takaya N, Nakagawa T, Fukui T, Fukuda H, Watanabe N, Yoshizumi T, Nakamura T, Matsuzawa Y, Yamakado M, Shimomura I: Absolute value of visceral fat area measured on computed tomography scans and obesity-related cardiovascular risk factors in large-scale Japanese general population (the VACATION-J study). Ann Med, 2012; 44: 82-92","DOI":"10.3109\/07853890.2010.526138"},{"key":"598","doi-asserted-by":"crossref","unstructured":"598) Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner \u017d, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT: 2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J, 2016; 37: 2999-3058","DOI":"10.1093\/eurheartj\/ehw272"},{"key":"599","doi-asserted-by":"crossref","unstructured":"599) Nishimura K, Okamura T, Watanabe M, Nakai M, Takegami M, Higashiyama A, Kokubo Y, Okayama A, Miyamoto Y: Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the framingham risk score: the suita study. J Atheroscler Thromb, 2014; 21: 784-798","DOI":"10.5551\/jat.19356"},{"key":"600","doi-asserted-by":"crossref","unstructured":"600) Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, Umemoto S, Egusa G, Ohmura H, Okamura T, Kihara S, Koba S, Saito I, Shoji T, Daida H, Tsukamoto K, Deguchi J, Dohi S, Dobashi K, Hamaguchi H, Hara M, Hiro T, Biro S, Fujioka Y, Maruyama C, Miyamoto Y, Murakami Y, Yokode M, Yoshida H, Rakugi H, Wakatsuki A, Yamashita S: Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb, 2018; 25: 846-984","DOI":"10.5551\/jat.GL2017"},{"key":"601","unstructured":"601) Sankai T, Miyagaki T, Iso H, Shimamoto T, Iida M, Tanigaki M, Naito Y, Sato S, Kiyama M, Kitamura A, et al.: [A population-based study of the proportion by type of stroke determined by computed tomography scan]. Nihon Koshu Eisei Zasshi, 1991; 38: 901-909"},{"key":"602","doi-asserted-by":"crossref","unstructured":"602) Konishi M, Iso H, Komachi Y, Iida M, Shimamoto T, Jacobs DR, Jr., Terao A, Baba S, Sankai T, Ito M: Associations of serum total cholesterol, different types of stroke, and stenosis distribution of cerebral arteries. The Akita Pathology Study. Stroke, 1993; 24: 954-964","DOI":"10.1161\/01.STR.24.7.954"},{"key":"603","doi-asserted-by":"crossref","unstructured":"603) Kubo M, Hata J, Doi Y, Tanizaki Y, Iida M, Kiyohara Y: Secular trends in the incidence of and risk factors for ischemic stroke and its subtypes in Japanese population. Circulation, 2008; 118: 2672-2678","DOI":"10.1161\/CIRCULATIONAHA.107.743211"},{"key":"604","doi-asserted-by":"crossref","unstructured":"604) Cui R, Iso H, Yamagishi K, Saito I, Kokubo Y, Inoue M, Sawada N, Tsugane S: Trends in the proportions of stroke subtypes and coronary heart disease in the Japanese men and women from 1995 to 2009. Atherosclerosis, 2016; 248: 219-223","DOI":"10.1016\/j.atherosclerosis.2016.03.001"},{"key":"605","doi-asserted-by":"crossref","unstructured":"605) Harada A, Ueshima H, Kinoshita Y, Miura K, Ohkubo T, Asayama K, Ohashi Y: Absolute risk score for stroke, myocardial infarction, and all cardiovascular disease: Japan Arteriosclerosis Longitudinal Study. Hypertens Res, 2019; 42: 567-579","DOI":"10.1038\/s41440-019-0220-z"},{"key":"606","doi-asserted-by":"crossref","unstructured":"606) Honda T, Chen S, Hata J, Yoshida D, Hirakawa Y, Furuta Y, Shibata M, Sakata S, Kitazono T, Ninomiya T: Development and Validation of a Risk Prediction Model for Atherosclerotic Cardiovascular Disease in Japanese Adults: The Hisayama Study. J Atheroscler Thromb, 2021","DOI":"10.5551\/jat.61960"},{"key":"607","doi-asserted-by":"crossref","unstructured":"607) Honda T, Yoshida D, Hata J, Hirakawa Y, Ishida Y, Shibata M, Sakata S, Kitazono T, Ninomiya T: Development and validation of modified risk prediction models for cardiovascular disease and its subtypes: The Hisayama Study. Atherosclerosis, 2018; 279: 38-44","DOI":"10.1016\/j.atherosclerosis.2018.10.014"},{"key":"608","doi-asserted-by":"crossref","unstructured":"608) Yatsuya H, Iso H, Yamagishi K, Kokubo Y, Saito I, Suzuki K, Sawada N, Inoue M, Tsugane S: Development of a point-based prediction model for the incidence of total stroke: Japan public health center study. Stroke, 2013; 44: 1295-1302","DOI":"10.1161\/STROKEAHA.111.677534"},{"key":"609","doi-asserted-by":"crossref","unstructured":"609) Okuda N, Kadota A, Nishi N, Miura K, Ohkubo T, Miyagawa N, Satoh A, Kita Y, Hayakawa T, Takashima N, Fujiyoshi A, Okayama A, Okamura T, Ueshima H: Association of Work Situation With Cardiovascular Disease Mortality Risk Among Working-Age Japanese Men - A 20-Year Follow-up of NIPPON DATA90. Circ J, 2019; 83: 1506-1513","DOI":"10.1253\/circj.CJ-18-1067"},{"key":"610","doi-asserted-by":"crossref","unstructured":"610) Dalton JE, Perzynski AT, Zidar DA, Rothberg MB, Coulton CJ, Milinovich AT, Einstadter D, Karichu JK, Dawson NV: Accuracy of Cardiovascular Risk Prediction Varies by Neighborhood Socioeconomic Position: A Retrospective Cohort Study. Ann Intern Med, 2017; 167: 456-464","DOI":"10.7326\/M16-2543"},{"key":"611","doi-asserted-by":"crossref","unstructured":"611) Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, Greenland P, Van Horn L, Tracy RP, Lloyd-Jones DM: Lifetime risks of cardiovascular disease. N Engl J Med, 2012; 366: 321-329","DOI":"10.1056\/NEJMoa1012848"},{"key":"612","doi-asserted-by":"crossref","unstructured":"612) Satoh M, Ohkubo T, Asayama K, Murakami Y, Sugiyama D, Yamada M, Saitoh S, Sakata K, Irie F, Sairenchi T, Ishikawa S, Kiyama M, Ohnishi H, Miura K, Imai Y, Ueshima H, Okamura T: Lifetime Risk of Stroke and Coronary Heart Disease Deaths According to Blood Pressure Level: EPOCH-JAPAN (Evidence for Cardiovascular Prevention From Observational Cohorts in Japan). Hypertension, 2019; 73: 52-59","DOI":"10.1161\/HYPERTENSIONAHA.118.11635"},{"key":"613","doi-asserted-by":"crossref","unstructured":"613) Fager G, Wiklund O: Cholesterol reduction and clinical benefit. Are there limits to our expectations? Arterioscler Thromb Vasc Biol, 1997; 17: 3527-3533","DOI":"10.1161\/01.ATV.17.12.3527"},{"key":"614","doi-asserted-by":"crossref","unstructured":"614) Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005; 366: 1267-1278","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"615","doi-asserted-by":"crossref","unstructured":"615) Saiki Y, Otsuka T, Kato K, Kawada T: A Proposal for the Optimal Management Target for Serum Non-High-Density Lipoprotein Cholesterol Level in Low-Risk Japanese Workers. J Atheroscler Thromb, 2016; 23: 422-430","DOI":"10.5551\/jat.33068"},{"key":"616","doi-asserted-by":"crossref","unstructured":"616) Kuwabara K, Harada S, Sugiyama D, Kurihara A, Kubota Y, Higashiyama A, Hirata T, Nishida Y, Kawasaki M, Takebayashi T, Okamura T: Relationship between Non-High-Density Lipoprotein Cholesterol and Low-Density Lipoprotein Cholesterol in the General Population. J Atheroscler Thromb, 2016; 23: 477-490","DOI":"10.5551\/jat.33100"},{"key":"617","doi-asserted-by":"crossref","unstructured":"617) Mons U, M\u00fcezzinler A, Gellert C, Sch\u00f6ttker B, Abnet CC, Bobak M, de Groot L, Freedman ND, Jansen E, Kee F, Kromhout D, Kuulasmaa K, Laatikainen T, O\u2019Doherty MG, Bueno-de-Mesquita B, Orfanos P, Peters A, van der Schouw YT, Wilsgaard T, Wolk A, Trichopoulou A, Boffetta P, Brenner H: Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium. BMJ, 2015; 350: h1551","DOI":"10.1136\/bmj.h1551"},{"key":"618","doi-asserted-by":"crossref","unstructured":"618) Jeong SM, Jeon KH, Shin DW, Han K, Kim D, Park SH, Cho MH, Lee CM, Nam KW, Lee SP: Smoking cessation, but not reduction, reduces cardiovascular disease incidence. Eur Heart J, 2021; 42: 4141-4153","DOI":"10.1093\/eurheartj\/ehab578"},{"key":"619","doi-asserted-by":"crossref","unstructured":"619) Tan CE, Glantz SA: Association between smoke-free legislation and hospitalizations for cardiac, cerebrovascular, and respiratory diseases: a meta-analysis. Circulation, 2012; 126: 2177-2183","DOI":"10.1161\/CIRCULATIONAHA.112.121301"},{"key":"620","doi-asserted-by":"crossref","unstructured":"620) Stead LF, Buitrago D, Preciado N, Sanchez G, Hartmann-Boyce J, Lancaster T: Physician advice for smoking cessation. Cochrane Database Syst Rev, 2013; 2013: Cd000165","DOI":"10.1002\/14651858.CD000165.pub4"},{"key":"621","doi-asserted-by":"crossref","unstructured":"621) Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T: Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev, 2018; 5: Cd000146","DOI":"10.1002\/14651858.CD000146.pub5"},{"key":"622","doi-asserted-by":"crossref","unstructured":"622) Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T: Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev, 2016; 2016: Cd006103","DOI":"10.1002\/14651858.CD006103.pub7"},{"key":"623","unstructured":"623) The Japanese Circulation Society, The Japan Lung Cancer Society, The Japanese Respiratory Society: Standard Procedures for Smoking Cessation Treatment, 8th ed., http:\/\/j-circ.or.jp\/kinen\/anti_smoke_std\/pdf\/anti_smoke_std_rev8_.pdf, 2021 (in Japanese)"},{"key":"624","doi-asserted-by":"crossref","unstructured":"624) Masaki K, Tateno H, Nomura A, Muto T, Suzuki S, Satake K, Hida E, Fukunaga K: A randomized controlled trial of a smoking cessation smartphone application with a carbon monoxide checker. NPJ Digit Med, 2020; 3: 35","DOI":"10.1038\/s41746-020-0243-5"},{"key":"625","doi-asserted-by":"crossref","unstructured":"625) Hirano T, Tabuchi T, Nakahara R, Kunugita N, Mochizuki-Kobayashi Y: Electronic Cigarette Use and Smoking Abstinence in Japan: A Cross-Sectional Study of Quitting Methods. Int J Environ Res Public Health, 2017; 14","DOI":"10.3390\/ijerph14020202"},{"key":"626","doi-asserted-by":"crossref","unstructured":"626) Aubin HJ, Farley A, Lycett D, Lahmek P, Aveyard P: Weight gain in smokers after quitting cigarettes: meta-analysis. BMJ, 2012; 345: e4439","DOI":"10.1136\/bmj.e4439"},{"key":"627","doi-asserted-by":"crossref","unstructured":"627) Gepner AD, Piper ME, Johnson HM, Fiore MC, Baker TB, Stein JH: Effects of smoking and smoking cessation on lipids and lipoproteins: outcomes from a randomized clinical trial. Am Heart J, 2011; 161: 145-151","DOI":"10.1016\/j.ahj.2010.09.023"},{"key":"628","doi-asserted-by":"crossref","unstructured":"628) Komiyama M, Shimada S, Wada H, Yamakage H, Satoh-Asahara N, Shimatsu A, Akao M, Morimoto T, Takahashi Y, Hasegawa K: Time-dependent Changes of Atherosclerotic LDL Complexes after Smoking Cessation. J Atheroscler Thromb, 2016; 23: 1270-1275","DOI":"10.5551\/jat.34280"},{"key":"629","doi-asserted-by":"crossref","unstructured":"629) Hu Y, Zong G, Liu G, Wang M, Rosner B, Pan A, Willett WC, Manson JE, Hu FB, Sun Q: Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality. N Engl J Med, 2018; 379: 623-632","DOI":"10.1056\/NEJMoa1803626"},{"key":"630","doi-asserted-by":"crossref","unstructured":"630) Reinert DF, Allen JP: The Alcohol Use Disorders Identification Test (AUDIT): a review of recent research. Alcohol Clin Exp Res, 2002; 26: 272-279","DOI":"10.1111\/j.1530-0277.2002.tb02534.x"},{"key":"631","doi-asserted-by":"crossref","unstructured":"631) \u00c1lvarez-Bueno C, Rodr\u00edguez-Mart\u00edn B, Garc\u00eda-Ortiz L, G\u00f3mez-Marcos M, Mart\u00ednez-Vizca\u00edno V: Effectiveness of brief interventions in primary health care settings to decrease alcohol consumption by adult non-dependent drinkers: a systematic review of systematic reviews. Prev Med, 2015; 76 Suppl: S33-38","DOI":"10.1016\/j.ypmed.2014.12.010"},{"key":"632","doi-asserted-by":"crossref","unstructured":"632) Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW, Jr., Kemper AR, Kubik M, Landefeld CS, Mangione CM, Silverstein M, Simon MA, Tseng CW, Wong JB: Screening and Behavioral Counseling Interventions to Reduce Unhealthy Alcohol Use in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. JAMA, 2018; 320: 1899-1909","DOI":"10.1001\/jama.2018.16789"},{"key":"633","unstructured":"633) Maesato H: Measures to Alcohol Problem in Japan, Revised Manual for Alcohol Health Guidance, 2016"},{"key":"634","unstructured":"634) Yuzuriha T: Early Intervention Programs for Alcohol-Related Problems, HAPPY. Journal of clinical and experimental medicine, 2007; 9: 728-732"},{"key":"635","doi-asserted-by":"crossref","unstructured":"635) Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sj\u00f6str\u00f6m L: Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J (Clin Res Ed), 1984; 289: 1257-1261","DOI":"10.1136\/bmj.289.6454.1257"},{"key":"636","doi-asserted-by":"crossref","unstructured":"636) Larsson B, Sv\u00e4rdsudd K, Welin L, Wilhelmsen L, Bj\u00f6rntorp P, Tibblin G: Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J (Clin Res Ed), 1984; 288: 1401-1404","DOI":"10.1136\/bmj.288.6428.1401"},{"key":"637","doi-asserted-by":"crossref","unstructured":"637) Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, Shofer JB, Fish BE, Knopp RH, Kahn SE: Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes, 2004; 53: 2087-2094","DOI":"10.2337\/diabetes.53.8.2087"},{"key":"638","doi-asserted-by":"crossref","unstructured":"638) Matsuzawa Y: The metabolic syndrome and adipocytokines. FEBS Lett, 2006; 580: 2917-2921","DOI":"10.1016\/j.febslet.2006.04.028"},{"key":"639","doi-asserted-by":"crossref","unstructured":"639) Anderson JW, Konz EC, Frederich RC, Wood CL: Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr, 2001; 74: 579-584","DOI":"10.1093\/ajcn\/74.5.579"},{"key":"640","doi-asserted-by":"crossref","unstructured":"640) Muramoto A, Matsushita M, Kato A, Yamamoto N, Koike G, Nakamura M, Numata T, Tamakoshi A, Tsushita K: Three percent weight reduction is the minimum requirement to improve health hazards in obese and overweight people in Japan. Obes Res Clin Pract, 2014; 8: e466-475","DOI":"10.1016\/j.orcp.2013.10.003"},{"key":"641","doi-asserted-by":"crossref","unstructured":"641) Tsushita K, A SH, Miura K, Ito Y, Fukuda T, Kitamura A, Tatara K: Rationale and Descriptive Analysis of Specific Health Guidance: the Nationwide Lifestyle Intervention Program Targeting Metabolic Syndrome in Japan. J Atheroscler Thromb, 2018; 25: 308-322","DOI":"10.5551\/jat.42010"},{"key":"642","doi-asserted-by":"crossref","unstructured":"642) Nakao YM, Miyamoto Y, Ueshima K, Nakao K, Nakai M, Nishimura K, Yasuno S, Hosoda K, Ogawa Y, Itoh H, Ogawa H, Kangawa K, Nakao K: Effectiveness of nationwide screening and lifestyle intervention for abdominal obesity and cardiometabolic risks in Japan: The metabolic syndrome and comprehensive lifestyle intervention study on nationwide database in Japan (MetS ACTION-J study). PLoS One, 2018; 13: e0190862","DOI":"10.1371\/journal.pone.0190862"},{"key":"643","doi-asserted-by":"crossref","unstructured":"643) Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, Loria CM, Millen BE, Nonas CA, Pi-Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Yanovski SZ, Jordan HS, Kendall KA, Lux LJ, Mentor-Marcel R, Morgan LC, Trisolini MG, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC, Jr., Tomaselli GF: 2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation, 2014; 129: S102-138","DOI":"10.1161\/01.cir.0000437739.71477.ee"},{"key":"644","doi-asserted-by":"crossref","unstructured":"644) Caleyachetty R, Thomas GN, Toulis KA, Mohammed N, Gokhale KM, Balachandran K, Nirantharakumar K: Metabolically Healthy Obese and Incident Cardiovascular Disease Events Among 3.5 Million Men and Women. J Am Coll Cardiol, 2017; 70: 1429-1437","DOI":"10.1016\/j.jacc.2017.07.763"},{"key":"645","doi-asserted-by":"crossref","unstructured":"645) Lassale C, Tzoulaki I, Moons KGM, Sweeting M, Boer J, Johnson L, Huerta JM, Agnoli C, Freisling H, Weiderpass E, Wennberg P, van der AD, Arriola L, Benetou V, Boeing H, Bonnet F, Colorado-Yohar SM, Engstr\u00f6m G, Eriksen AK, Ferrari P, Grioni S, Johansson M, Kaaks R, Katsoulis M, Katzke V, Key TJ, Matullo G, Melander O, Molina-Portillo E, Moreno-Iribas C, Norberg M, Overvad K, Panico S, Quir\u00f3s JR, Saieva C, Skeie G, Steffen A, Stepien M, Tj\u00f8nneland A, Trichopoulou A, Tumino R, van der Schouw YT, Verschuren WMM, Langenberg C, Di Angelantonio E, Riboli E, Wareham NJ, Danesh J, Butterworth AS: Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis. Eur Heart J, 2018; 39: 397-406","DOI":"10.1093\/eurheartj\/ehx448"},{"key":"646","doi-asserted-by":"crossref","unstructured":"646) Eckel N, Li Y, Kuxhaus O, Stefan N, Hu FB, Schulze MB: Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses\u2019 Health Study): 30 year follow-up from a prospective cohort study. Lancet Diabetes Endocrinol, 2018; 6: 714-724","DOI":"10.1016\/S2213-8587(18)30137-2"},{"key":"647","doi-asserted-by":"crossref","unstructured":"647) Kramer CK, Zinman B, Retnakaran R: Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann Intern Med, 2013; 159: 758-769","DOI":"10.7326\/0003-4819-159-11-201312030-00008"},{"key":"648","doi-asserted-by":"crossref","unstructured":"648) Cui R, Iso H, Toyoshima H, Date C, Yamamoto A, Kikuchi S, Kondo T, Watanabe Y, Koizumi A, Wada Y, Inaba Y, Tamakoshi A: Body mass index and mortality from cardiovascular disease among Japanese men and women: the JACC study. Stroke, 2005; 36: 1377-1382","DOI":"10.1161\/01.STR.0000169925.57251.4e"},{"key":"649","doi-asserted-by":"crossref","unstructured":"649) Global B.M.I. Mortality Collaboration, Di Angelantonio E, Bhupathiraju Sh N, Wormser D, Gao P, Kaptoge S, Berrington de Gonzalez A, Cairns BJ, Huxley R, Jackson Ch L, Joshy G, Lewington S, Manson JE, Murphy N, Patel AV, Samet JM, Woodward M, Zheng W, Zhou M, Bansal N, Barricarte A, Carter B, Cerhan JR, Smith GD, Fang X, Franco OH, Green J, Halsey J, Hildebrand JS, Jung KJ, Korda RJ, McLerran DF, Moore SC, O\u2019Keeffe LM, Paige E, Ramond A, Reeves GK, Rolland B, Sacerdote C, Sattar N, Sofianopoulou E, Stevens J, Thun M, Ueshima H, Yang L, Yun YD, Willeit P, Banks E, Beral V, Chen Z, Gapstur SM, Gunter MJ, Hartge P, Jee SH, Lam TH, Peto R, Potter JD, Willett WC, Thompson SG, Danesh J, Hu FB: Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet, 2016; 388: 776-786","DOI":"10.1016\/S0140-6736(16)30175-1"},{"key":"650","doi-asserted-by":"crossref","unstructured":"650) Ma C, Avenell A, Bolland M, Hudson J, Stewart F, Robertson C, Sharma P, Fraser C, MacLennan G: Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. BMJ, 2017; 359: j4849","DOI":"10.1136\/bmj.j4849"},{"key":"651","doi-asserted-by":"crossref","unstructured":"651) Zhang X, Devlin HM, Smith B, Imperatore G, Thomas W, Lobelo F, Ali MK, Norris K, Gruss S, Bardenheier B, Cho P, Garcia de Quevedo I, Mudaliar U, Jones CD, Durthaler JM, Saaddine J, Geiss LS, Gregg EW: Effect of lifestyle interventions on cardiovascular risk factors among adults without impaired glucose tolerance or diabetes: A systematic review and meta-analysis. PLoS One, 2017; 12: e0176436","DOI":"10.1371\/journal.pone.0176436"},{"key":"652","unstructured":"652) Tsushita K: Health Labour Sciences Research: Research on the Effects of Lifestyle-related Disease Prevention Activities and Disease Management on Health Indicators and the Effects of Medical Cost Optimization, 2011 (in Japanese)"},{"key":"653","unstructured":"653) Ministry of Labour and Welfare: Dietary Reference Intakes for Japanese 2020 in Japanese https:\/\/www.mhlw.go.jp\/content\/10904750\/000586553.pdf (in Japanese)"},{"key":"654","doi-asserted-by":"crossref","unstructured":"654) Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H, Osawa H, Taguchi A, Tanizawa Y, Tobe K, Yoshioka N: Japanese Clinical Practice Guideline for Diabetes 2019. J Diabetes Investig, 2020; 11: 1020-1076","DOI":"10.1111\/jdi.13306"},{"key":"655","doi-asserted-by":"crossref","unstructured":"655) Seidelmann SB, Claggett B, Cheng S, Henglin M, Shah A, Steffen LM, Folsom AR, Rimm EB, Willett WC, Solomon SD: Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis. Lancet Public Health, 2018; 3: e419-e428","DOI":"10.1016\/S2468-2667(18)30135-X"},{"key":"656","doi-asserted-by":"crossref","unstructured":"656) Mansoor N, Vinknes KJ, Veier\u00f8d MB, Retterst\u00f8l K: Effects of low-carbohydrate diets v. low-fat diets on body weight and cardiovascular risk factors: a meta-analysis of randomised controlled trials. Br J Nutr, 2016; 115: 466-479","DOI":"10.1017\/S0007114515004699"},{"key":"657","doi-asserted-by":"crossref","unstructured":"657) Lu M, Wan Y, Yang B, Huggins CE, Li D: Effects of low-fat compared with high-fat diet on cardiometabolic indicators in people with overweight and obesity without overt metabolic disturbance: a systematic review and meta-analysis of randomised controlled trials. Br J Nutr, 2018; 119: 96-108","DOI":"10.1017\/S0007114517002902"},{"key":"658","doi-asserted-by":"crossref","unstructured":"658) Hooper L, Summerbell CD, Higgins JP, Thompson RL, Clements G, Capps N, Davey S, Riemersma RA, Ebrahim S: Reduced or modified dietary fat for preventing cardiovascular disease. Cochrane Database Syst Rev, 2001: Cd002137","DOI":"10.1002\/14651858.CD002137"},{"key":"659","doi-asserted-by":"crossref","unstructured":"659) Budhathoki S, Sawada N, Iwasaki M, Yamaji T, Goto A, Kotemori A, Ishihara J, Takachi R, Charvat H, Mizoue T, Iso H, Tsugane S, Japan Public Health Center-based Prospective Study G: Association of Animal and Plant Protein Intake With All-Cause and Cause-Specific Mortality in a Japanese Cohort. JAMA Intern Med, 2019; 179: 1509-1518","DOI":"10.1001\/jamainternmed.2019.2806"},{"key":"660","doi-asserted-by":"crossref","unstructured":"660) Schwingshackl L, Hoffmann G: Long-term effects of low-fat diets either low or high in protein on cardiovascular and metabolic risk factors: a systematic review and meta-analysis. Nutr J, 2013; 12: 48","DOI":"10.1186\/1475-2891-12-48"},{"key":"661","doi-asserted-by":"crossref","unstructured":"661) Kromhout D, Menotti A, Bloemberg B, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F, Giampaoli S, Jansen A, et al.: Dietary saturated and trans fatty acids and cholesterol and 25-year mortality from coronary heart disease: the Seven Countries Study. Prev Med, 1995; 24: 308-315","DOI":"10.1006\/pmed.1995.1049"},{"key":"662","doi-asserted-by":"crossref","unstructured":"662) Tanasescu M, Cho E, Manson JE, Hu FB: Dietary fat and cholesterol and the risk of cardiovascular disease among women with type 2 diabetes. Am J Clin Nutr, 2004; 79: 999-1005","DOI":"10.1093\/ajcn\/79.6.999"},{"key":"663","doi-asserted-by":"crossref","unstructured":"663) Jakobsen MU, O\u2019Reilly EJ, Heitmann BL, Pereira MA, B\u00e4lter K, Fraser GE, Goldbourt U, Hallmans G, Knekt P, Liu S, Pietinen P, Spiegelman D, Stevens J, Virtamo J, Willett WC, Ascherio A: Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11 cohort studies. Am J Clin Nutr, 2009; 89: 1425-1432","DOI":"10.3945\/ajcn.2008.27124"},{"key":"664","doi-asserted-by":"crossref","unstructured":"664) Guasch-Ferr\u00e9 M, Babio N, Mart\u00ednez-Gonz\u00e1lez MA, Corella D, Ros E, Mart\u00edn-Pel\u00e1ez S, Estruch R, Ar\u00f3s F, G\u00f3mez-Gracia E, Fiol M, Santos-Lozano JM, Serra-Majem L, Bull\u00f3 M, Toledo E, Barrag\u00e1n R, Fit\u00f3 M, Gea A, Salas-Salvad\u00f3 J: Dietary fat intake and risk of cardiovascular disease and all-cause mortality in a population at high risk of cardiovascular disease. Am J Clin Nutr, 2015; 102: 1563-1573","DOI":"10.3945\/ajcn.115.116046"},{"key":"665","doi-asserted-by":"crossref","unstructured":"665) Blekkenhorst LC, Prince RL, Hodgson JM, Lim WH, Zhu K, Devine A, Thompson PL, Lewis JR: Dietary saturated fat intake and atherosclerotic vascular disease mortality in elderly women: a prospective cohort study. Am J Clin Nutr, 2015; 101: 1263-1268","DOI":"10.3945\/ajcn.114.102392"},{"key":"666","doi-asserted-by":"crossref","unstructured":"666) Puaschitz NG, Strand E, Norekv\u00e5l TM, Dierkes J, Dahl L, Svingen GF, Assmus J, Schartum-Hansen H, \u00d8yen J, Pedersen EK, Drevon CA, Tell GS, Nyg\u00e5rd O: Dietary intake of saturated fat is not associated with risk of coronary events or mortality in patients with established coronary artery disease. J Nutr, 2015; 145: 299-305","DOI":"10.3945\/jn.114.203505"},{"key":"667","doi-asserted-by":"crossref","unstructured":"667) Siri-Tarino PW, Sun Q, Hu FB, Krauss RM: Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. Am J Clin Nutr, 2010; 91: 535-546","DOI":"10.3945\/ajcn.2009.27725"},{"key":"668","doi-asserted-by":"crossref","unstructured":"668) Wang DD, Li Y, Chiuve SE, Stampfer MJ, Manson JE, Rimm EB, Willett WC, Hu FB: Association of Specific Dietary Fats With Total and Cause-Specific Mortality. JAMA Intern Med, 2016; 176: 1134-1145","DOI":"10.1001\/jamainternmed.2016.2417"},{"key":"669","doi-asserted-by":"crossref","unstructured":"669) de Souza RJ, Mente A, Maroleanu A, Cozma AI, Ha V, Kishibe T, Uleryk E, Budylowski P, Sch\u00fcnemann H, Beyene J, Anand SS: Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. BMJ, 2015; 351: h3978","DOI":"10.1136\/bmj.h3978"},{"key":"670","doi-asserted-by":"crossref","unstructured":"670) Hooper L, Martin N, Abdelhamid A, Davey Smith G: Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev, 2015","DOI":"10.1002\/14651858.CD011737"},{"key":"671","doi-asserted-by":"crossref","unstructured":"671) Mozaffarian D, Micha R, Wallace S: Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med, 2010; 7: e1000252","DOI":"10.1371\/journal.pmed.1000252"},{"key":"672","doi-asserted-by":"crossref","unstructured":"672) Schwingshackl L, Schwedhelm C, Hoffmann G, Lampousi AM, Kn\u00fcppel S, Iqbal K, Bechthold A, Schlesinger S, Boeing H: Food groups and risk of all-cause mortality: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr, 2017; 105: 1462-1473","DOI":"10.3945\/ajcn.117.153148"},{"key":"673","doi-asserted-by":"crossref","unstructured":"673) Bechthold A, Boeing H, Schwedhelm C, Hoffmann G, Kn\u00fcppel S, Iqbal K, De Henauw S, Michels N, Devleesschauwer B, Schlesinger S, Schwingshackl L: Food groups and risk of coronary heart disease, stroke and heart failure: A systematic review and dose-response meta-analysis of prospective studies. Crit Rev Food Sci Nutr, 2019; 59: 1071-1090","DOI":"10.1080\/10408398.2017.1392288"},{"key":"674","doi-asserted-by":"crossref","unstructured":"674) Nagao M, Iso H, Yamagishi K, Date C, Tamakoshi A: Meat consumption in relation to mortality from cardiovascular disease among Japanese men and women. Eur J Clin Nutr, 2012; 66: 687-693","DOI":"10.1038\/ejcn.2012.6"},{"key":"675","doi-asserted-by":"crossref","unstructured":"675) Horikawa C, Kamada C, Tanaka S, Tanaka S, Araki A, Ito H, Matsunaga S, Fujihara K, Yoshimura Y, Ohashi Y, Akanuma Y, Sone H: Meat intake and incidence of cardiovascular disease in Japanese patients with type 2 diabetes: analysis of the Japan Diabetes Complications Study (JDCS). Eur J Nutr, 2019; 58: 281-290","DOI":"10.1007\/s00394-017-1592-y"},{"key":"676","doi-asserted-by":"crossref","unstructured":"676) Iso H, Stampfer MJ, Manson JE, Rexrode K, Hu F, Hennekens CH, Colditz GA, Speizer FE, Willett WC: Prospective study of fat and protein intake and risk of intraparenchymal hemorrhage in women. Circulation, 2001; 103: 856-863","DOI":"10.1161\/01.CIR.103.6.856"},{"key":"677","doi-asserted-by":"crossref","unstructured":"677) Iso H, Sato S, Kitamura A, Naito Y, Shimamoto T, Komachi Y: Fat and protein intakes and risk of intraparenchymal hemorrhage among middle-aged Japanese. Am J Epidemiol, 2003; 157: 32-39","DOI":"10.1093\/aje\/kwf166"},{"key":"678","doi-asserted-by":"crossref","unstructured":"678) Yamagishi K, Iso H, Yatsuya H, Tanabe N, Date C, Kikuchi S, Yamamoto A, Inaba Y, Tamakoshi A: Dietary intake of saturated fatty acids and mortality from cardiovascular disease in Japanese: the Japan Collaborative Cohort Study for Evaluation of Cancer Risk (JACC) Study. Am J Clin Nutr, 2010; 92: 759-765","DOI":"10.3945\/ajcn.2009.29146"},{"key":"679","unstructured":"679) Yamagishi K, Iso H, Kokubo Y, Saito I, Yatsuya H, Ishihara J, Inoue M, Tsugane S: Dietary intake of saturated fatty acids and incident stroke and coronary heart disease in Japanese communities: the JPHC Study. Eur Heart J, 2013; 34: 1225-1232"},{"key":"680","doi-asserted-by":"crossref","unstructured":"680) Muto M, Ezaki O: High Dietary Saturated Fat is Associated with a Low Risk of Intracerebral Hemorrhage and Ischemic Stroke in Japanese but not in Non-Japanese: A Review and Meta-Analysis of Prospective Cohort Studies. J Atheroscler Thromb, 2018; 25: 375-392","DOI":"10.5551\/jat.41632"},{"key":"681","doi-asserted-by":"crossref","unstructured":"681) Nakamura Y, Okuda N, Turin TC, Fujiyoshi A, Okamura T, Hayakawa T, Yoshita K, Miura K, Ueshima H: Fatty acids intakes and serum lipid profiles: NIPPON DATA90 and the national nutrition monitoring. J Epidemiol, 2010; 20 Suppl 3: S544-548","DOI":"10.2188\/jea.JE20090223"},{"key":"682","doi-asserted-by":"crossref","unstructured":"682) Fattore E, Bosetti C, Brighenti F, Agostoni C, Fattore G: Palm oil and blood lipid-related markers of cardiovascular disease: a systematic review and meta-analysis of dietary intervention trials. Am J Clin Nutr, 2014; 99: 1331-1350","DOI":"10.3945\/ajcn.113.081190"},{"key":"683","doi-asserted-by":"crossref","unstructured":"683) Engel S, Tholstrup T: Butter increased total and LDL cholesterol compared with olive oil but resulted in higher HDL cholesterol compared with a habitual diet. Am J Clin Nutr, 2015; 102: 309-315","DOI":"10.3945\/ajcn.115.112227"},{"key":"684","doi-asserted-by":"crossref","unstructured":"684) Vafeiadou K, Weech M, Altowaijri H, Todd S, Yaqoob P, Jackson KG, Lovegrove JA: Replacement of saturated with unsaturated fats had no impact on vascular function but beneficial effects on lipid biomarkers, E-selectin, and blood pressure: results from the randomized, controlled Dietary Intervention and VAScular function (DIVAS) study. Am J Clin Nutr, 2015; 102: 40-48","DOI":"10.3945\/ajcn.114.097089"},{"key":"685","doi-asserted-by":"crossref","unstructured":"685) Ginsberg HN, Kris-Etherton P, Dennis B, Elmer PJ, Ershow A, Lefevre M, Pearson T, Roheim P, Ramakrishnan R, Reed R, Stewart K, Stewart P, Phillips K, Anderson N: Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1. Arterioscler Thromb Vasc Biol, 1998; 18: 441-449","DOI":"10.1161\/01.ATV.18.3.441"},{"key":"686","doi-asserted-by":"crossref","unstructured":"686) Barr SL, Ramakrishnan R, Johnson C, Holleran S, Dell RB, Ginsberg HN: Reducing total dietary fat without reducing saturated fatty acids does not significantly lower total plasma cholesterol concentrations in normal males. Am J Clin Nutr, 1992; 55: 675-681","DOI":"10.1093\/ajcn\/55.3.675"},{"key":"687","doi-asserted-by":"crossref","unstructured":"687) Wardlaw GM, Snook JT: Effect of diets high in butter, corn oil, or high-oleic acid sunflower oil on serum lipids and apolipoproteins in men. Am J Clin Nutr, 1990; 51: 815-821","DOI":"10.1093\/ajcn\/51.5.815"},{"key":"688","doi-asserted-by":"crossref","unstructured":"688) Temme EH, Mensink RP, Hornstra G: Comparison of the effects of diets enriched in lauric, palmitic, or oleic acids on serum lipids and lipoproteins in healthy women and men. Am J Clin Nutr, 1996; 63: 897-903","DOI":"10.1093\/ajcn\/63.6.897"},{"key":"689","doi-asserted-by":"crossref","unstructured":"689) Bergeron N, Chiu S, Williams PT, S MK, Krauss RM: Effects of red meat, white meat, and nonmeat protein sources on atherogenic lipoprotein measures in the context of low compared with high saturated fat intake: a randomized controlled trial. Am J Clin Nutr, 2019; 110: 24-33","DOI":"10.1093\/ajcn\/nqz035"},{"key":"690","doi-asserted-by":"crossref","unstructured":"690) Haub MD, Wells AM, Campbell WW: Beef and soy-based food supplements differentially affect serum lipoprotein-lipid profiles because of changes in carbohydrate intake and novel nutrient intake ratios in older men who resistive-train. Metabolism, 2005; 54: 769-774","DOI":"10.1016\/j.metabol.2005.01.019"},{"key":"691","doi-asserted-by":"crossref","unstructured":"691) Jensen RG: The composition of bovine milk lipids: January 1995 to December 2000. J Dairy Sci, 2002; 85: 295-350","DOI":"10.3168\/jds.S0022-0302(02)74079-4"},{"key":"692","doi-asserted-by":"crossref","unstructured":"692) Willett WC, Ludwig DS: Milk and Health. N Engl J Med, 2020; 382: 644-654","DOI":"10.1056\/NEJMra1903547"},{"key":"693","doi-asserted-by":"crossref","unstructured":"693) Huang LY, Wahlqvist ML, Huang YC, Lee MS: Optimal dairy intake is predicated on total, cardiovascular, and stroke mortalities in a Taiwanese cohort. J Am Coll Nutr, 2014; 33: 426-436","DOI":"10.1080\/07315724.2013.875328"},{"key":"694","doi-asserted-by":"crossref","unstructured":"694) Yu E, Hu FB: Dairy Products, Dairy Fatty Acids, and the Prevention of Cardiometabolic Disease: a Review of Recent Evidence. Curr Atheroscler Rep, 2018; 20: 24","DOI":"10.1007\/s11883-018-0724-z"},{"key":"695","doi-asserted-by":"crossref","unstructured":"695) Roy SJ, Lapierre SS, Baker BD, Delfausse LA, Machin DR, Tanaka H: High dietary intake of whole milk and full-fat dairy products does not exert hypotensive effects in adults with elevated blood pressure. Nutr Res, 2019; 64: 72-81","DOI":"10.1016\/j.nutres.2019.01.003"},{"key":"696","doi-asserted-by":"crossref","unstructured":"696) Gardner CD, Messina M, Kiazand A, Morris JL, Franke AA: Effect of two types of soy milk and dairy milk on plasma lipids in hypercholesterolemic adults: a randomized trial. J Am Coll Nutr, 2007; 26: 669-677","DOI":"10.1080\/07315724.2007.10719646"},{"key":"697","doi-asserted-by":"crossref","unstructured":"697) Khaw KT, Sharp SJ, Finikarides L, Afzal I, Lentjes M, Luben R, Forouhi NG: Randomised trial of coconut oil, olive oil or butter on blood lipids and other cardiovascular risk factors in healthy men and women. BMJ Open, 2018; 8: e020167","DOI":"10.1136\/bmjopen-2017-020167"},{"key":"698","doi-asserted-by":"crossref","unstructured":"698) Chisholm A, Mann J, Sutherland W, Duncan A, Skeaff M, Frampton C: Effect on lipoprotein profile of replacing butter with margarine in a low fat diet: randomised crossover study with hypercholesterolaemic subjects. BMJ, 1996; 312: 931-934","DOI":"10.1136\/bmj.312.7036.931"},{"key":"699","doi-asserted-by":"crossref","unstructured":"699) Hendrie GA, Golley RK: Changing from regular-fat to low-fat dairy foods reduces saturated fat intake but not energy intake in 4-13-y-old children. Am J Clin Nutr, 2011; 93: 1117-1127","DOI":"10.3945\/ajcn.110.010694"},{"key":"700","doi-asserted-by":"crossref","unstructured":"700) Hidaka H, Takiwaki M, Yamashita M, Kawasaki K, Sugano M, Honda T: Consumption of nonfat milk results in a less atherogenic lipoprotein profile: a pilot study. Ann Nutr Metab, 2012; 61: 111-116","DOI":"10.1159\/000339261"},{"key":"701","doi-asserted-by":"crossref","unstructured":"701) Villalpando S, Lara Zamudio Y, Shamah-Levy T, Mundo-Rosas V, Manzano AC, Lamadrid-Figueroa H: Substitution of whole cows\u2019 milk with defatted milk for 4 months reduced serum total cholesterol, HDL-cholesterol and total apoB in a sample of Mexican school-age children (6-16 years of age). Br J Nutr, 2015; 114: 788-795","DOI":"10.1017\/S0007114515002330"},{"key":"702","doi-asserted-by":"crossref","unstructured":"702) Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM: Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet, 1989; 2: 757-761","DOI":"10.1016\/S0140-6736(89)90828-3"},{"key":"703","doi-asserted-by":"crossref","unstructured":"703) Burr ML, Ashfield-Watt PA, Dunstan FD, Fehily AM, Breay P, Ashton T, Zotos PC, Haboubi NA, Elwood PC: Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr, 2003; 57: 193-200","DOI":"10.1038\/sj.ejcn.1601539"},{"key":"704","doi-asserted-by":"crossref","unstructured":"704) Kotwal S, Jun M, Sullivan D, Perkovic V, Neal B: Omega 3 Fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes, 2012; 5: 808-818","DOI":"10.1161\/CIRCOUTCOMES.112.966168"},{"key":"705","doi-asserted-by":"crossref","unstructured":"705) Balk EM, Adams GP, Langberg V, Halladay C, Chung M, Lin L, Robertson S, Yip A, Steele D, Smith BT, Lau J, Lichtenstein AH, Trikalinos TA: Omega-3 Fatty Acids and Cardiovascular Disease: An Updated Systematic Review. Evid Rep Technol Assess (Full Rep), 2016: 1-1252","DOI":"10.23970\/AHRQEPCERTA223"},{"key":"706","doi-asserted-by":"crossref","unstructured":"706) Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, Deane KH, AlAbdulghafoor FK, Summerbell CD, Worthington HV, Song F, Hooper L: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev, 2018; 11: Cd003177","DOI":"10.1002\/14651858.CD003177.pub4"},{"key":"707","doi-asserted-by":"crossref","unstructured":"707) Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, Geleijnse JM, Rauch B, Ness A, Galan P, Chew EY, Bosch J, Collins R, Lewington S, Armitage J, Clarke R: Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals. JAMA Cardiol, 2018; 3: 225-234","DOI":"10.1001\/jamacardio.2017.5205"},{"key":"708","doi-asserted-by":"crossref","unstructured":"708) Hu Y, Hu FB, Manson JE: Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants. J Am Heart Assoc, 2019; 8: e013543","DOI":"10.1161\/JAHA.119.013543"},{"key":"709","doi-asserted-by":"crossref","unstructured":"709) Alexander DD, Miller PE, Van Elswyk ME, Kuratko CN, Bylsma LC: A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain Omega-3 Fatty Acids and Coronary Heart Disease Risk. Mayo Clin Proc, 2017; 92: 15-29","DOI":"10.1016\/j.mayocp.2016.10.018"},{"key":"710","doi-asserted-by":"crossref","unstructured":"710) Hu FB, Bronner L, Willett WC, Stampfer MJ, Rexrode KM, Albert CM, Hunter D, Manson JE: Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA, 2002; 287: 1815-1821","DOI":"10.1001\/jama.287.14.1815"},{"key":"711","doi-asserted-by":"crossref","unstructured":"711) Iso H, Rexrode KM, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, Hennekens CH, Willett WC: Intake of fish and omega-3 fatty acids and risk of stroke in women. JAMA, 2001; 285: 304-312","DOI":"10.1001\/jama.285.3.304"},{"key":"712","doi-asserted-by":"crossref","unstructured":"712) Str\u00f8m M, Halldorsson TI, Mortensen EL, Torp-Pedersen C, Olsen SF: Fish, n-3 fatty acids, and cardiovascular diseases in women of reproductive age: a prospective study in a large national cohort. Hypertension, 2012; 59: 36-43","DOI":"10.1161\/HYPERTENSIONAHA.111.179382"},{"key":"713","doi-asserted-by":"crossref","unstructured":"713) de Goede J, Geleijnse JM, Boer JM, Kromhout D, Verschuren WM: Marine (n-3) fatty acids, fish consumption, and the 10-year risk of fatal and nonfatal coronary heart disease in a large population of Dutch adults with low fish intake. J Nutr, 2010; 140: 1023-1028","DOI":"10.3945\/jn.109.119271"},{"key":"714","doi-asserted-by":"crossref","unstructured":"714) Ascherio A, Rimm EB, Stampfer MJ, Giovannucci EL, Willett WC: Dietary intake of marine n-3 fatty acids, fish intake, and the risk of coronary disease among men. N Engl J Med, 1995; 332: 977-982","DOI":"10.1056\/NEJM199504133321501"},{"key":"715","doi-asserted-by":"crossref","unstructured":"715) Manger MS, Strand E, Ebbing M, Seifert R, Refsum H, Nordrehaug JE, Nilsen DW, Drevon CA, Tell GS, Bleie O, Vollset SE, Pedersen ER, Nyg\u00e5rd O: Dietary intake of n-3 long-chain polyunsaturated fatty acids and coronary events in Norwegian patients with coronary artery disease. Am J Clin Nutr, 2010; 92: 244-251","DOI":"10.3945\/ajcn.2010.29175"},{"key":"716","doi-asserted-by":"crossref","unstructured":"716) Streppel MT, Ock\u00e9 MC, Boshuizen HC, Kok FJ, Kromhout D: Long-term fish consumption and n-3 fatty acid intake in relation to (sudden) coronary heart disease death: the Zutphen study. Eur Heart J, 2008; 29: 2024-2030","DOI":"10.1093\/eurheartj\/ehn294"},{"key":"717","doi-asserted-by":"crossref","unstructured":"717) Lentjes MAH, Keogh RH, Welch AA, Mulligan AA, Luben RN, Wareham NJ, Khaw KT: Longitudinal associations between marine omega-3 supplement users and coronary heart disease in a UK population-based cohort. BMJ Open, 2017; 7: e017471","DOI":"10.1136\/bmjopen-2017-017471"},{"key":"718","doi-asserted-by":"crossref","unstructured":"718) Saber H, Yakoob MY, Shi P, Longstreth WT, Jr., Lemaitre RN, Siscovick D, Rexrode KM, Willett WC, Mozaffarian D: Omega-3 Fatty Acids and Incident Ischemic Stroke and Its Atherothrombotic and Cardioembolic Subtypes in 3 US Cohorts. Stroke, 2017; 48: 2678-2685","DOI":"10.1161\/STROKEAHA.117.018235"},{"key":"719","doi-asserted-by":"crossref","unstructured":"719) Zhuang P, Zhang Y, He W, Chen X, Chen J, He L, Mao L, Wu F, Jiao J: Dietary Fats in Relation to Total and Cause-Specific Mortality in a Prospective Cohort of 521 120 Individuals With 16 Years of Follow-Up. Circ Res, 2019; 124: 757-768","DOI":"10.1161\/CIRCRESAHA.118.314038"},{"key":"720","doi-asserted-by":"crossref","unstructured":"720) Koh AS, Pan A, Wang R, Odegaard AO, Pereira MA, Yuan JM, Koh WP: The association between dietary omega-3 fatty acids and cardiovascular death: the Singapore Chinese Health Study. Eur J Prev Cardiol, 2015; 22: 364-372","DOI":"10.1177\/2047487313517576"},{"key":"721","doi-asserted-by":"crossref","unstructured":"721) Ven\u00f8 SK, Bork CS, Jakobsen MU, Lundbye-Christensen S, McLennan PL, Bach FW, Overvad K, Schmidt EB: Marine n-3 Polyunsaturated Fatty Acids and the Risk of Ischemic Stroke. Stroke, 2019; 50: 274-282","DOI":"10.1161\/STROKEAHA.118.023384"},{"key":"722","doi-asserted-by":"crossref","unstructured":"722) Iso H, Kobayashi M, Ishihara J, Sasaki S, Okada K, Kita Y, Kokubo Y, Tsugane S: Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation, 2006; 113: 195-202","DOI":"10.1161\/CIRCULATIONAHA.105.581355"},{"key":"723","doi-asserted-by":"crossref","unstructured":"723) Yamagishi K, Iso H, Date C, Fukui M, Wakai K, Kikuchi S, Inaba Y, Tanabe N, Tamakoshi A: Fish, omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women the JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk) Study. J Am Coll Cardiol, 2008; 52: 988-996","DOI":"10.1016\/j.jacc.2008.06.018"},{"key":"724","doi-asserted-by":"crossref","unstructured":"724) Miyagawa N, Miura K, Okuda N, Kadowaki T, Takashima N, Nagasawa SY, Nakamura Y, Matsumura Y, Hozawa A, Fujiyoshi A, Hisamatsu T, Yoshita K, Sekikawa A, Ohkubo T, Abbott RD, Okamura T, Okayama A, Ueshima H: Long-chain n-3 polyunsaturated fatty acids intake and cardiovascular disease mortality risk in Japanese: a 24-year follow-up of NIPPON DATA80. Atherosclerosis, 2014; 232: 384-389","DOI":"10.1016\/j.atherosclerosis.2013.11.073"},{"key":"725","doi-asserted-by":"crossref","unstructured":"725) Cheng P, Huang W, Bai S, Wu Y, Yu J, Zhu X, Qi Z, Shao W, Xie P: BMI Affects the Relationship between Long Chain N-3 Polyunsaturated Fatty Acid Intake and Stroke Risk: a Meta-Analysis. Sci Rep, 2015; 5: 14161","DOI":"10.1038\/srep14161"},{"key":"726","doi-asserted-by":"crossref","unstructured":"726) Leslie MA, Cohen DJ, Liddle DM, Robinson LE, Ma DW: A review of the effect of omega-3 polyunsaturated fatty acids on blood triacylglycerol levels in normolipidemic and borderline hyperlipidemic individuals. Lipids Health Dis, 2015; 14: 53","DOI":"10.1186\/s12944-015-0049-7"},{"key":"727","doi-asserted-by":"crossref","unstructured":"727) Eslick GD, Howe PR, Smith C, Priest R, Bensoussan A: Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol, 2009; 136: 4-16","DOI":"10.1016\/j.ijcard.2008.03.092"},{"key":"728","doi-asserted-by":"crossref","unstructured":"728) Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J: Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis, 2006; 189: 19-30","DOI":"10.1016\/j.atherosclerosis.2006.02.012"},{"key":"729","unstructured":"729) Agren JJ, H\u00e4nninen O, Julkunen A, Fogelholm L, Vidgren H, Schwab U, Pynn\u00f6nen O, Uusitupa M: Fish diet, fish oil and docosahexaenoic acid rich oil lower fasting and postprandial plasma lipid levels. Eur J Clin Nutr, 1996; 50: 765-771"},{"key":"730","doi-asserted-by":"crossref","unstructured":"730) Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, Jacobson TA, Engler MB, Miller M, Robinson JG, Blum CB, Rodriguez-Leyva D, de Ferranti SD, Welty FK: Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation, 2019; 140: e673-e691","DOI":"10.1161\/CIR.0000000000000709"},{"key":"731","doi-asserted-by":"crossref","unstructured":"731) Bork CS, Ven\u00f8 SK, Lundbye-Christensen S, Jakobsen MU, Tj\u00f8nneland A, Schmidt EB, Overvad K: Dietary Intake of \u03b1-Linolenic Acid Is Not Appreciably Associated with Risk of Ischemic Stroke among Middle-Aged Danish Men and Women. J Nutr, 2018; 148: 952-958","DOI":"10.1093\/jn\/nxy056"},{"key":"732","doi-asserted-by":"crossref","unstructured":"732) Bork CS, Lasota AN, Lundbye-Christensen S, Jakobsen MU, Tj\u00f8nneland A, Calder PC, Schmidt EB, Overvad K: Intake of \u03b1-linolenic acid is not consistently associated with a lower risk of peripheral artery disease: results from a Danish cohort study. Br J Nutr, 2019; 122: 86-92","DOI":"10.1017\/S0007114519000874"},{"key":"733","doi-asserted-by":"crossref","unstructured":"733) Wei J, Hou R, Xi Y, Kowalski A, Wang T, Yu Z, Hu Y, Chandrasekar EK, Sun H, Ali MK: The association and dose-response relationship between dietary intake of \u03b1-linolenic acid and risk of CHD: a systematic review and meta-analysis of cohort studies. Br J Nutr, 2018; 119: 83-89","DOI":"10.1017\/S0007114517003294"},{"key":"734","doi-asserted-by":"crossref","unstructured":"734) Zhou Q, Zhang Z, Wang P, Zhang B, Chen C, Zhang C, Su Y: EPA+DHA, but not ALA, Improved Lipids and Inflammation Status in Hypercholesterolemic Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. Mol Nutr Food Res, 2019; 63: e1801157","DOI":"10.1002\/mnfr.201801157"},{"key":"735","doi-asserted-by":"crossref","unstructured":"735) Hooper L, Martin N, Jimoh OF, Kirk C, Foster E, Abdelhamid AS: Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev, 2020; 5: Cd011737","DOI":"10.1002\/14651858.CD011737.pub2"},{"key":"736","doi-asserted-by":"crossref","unstructured":"736) de Oliveira Otto MC, Wu JH, Baylin A, Vaidya D, Rich SS, Tsai MY, Jacobs DR, Jr., Mozaffarian D: Circulating and dietary omega-3 and omega-6 polyunsaturated fatty acids and incidence of CVD in the Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc, 2013; 2: e000506","DOI":"10.1161\/JAHA.113.000506"},{"key":"737","doi-asserted-by":"crossref","unstructured":"737) Chowdhury R, Warnakula S, Kunutsor S, Crowe F, Ward HA, Johnson L, Franco OH, Butterworth AS, Forouhi NG, Thompson SG, Khaw KT, Mozaffarian D, Danesh J, Di Angelantonio E: Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med, 2014; 160: 398-406","DOI":"10.7326\/M13-1788"},{"key":"738","doi-asserted-by":"crossref","unstructured":"738) Hamley S: The effect of replacing saturated fat with mostly n-6 polyunsaturated fat on coronary heart disease: a meta-analysis of randomised controlled trials. Nutr J, 2017; 16: 30","DOI":"10.1186\/s12937-017-0254-5"},{"key":"739","doi-asserted-by":"crossref","unstructured":"739) Hooper L, Al-Khudairy L, Abdelhamid AS, Rees K, Brainard JS, Brown TJ, Ajabnoor SM, O\u2019Brien AT, Winstanley LE, Donaldson DH, Song F, Deane KH: Omega-6 fats for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev, 2018; 11: Cd011094","DOI":"10.1002\/14651858.CD011094.pub4"},{"key":"740","doi-asserted-by":"crossref","unstructured":"740) Farvid MS, Ding M, Pan A, Sun Q, Chiuve SE, Steffen LM, Willett WC, Hu FB: Dietary linoleic acid and risk of coronary heart disease: a systematic review and meta-analysis of prospective cohort studies. Circulation, 2014; 130: 1568-1578","DOI":"10.1161\/CIRCULATIONAHA.114.010236"},{"key":"741","doi-asserted-by":"crossref","unstructured":"741) Schwingshackl L, Hoffmann G: Monounsaturated fatty acids, olive oil and health status: a systematic review and meta-analysis of cohort studies. Lipids Health Dis, 2014; 13: 154","DOI":"10.1186\/1476-511X-13-154"},{"key":"742","doi-asserted-by":"crossref","unstructured":"742) Zong G, Li Y, Sampson L, Dougherty LW, Willett WC, Wanders AJ, Alssema M, Zock PL, Hu FB, Sun Q: Monounsaturated fats from plant and animal sources in relation to risk of coronary heart disease among US men and women. Am J Clin Nutr, 2018; 107: 445-453","DOI":"10.1093\/ajcn\/nqx004"},{"key":"743","unstructured":"743) Foley M, Ball M, Chisholm A, Duncan A, Spears G, Mann J: Should mono- or poly-unsaturated fats replace saturated fat in the diet? Eur J Clin Nutr, 1992; 46: 429-436"},{"key":"744","doi-asserted-by":"crossref","unstructured":"744) Berglund L, Lefevre M, Ginsberg HN, Kris-Etherton PM, Elmer PJ, Stewart PW, Ershow A, Pearson TA, Dennis BH, Roheim PS, Ramakrishnan R, Reed R, Stewart K, Phillips KM: Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states. Am J Clin Nutr, 2007; 86: 1611-1620","DOI":"10.1093\/ajcn\/86.6.1611"},{"key":"745","doi-asserted-by":"crossref","unstructured":"745) Mensink RP, Katan MB: Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials. Arterioscler Thromb, 1992; 12: 911-919","DOI":"10.1161\/01.ATV.12.8.911"},{"key":"746","doi-asserted-by":"crossref","unstructured":"746) Ginsberg HN, Barr SL, Gilbert A, Karmally W, Deckelbaum R, Kaplan K, Ramakrishnan R, Holleran S, Dell RB: Reduction of plasma cholesterol levels in normal men on an American Heart Association Step 1 diet or a Step 1 diet with added monounsaturated fat. N Engl J Med, 1990; 322: 574-579","DOI":"10.1056\/NEJM199003013220902"},{"key":"747","doi-asserted-by":"crossref","unstructured":"747) Thijssen MA, Mensink RP: Small differences in the effects of stearic acid, oleic acid, and linoleic acid on the serum lipoprotein profile of humans. Am J Clin Nutr, 2005; 82: 510-516","DOI":"10.1093\/ajcn.82.3.510"},{"key":"748","doi-asserted-by":"crossref","unstructured":"748) Schwingshackl L, Strasser B, Hoffmann G: Effects of monounsaturated fatty acids on cardiovascular risk factors: a systematic review and meta-analysis. Ann Nutr Metab, 2011; 59: 176-186","DOI":"10.1159\/000334071"},{"key":"749","doi-asserted-by":"crossref","unstructured":"749) de Roos B, Wanders AJ, Wood S, Horgan G, Rucklige G, Reid M, Siebelink E, Brouwer IA: A high intake of industrial or ruminant trans fatty acids does not affect the plasma proteome in healthy men. Proteomics, 2011; 11: 3928-3934","DOI":"10.1002\/pmic.201100163"},{"key":"750","doi-asserted-by":"crossref","unstructured":"750) Wanders AJ, Brouwer IA, Siebelink E, Katan MB: Effect of a high intake of conjugated linoleic acid on lipoprotein levels in healthy human subjects. PLoS One, 2010; 5: e9000","DOI":"10.1371\/journal.pone.0009000"},{"key":"751","doi-asserted-by":"crossref","unstructured":"751) Lacroix E, Charest A, Cyr A, Baril-Gravel L, Lebeuf Y, Paquin P, Chouinard PY, Couture P, Lamarche B: Randomized controlled study of the effect of a butter naturally enriched in trans fatty acids on blood lipids in healthy women. Am J Clin Nutr, 2012; 95: 318-325","DOI":"10.3945\/ajcn.111.023408"},{"key":"752","doi-asserted-by":"crossref","unstructured":"752) Gayet-Boyer C, Tenenhaus-Aziza F, Prunet C, Marmonier C, Malpuech-Brug\u00e8re C, Lamarche B, Chardigny JM: Is there a linear relationship between the dose of ruminant trans-fatty acids and cardiovascular risk markers in healthy subjects: results from a systematic review and meta-regression of randomised clinical trials. Br J Nutr, 2014; 112: 1914-1922","DOI":"10.1017\/S0007114514002578"},{"key":"753","doi-asserted-by":"crossref","unstructured":"753) Mori K, Ishida T, Yasuda T, Hasokawa M, Monguchi T, Sasaki M, Kondo K, Nakajima H, Shinohara M, Shinke T, Irino Y, Toh R, Nishimura K, Hirata K: Serum Trans-Fatty Acid Concentration Is Elevated in Young Patients With Coronary Artery Disease in Japan. Circ J, 2015; 79: 2017-2025","DOI":"10.1253\/circj.CJ-14-0750"},{"key":"754","doi-asserted-by":"crossref","unstructured":"754) Nagasawa Y, Shinke T, Toh R, Ishida T, Otake H, Takaya T, Sugiyama D, Toba T, Kuroda M, Takahashi H, Terashita D, Tahara N, Shinkura Y, Uzu K, Kashiwagi D, Kuroda K, Nagano Y, Yamamoto H, Yanaka K, Tsukiyama Y, Hirata KI: The impact of serum trans fatty acids concentration on plaque vulnerability in patients with coronary artery disease: Assessment via optical coherence tomography. Atherosclerosis, 2017; 265: 312-317","DOI":"10.1016\/j.atherosclerosis.2017.06.922"},{"key":"755","doi-asserted-by":"crossref","unstructured":"755) Honda T, Ohara T, Shinohara M, Hata J, Toh R, Yoshida D, Shibata M, Ishida T, Hirakawa Y, Irino Y, Sakata S, Uchida K, Kitazono T, Kanba S, Hirata KI, Ninomiya T: Serum elaidic acid concentration and risk of dementia: The Hisayama Study. Neurology, 2019; 93: e2053-e2064","DOI":"10.1212\/WNL.0000000000008464"},{"key":"756","doi-asserted-by":"crossref","unstructured":"756) Mozaffarian D, Aro A, Willett WC: Health effects of trans-fatty acids: experimental and observational evidence. Eur J Clin Nutr, 2009; 63 Suppl 2: S5-21","DOI":"10.1038\/sj.ejcn.1602973"},{"key":"757","doi-asserted-by":"crossref","unstructured":"757) Pietinen P, Ascherio A, Korhonen P, Hartman AM, Willett WC, Albanes D, Virtamo J: Intake of fatty acids and risk of coronary heart disease in a cohort of Finnish men. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Am J Epidemiol, 1997; 145: 876-887","DOI":"10.1093\/oxfordjournals.aje.a009047"},{"key":"758","doi-asserted-by":"crossref","unstructured":"758) Oomen CM, Ock\u00e9 MC, Feskens EJ, van Erp-Baart MA, Kok FJ, Kromhout D: Association between trans fatty acid intake and 10-year risk of coronary heart disease in the Zutphen Elderly Study: a prospective population-based study. Lancet, 2001; 357: 746-751","DOI":"10.1016\/S0140-6736(00)04166-0"},{"key":"759","doi-asserted-by":"crossref","unstructured":"759) Mozaffarian D, Clarke R: Quantitative effects on cardiovascular risk factors and coronary heart disease risk of replacing partially hydrogenated vegetable oils with other fats and oils. Eur J Clin Nutr, 2009; 63 Suppl 2: S22-33","DOI":"10.1038\/sj.ejcn.1602976"},{"key":"760","doi-asserted-by":"crossref","unstructured":"760) Nestel P, Noakes M, Belling B, McArthur R, Clifton P, Janus E, Abbey M: Plasma lipoprotein lipid and Lp[a] changes with substitution of elaidic acid for oleic acid in the diet. J Lipid Res, 1992; 33: 1029-1036","DOI":"10.1016\/S0022-2275(20)41418-X"},{"key":"761","doi-asserted-by":"crossref","unstructured":"761) Vega-L\u00f3pez S, Ausman LM, Jalbert SM, Erkkil\u00e4 AT, Lichtenstein AH: Palm and partially hydrogenated soybean oils adversely alter lipoprotein profiles compared with soybean and canola oils in moderately hyperlipidemic subjects. Am J Clin Nutr, 2006; 84: 54-62","DOI":"10.1093\/ajcn\/84.1.54"},{"key":"762","doi-asserted-by":"crossref","unstructured":"762) Mozaffarian D, de Oliveira Otto MC, Lemaitre RN, Fretts AM, Hotamisligil G, Tsai MY, Siscovick DS, Nettleton JA: trans-Palmitoleic acid, other dairy fat biomarkers, and incident diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Clin Nutr, 2013; 97: 854-861","DOI":"10.3945\/ajcn.112.045468"},{"key":"763","doi-asserted-by":"crossref","unstructured":"763) Aro A, Jauhiainen M, Partanen R, Salminen I, Mutanen M: Stearic acid, trans fatty acids, and dairy fat: effects on serum and lipoprotein lipids, apolipoproteins, lipoprotein(a), and lipid transfer proteins in healthy subjects. Am J Clin Nutr, 1997; 65: 1419-1426","DOI":"10.1093\/ajcn\/65.5.1419"},{"key":"764","doi-asserted-by":"crossref","unstructured":"764) Mensink RP, Zock PL, Katan MB, Hornstra G: Effect of dietary cis and trans fatty acids on serum lipoprotein[a] levels in humans. J Lipid Res, 1992; 33: 1493-1501","DOI":"10.1016\/S0022-2275(20)41404-X"},{"key":"765","doi-asserted-by":"crossref","unstructured":"765) Gebauer SK, Destaillats F, Dionisi F, Krauss RM, Baer DJ: Vaccenic acid and trans fatty acid isomers from partially hydrogenated oil both adversely affect LDL cholesterol: a double-blind, randomized controlled trial. Am J Clin Nutr, 2015; 102: 1339-1346","DOI":"10.3945\/ajcn.115.116129"},{"key":"766","unstructured":"766) Ministry of Agriculture, Forestry and Fisheries: Information on trans fatty acids, https:\/\/www.maff.go.jp\/j\/syouan\/seisaku\/trans_fat\/ 2022, (in Japanese)"},{"key":"767","unstructured":"767) Joint-WHO\/FAO-ExpertConsultation: Diet, Nutrition and the Prevention of Chonic Diseases, http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/42665\/WHO_TRS_916.pdf;jsessionid=3C16B0B5645DCBA1E6146E7F4C1761F0?sequence=1, 2003"},{"key":"768","doi-asserted-by":"crossref","unstructured":"768) Uauy R, Aro A, Clarke R, Ghafoorunissa., L\u2019Abbe M, Mozaffarian D, Skeaff M, Stender S, Tacke M: WHO Scientific Update on trans fatty acids: summary and conclusions. Eur J Clin Nutr, 2009; 63: S68\u2013S75","DOI":"10.1038\/ejcn.2009.15"},{"key":"769","doi-asserted-by":"crossref","unstructured":"769) McGee D, Reed D, Stemmerman G, Rhoads G, Yano K, Feinleib M: The relationship of dietary fat and cholesterol to mortality in 10 years: the Honolulu Heart Program. Int J Epidemiol, 1985; 14: 97-105","DOI":"10.1093\/ije\/14.1.97"},{"key":"770","doi-asserted-by":"crossref","unstructured":"770) Posner BM, Cobb JL, Belanger AJ, Cupples LA, D\u2019Agostino RB, Stokes J, 3rd: Dietary lipid predictors of coronary heart disease in men. The Framingham Study. Arch Intern Med, 1991; 151: 1181-1187","DOI":"10.1001\/archinte.151.6.1181"},{"key":"771","doi-asserted-by":"crossref","unstructured":"771) Xu J, Eilat-Adar S, Loria C, Goldbourt U, Howard BV, Fabsitz RR, Zephier EM, Mattil C, Lee ET: Dietary fat intake and risk of coronary heart disease: the Strong Heart Study. Am J Clin Nutr, 2006; 84: 894-902","DOI":"10.1093\/ajcn\/84.4.894"},{"key":"772","doi-asserted-by":"crossref","unstructured":"772) Zhong VW, Van Horn L, Cornelis MC, Wilkins JT, Ning H, Carnethon MR, Greenland P, Mentz RJ, Tucker KL, Zhao L, Norwood AF, Lloyd-Jones DM, Allen NB: Associations of Dietary Cholesterol or Egg Consumption With Incident Cardiovascular Disease and Mortality. JAMA, 2019; 321: 1081-1095","DOI":"10.1001\/jama.2019.1572"},{"key":"773","doi-asserted-by":"crossref","unstructured":"773) Li Y, Zhou C, Zhou X, Li L: Egg consumption and risk of cardiovascular diseases and diabetes: a meta-analysis. Atherosclerosis, 2013; 229: 524-530","DOI":"10.1016\/j.atherosclerosis.2013.04.003"},{"key":"774","doi-asserted-by":"crossref","unstructured":"774) Millen BE, Franz MM, Quatromoni PA, Gagnon DR, Sonnenberg LM, Ordovas JM, Wilson PW, Schaefer EJ, Cupples LA: Diet and plasma lipids in women. I. Macronutrients and plasma total and low-density lipoprotein cholesterol in women: the Framingham nutrition studies. J Clin Epidemiol, 1996; 49: 657-663","DOI":"10.1016\/0895-4356(96)00030-3"},{"key":"775","doi-asserted-by":"crossref","unstructured":"775) Johnson C, Greenland P: Effects of exercise, dietary cholesterol, and dietary fat on blood lipids. Arch Intern Med, 1990; 150: 137-141","DOI":"10.1001\/archinte.150.1.137"},{"key":"776","doi-asserted-by":"crossref","unstructured":"776) Fielding CJ, Havel RJ, Todd KM, Yeo KE, Schloetter MC, Weinberg V, Frost PH: Effects of dietary cholesterol and fat saturation on plasma lipoproteins in an ethnically diverse population of healthy young men. J Clin Invest, 1995; 95: 611-618","DOI":"10.1172\/JCI117705"},{"key":"777","doi-asserted-by":"crossref","unstructured":"777) Berger S, Raman G, Vishwanathan R, Jacques PF, Johnson EJ: Dietary cholesterol and cardiovascular disease: a systematic review and meta-analysis. Am J Clin Nutr, 2015; 102: 276-294","DOI":"10.3945\/ajcn.114.100305"},{"key":"778","doi-asserted-by":"crossref","unstructured":"778) Nicklas BJ, Katzel LI, Bunyard LB, Dennis KE, Goldberg AP: Effects of an American Heart Association diet and weight loss on lipoprotein lipids in obese, postmenopausal women. Am J Clin Nutr, 1997; 66: 853-859","DOI":"10.1093\/ajcn\/66.4.853"},{"key":"779","doi-asserted-by":"crossref","unstructured":"779) Dengel JL, Katzel LI, Goldberg AP: Effect of an American Heart Association diet, with or without weight loss, on lipids in obese middle-aged and older men. Am J Clin Nutr, 1995; 62: 715-721","DOI":"10.1093\/ajcn\/62.4.715"},{"key":"780","doi-asserted-by":"crossref","unstructured":"780) Lichtenstein AH, Ausman LM, Jalbert SM, Vilella-Bach M, Jauhiainen M, McGladdery S, Erkkil\u00e4 AT, Ehnholm C, Frohlich J, Schaefer EJ: Efficacy of a Therapeutic Lifestyle Change\/Step 2 diet in moderately hypercholesterolemic middle-aged and elderly female and male subjects. J Lipid Res, 2002; 43: 264-273","DOI":"10.1016\/S0022-2275(20)30168-1"},{"key":"781","doi-asserted-by":"crossref","unstructured":"781) Rivellese AA, Auletta P, Marotta G, Saldalamacchia G, Giacco A, Mastrilli V, Vaccaro O, Riccardi G: Long term metabolic effects of two dietary methods of treating hyperlipidaemia. BMJ, 1994; 308: 227-231","DOI":"10.1136\/bmj.308.6923.227"},{"key":"782","doi-asserted-by":"crossref","unstructured":"782) Vincent MJ, Allen B, Palacios OM, Haber LT, Maki KC: Meta-regression analysis of the effects of dietary cholesterol intake on LDL and HDL cholesterol. Am J Clin Nutr, 2019; 109: 7-16","DOI":"10.1093\/ajcn\/nqy273"},{"key":"783","doi-asserted-by":"crossref","unstructured":"783) Katan MB, Beynen AC, de Vries JH, Nobels A: Existence of consistent hypo- and hyperresponders to dietary cholesterol in man. Am J Epidemiol, 1986; 123: 221-234","DOI":"10.1093\/oxfordjournals.aje.a114231"},{"key":"784","doi-asserted-by":"crossref","unstructured":"784) Djouss\u00e9 L, Gaziano JM: Dietary cholesterol and coronary artery disease: a systematic review. Curr Atheroscler Rep, 2009; 11: 418-422","DOI":"10.1007\/s11883-009-0063-1"},{"key":"785","doi-asserted-by":"crossref","unstructured":"785) Clifton PM, Kestin M, Abbey M, Drysdale M, Nestel PJ: Relationship between sensitivity to dietary fat and dietary cholesterol. Arteriosclerosis, 1990; 10: 394-401","DOI":"10.1161\/01.ATV.10.3.394"},{"key":"786","doi-asserted-by":"crossref","unstructured":"786) Ginsberg HN, Karmally W, Siddiqui M, Holleran S, Tall AR, Rumsey SC, Deckelbaum RJ, Blaner WS, Ramakrishnan R: A dose-response study of the effects of dietary cholesterol on fasting and postprandial lipid and lipoprotein metabolism in healthy young men. Arterioscler Thromb, 1994; 14: 576-586","DOI":"10.1161\/01.ATV.14.4.576"},{"key":"787","unstructured":"787) Chakrabarty G, Manjunatha S, Bijlani RL, Ray RB, Mahapatra SC, Mehta N, Lakshmy R, Vashisht S, Manchanda SC: The effect of ingestion of egg on the serum lipid profile of healthy young Indians. Indian J Physiol Pharmacol, 2004; 48: 286-292"},{"key":"788","doi-asserted-by":"crossref","unstructured":"788) Herron KL, Vega-Lopez S, Conde K, Ramjiganesh T, Shachter NS, Fernandez ML: Men classified as hypo- or hyperresponders to dietary cholesterol feeding exhibit differences in lipoprotein metabolism. J Nutr, 2003; 133: 1036-1042","DOI":"10.1093\/jn\/133.4.1036"},{"key":"789","doi-asserted-by":"crossref","unstructured":"789) Flaim E, Ferreri LF, Thye FW, Hill JE, Ritchey SJ: Plasma lipid and lipoprotein cholesterol concentrations in adult males consuming normal and high cholesterol diets under controlled conditions. Am J Clin Nutr, 1981; 34: 1103-1108","DOI":"10.1093\/ajcn\/34.6.1103"},{"key":"790","doi-asserted-by":"crossref","unstructured":"790) Sacks FM, Salazar J, Miller L, Foster JM, Sutherland M, Samonds KW, Albers JJ, Kass EH: Ingestion of egg raises plasma low density lipoproteins in free-living subjects. Lancet, 1984; 1: 647-649","DOI":"10.1016\/S0140-6736(84)92168-8"},{"key":"791","doi-asserted-by":"crossref","unstructured":"791) Roberts SL, McMurry MP, Connor WE: Does egg feeding (i.e., dietary cholesterol) affect plasma cholesterol levels in humans? The results of a double-blind study. Am J Clin Nutr, 1981; 34: 2092-2099","DOI":"10.1093\/ajcn\/34.10.2092"},{"key":"792","unstructured":"792) Knopp RH, Retzlaff BM, Walden CE, Dowdy AA, Tsunehara CH, Austin MA, Nguyen T: A double-blind, randomized, controlled trial of the effects of two eggs per day in moderately hypercholesterolemic and combined hyperlipidemic subjects taught the NCEP step I diet. J Am Coll Nutr, 1997; 16: 551-561"},{"key":"793","doi-asserted-by":"crossref","unstructured":"793) Severins N, Mensink RP, Plat J: Effects of lutein-enriched egg yolk in buttermilk or skimmed milk on serum lipids &amp; lipoproteins of mildly hypercholesterolemic subjects. Nutr Metab Cardiovasc Dis, 2015; 25: 210-217","DOI":"10.1016\/j.numecd.2014.10.003"},{"key":"794","doi-asserted-by":"crossref","unstructured":"794) Baumgartner S, Kelly ER, van der Made S, Berendschot TT, Husche C, L\u00fctjohann D, Plat J: The influence of consuming an egg or an egg-yolk buttermilk drink for 12 wk on serum lipids, inflammation, and liver function markers in human volunteers. Nutrition, 2013; 29: 1237-1244","DOI":"10.1016\/j.nut.2013.03.020"},{"key":"795","doi-asserted-by":"crossref","unstructured":"795) Flynn MA, Nolph GB, Flynn TC, Kahrs R, Krause G: Effect of dietary egg on human serum cholesterol and triglycerides. Am J Clin Nutr, 1979; 32: 1051-1057","DOI":"10.1093\/ajcn\/32.5.1051"},{"key":"796","doi-asserted-by":"crossref","unstructured":"796) Fuller NR, Caterson ID, Sainsbury A, Denyer G, Fong M, Gerofi J, Baqleh K, Williams KH, Lau NS, Markovic TP: The effect of a high-egg diet on cardiovascular risk factors in people with type 2 diabetes: the Diabetes and Egg (DIABEGG) study-a 3-mo randomized controlled trial. Am J Clin Nutr, 2015; 101: 705-713","DOI":"10.3945\/ajcn.114.096925"},{"key":"797","doi-asserted-by":"crossref","unstructured":"797) Katz DL, Gnanaraj J, Treu JA, Ma Y, Kavak Y, Njike VY: Effects of egg ingestion on endothelial function in adults with coronary artery disease: a randomized, controlled, crossover trial. Am Heart J, 2015; 169: 162-169","DOI":"10.1016\/j.ahj.2014.10.001"},{"key":"798","doi-asserted-by":"crossref","unstructured":"798) Blesso CN, Andersen CJ, Barona J, Volek JS, Fernandez ML: Whole egg consumption improves lipoprotein profiles and insulin sensitivity to a greater extent than yolk-free egg substitute in individuals with metabolic syndrome. Metabolism, 2013; 62: 400-410","DOI":"10.1016\/j.metabol.2012.08.014"},{"key":"799","doi-asserted-by":"crossref","unstructured":"799) Pearce KL, Clifton PM, Noakes M: Egg consumption as part of an energy-restricted high-protein diet improves blood lipid and blood glucose profiles in individuals with type 2 diabetes. Br J Nutr, 2011; 105: 584-592","DOI":"10.1017\/S0007114510003983"},{"key":"800","doi-asserted-by":"crossref","unstructured":"800) Weggemans RM, Zock PL, Katan MB: Dietary cholesterol from eggs increases the ratio of total cholesterol to high-density lipoprotein cholesterol in humans: a meta-analysis. Am J Clin Nutr, 2001; 73: 885-891","DOI":"10.1093\/ajcn\/73.5.885"},{"key":"801","doi-asserted-by":"crossref","unstructured":"801) Rouhani MH, Rashidi-Pourfard N, Salehi-Abargouei A, Karimi M, Haghighatdoost F: Effects of Egg Consumption on Blood Lipids: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. J Am Coll Nutr, 2018; 37: 99-110","DOI":"10.1080\/07315724.2017.1366878"},{"key":"802","unstructured":"802) Hu FB, Stampfer MJ, Rimm EB, Manson JE, Ascherio A, Colditz GA, Rosner BA, Spiegelman D, Speizer FE, Sacks FM, Hennekens CH, Willett WC: A prospective study of egg consumption and risk of cardiovascular disease in men and women. JAMA, 1999; 281: 1387-1394"},{"key":"803","unstructured":"803) Qureshi AI, Suri FK, Ahmed S, Nasar A, Divani AA, Kirmani JF: Regular egg consumption does not increase the risk of stroke and cardiovascular diseases. Med Sci Monit, 2007; 13: Cr1-8"},{"key":"804","doi-asserted-by":"crossref","unstructured":"804) Houston DK, Ding J, Lee JS, Garcia M, Kanaya AM, Tylavsky FA, Newman AB, Visser M, Kritchevsky SB: Dietary fat and cholesterol and risk of cardiovascular disease in older adults: the Health ABC Study. Nutr Metab Cardiovasc Dis, 2011; 21: 430-437","DOI":"10.1016\/j.numecd.2009.11.007"},{"key":"805","doi-asserted-by":"crossref","unstructured":"805) Shin JY, Xun P, Nakamura Y, He K: Egg consumption in relation to risk of cardiovascular disease and diabetes: a systematic review and meta-analysis. Am J Clin Nutr, 2013; 98: 146-159","DOI":"10.3945\/ajcn.112.051318"},{"key":"806","doi-asserted-by":"crossref","unstructured":"806) Soliman GA: Dietary Fiber, Atherosclerosis, and Cardiovascular Disease. Nutrients, 2019; 11","DOI":"10.3390\/nu11051155"},{"key":"807","doi-asserted-by":"crossref","unstructured":"807) Wang Y, Harding SV, Thandapilly SJ, Tosh SM, Jones PJH, Ames NP: Barley \u03b2-glucan reduces blood cholesterol levels via interrupting bile acid metabolism. Br J Nutr, 2017; 118: 822-829","DOI":"10.1017\/S0007114517002835"},{"key":"808","doi-asserted-by":"crossref","unstructured":"808) Eshak ES, Iso H, Date C, Kikuchi S, Watanabe Y, Wada Y, Wakai K, Tamakoshi A: Dietary fiber intake is associated with reduced risk of mortality from cardiovascular disease among Japanese men and women. J Nutr, 2010; 140: 1445-1453","DOI":"10.3945\/jn.110.122358"},{"key":"809","doi-asserted-by":"crossref","unstructured":"809) Kokubo Y, Iso H, Saito I, Yamagishi K, Ishihara J, Inoue M, Tsugane S: Dietary fiber intake and risk of cardiovascular disease in the Japanese population: the Japan Public Health Center-based study cohort. Eur J Clin Nutr, 2011; 65: 1233-1241","DOI":"10.1038\/ejcn.2011.100"},{"key":"810","doi-asserted-by":"crossref","unstructured":"810) Yang Y, Zhao LG, Wu QJ, Ma X, Xiang YB: Association between dietary fiber and lower risk of all-cause mortality: a meta-analysis of cohort studies. Am J Epidemiol, 2015; 181: 83-91","DOI":"10.1093\/aje\/kwu257"},{"key":"811","doi-asserted-by":"crossref","unstructured":"811) Liu L, Wang S, Liu J: Fiber consumption and all-cause, cardiovascular, and cancer mortalities: a systematic review and meta-analysis of cohort studies. Mol Nutr Food Res, 2015; 59: 139-146","DOI":"10.1002\/mnfr.201400449"},{"key":"812","doi-asserted-by":"crossref","unstructured":"812) Hajishafiee M, Saneei P, Benisi-Kohansal S, Esmaillzadeh A: Cereal fibre intake and risk of mortality from all causes, CVD, cancer and inflammatory diseases: a systematic review and meta-analysis of prospective cohort studies. Br J Nutr, 2016; 116: 343-352","DOI":"10.1017\/S0007114516001938"},{"key":"813","doi-asserted-by":"crossref","unstructured":"813) Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L: Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. Lancet, 2019; 393: 434-445","DOI":"10.1016\/S0140-6736(18)31809-9"},{"key":"814","doi-asserted-by":"crossref","unstructured":"814) Kim Y, Je Y: Dietary fibre intake and mortality from cardiovascular disease and all cancers: A meta-analysis of prospective cohort studies. Arch Cardiovasc Dis, 2016; 109: 39-54","DOI":"10.1016\/j.acvd.2015.09.005"},{"key":"815","doi-asserted-by":"crossref","unstructured":"815) Threapleton DE, Greenwood DC, Evans CE, Cleghorn CL, Nykjaer C, Woodhead C, Cade JE, Gale CP, Burley VJ: Dietary fibre intake and risk of cardiovascular disease: systematic review and meta-analysis. BMJ, 2013; 347: f6879","DOI":"10.1136\/bmj.f6879"},{"key":"816","doi-asserted-by":"crossref","unstructured":"816) Chen GC, Lv DB, Pang Z, Dong JY, Liu QF: Dietary fiber intake and stroke risk: a meta-analysis of prospective cohort studies. Eur J Clin Nutr, 2013; 67: 96-100","DOI":"10.1038\/ejcn.2012.158"},{"key":"817","doi-asserted-by":"crossref","unstructured":"817) Zhang Z, Xu G, Liu D, Zhu W, Fan X, Liu X: Dietary fiber consumption and risk of stroke. Eur J Epidemiol, 2013; 28: 119-130","DOI":"10.1007\/s10654-013-9783-1"},{"key":"818","doi-asserted-by":"crossref","unstructured":"818) Threapleton DE, Greenwood DC, Evans CE, Cleghorn CL, Nykjaer C, Woodhead C, Cade JE, Gale CP, Burley VJ: Dietary fiber intake and risk of first stroke: a systematic review and meta-analysis. Stroke, 2013; 44: 1360-1368","DOI":"10.1161\/STROKEAHA.111.000151"},{"key":"819","doi-asserted-by":"crossref","unstructured":"819) Hartley L, May MD, Loveman E, Colquitt JL, Rees K: Dietary fibre for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev, 2016; 2016: Cd011472","DOI":"10.1002\/14651858.CD011472.pub2"},{"key":"820","doi-asserted-by":"crossref","unstructured":"820) Whitehead A, Beck EJ, Tosh S, Wolever TM: Cholesterol-lowering effects of oat \u03b2-glucan: a meta-analysis of randomized controlled trials. Am J Clin Nutr, 2014; 100: 1413-1421","DOI":"10.3945\/ajcn.114.086108"},{"key":"821","doi-asserted-by":"crossref","unstructured":"821) Brown L, Rosner B, Willett WW, Sacks FM: Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr, 1999; 69: 30-42","DOI":"10.1093\/ajcn\/69.1.30"},{"key":"822","doi-asserted-by":"crossref","unstructured":"822) Ho HV, Sievenpiper JL, Zurbau A, Blanco Mejia S, Jovanovski E, Au-Yeung F, Jenkins AL, Vuksan V: The effect of oat \u03b2-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: a systematic review and meta-analysis of randomised-controlled trials. Br J Nutr, 2016; 116: 1369-1382","DOI":"10.1017\/S000711451600341X"},{"key":"823","doi-asserted-by":"crossref","unstructured":"823) Ho HVT, Jovanovski E, Zurbau A, Blanco Mejia S, Sievenpiper JL, Au-Yeung F, Jenkins AL, Duvnjak L, Leiter L, Vuksan V: A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets non-HDL cholesterol and apolipoprotein B. Am J Clin Nutr, 2017; 105: 1239-1247","DOI":"10.3945\/ajcn.116.142158"},{"key":"824","doi-asserted-by":"crossref","unstructured":"824) Aune D, Keum N, Giovannucci E, Fadnes LT, Boffetta P, Greenwood DC, Tonstad S, Vatten LJ, Riboli E, Norat T: Whole grain consumption and risk of cardiovascular disease, cancer, and all cause and cause specific mortality: systematic review and dose-response meta-analysis of prospective studies. BMJ, 2016; 353: i2716","DOI":"10.1136\/bmj.i2716"},{"key":"825","doi-asserted-by":"crossref","unstructured":"825) Zong G, Gao A, Hu FB, Sun Q: Whole Grain Intake and Mortality From All Causes, Cardiovascular Disease, and Cancer: A Meta-Analysis of Prospective Cohort Studies. Circulation, 2016; 133: 2370-2380","DOI":"10.1161\/CIRCULATIONAHA.115.021101"},{"key":"826","doi-asserted-by":"crossref","unstructured":"826) Zhang B, Zhao Q, Guo W, Bao W, Wang X: Association of whole grain intake with all-cause, cardiovascular, and cancer mortality: a systematic review and dose-response meta-analysis from prospective cohort studies. Eur J Clin Nutr, 2018; 72: 57-65","DOI":"10.1038\/ejcn.2017.149"},{"key":"827","doi-asserted-by":"crossref","unstructured":"827) Wu H, Flint AJ, Qi Q, van Dam RM, Sampson LA, Rimm EB, Holmes MD, Willett WC, Hu FB, Sun Q: Association between dietary whole grain intake and risk of mortality: two large prospective studies in US men and women. JAMA Intern Med, 2015; 175: 373-384","DOI":"10.1001\/jamainternmed.2014.6283"},{"key":"828","doi-asserted-by":"crossref","unstructured":"828) Tang G, Wang D, Long J, Yang F, Si L: Meta-analysis of the association between whole grain intake and coronary heart disease risk. Am J Cardiol, 2015; 115: 625-629","DOI":"10.1016\/j.amjcard.2014.12.015"},{"key":"829","doi-asserted-by":"crossref","unstructured":"829) Mellen PB, Walsh TF, Herrington DM: Whole grain intake and cardiovascular disease: a meta-analysis. Nutr Metab Cardiovasc Dis, 2008; 18: 283-290","DOI":"10.1016\/j.numecd.2006.12.008"},{"key":"830","doi-asserted-by":"crossref","unstructured":"830) Muraki I, Wu H, Imamura F, Laden F, Rimm EB, Hu FB, Willett WC, Sun Q: Rice consumption and risk of cardiovascular disease: results from a pooled analysis of 3 U.S. cohorts. Am J Clin Nutr, 2015; 101: 164-172","DOI":"10.3945\/ajcn.114.087551"},{"key":"831","doi-asserted-by":"crossref","unstructured":"831) Eshak ES, Iso H, Yamagishi K, Kokubo Y, Saito I, Yatsuya H, Sawada N, Inoue M, Tsugane S: Rice consumption is not associated with risk of cardiovascular disease morbidity or mortality in Japanese men and women: a large population-based, prospective cohort study. Am J Clin Nutr, 2014; 100: 199-207","DOI":"10.3945\/ajcn.113.079038"},{"key":"832","doi-asserted-by":"crossref","unstructured":"832) Eshak ES, Iso H, Date C, Yamagishi K, Kikuchi S, Watanabe Y, Wada Y, Tamakoshi A: Rice intake is associated with reduced risk of mortality from cardiovascular disease in Japanese men but not women. J Nutr, 2011; 141: 595-602","DOI":"10.3945\/jn.110.132167"},{"key":"833","doi-asserted-by":"crossref","unstructured":"833) Shimabukuro M, Higa M, Kinjo R, Yamakawa K, Tanaka H, Kozuka C, Yabiku K, Taira S, Sata M, Masuzaki H: Effects of the brown rice diet on visceral obesity and endothelial function: the BRAVO study. Br J Nutr, 2014; 111: 310-320","DOI":"10.1017\/S0007114513002432"},{"key":"834","doi-asserted-by":"crossref","unstructured":"834) Kondo K, Morino K, Nishio Y, Ishikado A, Arima H, Nakao K, Nakagawa F, Nikami F, Sekine O, Nemoto KI, Suwa M, Matsumoto M, Miura K, Makino T, Ugi S, Maegawa H: Fiber-rich diet with brown rice improves endothelial function in type 2 diabetes mellitus: A randomized controlled trial. PLoS One, 2017; 12: e0179869","DOI":"10.1371\/journal.pone.0179869"},{"key":"835","doi-asserted-by":"crossref","unstructured":"835) Larsson SC, Wolk A: Potato consumption and risk of cardiovascular disease: 2 prospective cohort studies. Am J Clin Nutr, 2016; 104: 1245-1252","DOI":"10.3945\/ajcn.116.142422"},{"key":"836","doi-asserted-by":"crossref","unstructured":"836) Dilis V, Katsoulis M, Lagiou P, Trichopoulos D, Naska A, Trichopoulou A: Mediterranean diet and CHD: the Greek European Prospective Investigation into Cancer and Nutrition cohort. Br J Nutr, 2012; 108: 699-709","DOI":"10.1017\/S0007114512001821"},{"key":"837","doi-asserted-by":"crossref","unstructured":"837) Schwingshackl L, Schwedhelm C, Hoffmann G, Boeing H: Potatoes and risk of chronic disease: a systematic review and dose-response meta-analysis. Eur J Nutr, 2019; 58: 2243-2251","DOI":"10.1007\/s00394-018-1774-2"},{"key":"838","doi-asserted-by":"crossref","unstructured":"838) Holl\u00e6nder PL, Ross AB, Kristensen M: Whole-grain and blood lipid changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies. Am J Clin Nutr, 2015; 102: 556-572","DOI":"10.3945\/ajcn.115.109165"},{"key":"839","doi-asserted-by":"crossref","unstructured":"839) Ho HV, Sievenpiper JL, Zurbau A, Blanco Mejia S, Jovanovski E, Au-Yeung F, Jenkins AL, Vuksan V: A systematic review and meta-analysis of randomized controlled trials of the effect of barley \u03b2-glucan on LDL-C, non-HDL-C and apoB for cardiovascular disease risk reduction(i-iv). Eur J Clin Nutr, 2016; 70: 1239-1245","DOI":"10.1038\/ejcn.2016.89"},{"key":"840","doi-asserted-by":"crossref","unstructured":"840) Hui S, Liu K, Lang H, Liu Y, Wang X, Zhu X, Doucette S, Yi L, Mi M: Comparative effects of different whole grains and brans on blood lipid: a network meta-analysis. Eur J Nutr, 2019; 58: 2779-2787","DOI":"10.1007\/s00394-018-1827-6"},{"key":"841","doi-asserted-by":"crossref","unstructured":"841) Ripsin CM, Keenan JM, Jacobs DR, Jr., Elmer PJ, Welch RR, Van Horn L, Liu K, Turnbull WH, Thye FW, Kestin M, et al.: Oat products and lipid lowering. A meta-analysis. JAMA, 1992; 267: 3317-3325","DOI":"10.1001\/jama.267.24.3317"},{"key":"842","doi-asserted-by":"crossref","unstructured":"842) Li L, Lietz G, Seal C: Buckwheat and CVD Risk Markers: A Systematic Review and Meta-Analysis. Nutrients, 2018; 10","DOI":"10.3390\/nu10050619"},{"key":"843","doi-asserted-by":"crossref","unstructured":"843) Vega-L\u00f3pez S, Venn BJ, Slavin JL: Relevance of the Glycemic Index and Glycemic Load for Body Weight, Diabetes, and Cardiovascular Disease. Nutrients, 2018; 10","DOI":"10.3390\/nu10101361"},{"key":"844","doi-asserted-by":"crossref","unstructured":"844) Wang X, Ouyang Y, Liu J, Zhu M, Zhao G, Bao W, Hu FB: Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies. BMJ, 2014; 349: g4490","DOI":"10.1136\/bmj.g4490"},{"key":"845","doi-asserted-by":"crossref","unstructured":"845) Aune D, Giovannucci E, Boffetta P, Fadnes LT, Keum N, Norat T, Greenwood DC, Riboli E, Vatten LJ, Tonstad S: Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality-a systematic review and dose-response meta-analysis of prospective studies. Int J Epidemiol, 2017; 46: 1029-1056","DOI":"10.1093\/ije\/dyw319"},{"key":"846","doi-asserted-by":"crossref","unstructured":"846) Gan Y, Tong X, Li L, Cao S, Yin X, Gao C, Herath C, Li W, Jin Z, Chen Y, Lu Z: Consumption of fruit and vegetable and risk of coronary heart disease: a meta-analysis of prospective cohort studies. Int J Cardiol, 2015; 183: 129-137","DOI":"10.1016\/j.ijcard.2015.01.077"},{"key":"847","doi-asserted-by":"crossref","unstructured":"847) Dauchet L, Amouyel P, Dallongeville J: Fruit and vegetable consumption and risk of stroke: a meta-analysis of cohort studies. Neurology, 2005; 65: 1193-1197","DOI":"10.1212\/01.wnl.0000180600.09719.53"},{"key":"848","doi-asserted-by":"crossref","unstructured":"848) Hu D, Huang J, Wang Y, Zhang D, Qu Y: Fruits and vegetables consumption and risk of stroke: a meta-analysis of prospective cohort studies. Stroke, 2014; 45: 1613-1619","DOI":"10.1161\/STROKEAHA.114.004836"},{"key":"849","doi-asserted-by":"crossref","unstructured":"849) Yip CSC, Chan W, Fielding R: The Associations of Fruit and Vegetable Intakes with Burden of Diseases: A Systematic Review of Meta-Analyses. J Acad Nutr Diet, 2019; 119: 464-481","DOI":"10.1016\/j.jand.2018.11.007"},{"key":"850","doi-asserted-by":"crossref","unstructured":"850) Li M, Fan Y, Zhang X, Hou W, Tang Z: Fruit and vegetable intake and risk of type 2 diabetes mellitus: meta-analysis of prospective cohort studies. BMJ Open, 2014; 4: e005497","DOI":"10.1136\/bmjopen-2014-005497"},{"key":"851","doi-asserted-by":"crossref","unstructured":"851) Okuda N, Miura K, Okayama A, Okamura T, Abbott RD, Nishi N, Fujiyoshi A, Kita Y, Nakamura Y, Miyagawa N, Hayakawa T, Ohkubo T, Kiyohara Y, Ueshima H: Fruit and vegetable intake and mortality from cardiovascular disease in Japan: a 24-year follow-up of the NIPPON DATA80 Study. Eur J Clin Nutr, 2015; 69: 482-488","DOI":"10.1038\/ejcn.2014.276"},{"key":"852","doi-asserted-by":"crossref","unstructured":"852) Sauvaget C, Nagano J, Allen N, Kodama K: Vegetable and fruit intake and stroke mortality in the Hiroshima\/Nagasaki Life Span Study. Stroke, 2003; 34: 2355-2360","DOI":"10.1161\/01.STR.0000089293.29739.97"},{"key":"853","doi-asserted-by":"crossref","unstructured":"853) Yoshizaki T, Ishihara J, Kotemori A, Yamamoto J, Kokubo Y, Saito I, Yatsuya H, Yamagishi K, Sawada N, Iwasaki M, Iso H, Tsugane S: Association of Vegetable, Fruit, and Okinawan Vegetable Consumption With Incident Stroke and Coronary Heart Disease. J Epidemiol, 2020; 30: 37-45","DOI":"10.2188\/jea.JE20180130"},{"key":"854","doi-asserted-by":"crossref","unstructured":"854) Filippini T, Naska A, Kasdagli MI, Torres D, Lopes C, Carvalho C, Moreira P, Malavolti M, Orsini N, Whelton PK, Vinceti M: Potassium Intake and Blood Pressure: A Dose-Response Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc, 2020; 9: e015719","DOI":"10.1161\/JAHA.119.015719"},{"key":"855","doi-asserted-by":"crossref","unstructured":"855) Schwedhelm C, Schwingshackl L, Agogo GO, Sonestedt E, Boeing H, Kn\u00fcppel S: Associations of food groups and cardiometabolic and inflammatory biomarkers: does the meal matter? Br J Nutr, 2019; 122: 707-716","DOI":"10.1017\/S000711451900151X"},{"key":"856","doi-asserted-by":"crossref","unstructured":"856) Chung GKK, Yu RHY, Ho SSY, Woo J, Ho SC: Associations of consuming specific fruit and vegetable subgroups with LDL-C status in early postmenopausal Chinese women. Menopause, 2018; 25: 436-443","DOI":"10.1097\/GME.0000000000001008"},{"key":"857","doi-asserted-by":"crossref","unstructured":"857) Hadi A, Askarpour M, Miraghajani M, Symonds ME, Sheikhi A, Ghaedi E: Effects of strawberry supplementation on cardiovascular risk factors: a comprehensive systematic review and meta-analysis of randomized controlled trials. Food Funct, 2019; 10: 6987-6998","DOI":"10.1039\/C9FO01684H"},{"key":"858","doi-asserted-by":"crossref","unstructured":"858) Curtis PJ, van der Velpen V, Berends L, Jennings A, Feelisch M, Umpleby AM, Evans M, Fernandez BO, Meiss MS, Minnion M, Potter J, Minihane AM, Kay CD, Rimm EB, Cassidy A: Blueberries improve biomarkers of cardiometabolic function in participants with metabolic syndrome-results from a 6-month, double-blind, randomized controlled trial. Am J Clin Nutr, 2019; 109: 1535-1545","DOI":"10.1093\/ajcn\/nqy380"},{"key":"859","doi-asserted-by":"crossref","unstructured":"859) Lu\u00eds \u00c2, Domingues F, Pereira L: Association between berries intake and cardiovascular diseases risk factors: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. Food Funct, 2018; 9: 740-757","DOI":"10.1039\/C7FO01551H"},{"key":"860","doi-asserted-by":"crossref","unstructured":"860) Huang H, Chen G, Liao D, Zhu Y, Xue X: Effects of Berries Consumption on Cardiovascular Risk Factors: A Meta-analysis with Trial Sequential Analysis of Randomized Controlled Trials. Sci Rep, 2016; 6: 23625","DOI":"10.1038\/srep23625"},{"key":"861","doi-asserted-by":"crossref","unstructured":"861) Ghaedi E, Moradi S, Aslani Z, Kord-Varkaneh H, Miraghajani M, Mohammadi H: Effects of grape products on blood lipids: a systematic review and dose-response meta-analysis of randomized controlled trials. Food Funct, 2019; 10: 6399-6416","DOI":"10.1039\/C9FO01248F"},{"key":"862","doi-asserted-by":"crossref","unstructured":"862) Tenore GC, Caruso D, Buonomo G, D&apos;Urso E, D&apos;Avino M, Campiglia P, Marinelli L, Novellino E: Annurca (Malus pumila Miller cv. Annurca) apple as a functional food for the contribution to a healthy balance of plasma cholesterol levels: results of a randomized clinical trial. J Sci Food Agric, 2017; 97: 2107-2115","DOI":"10.1002\/jsfa.8016"},{"key":"863","doi-asserted-by":"crossref","unstructured":"863) Gorinstein S, Caspi A, Libman I, Lerner HT, Huang D, Leontowicz H, Leontowicz M, Tashma Z, Katrich E, Feng S, Trakhtenberg S: Red grapefruit positively influences serum triglyceride level in patients suffering from coronary atherosclerosis: studies in vitro and in humans. J Agric Food Chem, 2006; 54: 1887-1892","DOI":"10.1021\/jf058171g"},{"key":"864","doi-asserted-by":"crossref","unstructured":"864) Gorinstein S, Caspi A, Libman I, Katrich E, Lerner HT, Trakhtenberg S: Preventive effects of diets supplemented with sweetie fruits in hypercholesterolemic patients suffering from coronary artery disease. Prev Med, 2004; 38: 841-847","DOI":"10.1016\/j.ypmed.2003.12.021"},{"key":"865","doi-asserted-by":"crossref","unstructured":"865) Moazzen H, Alizadeh M: Effects of Pomegranate Juice on Cardiovascular Risk Factors in Patients with Metabolic Syndrome: a Double-Blinded, Randomized Crossover Controlled Trial. Plant Foods Hum Nutr, 2017; 72: 126-133","DOI":"10.1007\/s11130-017-0605-6"},{"key":"866","doi-asserted-by":"crossref","unstructured":"866) Gammon CS, Kruger R, Conlon CA, von Hurst PR, Jones B, Stonehouse W: Inflammatory status modulates plasma lipid and inflammatory marker responses to kiwifruit consumption in hypercholesterolaemic men. Nutr Metab Cardiovasc Dis, 2014; 24: 91-99","DOI":"10.1016\/j.numecd.2013.06.001"},{"key":"867","doi-asserted-by":"crossref","unstructured":"867) Toh DWK, Koh ES, Kim JE: Incorporating healthy dietary changes in addition to an increase in fruit and vegetable intake further improves the status of cardiovascular disease risk factors: A systematic review, meta-regression, and meta-analysis of randomized controlled trials. Nutr Rev, 2020; 78: 532-545","DOI":"10.1093\/nutrit\/nuz104"},{"key":"868","doi-asserted-by":"crossref","unstructured":"868) Shin JY, Kim JY, Kang HT, Han KH, Shim JY: Effect of fruits and vegetables on metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials. Int J Food Sci Nutr, 2015; 66: 416-425","DOI":"10.3109\/09637486.2015.1025716"},{"key":"869","unstructured":"869) Committee for the Revision of Guidelines of the Japanese Society of Gout and Uric &amp; nucleic Acids: Guideline for the management of hyperuricemia and gout. Ver3. 2019, Shindan to Chiryo sha, 2019 (in Japanese)"},{"key":"870","doi-asserted-by":"crossref","unstructured":"870) Anderson CA, Appel LJ, Okuda N, Brown IJ, Chan Q, Zhao L, Ueshima H, Kesteloot H, Miura K, Curb JD, Yoshita K, Elliott P, Yamamoto ME, Stamler J: Dietary sources of sodium in China, Japan, the United Kingdom, and the United States, women and men aged 40 to 59 years: the INTERMAP study. J Am Diet Assoc, 2010; 110: 736-745","DOI":"10.1016\/j.jada.2010.02.007"},{"key":"871","doi-asserted-by":"crossref","unstructured":"871) Miura K, Okuda N, Turin TC, Takashima N, Nakagawa H, Nakamura K, Yoshita K, Okayama A, Ueshima H: Dietary salt intake and blood pressure in a representative Japanese population: baseline analyses of NIPPON DATA80. J Epidemiol, 2010; 20 Suppl 3: S524-530","DOI":"10.2188\/jea.JE20090220"},{"key":"872","doi-asserted-by":"crossref","unstructured":"872) Kwok CS, Gulati M, Michos ED, Potts J, Wu P, Watson L, Loke YK, Mallen C, Mamas MA: Dietary components and risk of cardiovascular disease and all-cause mortality: a review of evidence from meta-analyses. Eur J Prev Cardiol, 2019; 26: 1415-1429","DOI":"10.1177\/2047487319843667"},{"key":"873","doi-asserted-by":"crossref","unstructured":"873) Khan TA, Tayyiba M, Agarwal A, Mejia SB, de Souza RJ, Wolever TMS, Leiter LA, Kendall CWC, Jenkins DJA, Sievenpiper JL: Relation of Total Sugars, Sucrose, Fructose, and Added Sugars With the Risk of Cardiovascular Disease: A Systematic Review and Dose-Response Meta-analysis of Prospective Cohort Studies. Mayo Clin Proc, 2019; 94: 2399-2414","DOI":"10.1016\/j.mayocp.2019.05.034"},{"key":"874","doi-asserted-by":"crossref","unstructured":"874) Micha R, Shulkin ML, Pe\u00f1alvo JL, Khatibzadeh S, Singh GM, Rao M, Fahimi S, Powles J, Mozaffarian D: Etiologic effects and optimal intakes of foods and nutrients for risk of cardiovascular diseases and diabetes: Systematic reviews and meta-analyses from the Nutrition and Chronic Diseases Expert Group (NutriCoDE). PLoS One, 2017; 12: e0175149","DOI":"10.1371\/journal.pone.0175149"},{"key":"875","doi-asserted-by":"crossref","unstructured":"875) Auerbach BJ, Dibey S, Vallila-Buchman P, Kratz M, Krieger J: Review of 100% Fruit Juice and Chronic Health Conditions: Implications for Sugar-Sweetened Beverage Policy. Adv Nutr, 2018; 9: 78-85","DOI":"10.1093\/advances\/nmx006"},{"key":"876","doi-asserted-by":"crossref","unstructured":"876) Collin LJ, Judd S, Safford M, Vaccarino V, Welsh JA: Association of Sugary Beverage Consumption With Mortality Risk in US Adults: A Secondary Analysis of Data From the REGARDS Study. JAMA Netw Open, 2019; 2: e193121","DOI":"10.1001\/jamanetworkopen.2019.3121"},{"key":"877","doi-asserted-by":"crossref","unstructured":"877) de Koning L, Malik VS, Kellogg MD, Rimm EB, Willett WC, Hu FB: Sweetened beverage consumption, incident coronary heart disease, and biomarkers of risk in men. Circulation, 2012; 125: 1735-1741, s1731","DOI":"10.1161\/CIRCULATIONAHA.111.067017"},{"key":"878","doi-asserted-by":"crossref","unstructured":"878) Xi B, Huang Y, Reilly KH, Li S, Zheng R, Barrio-Lopez MT, Martinez-Gonzalez MA, Zhou D: Sugar-sweetened beverages and risk of hypertension and CVD: a dose-response meta-analysis. Br J Nutr, 2015; 113: 709-717","DOI":"10.1017\/S0007114514004383"},{"key":"879","doi-asserted-by":"crossref","unstructured":"879) Imamura F, O&apos;Connor L, Ye Z, Mursu J, Hayashino Y, Bhupathiraju SN, Forouhi NG: Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of population attributable fraction. Br J Sports Med, 2016; 50: 496-504","DOI":"10.1136\/bjsports-2016-h3576rep"},{"key":"880","doi-asserted-by":"crossref","unstructured":"880) Eshak ES, Iso H, Kokubo Y, Saito I, Yamagishi K, Inoue M, Tsugane S: Soft drink intake in relation to incident ischemic heart disease, stroke, and stroke subtypes in Japanese men and women: the Japan Public Health Centre-based study cohort I. Am J Clin Nutr, 2012; 96: 1390-1397","DOI":"10.3945\/ajcn.112.037903"},{"key":"881","doi-asserted-by":"crossref","unstructured":"881) Chiavaroli L, de Souza RJ, Ha V, Cozma AI, Mirrahimi A, Wang DD, Yu M, Carleton AJ, Di Buono M, Jenkins AL, Leiter LA, Wolever TM, Beyene J, Kendall CW, Jenkins DJ, Sievenpiper JL: Effect of Fructose on Established Lipid Targets: A Systematic Review and Meta-Analysis of Controlled Feeding Trials. J Am Heart Assoc, 2015; 4: e001700","DOI":"10.1161\/JAHA.114.001700"},{"key":"882","doi-asserted-by":"crossref","unstructured":"882) David Wang D, Sievenpiper JL, de Souza RJ, Cozma AI, Chiavaroli L, Ha V, Mirrahimi A, Carleton AJ, Di Buono M, Jenkins AL, Leiter LA, Wolever TM, Beyene J, Kendall CW, Jenkins DJ: Effect of fructose on postprandial triglycerides: a systematic review and meta-analysis of controlled feeding trials. Atherosclerosis, 2014; 232: 125-133","DOI":"10.1016\/j.atherosclerosis.2013.10.019"},{"key":"883","doi-asserted-by":"crossref","unstructured":"883) Livesey G, Taylor R: Fructose consumption and consequences for glycation, plasma triacylglycerol, and body weight: meta-analyses and meta-regression models of intervention studies. Am J Clin Nutr, 2008; 88: 1419-1437","DOI":"10.3945\/ajcn.2007.25700"},{"key":"884","doi-asserted-by":"crossref","unstructured":"884) Evans RA, Frese M, Romero J, Cunningham JH, Mills KE: Fructose replacement of glucose or sucrose in food or beverages lowers postprandial glucose and insulin without raising triglycerides: a systematic review and meta-analysis. Am J Clin Nutr, 2017; 106: 506-518","DOI":"10.3945\/ajcn.116.145151"},{"key":"885","doi-asserted-by":"crossref","unstructured":"885) Evans RA, Frese M, Romero J, Cunningham JH, Mills KE: Chronic fructose substitution for glucose or sucrose in food or beverages has little effect on fasting blood glucose, insulin, or triglycerides: a systematic review and meta-analysis. Am J Clin Nutr, 2017; 106: 519-529","DOI":"10.3945\/ajcn.116.145169"},{"key":"886","doi-asserted-by":"crossref","unstructured":"886) Kelishadi R, Mansourian M, Heidari-Beni M: Association of fructose consumption and components of metabolic syndrome in human studies: a systematic review and meta-analysis. Nutrition, 2014; 30: 503-510","DOI":"10.1016\/j.nut.2013.08.014"},{"key":"887","doi-asserted-by":"crossref","unstructured":"887) Mozaffarian D, Appel LJ, Van Horn L: Components of a cardioprotective diet: new insights. Circulation, 2011; 123: 2870-2891","DOI":"10.1161\/CIRCULATIONAHA.110.968735"},{"key":"888","doi-asserted-by":"crossref","unstructured":"888) Kromhout D, Keys A, Aravanis C, Buzina R, Fidanza F, Giampaoli S, Jansen A, Menotti A, Nedeljkovic S, Pekkarinen M, et al.: Food consumption patterns in the 1960s in seven countries. Am J Clin Nutr, 1989; 49: 889-894","DOI":"10.1093\/ajcn\/49.5.889"},{"key":"889","unstructured":"889) National Institute of Health and Nutrition: Current Status of National Nutrition, https:\/\/www.nibiohn.go.jp\/eiken\/chosa\/kokumin_eiyou\/ (in Japanese)"},{"key":"890","doi-asserted-by":"crossref","unstructured":"890) Shimazu T, Kuriyama S, Hozawa A, Ohmori K, Sato Y, Nakaya N, Nishino Y, Tsubono Y, Tsuji I: Dietary patterns and cardiovascular disease mortality in Japan: a prospective cohort study. Int J Epidemiol, 2007; 36: 600-609","DOI":"10.1093\/ije\/dym005"},{"key":"891","doi-asserted-by":"crossref","unstructured":"891) Maruyama K, Iso H, Date C, Kikuchi S, Watanabe Y, Wada Y, Inaba Y, Tamakoshi A: Dietary patterns and risk of cardiovascular deaths among middle-aged Japanese: JACC Study. Nutr Metab Cardiovasc Dis, 2013; 23: 519-527","DOI":"10.1016\/j.numecd.2011.10.007"},{"key":"892","doi-asserted-by":"crossref","unstructured":"892) Okada E, Nakamura K, Ukawa S, Wakai K, Date C, Iso H, Tamakoshi A: The Japanese food score and risk of all-cause, CVD and cancer mortality: the Japan Collaborative Cohort Study. Br J Nutr, 2018; 120: 464-471","DOI":"10.1017\/S000711451800154X"},{"key":"893","doi-asserted-by":"crossref","unstructured":"893) Nanri A, Mizoue T, Shimazu T, Ishihara J, Takachi R, Noda M, Iso H, Sasazuki S, Sawada N, Tsugane S: Dietary patterns and all-cause, cancer, and cardiovascular disease mortality in Japanese men and women: The Japan public health center-based prospective study. PLoS One, 2017; 12: e0174848","DOI":"10.1371\/journal.pone.0174848"},{"key":"894","doi-asserted-by":"crossref","unstructured":"894) Nakamura Y, Ueshima H, Okamura T, Kadowaki T, Hayakawa T, Kita Y, Abbott RD, Okayama A: A Japanese diet and 19-year mortality: national integrated project for prospective observation of non-communicable diseases and its trends in the aged, 1980. Br J Nutr, 2009; 101: 1696-1705","DOI":"10.1017\/S0007114508111503"},{"key":"895","doi-asserted-by":"crossref","unstructured":"895) Matsuyama S, Sawada N, Tomata Y, Zhang S, Goto A, Yamaji T, Iwasaki M, Inoue M, Tsuji I, Tsugane S: Association between adherence to the Japanese diet and all-cause and cause-specific mortality: the Japan Public Health Center-based Prospective Study. Eur J Nutr, 2021; 60: 1327-1336","DOI":"10.1007\/s00394-020-02330-0"},{"key":"896","doi-asserted-by":"crossref","unstructured":"896) Abe S, Zhang S, Tomata Y, Tsuduki T, Sugawara Y, Tsuji I: Japanese diet and survival time: The Ohsaki Cohort 1994 study. Clin Nutr, 2020; 39: 298-303","DOI":"10.1016\/j.clnu.2019.02.010"},{"key":"897","doi-asserted-by":"crossref","unstructured":"897) Maruyama C, Nakano R, Shima M, Mae A, Shijo Y, Nakamura E, Okabe Y, Park S, Kameyama N, Hirai S, Nakanishi M, Uchida K, Nishiyama H: Effects of a Japan Diet Intake Program on Metabolic Parameters in Middle-Aged Men. J Atheroscler Thromb, 2017; 24: 393-401","DOI":"10.5551\/jat.36780"},{"key":"898","doi-asserted-by":"crossref","unstructured":"898) Shijo Y, Maruyama C, Nakamura E, Nakano R, Shima M, Mae A, Okabe Y, Park S, Kameyama N, Hirai S: Japan Diet Intake Changes Serum Phospholipid Fatty Acid Compositions in Middle-Aged Men: A Pilot Study. J Atheroscler Thromb, 2019; 26: 3-13","DOI":"10.5551\/jat.43448"},{"key":"899","doi-asserted-by":"crossref","unstructured":"899) Maruyama C, Shijo Y, Kameyama N, Umezawa A, Sato A, Nishitani A, Ayaori M, Ikewaki K, Waki M, Teramoto T: Effects of Nutrition Education Program for the Japan Diet on Serum LDL-Cholesterol Concentration in Patients with Dyslipidemia: A Randomized Controlled Trial. J Atheroscler Thromb, 2021; 28: 1035-1051","DOI":"10.5551\/jat.60376"},{"key":"900","doi-asserted-by":"crossref","unstructured":"900) Tada N, Maruyama C, Koba S, Tanaka H, Birou S, Teramoto T, Sasaki J: Japanese dietary lifestyle and cardiovascular disease. J Atheroscler Thromb, 2011; 18: 723-734","DOI":"10.5551\/jat.8193"},{"key":"901","unstructured":"901) Maruyama C, Kameyama N, Doi E, Nagai N, Okuda N, Fujioka Y, Masuda D, Morino K, Yoshida H, Waki M, Hirai S: The Japan Diet - Diet for the Prevention of ASCVD, https:\/\/www.j-athero.org\/jp\/wp-content\/uploads\/en\/publications\/pdf\/TheJapanDiet_DigestEdition.pdf, 2020"},{"key":"902","unstructured":"902) Ministry of Health, Labour and Welfare: the National Health and Nutrition Survey. https:\/\/www.mhlw.go.jp\/content\/000711006.pdf, 2020 in Japanese"},{"key":"903","doi-asserted-by":"crossref","unstructured":"903) Namazi N, Saneei P, Larijani B, Esmaillzadeh A: Soy product consumption and the risk of all-cause, cardiovascular and cancer mortality: a systematic review and meta-analysis of cohort studies. Food Funct, 2018; 9: 2576-2588","DOI":"10.1039\/C7FO01622K"},{"key":"904","doi-asserted-by":"crossref","unstructured":"904) Shirai K, Kobayashi J, Inadera H, Ohkubo Y, Mori S, Saito Y, Yoshida S: Type I hyperlipoproteinemia caused by lipoprotein lipase defect in lipid-interface recognition was relieved by administration of medium-chain triglyceride. Metabolism, 1992; 41: 1161-1164","DOI":"10.1016\/0026-0495(92)90003-S"},{"key":"905","doi-asserted-by":"crossref","unstructured":"905) Rouis M, Dugi KA, Previato L, Patterson AP, Brunzell JD, Brewer HB, Santamarina-Fojo S: Therapeutic response to medium-chain triglycerides and omega-3 fatty acids in a patient with the familial chylomicronemia syndrome. Arterioscler Thromb Vasc Biol, 1997; 17: 1400-1406","DOI":"10.1161\/01.ATV.17.7.1400"},{"key":"906","doi-asserted-by":"crossref","unstructured":"906) Sheerah HA, Eshak ES, Cui R, Imano H, Iso H, Tamakoshi A: Relationship Between Dietary Vitamin D and Deaths From Stroke and Coronary Heart Disease: The Japan Collaborative Cohort Study. Stroke, 2018; 49: 454-457","DOI":"10.1161\/STROKEAHA.117.019417"},{"key":"907","doi-asserted-by":"crossref","unstructured":"907) Shi H, Chen H, Zhang Y, Li J, Fu K, Xue W, Teng W, Tian L: 25-Hydroxyvitamin D level, vitamin D intake, and risk of stroke: A dose-response meta-analysis. Clin Nutr, 2020; 39: 2025-2034","DOI":"10.1016\/j.clnu.2019.08.029"},{"key":"908","doi-asserted-by":"crossref","unstructured":"908) Parker J, Hashmi O, Dutton D, Mavrodaris A, Stranges S, Kandala NB, Clarke A, Franco OH: Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas, 2010; 65: 225-236","DOI":"10.1016\/j.maturitas.2009.12.013"},{"key":"909","doi-asserted-by":"crossref","unstructured":"909) Grandi NC, Breitling LP, Brenner H: Vitamin D and cardiovascular disease: systematic review and meta-analysis of prospective studies. Prev Med, 2010; 51: 228-233","DOI":"10.1016\/j.ypmed.2010.06.013"},{"key":"910","doi-asserted-by":"crossref","unstructured":"910) Wang L, Song Y, Manson JE, Pilz S, M\u00e4rz W, Micha\u00eblsson K, Lundqvist A, Jassal SK, Barrett-Connor E, Zhang C, Eaton CB, May HT, Anderson JL, Sesso HD: Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes, 2012; 5: 819-829","DOI":"10.1161\/CIRCOUTCOMES.112.967604"},{"key":"911","doi-asserted-by":"crossref","unstructured":"911) Sun Q, Pan A, Hu FB, Manson JE, Rexrode KM: 25-Hydroxyvitamin D levels and the risk of stroke: a prospective study and meta-analysis. Stroke, 2012; 43: 1470-1477","DOI":"10.1161\/STROKEAHA.111.636910"},{"key":"912","doi-asserted-by":"crossref","unstructured":"912) Zhang R, Li B, Gao X, Tian R, Pan Y, Jiang Y, Gu H, Wang Y, Wang Y, Liu G: Serum 25-hydroxyvitamin D and the risk of cardiovascular disease: dose-response meta-analysis of prospective studies. Am J Clin Nutr, 2017; 105: 810-819","DOI":"10.3945\/ajcn.116.140392"},{"key":"913","doi-asserted-by":"crossref","unstructured":"913) Gholami F, Moradi G, Zareei B, Rasouli MA, Nikkhoo B, Roshani D, Ghaderi E: The association between circulating 25-hydroxyvitamin D and cardiovascular diseases: a meta-analysis of prospective cohort studies. BMC Cardiovasc Disord, 2019; 19: 248","DOI":"10.1186\/s12872-019-1236-7"},{"key":"914","doi-asserted-by":"crossref","unstructured":"914) Chowdhury R, Kunutsor S, Vitezova A, Oliver-Williams C, Chowdhury S, Kiefte-de-Jong JC, Khan H, Baena CP, Prabhakaran D, Hoshen MB, Feldman BS, Pan A, Johnson L, Crowe F, Hu FB, Franco OH: Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ, 2014; 348: g1903","DOI":"10.1136\/bmj.g1903"},{"key":"915","doi-asserted-by":"crossref","unstructured":"915) Br\u00f8ndum-Jacobsen P, Benn M, Jensen GB, Nordestgaard BG: 25-hydroxyvitamin d levels and risk of ischemic heart disease, myocardial infarction, and early death: population-based study and meta-analyses of 18 and 17 studies. Arterioscler Thromb Vasc Biol, 2012; 32: 2794-2802","DOI":"10.1161\/ATVBAHA.112.248039"},{"key":"916","doi-asserted-by":"crossref","unstructured":"916) Chowdhury R, Stevens S, Ward H, Chowdhury S, Sajjad A, Franco OH: Circulating vitamin D, calcium and risk of cerebrovascular disease: a systematic review and meta-analysis. Eur J Epidemiol, 2012; 27: 581-591","DOI":"10.1007\/s10654-012-9729-z"},{"key":"917","doi-asserted-by":"crossref","unstructured":"917) Zhou R, Wang M, Huang H, Li W, Hu Y, Wu T: Lower Vitamin D Status Is Associated with an Increased Risk of Ischemic Stroke: A Systematic Review and Meta-Analysis. Nutrients, 2018; 10","DOI":"10.3390\/nu10030277"},{"key":"918","doi-asserted-by":"crossref","unstructured":"918) Kunutsor SK, Apekey TA, Steur M: Vitamin D and risk of future hypertension: meta-analysis of 283,537 participants. Eur J Epidemiol, 2013; 28: 205-221","DOI":"10.1007\/s10654-013-9790-2"},{"key":"919","doi-asserted-by":"crossref","unstructured":"919) Qi D, Nie XL, Wu S, Cai J: Vitamin D and hypertension: Prospective study and meta-analysis. PLoS One, 2017; 12: e0174298","DOI":"10.1371\/journal.pone.0174298"},{"key":"920","doi-asserted-by":"crossref","unstructured":"920) Cheng P, Wang L, Ning S, Liu Z, Lin H, Chen S, Zhu J: Vitamin E intake and risk of stroke: a meta-analysis. Br J Nutr, 2018; 120: 1181-1188","DOI":"10.1017\/S0007114518002647"},{"key":"921","doi-asserted-by":"crossref","unstructured":"921) Nagao M, Moriyama Y, Yamagishi K, Iso H, Tamakoshi A: Relation of serum \u03b1- and \u03b3-tocopherol levels to cardiovascular disease-related mortality among Japanese men and women. J Epidemiol, 2012; 22: 402-410","DOI":"10.2188\/jea.JE20120002"},{"key":"922","doi-asserted-by":"crossref","unstructured":"922) Aune D, Keum N, Giovannucci E, Fadnes LT, Boffetta P, Greenwood DC, Tonstad S, Vatten LJ, Riboli E, Norat T: Dietary intake and blood concentrations of antioxidants and the risk of cardiovascular disease, total cancer, and all-cause mortality: a systematic review and dose-response meta-analysis of prospective studies. Am J Clin Nutr, 2018; 108: 1069-1091","DOI":"10.1093\/ajcn\/nqy097"},{"key":"923","doi-asserted-by":"crossref","unstructured":"923) Jayedi A, Rashidy-Pour A, Parohan M, Zargar MS, Shab-Bidar S: Dietary and circulating vitamin C, vitamin E, \u03b2-carotene and risk of total cardiovascular mortality: a systematic review and dose-response meta-analysis of prospective observational studies. Public Health Nutr, 2019; 22: 1872-1887","DOI":"10.1017\/S1368980018003725"},{"key":"924","doi-asserted-by":"crossref","unstructured":"924) Chen GC, Lu DB, Pang Z, Liu QF: Vitamin C intake, circulating vitamin C and risk of stroke: a meta-analysis of prospective studies. J Am Heart Assoc, 2013; 2: e000329","DOI":"10.1161\/JAHA.113.000329"},{"key":"925","doi-asserted-by":"crossref","unstructured":"925) Kubota Y, Iso H, Date C, Kikuchi S, Watanabe Y, Wada Y, Inaba Y, Tamakoshi A: Dietary intakes of antioxidant vitamins and mortality from cardiovascular disease: the Japan Collaborative Cohort Study (JACC) study. Stroke, 2011; 42: 1665-1672","DOI":"10.1161\/STROKEAHA.110.601526"},{"key":"926","doi-asserted-by":"crossref","unstructured":"926) Knekt P, Ritz J, Pereira MA, O&apos;Reilly EJ, Augustsson K, Fraser GE, Goldbourt U, Heitmann BL, Hallmans G, Liu S, Pietinen P, Spiegelman D, Stevens J, Virtamo J, Willett WC, Rimm EB, Ascherio A: Antioxidant vitamins and coronary heart disease risk: a pooled analysis of 9 cohorts. Am J Clin Nutr, 2004; 80: 1508-1520","DOI":"10.1093\/ajcn\/80.6.1508"},{"key":"927","doi-asserted-by":"crossref","unstructured":"927) Mirhosseini N, Rainsbury J, Kimball SM: Vitamin D Supplementation, Serum 25(OH)D Concentrations and Cardiovascular Disease Risk Factors: A Systematic Review and Meta-Analysis. Front Cardiovasc Med, 2018; 5: 87","DOI":"10.3389\/fcvm.2018.00087"},{"key":"928","doi-asserted-by":"crossref","unstructured":"928) Dibaba DT: Effect of vitamin D supplementation on serum lipid profiles: a systematic review and meta-analysis. Nutr Rev, 2019; 77: 890-902","DOI":"10.1093\/nutrit\/nuz037"},{"key":"929","doi-asserted-by":"crossref","unstructured":"929) Loffredo L, Perri L, Di Castelnuovo A, Iacoviello L, De Gaetano G, Violi F: Supplementation with vitamin E alone is associated with reduced myocardial infarction: a meta-analysis. Nutr Metab Cardiovasc Dis, 2015; 25: 354-363","DOI":"10.1016\/j.numecd.2015.01.008"},{"key":"930","doi-asserted-by":"crossref","unstructured":"930) Ashor AW, Siervo M, Lara J, Oggioni C, Mathers JC: Antioxidant vitamin supplementation reduces arterial stiffness in adults: a systematic review and meta-analysis of randomized controlled trials. J Nutr, 2014; 144: 1594-1602","DOI":"10.3945\/jn.114.195826"},{"key":"931","doi-asserted-by":"crossref","unstructured":"931) Salonen RM, Nyyss\u00f6nen K, Kaikkonen J, Porkkala-Sarataho E, Voutilainen S, Rissanen TH, Tuomainen TP, Valkonen VP, Ristonmaa U, Lakka HM, Vanharanta M, Salonen JT, Poulsen HE: Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Circulation, 2003; 107: 947-953","DOI":"10.1161\/01.CIR.0000050626.25057.51"},{"key":"932","doi-asserted-by":"crossref","unstructured":"932) Wong SK, Chin KY, Suhaimi FH, Ahmad F, Ima-Nirwana S: Vitamin E As a Potential Interventional Treatment for Metabolic Syndrome: Evidence from Animal and Human Studies. Front Pharmacol, 2017; 8: 444","DOI":"10.3389\/fphar.2017.00444"},{"key":"933","doi-asserted-by":"crossref","unstructured":"933) Wong SK, Kamisah Y, Mohamed N, Muhammad N, Masbah N, Fahami NAM, Mohamed IN, Shuid AN, Saad QM, Abdullah A, Mohamad NV, Ibrahim NI, Pang KL, Chow YY, Thong BKS, Subramaniam S, Chan CY, Ima-Nirwana S, Chin AK: Potential Role of Tocotrienols on Non-Communicable Diseases: A Review of Current Evidence. Nutrients, 2020; 12","DOI":"10.3390\/nu12010259"},{"key":"934","doi-asserted-by":"crossref","unstructured":"934) Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K, Lichtenstein AH, Lau J, Balk EM: Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med, 2010; 152: 307-314","DOI":"10.7326\/0003-4819-152-5-201003020-00009"},{"key":"935","doi-asserted-by":"crossref","unstructured":"935) Barbarawi M, Kheiri B, Zayed Y, Barbarawi O, Dhillon H, Swaid B, Yelangi A, Sundus S, Bachuwa G, Alkotob ML, Manson JE: Vitamin D Supplementation and Cardiovascular Disease Risks in More Than 83 000 Individuals in 21 Randomized Clinical Trials: A Meta-analysis. JAMA Cardiol, 2019; 4: 765-776","DOI":"10.1001\/jamacardio.2019.1870"},{"key":"936","doi-asserted-by":"crossref","unstructured":"936) Swart KM, Lips P, Brouwer IA, Jorde R, Heymans MW, Grimnes G, Gr\u00fcbler MR, Gaksch M, Tomaschitz A, Pilz S, Eiriksdottir G, Gudnason V, Wamberg L, Rejnmark L, Sempos CT, Durazo-Arvizu RA, Dowling KG, Hull G, \u0160krab\u00e1kov\u00e1 Z, Kiely M, Cashman KD, van Schoor NM: Effects of vitamin D supplementation on markers for cardiovascular disease and type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials. Am J Clin Nutr, 2018; 107: 1043-1053","DOI":"10.1093\/ajcn\/nqy078"},{"key":"937","doi-asserted-by":"crossref","unstructured":"937) Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP: Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ, 2014; 348: g2035","DOI":"10.1136\/bmj.g2035"},{"key":"938","doi-asserted-by":"crossref","unstructured":"938) Elamin MB, Abu Elnour NO, Elamin KB, Fatourechi MM, Alkatib AA, Almandoz JP, Liu H, Lane MA, Mullan RJ, Hazem A, Erwin PJ, Hensrud DD, Murad MH, Montori VM: Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab, 2011; 96: 1931-1942","DOI":"10.1210\/jc.2011-0398"},{"key":"939","doi-asserted-by":"crossref","unstructured":"939) Ford JA, MacLennan GS, Avenell A, Bolland M, Grey A, Witham M: Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis. Am J Clin Nutr, 2014; 100: 746-755","DOI":"10.3945\/ajcn.113.082602"},{"key":"940","doi-asserted-by":"crossref","unstructured":"940) Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ: Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet, 2003; 361: 2017-2023","DOI":"10.1016\/S0140-6736(03)13637-9"},{"key":"941","doi-asserted-by":"crossref","unstructured":"941) Eidelman RS, Hollar D, Hebert PR, Lamas GA, Hennekens CH: Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease. Arch Intern Med, 2004; 164: 1552-1556","DOI":"10.1001\/archinte.164.14.1552"},{"key":"942","doi-asserted-by":"crossref","unstructured":"942) Ashor AW, Brown R, Keenan PD, Willis ND, Siervo M, Mathers JC: Limited evidence for a beneficial effect of vitamin C supplementation on biomarkers of cardiovascular diseases: an umbrella review of systematic reviews and meta-analyses. Nutr Res, 2019; 61: 1-12","DOI":"10.1016\/j.nutres.2018.08.005"},{"key":"943","doi-asserted-by":"crossref","unstructured":"943) Jenkins DJA, Spence JD, Giovannucci EL, Kim YI, Josse R, Vieth R, Blanco Mejia S, Viguiliouk E, Nishi S, Sahye-Pudaruth S, Paquette M, Patel D, Mitchell S, Kavanagh M, Tsirakis T, Bachiri L, Maran A, Umatheva N, McKay T, Trinidad G, Bernstein D, Chowdhury A, Correa-Betanzo J, Del Principe G, Hajizadeh A, Jayaraman R, Jenkins A, Jenkins W, Kalaichandran R, Kirupaharan G, Manisekaran P, Qutta T, Shahid R, Silver A, Villegas C, White J, Kendall CWC, Pichika SC, Sievenpiper JL: Supplemental Vitamins and Minerals for CVD Prevention and Treatment. J Am Coll Cardiol, 2018; 71: 2570-2584","DOI":"10.1016\/j.jacc.2018.04.020"},{"key":"944","doi-asserted-by":"crossref","unstructured":"944) Bleys J, Miller ER, 3rd, Pastor-Barriuso R, Appel LJ, Guallar E: Vitamin-mineral supplementation and the progression of atherosclerosis: a meta-analysis of randomized controlled trials. Am J Clin Nutr, 2006; 84: 880-887; quiz 954-885","DOI":"10.1093\/ajcn\/84.4.880"},{"key":"945","doi-asserted-by":"crossref","unstructured":"945) Ye Y, Li J, Yuan Z: Effect of antioxidant vitamin supplementation on cardiovascular outcomes: a meta-analysis of randomized controlled trials. PLoS One, 2013; 8: e56803","DOI":"10.1371\/journal.pone.0056803"},{"key":"946","doi-asserted-by":"crossref","unstructured":"946) Khan SU, Khan MU, Riaz H, Valavoor S, Zhao D, Vaughan L, Okunrintemi V, Riaz IB, Khan MS, Kaluski E, Murad MH, Blaha MJ, Guallar E, Michos ED: Effects of Nutritional Supplements and Dietary Interventions on Cardiovascular Outcomes: An Umbrella Review and Evidence Map. Ann Intern Med, 2019; 171: 190-198","DOI":"10.7326\/M19-0341"},{"key":"947","doi-asserted-by":"crossref","unstructured":"947) Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, Ross C, Arnold A, Sleight P, Probstfield J, Dagenais GR: Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA, 2005; 293: 1338-1347","DOI":"10.1001\/jama.293.11.1338"},{"key":"948","doi-asserted-by":"crossref","unstructured":"948) Lee DH, Folsom AR, Harnack L, Halliwell B, Jacobs DR, Jr.: Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes? Am J Clin Nutr, 2004; 80: 1194-1200","DOI":"10.1093\/ajcn\/80.5.1194"},{"key":"949","doi-asserted-by":"crossref","unstructured":"949) Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, Rogers WJ, Ouyang P, Thompson P, Tardif JC, Higginson L, Bittner V, Steffes M, Gordon DJ, Proschan M, Younes N, Verter JI: Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA, 2002; 288: 2432-2440","DOI":"10.1001\/jama.288.19.2432"},{"key":"950","doi-asserted-by":"crossref","unstructured":"950) Sch\u00fcrks M, Glynn RJ, Rist PM, Tzourio C, Kurth T: Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ, 2010; 341: c5702","DOI":"10.1136\/bmj.c5702"},{"key":"951","unstructured":"951) Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Glynn RJ, Gaziano JM: Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians&apos; Health Study II randomized controlled trial. JAMA, 2008; 300: 2123-2133"},{"key":"952","unstructured":"952) Food Safety Commission of Japan, Cabinet Office: Effects of excessive vitamin A intake, https:\/\/www.fsc.go.jp\/topics\/factsheet-vitamin-a.pdf (in Japanese)"},{"key":"953","doi-asserted-by":"crossref","unstructured":"953) Murai U, Yamagishi K, Sata M, Kokubo Y, Saito I, Yatsuya H, Ishihara J, Inoue M, Sawada N, Iso H, Tsugane S: Seaweed intake and risk of cardiovascular disease: the Japan Public Health Center-based Prospective (JPHC) Study. Am J Clin Nutr, 2019; 110: 1449-1455","DOI":"10.1093\/ajcn\/nqz231"},{"key":"954","doi-asserted-by":"crossref","unstructured":"954) Kishida R, Yamagishi K, Muraki I, Sata M, Tamakoshi A, Iso H: Frequency of Seaweed Intake and Its Association with Cardiovascular Disease Mortality: The JACC Study. J Atheroscler Thromb, 2020; 27: 1340-1347","DOI":"10.5551\/jat.53447"},{"key":"955","doi-asserted-by":"crossref","unstructured":"955) Chichibu H, Yamagishi K, Kishida R, Maruyama K, Hayama-Terada M, Shimizu Y, Muraki I, Umesawa M, Cui R, Imano H, Ohira T, Tanigawa T, Sankai T, Okada T, Kitamura A, Kiyama M, Iso H: Seaweed Intake and Risk of Cardiovascular Disease: The Circulatory Risk in Communities Study (CIRCS). J Atheroscler Thromb, 2021; 28: 1298-1306","DOI":"10.5551\/jat.61390"},{"key":"956","doi-asserted-by":"crossref","unstructured":"956) Yan Z, Zhang X, Li C, Jiao S, Dong W: Association between consumption of soy and risk of cardiovascular disease: A meta-analysis of observational studies. Eur J Prev Cardiol, 2017; 24: 735-747","DOI":"10.1177\/2047487316686441"},{"key":"957","doi-asserted-by":"crossref","unstructured":"957) Lou D, Li Y, Yan G, Bu J, Wang H: Soy Consumption with Risk of Coronary Heart Disease and Stroke: A Meta-Analysis of Observational Studies. Neuroepidemiology, 2016; 46: 242-252","DOI":"10.1159\/000444324"},{"key":"958","doi-asserted-by":"crossref","unstructured":"958) Nguyen HN, Miyagawa N, Miura K, Okuda N, Yoshita K, Arai Y, Nakagawa H, Sakata K, Ojima T, Kadota A, Takashima N, Fujiyoshi A, Ohkubo T, Abbott RD, Okamura T, Okayama A, Ueshima H: Dietary tofu intake and long-term risk of death from stroke in a general population. Clin Nutr, 2018; 37: 182-188","DOI":"10.1016\/j.clnu.2016.11.021"},{"key":"959","doi-asserted-by":"crossref","unstructured":"959) Nagata C, Wada K, Tamura T, Konishi K, Goto Y, Koda S, Kawachi T, Tsuji M, Nakamura K: Dietary soy and natto intake and cardiovascular disease mortality in Japanese adults: the Takayama study. Am J Clin Nutr, 2017; 105: 426-431","DOI":"10.3945\/ajcn.116.137281"},{"key":"960","doi-asserted-by":"crossref","unstructured":"960) Anderson JW, Bush HM: Soy protein effects on serum lipoproteins: a quality assessment and meta-analysis of randomized, controlled studies. J Am Coll Nutr, 2011; 30: 79-91","DOI":"10.1080\/07315724.2011.10719947"},{"key":"961","doi-asserted-by":"crossref","unstructured":"961) Blanco Mejia S, Messina M, Li SS, Viguiliouk E, Chiavaroli L, Khan TA, Srichaikul K, Mirrahimi A, Sievenpiper JL, Kris-Etherton P, Jenkins DJA: A Meta-Analysis of 46 Studies Identified by the FDA Demonstrates that Soy Protein Decreases Circulating LDL and Total Cholesterol Concentrations in Adults. J Nutr, 2019; 149: 968-981","DOI":"10.1093\/jn\/nxz020"},{"key":"962","doi-asserted-by":"crossref","unstructured":"962) Tokede OA, Onabanjo TA, Yansane A, Gaziano JM, Djouss\u00e9 L: Soya products and serum lipids: a meta-analysis of randomised controlled trials. Br J Nutr, 2015; 114: 831-843","DOI":"10.1017\/S0007114515002603"},{"key":"963","doi-asserted-by":"crossref","unstructured":"963) Eslami O, Shidfar F: Soy milk: A functional beverage with hypocholesterolemic effects? A systematic review of randomized controlled trials. Complement Ther Med, 2019; 42: 82-88","DOI":"10.1016\/j.ctim.2018.11.001"},{"key":"964","doi-asserted-by":"crossref","unstructured":"964) Weggemans RM, Trautwein EA: Relation between soy-associated isoflavones and LDL and HDL cholesterol concentrations in humans: a meta-analysis. Eur J Clin Nutr, 2003; 57: 940-946","DOI":"10.1038\/sj.ejcn.1601628"},{"key":"965","doi-asserted-by":"crossref","unstructured":"965) de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, Guidollet J, Touboul P, Delaye J: Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet, 1994; 343: 1454-1459","DOI":"10.1016\/S0140-6736(94)92580-1"},{"key":"966","doi-asserted-by":"crossref","unstructured":"966) de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N: Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation, 1999; 99: 779-785","DOI":"10.1161\/01.CIR.99.6.779"},{"key":"967","doi-asserted-by":"crossref","unstructured":"967) Estruch R, Ros E, Salas-Salvad\u00f3 J, Covas MI, Corella D, Ar\u00f3s F, G\u00f3mez-Gracia E, Ruiz-Guti\u00e9rrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pint\u00f3 X, Basora J, Mu\u00f1oz MA, Sorl\u00ed JV, Mart\u00ednez JA, Fit\u00f3 M, Gea A, Hern\u00e1n MA, Mart\u00ednez-Gonz\u00e1lez MA: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med, 2018; 378: e34","DOI":"10.1056\/NEJMoa1800389"},{"key":"968","doi-asserted-by":"crossref","unstructured":"968) Liyanage T, Ninomiya T, Wang A, Neal B, Jun M, Wong MG, Jardine M, Hillis GS, Perkovic V: Effects of the Mediterranean Diet on Cardiovascular Outcomes-A Systematic Review and Meta-Analysis. PLoS One, 2016; 11: e0159252","DOI":"10.1371\/journal.pone.0159252"},{"key":"969","doi-asserted-by":"crossref","unstructured":"969) Rees K, Takeda A, Martin N, Ellis L, Wijesekara D, Vepa A, Das A, Hartley L, Stranges S: Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev, 2019; 3: Cd009825","DOI":"10.1002\/14651858.CD009825.pub3"},{"key":"970","doi-asserted-by":"crossref","unstructured":"970) Panizza CE, Lim U, Yonemori KM, Cassel KD, Wilkens LR, Harvie MN, Maskarinec G, Delp EJ, Lampe JW, Shepherd JA, Le Marchand L, Boushey CJ: Effects of Intermittent Energy Restriction Combined with a Mediterranean Diet on Reducing Visceral Adiposity: A Randomized Active Comparator Pilot Study. Nutrients, 2019; 11","DOI":"10.3390\/nu11061386"},{"key":"971","doi-asserted-by":"crossref","unstructured":"971) Yang J, Farioli A, Korre M, Kales SN: Modified Mediterranean diet score and cardiovascular risk in a North American working population. PLoS One, 2014; 9: e87539","DOI":"10.1371\/journal.pone.0087539"},{"key":"972","doi-asserted-by":"crossref","unstructured":"972) Murakami K, Livingstone MBE, Sasaki S: Diet quality scores in relation to metabolic risk factors in Japanese adults: a cross-sectional analysis from the 2012 National Health and Nutrition Survey, Japan. Eur J Nutr, 2019; 58: 2037-2050","DOI":"10.1007\/s00394-018-1762-6"},{"key":"973","doi-asserted-by":"crossref","unstructured":"973) Fung TT, Chiuve SE, McCullough ML, Rexrode KM, Logroscino G, Hu FB: Adherence to a DASH-style diet and risk of coronary heart disease and stroke in women. Arch Intern Med, 2008; 168: 713-720","DOI":"10.1001\/archinte.168.7.713"},{"key":"974","doi-asserted-by":"crossref","unstructured":"974) Sotos-Prieto M, Bhupathiraju SN, Mattei J, Fung TT, Li Y, Pan A, Willett WC, Rimm EB, Hu FB: Changes in Diet Quality Scores and Risk of Cardiovascular Disease Among US Men and Women. Circulation, 2015; 132: 2212-2219","DOI":"10.1161\/CIRCULATIONAHA.115.017158"},{"key":"975","doi-asserted-by":"crossref","unstructured":"975) Reedy J, Krebs-Smith SM, Miller PE, Liese AD, Kahle LL, Park Y, Subar AF: Higher diet quality is associated with decreased risk of all-cause, cardiovascular disease, and cancer mortality among older adults. J Nutr, 2014; 144: 881-889","DOI":"10.3945\/jn.113.189407"},{"key":"976","doi-asserted-by":"crossref","unstructured":"976) Chiavaroli L, Viguiliouk E, Nishi SK, Blanco Mejia S, Raheli\u0107 D, Kahleov\u00e1 H, Salas-Salvad\u00f3 J, Kendall CW, Sievenpiper JL: DASH Dietary Pattern and Cardiometabolic Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses. Nutrients, 2019; 11","DOI":"10.3390\/nu11020338"},{"key":"977","doi-asserted-by":"crossref","unstructured":"977) Kahleova H, Salas-Salvad\u00f3 J, Raheli\u0107 D, Kendall CW, Rembert E, Sievenpiper JL: Dietary Patterns and Cardiometabolic Outcomes in Diabetes: A Summary of Systematic Reviews and Meta-Analyses. Nutrients, 2019; 11","DOI":"10.3390\/nu11092209"},{"key":"978","doi-asserted-by":"crossref","unstructured":"978) Yang ZQ, Yang Z, Duan ML: Dietary approach to stop hypertension diet and risk of coronary artery disease: a meta-analysis of prospective cohort studies. Int J Food Sci Nutr, 2019; 70: 668-674","DOI":"10.1080\/09637486.2019.1570490"},{"key":"979","doi-asserted-by":"crossref","unstructured":"979) Soltani S, Arablou T, Jayedi A, Salehi-Abargouei A: Adherence to the dietary approaches to stop hypertension (DASH) diet in relation to all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective cohort studies. Nutr J, 2020; 19: 37","DOI":"10.1186\/s12937-020-00554-8"},{"key":"980","doi-asserted-by":"crossref","unstructured":"980) Salehi-Abargouei A, Maghsoudi Z, Shirani F, Azadbakht L: Effects of Dietary Approaches to Stop Hypertension (DASH)-style diet on fatal or nonfatal cardiovascular diseases--incidence: a systematic review and meta-analysis on observational prospective studies. Nutrition, 2013; 29: 611-618","DOI":"10.1016\/j.nut.2012.12.018"},{"key":"981","doi-asserted-by":"crossref","unstructured":"981) Schwingshackl L, Bogensberger B, Hoffmann G: Diet Quality as Assessed by the Healthy Eating Index, Alternate Healthy Eating Index, Dietary Approaches to Stop Hypertension Score, and Health Outcomes: An Updated Systematic Review and Meta-Analysis of Cohort Studies. J Acad Nutr Diet, 2018; 118: 74-100.e111","DOI":"10.1016\/j.jand.2017.08.024"},{"key":"982","doi-asserted-by":"crossref","unstructured":"982) Schwingshackl L, Hoffmann G: Diet quality as assessed by the Healthy Eating Index, the Alternate Healthy Eating Index, the Dietary Approaches to Stop Hypertension score, and health outcomes: a systematic review and meta-analysis of cohort studies. J Acad Nutr Diet, 2015; 115: 780-800.e785","DOI":"10.1016\/j.jand.2014.12.009"},{"key":"983","doi-asserted-by":"crossref","unstructured":"983) Filippou CD, Tsioufis CP, Thomopoulos CG, Mihas CC, Dimitriadis KS, Sotiropoulou LI, Chrysochoou CA, Nihoyannopoulos PI, Tousoulis DM: Dietary Approaches to Stop Hypertension (DASH) Diet and Blood Pressure Reduction in Adults with and without Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Adv Nutr, 2020; 11: 1150-1160","DOI":"10.1093\/advances\/nmaa041"},{"key":"984","doi-asserted-by":"crossref","unstructured":"984) Siervo M, Lara J, Chowdhury S, Ashor A, Oggioni C, Mathers JC: Effects of the Dietary Approach to Stop Hypertension (DASH) diet on cardiovascular risk factors: a systematic review and meta-analysis. Br J Nutr, 2015; 113: 1-15","DOI":"10.1017\/S0007114514003341"},{"key":"985","doi-asserted-by":"crossref","unstructured":"985) Kawamura A, Kajiya K, Kishi H, Inagaki J, Mitarai M, Oda H, Umemoto S, Kobayashi S: Effects of the DASH-JUMP dietary intervention in Japanese participants with high-normal blood pressure and stage 1 hypertension: an open-label single-arm trial. Hypertens Res, 2016; 39: 777-785","DOI":"10.1038\/hr.2016.76"},{"key":"986","doi-asserted-by":"crossref","unstructured":"986) Umemoto S, Onaka U, Kawano R, Kawamura A, Motoi S, Honda N, Kanazashi H, Mitarai M: Effects of a Japanese Cuisine-Based Antihypertensive Diet and Fish Oil on Blood Pressure and Its Variability in Participants with Untreated Normal High Blood Pressure or Stage I Hypertension: A Feasibility Randomized Controlled Study. J Atheroscler Thromb, 2022; 29: 152-173","DOI":"10.5551\/jat.57802"},{"key":"987","doi-asserted-by":"crossref","unstructured":"987) Ros E: Health benefits of nut consumption. Nutrients, 2010; 2: 652-682","DOI":"10.3390\/nu2070652"},{"key":"988","doi-asserted-by":"crossref","unstructured":"988) Aune D, Keum N, Giovannucci E, Fadnes LT, Boffetta P, Greenwood DC, Tonstad S, Vatten LJ, Riboli E, Norat T: Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective studies. BMC Med, 2016; 14: 207","DOI":"10.1186\/s12916-016-0730-3"},{"key":"989","doi-asserted-by":"crossref","unstructured":"989) Aune D: Plant Foods, Antioxidant Biomarkers, and the Risk of Cardiovascular Disease, Cancer, and Mortality: A Review of the Evidence. Adv Nutr, 2019; 10: S404-s421","DOI":"10.1093\/advances\/nmz042"},{"key":"990","doi-asserted-by":"crossref","unstructured":"990) Brown RC, Gray AR, Tey SL, Chisholm A, Burley V, Greenwood DC, Cade J: Associations between Nut Consumption and Health Vary between Omnivores, Vegetarians, and Vegans. Nutrients, 2017; 9","DOI":"10.3390\/nu9111219"},{"key":"991","doi-asserted-by":"crossref","unstructured":"991) Chen GC, Zhang R, Mart\u00ednez-Gonz\u00e1lez MA, Zhang ZL, Bonaccio M, van Dam RM, Qin LQ: Nut consumption in relation to all-cause and cause-specific mortality: a meta-analysis 18 prospective studies. Food Funct, 2017; 8: 3893-3905","DOI":"10.1039\/C7FO00915A"},{"key":"992","doi-asserted-by":"crossref","unstructured":"992) Grosso G, Yang J, Marventano S, Micek A, Galvano F, Kales SN: Nut consumption on all-cause, cardiovascular, and cancer mortality risk: a systematic review and meta-analysis of epidemiologic studies. Am J Clin Nutr, 2015; 101: 783-793","DOI":"10.3945\/ajcn.114.099515"},{"key":"993","doi-asserted-by":"crossref","unstructured":"993) Mayhew AJ, de Souza RJ, Meyre D, Anand SS, Mente A: A systematic review and meta-analysis of nut consumption and incident risk of CVD and all-cause mortality. Br J Nutr, 2016; 115: 212-225","DOI":"10.1017\/S0007114515004316"},{"key":"994","doi-asserted-by":"crossref","unstructured":"994) Luo C, Zhang Y, Ding Y, Shan Z, Chen S, Yu M, Hu FB, Liu L: Nut consumption and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis. Am J Clin Nutr, 2014; 100: 256-269","DOI":"10.3945\/ajcn.113.076109"},{"key":"995","doi-asserted-by":"crossref","unstructured":"995) Weng YQ, Yao J, Guo ML, Qin QJ, Li P: Association between nut consumption and coronary heart disease: a meta-analysis. Coron Artery Dis, 2016; 27: 227-232","DOI":"10.1097\/MCA.0000000000000331"},{"key":"996","doi-asserted-by":"crossref","unstructured":"996) Ma L, Wang F, Guo W, Yang H, Liu Y, Zhang W: Nut consumption and the risk of coronary artery disease: a dose-response meta-analysis of 13 prospective studies. Thromb Res, 2014; 134: 790-794","DOI":"10.1016\/j.thromres.2014.06.017"},{"key":"997","doi-asserted-by":"crossref","unstructured":"997) Becerra-Tom\u00e1s N, Paz-Graniel I, C WCK, Kahleova H, Raheli\u0107 D, Sievenpiper JL, Salas-Salvad\u00f3 J: Nut consumption and incidence of cardiovascular diseases and cardiovascular disease mortality: a meta-analysis of prospective cohort studies. Nutr Rev, 2019; 77: 691-709","DOI":"10.1093\/nutrit\/nuz042"},{"key":"998","doi-asserted-by":"crossref","unstructured":"998) Zhang Z, Xu G, Wei Y, Zhu W, Liu X: Nut consumption and risk of stroke. Eur J Epidemiol, 2015; 30: 189-196","DOI":"10.1007\/s10654-015-9999-3"},{"key":"999","doi-asserted-by":"crossref","unstructured":"999) Shao C, Tang H, Zhao W, He J: Nut intake and stroke risk: A dose-response meta-analysis of prospective cohort studies. Sci Rep, 2016; 6: 30394","DOI":"10.1038\/srep30394"},{"key":"1000","doi-asserted-by":"crossref","unstructured":"1000) Sabat\u00e9 J, Oda K, Ros E: Nut consumption and blood lipid levels: a pooled analysis of 25 intervention trials. Arch Intern Med, 2010; 170: 821-827","DOI":"10.1001\/archinternmed.2010.79"},{"key":"1001","doi-asserted-by":"crossref","unstructured":"1001) Tey SL, Brown RC, Chisholm AW, Delahunty CM, Gray AR, Williams SM: Effects of different forms of hazelnuts on blood lipids and \u03b1-tocopherol concentrations in mildly hypercholesterolemic individuals. Eur J Clin Nutr, 2011; 65: 117-124","DOI":"10.1038\/ejcn.2010.200"},{"key":"1002","doi-asserted-by":"crossref","unstructured":"1002) Tey SL, Delahunty C, Gray A, Chisholm A, Brown RC: Effects of regular consumption of different forms of almonds and hazelnuts on acceptance and blood lipids. Eur J Nutr, 2015; 54: 483-487","DOI":"10.1007\/s00394-014-0808-7"},{"key":"1003","doi-asserted-by":"crossref","unstructured":"1003) Wu L, Piotrowski K, Rau T, Waldmann E, Broedl UC, Demmelmair H, Koletzko B, Stark RG, Nagel JM, Mantzoros CS, Parhofer KG: Walnut-enriched diet reduces fasting non-HDL-cholesterol and apolipoprotein B in healthy Caucasian subjects: a randomized controlled cross-over clinical trial. Metabolism, 2014; 63: 382-391","DOI":"10.1016\/j.metabol.2013.11.005"},{"key":"1004","doi-asserted-by":"crossref","unstructured":"1004) Banel DK, Hu FB: Effects of walnut consumption on blood lipids and other cardiovascular risk factors: a meta-analysis and systematic review. Am J Clin Nutr, 2009; 90: 56-63","DOI":"10.3945\/ajcn.2009.27457"},{"key":"1005","doi-asserted-by":"crossref","unstructured":"1005) Altamimi M, Zidan S, Badrasawi M: Effect of Tree Nuts Consumption on Serum Lipid Profile in Hyperlipidemic Individuals: A Systematic Review. Nutr Metab Insights, 2020; 13: 1178638820926521","DOI":"10.1177\/1178638820926521"},{"key":"1006","doi-asserted-by":"crossref","unstructured":"1006) Durstine JL, Grandjean PW, Davis PG, Ferguson MA, Alderson NL, DuBose KD: Blood lipid and lipoprotein adaptations to exercise: a quantitative analysis. Sports Med, 2001; 31: 1033-1062","DOI":"10.2165\/00007256-200131150-00002"},{"key":"1007","doi-asserted-by":"crossref","unstructured":"1007) Leon AS, Sanchez OA: Response of blood lipids to exercise training alone or combined with dietary intervention. Med Sci Sports Exerc, 2001; 33: S502-515; discussion S528-509","DOI":"10.1097\/00005768-200106001-00021"},{"key":"1008","doi-asserted-by":"crossref","unstructured":"1008) Kelley GA, Kelley KS, Tran ZV: Walking, lipids, and lipoproteins: a meta-analysis of randomized controlled trials. Prev Med, 2004; 38: 651-661","DOI":"10.1016\/j.ypmed.2003.12.012"},{"key":"1009","doi-asserted-by":"crossref","unstructured":"1009) Kelley GA, Kelley KS, Tran ZV: Aerobic exercise and lipids and lipoproteins in women: a meta-analysis of randomized controlled trials. J Womens Health (Larchmt), 2004; 13: 1148-1164","DOI":"10.1089\/jwh.2004.13.1148"},{"key":"1010","doi-asserted-by":"crossref","unstructured":"1010) Kelley GA, Kelley KS, Tran ZV: Exercise, lipids, and lipoproteins in older adults: a meta-analysis. Prev Cardiol, 2005; 8: 206-214","DOI":"10.1111\/j.0197-3118.2005.03769.x"},{"key":"1011","doi-asserted-by":"crossref","unstructured":"1011) Kelley GA, Kelley KS: Aerobic exercise and lipids and lipoproteins in men: a meta-analysis of randomized controlled trials. J Mens Health Gend, 2006; 3: 61-70","DOI":"10.1016\/j.jmhg.2005.09.003"},{"key":"1012","doi-asserted-by":"crossref","unstructured":"1012) Kodama S, Tanaka S, Saito K, Shu M, Sone Y, Onitake F, Suzuki E, Shimano H, Yamamoto S, Kondo K, Ohashi Y, Yamada N, Sone H: Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med, 2007; 167: 999-1008","DOI":"10.1001\/archinte.167.10.999"},{"key":"1013","doi-asserted-by":"crossref","unstructured":"1013) Igarashi Y, Akazawa N, Maeda S: Effects of Aerobic Exercise Alone on Lipids in Healthy East Asians: A Systematic Review and Meta-Analysis. J Atheroscler Thromb, 2019; 26: 488-503","DOI":"10.5551\/jat.45864"},{"key":"1014","doi-asserted-by":"crossref","unstructured":"1014) Igarashi Y, Nogami Y: Response of Lipids and Lipoproteins to Regular Aquatic Endurance Exercise: A Meta-Analysis of Randomized Controlled Trials. J Atheroscler Thromb, 2019; 26: 14-30","DOI":"10.5551\/jat.42937"},{"key":"1015","doi-asserted-by":"crossref","unstructured":"1015) Costa RR, Buttelli ACK, Vieira AF, Coconcelli L, Magalh\u00e3es RL, Delevatti RS, Kruel LFM: Effect of Strength Training on Lipid and Inflammatory Outcomes: Systematic Review With Meta-Analysis and Meta-Regression. J Phys Act Health, 2019; 16: 477-491","DOI":"10.1123\/jpah.2018-0317"},{"key":"1016","doi-asserted-by":"crossref","unstructured":"1016) Koba S, Tanaka H, Maruyama C, Tada N, Birou S, Teramoto T, Sasaki J: Physical activity in the Japan population: association with blood lipid levels and effects in reducing cardiovascular and all-cause mortality. J Atheroscler Thromb, 2011; 18: 833-845","DOI":"10.5551\/jat.8094"},{"key":"1017","doi-asserted-by":"crossref","unstructured":"1017) Palaz\u00f3n-Bru A, Hern\u00e1ndez-Lozano D, Gil-Guill\u00e9n VF: Which Physical Exercise Interventions Increase HDL-Cholesterol Levels? A Systematic Review of Meta-analyses of Randomized Controlled Trials. Sports Med, 2021; 51: 243-253","DOI":"10.1007\/s40279-020-01364-y"},{"key":"1018","doi-asserted-by":"crossref","unstructured":"1018) Igarashi Y, Akazawa N, Maeda S: Regular aerobic exercise and blood pressure in East Asians: A meta-analysis of randomized controlled trials. Clin Exp Hypertens, 2018; 40: 378-389","DOI":"10.1080\/10641963.2017.1384483"},{"key":"1019","doi-asserted-by":"crossref","unstructured":"1019) Hootman JM, Macera CA, Ainsworth BE, Addy CL, Martin M, Blair SN: Epidemiology of musculoskeletal injuries among sedentary and physically active adults. Med Sci Sports Exerc, 2002; 34: 838-844","DOI":"10.1097\/00005768-200205000-00017"},{"key":"1020","doi-asserted-by":"crossref","unstructured":"1020) Kelley GA, Kelley KS: Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. Prev Med, 2009; 48: 9-19","DOI":"10.1016\/j.ypmed.2008.10.010"},{"key":"1021","doi-asserted-by":"crossref","unstructured":"1021) Yang Z, Scott CA, Mao C, Tang J, Farmer AJ: Resistance exercise versus aerobic exercise for type 2 diabetes: a systematic review and meta-analysis. Sports Med, 2014; 44: 487-499","DOI":"10.1007\/s40279-013-0128-8"},{"key":"1022","doi-asserted-by":"crossref","unstructured":"1022) Cornelissen VA, Fagard RH, Coeckelberghs E, Vanhees L: Impact of resistance training on blood pressure and other cardiovascular risk factors: a meta-analysis of randomized, controlled trials. Hypertension, 2011; 58: 950-958","DOI":"10.1161\/HYPERTENSIONAHA.111.177071"},{"key":"1023","doi-asserted-by":"crossref","unstructured":"1023) Lemes \u00cd R, Ferreira PH, Linares SN, Machado AF, Pastre CM, Netto JJ: Resistance training reduces systolic blood pressure in metabolic syndrome: a systematic review and meta-analysis of randomised controlled trials. Br J Sports Med, 2016; 50: 1438-1442","DOI":"10.1136\/bjsports-2015-094715"},{"key":"1024","doi-asserted-by":"crossref","unstructured":"1024) Liu Y, Ye W, Chen Q, Zhang Y, Kuo CH, Korivi M: Resistance Exercise Intensity is Correlated with Attenuation of HbA1c and Insulin in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health, 2019; 16","DOI":"10.3390\/ijerph16010140"},{"key":"1025","doi-asserted-by":"crossref","unstructured":"1025) Hayashino Y, Jackson JL, Fukumori N, Nakamura F, Fukuhara S: Effects of supervised exercise on lipid profiles and blood pressure control in people with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Diabetes Res Clin Pract, 2012; 98: 349-360","DOI":"10.1016\/j.diabres.2012.10.004"},{"key":"1026","doi-asserted-by":"crossref","unstructured":"1026) Williams MA, Haskell WL, Ades PA, Amsterdam EA, Bittner V, Franklin BA, Gulanick M, Laing ST, Stewart KJ: Resistance exercise in individuals with and without cardiovascular disease: 2007 update: a scientific statement from the American Heart Association Council on Clinical Cardiology and Council on Nutrition, Physical Activity, and Metabolism. Circulation, 2007; 116: 572-584","DOI":"10.1161\/CIRCULATIONAHA.107.185214"},{"key":"1027","doi-asserted-by":"crossref","unstructured":"1027) Izquierdo M, Merchant RA, Morley JE, Anker SD, Aprahamian I, Arai H, Aubertin-Leheudre M, Bernabei R, Cadore EL, Cesari M, Chen LK, de Souto Barreto P, Duque G, Ferrucci L, Fielding RA, Garc\u00eda-Hermoso A, Guti\u00e9rrez-Robledo LM, Harridge SDR, Kirk B, Kritchevsky S, Landi F, Lazarus N, Martin FC, Marzetti E, Pahor M, Ram\u00edrez-V\u00e9lez R, Rodriguez-Ma\u00f1as L, Rolland Y, Ruiz JG, Theou O, Villareal DT, Waters DL, Won Won C, Woo J, Vellas B, Fiatarone Singh M: International Exercise Recommendations in Older Adults (ICFSR): Expert Consensus Guidelines. J Nutr Health Aging, 2021; 25: 824-853","DOI":"10.1007\/s12603-021-1665-8"},{"key":"1028","doi-asserted-by":"crossref","unstructured":"1028) Kelley GA, Kelley KS, Roberts S, Haskell W: Comparison of aerobic exercise, diet or both on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. Clin Nutr, 2012; 31: 156-167","DOI":"10.1016\/j.clnu.2011.11.011"},{"key":"1029","doi-asserted-by":"crossref","unstructured":"1029) Kelley GA, Kelley KS: Effects of Diet, Aerobic Exercise, or Both on Non-HDL-C in Adults: A Meta-Analysis of Randomized Controlled Trials. Cholesterol, 2012; 2012: 840935","DOI":"10.1155\/2012\/840935"},{"key":"1030","doi-asserted-by":"crossref","unstructured":"1030) Lee CD, Folsom AR, Blair SN: Physical activity and stroke risk: a meta-analysis. Stroke, 2003; 34: 2475-2481","DOI":"10.1161\/01.STR.0000091843.02517.9D"},{"key":"1031","doi-asserted-by":"crossref","unstructured":"1031) Oguma Y, Shinoda-Tagawa T: Physical activity decreases cardiovascular disease risk in women: review and meta-analysis. Am J Prev Med, 2004; 26: 407-418","DOI":"10.1016\/j.amepre.2004.02.007"},{"key":"1032","doi-asserted-by":"crossref","unstructured":"1032) Sofi F, Capalbo A, Cesari F, Abbate R, Gensini GF: Physical activity during leisure time and primary prevention of coronary heart disease: an updated meta-analysis of cohort studies. Eur J Cardiovasc Prev Rehabil, 2008; 15: 247-257","DOI":"10.1097\/HJR.0b013e3282f232ac"},{"key":"1033","doi-asserted-by":"crossref","unstructured":"1033) Hamer M, Chida Y: Active commuting and cardiovascular risk: a meta-analytic review. Prev Med, 2008; 46: 9-13","DOI":"10.1016\/j.ypmed.2007.03.006"},{"key":"1034","doi-asserted-by":"crossref","unstructured":"1034) Nocon M, Hiemann T, M\u00fcller-Riemenschneider F, Thalau F, Roll S, Willich SN: Association of physical activity with all-cause and cardiovascular mortality: a systematic review and meta-analysis. Eur J Cardiovasc Prev Rehabil, 2008; 15: 239-246","DOI":"10.1097\/HJR.0b013e3282f55e09"},{"key":"1035","doi-asserted-by":"crossref","unstructured":"1035) Zheng H, Orsini N, Amin J, Wolk A, Nguyen VT, Ehrlich F: Quantifying the dose-response of walking in reducing coronary heart disease risk: meta-analysis. Eur J Epidemiol, 2009; 24: 181-192","DOI":"10.1007\/s10654-009-9328-9"},{"key":"1036","doi-asserted-by":"crossref","unstructured":"1036) L\u00f6llgen H, B\u00f6ckenhoff A, Knapp G: Physical activity and all-cause mortality: an updated meta-analysis with different intensity categories. Int J Sports Med, 2009; 30: 213-224","DOI":"10.1055\/s-0028-1128150"},{"key":"1037","doi-asserted-by":"crossref","unstructured":"1037) Diep L, Kwagyan J, Kurantsin-Mills J, Weir R, Jayam-Trouth A: Association of physical activity level and stroke outcomes in men and women: a meta-analysis. J Womens Health (Larchmt), 2010; 19: 1815-1822","DOI":"10.1089\/jwh.2009.1708"},{"key":"1038","doi-asserted-by":"crossref","unstructured":"1038) Sattelmair J, Pertman J, Ding EL, Kohl HW, 3rd, Haskell W, Lee IM: Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation, 2011; 124: 789-795","DOI":"10.1161\/CIRCULATIONAHA.110.010710"},{"key":"1039","doi-asserted-by":"crossref","unstructured":"1039) Li J, Siegrist J: Physical activity and risk of cardiovascular disease--a meta-analysis of prospective cohort studies. Int J Environ Res Public Health, 2012; 9: 391-407","DOI":"10.3390\/ijerph9020391"},{"key":"1040","doi-asserted-by":"crossref","unstructured":"1040) Kodama S, Tanaka S, Heianza Y, Fujihara K, Horikawa C, Shimano H, Saito K, Yamada N, Ohashi Y, Sone H: Association between physical activity and risk of all-cause mortality and cardiovascular disease in patients with diabetes: a meta-analysis. Diabetes Care, 2013; 36: 471-479","DOI":"10.2337\/dc12-0783"},{"key":"1041","doi-asserted-by":"crossref","unstructured":"1041) Arem H, Moore SC, Patel A, Hartge P, Berrington de Gonzalez A, Visvanathan K, Campbell PT, Freedman M, Weiderpass E, Adami HO, Linet MS, Lee IM, Matthews CE: Leisure time physical activity and mortality: a detailed pooled analysis of the dose-response relationship. JAMA Intern Med, 2015; 175: 959-967","DOI":"10.1001\/jamainternmed.2015.0533"},{"key":"1042","doi-asserted-by":"crossref","unstructured":"1042) Hupin D, Roche F, Gremeaux V, Chatard JC, Oriol M, Gaspoz JM, Barth\u00e9l\u00e9my JC, Edouard P: Even a low-dose of moderate-to-vigorous physical activity reduces mortality by 22% in adults aged \u226560 years: a systematic review and meta-analysis. Br J Sports Med, 2015; 49: 1262-1267","DOI":"10.1136\/bjsports-2014-094306"},{"key":"1043","doi-asserted-by":"crossref","unstructured":"1043) Wahid A, Manek N, Nichols M, Kelly P, Foster C, Webster P, Kaur A, Friedemann Smith C, Wilkins E, Rayner M, Roberts N, Scarborough P: Quantifying the Association Between Physical Activity and Cardiovascular Disease and Diabetes: A Systematic Review and Meta-Analysis. J Am Heart Assoc, 2016; 5: e002495","DOI":"10.1161\/JAHA.115.002495"},{"key":"1044","doi-asserted-by":"crossref","unstructured":"1044) Kyu HH, Bachman VF, Alexander LT, Mumford JE, Afshin A, Estep K, Veerman JL, Delwiche K, Iannarone ML, Moyer ML, Cercy K, Vos T, Murray CJ, Forouzanfar MH: Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013. BMJ, 2016; 354: i3857","DOI":"10.1136\/bmj.i3857"},{"key":"1045","doi-asserted-by":"crossref","unstructured":"1045) Nordengen S, Andersen LB, Solbraa AK, Riiser A: Cycling is associated with a lower incidence of cardiovascular diseases and death: Part 1 - systematic review of cohort studies with meta-analysis. Br J Sports Med, 2019; 53: 870-878","DOI":"10.1136\/bjsports-2018-099099"},{"key":"1046","doi-asserted-by":"crossref","unstructured":"1046) Ramakrishnan R, He JR, Ponsonby AL, Woodward M, Rahimi K, Blair SN, Dwyer T: Objectively measured physical activity and all cause mortality: A systematic review and meta-analysis. Prev Med, 2021; 143: 106356","DOI":"10.1016\/j.ypmed.2020.106356"},{"key":"1047","doi-asserted-by":"crossref","unstructured":"1047) Ekelund U, Tarp J, Steene-Johannessen J, Hansen BH, Jefferis B, Fagerland MW, Whincup P, Diaz KM, Hooker SP, Chernofsky A, Larson MG, Spartano N, Vasan RS, Dohrn IM, Hagstr\u00f6mer M, Edwardson C, Yates T, Shiroma E, Anderssen SA, Lee IM: Dose-response associations between accelerometry measured physical activity and sedentary time and all cause mortality: systematic review and harmonised meta-analysis. BMJ, 2019; 366: l4570","DOI":"10.1136\/bmj.l4570"},{"key":"1048","doi-asserted-by":"crossref","unstructured":"1048) Amagasa S, Machida M, Fukushima N, Kikuchi H, Takamiya T, Odagiri Y, Inoue S: Is objectively measured light-intensity physical activity associated with health outcomes after adjustment for moderate-to-vigorous physical activity in adults? A systematic review. Int J Behav Nutr Phys Act, 2018; 15: 65","DOI":"10.1186\/s12966-018-0695-z"},{"key":"1049","doi-asserted-by":"crossref","unstructured":"1049) Cheng W, Zhang Z, Cheng W, Yang C, Diao L, Liu W: Associations of leisure-time physical activity with cardiovascular mortality: A systematic review and meta-analysis of 44 prospective cohort studies. Eur J Prev Cardiol, 2018; 25: 1864-1872","DOI":"10.1177\/2047487318795194"},{"key":"1050","doi-asserted-by":"crossref","unstructured":"1050) Kubota Y, Iso H, Yamagishi K, Sawada N, Tsugane S: Daily Total Physical Activity and Incident Cardiovascular Disease in Japanese Men and Women: Japan Public Health Center-Based Prospective Study. Circulation, 2017; 135: 1471-1473","DOI":"10.1161\/CIRCULATIONAHA.116.026557"},{"key":"1051","doi-asserted-by":"crossref","unstructured":"1051) Nakayama T, Date C, Yokoyama T, Yoshiike N, Yamaguchi M, Tanaka H: A 15.5-year follow-up study of stroke in a Japanese provincial city. The Shibata Study. Stroke, 1997; 28: 45-52","DOI":"10.1161\/01.STR.28.1.45"},{"key":"1052","doi-asserted-by":"crossref","unstructured":"1052) Sone H, Tanaka S, Tanaka S, Suzuki S, Seino H, Hanyu O, Sato A, Toyonaga T, Okita K, Ishibashi S, Kodama S, Akanuma Y, Yamada N: Leisure-time physical activity is a significant predictor of stroke and total mortality in Japanese patients with type 2 diabetes: analysis from the Japan Diabetes Complications Study (JDCS). Diabetologia, 2013; 56: 1021-1030","DOI":"10.1007\/s00125-012-2810-z"},{"key":"1053","doi-asserted-by":"crossref","unstructured":"1053) Kubota Y, Iso H, Yamagishi K, Sawada N, Tsugane S: Daily Total Physical Activity and Incident Stroke: The Japan Public Health Center-Based Prospective Study. Stroke, 2017; 48: 1730-1736","DOI":"10.1161\/STROKEAHA.117.017560"},{"key":"1054","doi-asserted-by":"crossref","unstructured":"1054) Noda H, Iso H, Toyoshima H, Date C, Yamamoto A, Kikuchi S, Koizumi A, Kondo T, Watanabe Y, Wada Y, Inaba Y, Tamakoshi A: Walking and sports participation and mortality from coronary heart disease and stroke. J Am Coll Cardiol, 2005; 46: 1761-1767","DOI":"10.1016\/j.jacc.2005.07.038"},{"key":"1055","doi-asserted-by":"crossref","unstructured":"1055) Shibata Y, Hayasaka S, Yamada T, Goto Y, Ojima T, Ishikawa S, Kayaba K, Gotoh T, Nakamura Y: Physical activity and cardiovascular disease in Japan: the Jichi Medical School Cohort Study. J Epidemiol, 2010; 20: 225-230","DOI":"10.2188\/jea.JE20090051"},{"key":"1056","doi-asserted-by":"crossref","unstructured":"1056) Ueshima K, Ishikawa-Takata K, Yorifuji T, Suzuki E, Kashima S, Takao S, Sugiyama M, Ohta T, Doi H: Physical activity and mortality risk in the Japanese elderly: a cohort study. Am J Prev Med, 2010; 38: 410-418","DOI":"10.1016\/j.amepre.2009.12.033"},{"key":"1057","doi-asserted-by":"crossref","unstructured":"1057) Inoue M, Iso H, Yamamoto S, Kurahashi N, Iwasaki M, Sasazuki S, Tsugane S: Daily total physical activity level and premature death in men and women: results from a large-scale population-based cohort study in Japan (JPHC study). Ann Epidemiol, 2008; 18: 522-530","DOI":"10.1016\/j.annepidem.2008.03.008"},{"key":"1058","doi-asserted-by":"crossref","unstructured":"1058) Fujita K, Takahashi H, Miura C, Ohkubo T, Sato Y, Ugajin T, Kurashima K, Tsubono Y, Tsuji I, Fukao A, Hisamichi S: Walking and mortality in Japan: the Miyagi Cohort Study. J Epidemiol, 2004; 14 Suppl 1: S26-32","DOI":"10.2188\/jea.14.S26"},{"key":"1059","doi-asserted-by":"crossref","unstructured":"1059) Seki N: [Relationships between walking hours, sleeping hours, meaningfulness of life (ikigai) and mortality in the elderly: prospective cohort study]. Nihon Eiseigaku Zasshi, 2001; 56: 535-540","DOI":"10.1265\/jjh.56.535"},{"key":"1060","doi-asserted-by":"crossref","unstructured":"1060) Hayasaka S, Shibata Y, Ishikawa S, Kayaba K, Gotoh T, Noda T, Murata C, Yamada T, Goto Y, Nakamura Y, Ojima T: Physical activity and all-cause mortality in Japan: the Jichi Medical School (JMS) Cohort Study. J Epidemiol, 2009; 19: 24-27","DOI":"10.2188\/jea.JE20080043"},{"key":"1061","doi-asserted-by":"crossref","unstructured":"1061) Kikuchi H, Inoue S, Lee IM, Odagiri Y, Sawada N, Inoue M, Tsugane S: Impact of Moderate-Intensity and Vigorous-Intensity Physical Activity on Mortality. Med Sci Sports Exerc, 2018; 50: 715-721","DOI":"10.1249\/MSS.0000000000001463"},{"key":"1062","doi-asserted-by":"crossref","unstructured":"1062) Yamamoto N, Miyazaki H, Shimada M, Nakagawa N, Sawada SS, Nishimuta M, Kimura Y, Kawakami R, Nagayama H, Asai H, Lee IM, Blair SN, Yoshitake Y: Daily step count and all-cause mortality in a sample of Japanese elderly people: a cohort study. BMC Public Health, 2018; 18: 540","DOI":"10.1186\/s12889-018-5434-5"},{"key":"1063","unstructured":"1063) Kamagata K, Shimomitsu T, Suzuki S, Suzuki T, Sudo M, Tanaka K, Tabata I, Toyama Y, Naitoh Y, Fukunaga T, Fujikawa M, Michinaga M, Miyachi M: Report of the Study Group on Revision of Exercise Standards and Guidelines. https:\/\/www.mhlw.go.jp\/content\/000306883.pdf, 2013 (in Japanese)"},{"key":"1064","doi-asserted-by":"crossref","unstructured":"1064) Saeidifard F, Medina-Inojosa JR, West CP, Olson TP, Somers VK, Bonikowske AR, Prokop LJ, Vinciguerra M, Lopez-Jimenez F: The association of resistance training with mortality: A systematic review and meta-analysis. Eur J Prev Cardiol, 2019; 26: 1647-1665","DOI":"10.1177\/2047487319850718"},{"key":"1065","doi-asserted-by":"crossref","unstructured":"1065) Tanasescu M, Leitzmann MF, Rimm EB, Willett WC, Stampfer MJ, Hu FB: Exercise type and intensity in relation to coronary heart disease in men. JAMA, 2002; 288: 1994-2000","DOI":"10.1001\/jama.288.16.1994"},{"key":"1066","doi-asserted-by":"crossref","unstructured":"1066) Shiroma EJ, Cook NR, Manson JE, Moorthy MV, Buring JE, Rimm EB, Lee IM: Strength Training and the Risk of Type 2 Diabetes and Cardiovascular Disease. Med Sci Sports Exerc, 2017; 49: 40-46","DOI":"10.1249\/MSS.0000000000001063"},{"key":"1067","doi-asserted-by":"crossref","unstructured":"1067) Izquierdo M, Merchant RA, Morley JE, Anker SD, Aprahamian I, Arai H, Aubertin-Leheudre M, Bernabei R, Cadore EL, Cesari M, Chen LK, De Souto Barreto P, Duque G, Ferrucci L, Fielding RA, Garc\u00eda-Hermoso A, Guti\u00e9rrez-Robledo LM, Harridge SDR, Kirk B, Kritchevsky S, Landi F, Lazarus N, Martin FC, Marzetti E, Pahor M, Ram\u00edrez-V\u00e9lez R, Rodriguez-Ma\u00f1as L, Rolland Y, Ruiz JG, Theou O, Villareal DT, Waters DL, Won CW, Woo J, Vellas B, Singh MF: International Exercise Recommendations in Older Adults (ICFSR): Expert Consensus Guidelines. J Nutr Health Aging, 2021; 25: 824-853","DOI":"10.1007\/s12603-021-1665-8"},{"key":"1068","doi-asserted-by":"crossref","unstructured":"1068) Gr\u00f8ntved A, Hu FB: Television viewing and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a meta-analysis. JAMA, 2011; 305: 2448-2455","DOI":"10.1001\/jama.2011.812"},{"key":"1069","doi-asserted-by":"crossref","unstructured":"1069) Biswas A, Oh PI, Faulkner GE, Bajaj RR, Silver MA, Mitchell MS, Alter DA: Sedentary time and its association with risk for disease incidence, mortality, and hospitalization in adults: a systematic review and meta-analysis. Ann Intern Med, 2015; 162: 123-132","DOI":"10.7326\/M14-1651"},{"key":"1070","doi-asserted-by":"crossref","unstructured":"1070) Zhao R, Bu W, Chen Y, Chen X: The Dose-Response Associations of Sedentary Time with Chronic Diseases and the Risk for All-Cause Mortality Affected by Different Health Status: A Systematic Review and Meta-Analysis. J Nutr Health Aging, 2020; 24: 63-70","DOI":"10.1007\/s12603-019-1298-3"},{"key":"1071","doi-asserted-by":"crossref","unstructured":"1071) Wilmot EG, Edwardson CL, Achana FA, Davies MJ, Gorely T, Gray LJ, Khunti K, Yates T, Biddle SJ: Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis. Diabetologia, 2012; 55: 2895-2905","DOI":"10.1007\/s00125-012-2677-z"},{"key":"1072","doi-asserted-by":"crossref","unstructured":"1072) Patterson R, McNamara E, Tainio M, de S\u00e1 TH, Smith AD, Sharp SJ, Edwards P, Woodcock J, Brage S, Wijndaele K: Sedentary behaviour and risk of all-cause, cardiovascular and cancer mortality, and incident type 2 diabetes: a systematic review and dose response meta-analysis. Eur J Epidemiol, 2018; 33: 811-829","DOI":"10.1007\/s10654-018-0380-1"},{"key":"1073","doi-asserted-by":"crossref","unstructured":"1073) Pandey A, Salahuddin U, Garg S, Ayers C, Kulinski J, Anand V, Mayo H, Kumbhani DJ, de Lemos J, Berry JD: Continuous Dose-Response Association Between Sedentary Time and Risk for Cardiovascular Disease: A Meta-analysis. JAMA Cardiol, 2016; 1: 575-583","DOI":"10.1001\/jamacardio.2016.1567"},{"key":"1074","doi-asserted-by":"crossref","unstructured":"1074) Kivim\u00e4ki M, Singh-Manoux A, Pentti J, Sabia S, Nyberg ST, Alfredsson L, Goldberg M, Knutsson A, Koskenvuo M, Koskinen A, Kouvonen A, Nordin M, Oksanen T, Strandberg T, Suominen SB, Theorell T, Vahtera J, V\u00e4\u00e4n\u00e4nen A, Virtanen M, Westerholm P, Westerlund H, Zins M, Seshadri S, Batty GD, Sipil\u00e4 PN, Shipley MJ, Lindbohm JV, Ferrie JE, Jokela M: Physical inactivity, cardiometabolic disease, and risk of dementia: an individual-participant meta-analysis. BMJ, 2019; 365: l1495","DOI":"10.1136\/bmj.l1495"},{"key":"1075","doi-asserted-by":"crossref","unstructured":"1075) Bailey DP, Hewson DJ, Champion RB, Sayegh SM: Sitting Time and Risk of Cardiovascular Disease and Diabetes: A Systematic Review and Meta-Analysis. Am J Prev Med, 2019; 57: 408-416","DOI":"10.1016\/j.amepre.2019.04.015"},{"key":"1076","doi-asserted-by":"crossref","unstructured":"1076) Takagi H, Hari Y, Nakashima K, Kuno T, Ando T: Meta-analysis of the Relation of Television-Viewing Time and Cardiovascular Disease. Am J Cardiol, 2019; 124: 1674-1683","DOI":"10.1016\/j.amjcard.2019.08.032"},{"key":"1077","doi-asserted-by":"crossref","unstructured":"1077) Ikehara S, Iso H, Wada Y, Tanabe N, Watanabe Y, Kikuchi S, Tamakoshi A: Television viewing time and mortality from stroke and coronary artery disease among Japanese men and women -- the Japan Collaborative Cohort Study. Circ J, 2015; 79: 2389-2395","DOI":"10.1253\/circj.CJ-14-1335"},{"key":"1078","doi-asserted-by":"crossref","unstructured":"1078) Loh R, Stamatakis E, Folkerts D, Allgrove JE, Moir HJ: Effects of Interrupting Prolonged Sitting with Physical Activity Breaks on Blood Glucose, Insulin and Triacylglycerol Measures: A Systematic Review and Meta-analysis. Sports Med, 2020; 50: 295-330","DOI":"10.1007\/s40279-019-01183-w"},{"key":"1079","doi-asserted-by":"crossref","unstructured":"1079) Chastin SF, Egerton T, Leask C, Stamatakis E: Meta-analysis of the relationship between breaks in sedentary behavior and cardiometabolic health. Obesity (Silver Spring), 2015; 23: 1800-1810","DOI":"10.1002\/oby.21180"},{"key":"1080","doi-asserted-by":"crossref","unstructured":"1080) Schwarzer R: Health action process approach (HAPA) as a theoretical framework to understand behavior change. Actualidades en Psicolog\u00eda, 2016; 30: 119-130","DOI":"10.15517\/ap.v30i121.23458"},{"key":"1081","doi-asserted-by":"crossref","unstructured":"1081) Greaves C, Gillison F, Stathi A, Bennett P, Reddy P, Dunbar J, Perry R, Messom D, Chandler R, Francis M, Davis M, Green C, Evans P, Taylor G: Waste the waist: a pilot randomised controlled trial of a primary care based intervention to support lifestyle change in people with high cardiovascular risk. Int J Behav Nutr Phys Act, 2015; 12: 1","DOI":"10.1186\/s12966-014-0159-z"},{"key":"1082","doi-asserted-by":"crossref","unstructured":"1082) Hettema J, Steele J, Miller WR: Motivational interviewing. Annu Rev Clin Psychol, 2005; 1: 91-111","DOI":"10.1146\/annurev.clinpsy.1.102803.143833"},{"key":"1083","doi-asserted-by":"crossref","unstructured":"1083) Hardcastle SJ, Taylor AH, Bailey MP, Harley RA, Hagger MS: Effectiveness of a motivational interviewing intervention on weight loss, physical activity and cardiovascular disease risk factors: a randomised controlled trial with a 12-month post-intervention follow-up. Int J Behav Nutr Phys Act, 2013; 10: 40","DOI":"10.1186\/1479-5868-10-40"},{"key":"1084","unstructured":"1084) Albert B: Social learning theory Englewood Cliffs, N.J. : Prentice Hall, 1977"},{"key":"1085","doi-asserted-by":"crossref","unstructured":"1085) Elmer PJ, Grimm R, Jr., Laing B, Grandits G, Svendsen K, Van Heel N, Betz E, Raines J, Link M, Stamler J, et al.: Lifestyle intervention: results of the Treatment of Mild Hypertension Study (TOMHS). Prev Med, 1995; 24: 378-388","DOI":"10.1006\/pmed.1995.1062"},{"key":"1086","doi-asserted-by":"crossref","unstructured":"1086) Greene GW, Rossi SR, Reed GR, Willey C, Prochaska JO: Stages of change for reducing dietary fat to 30% of energy or less. J Am Diet Assoc, 1994; 94: 1105-1110; quiz 1111-1102","DOI":"10.1016\/0002-8223(94)91127-4"},{"key":"1087","doi-asserted-by":"crossref","unstructured":"1087) Eriksson KM, Westborg CJ, Eliasson MC: A randomized trial of lifestyle intervention in primary healthcare for the modification of cardiovascular risk factors. Scand J Public Health, 2006; 34: 453-461","DOI":"10.1080\/14034940500489826"},{"key":"1088","doi-asserted-by":"crossref","unstructured":"1088) Nasser R, Cook SL, Dorsch KD, Haennel RG: Comparison of two nutrition education approaches to reduce dietary fat intake and serum lipids reveals registered dietitians are effective at disseminating information regardless of the educational approach. J Am Diet Assoc, 2006; 106: 850-859","DOI":"10.1016\/j.jada.2006.03.011"},{"key":"1089","doi-asserted-by":"crossref","unstructured":"1089) Ryo M, Nakamura T, Funahashi T, Noguchi M, Kishida K, Okauchi Y, Nishizawa H, Ogawa T, Kojima S, Ohira T, Okita K, Iwahashi H, Imagawa A, Matsuzawa Y, Shimomura I: Health education &quot;Hokenshido&quot; program reduced metabolic syndrome in the Amagasaki visceral fat study. Three-year follow-up study of 3,174 Japanese employees. Intern Med, 2011; 50: 1643-1648","DOI":"10.2169\/internalmedicine.50.5039"},{"key":"1090","doi-asserted-by":"crossref","unstructured":"1090) Rosenstock IM, Strecher VJ, Becker MH: Social learning theory and the Health Belief Model. Health Educ Q, 1988; 15: 175-183","DOI":"10.1177\/109019818801500203"},{"key":"1091","doi-asserted-by":"crossref","unstructured":"1091) Deci E, Ryan R: Intrinsic Motivation and Self-Determination in Human Behavior (Perspectives in Social Psychology), Springer, 1985","DOI":"10.1007\/978-1-4899-2271-7"},{"key":"1092","doi-asserted-by":"crossref","unstructured":"1092) Bandura A, Adams NE: Analysis of self-efficacy theory of behavioral change. Cognit Ther Res, 1977; 1: 287-310","DOI":"10.1007\/BF01663995"},{"key":"1093","doi-asserted-by":"crossref","unstructured":"1093) Burke LE, Dunbar-Jacob J, Orchard TJ, Sereika SM: Improving adherence to a cholesterol-lowering diet: a behavioral intervention study. Patient Educ Couns, 2005; 57: 134-142","DOI":"10.1016\/j.pec.2004.05.007"},{"key":"1094","doi-asserted-by":"crossref","unstructured":"1094) Flannery K, Resnick B, Galik E, Lipscomb J, McPhaul K, Shaughnessy M: The Worksite Heart Health Improvement Project (WHHIP): feasibility and efficacy. Public Health Nurs, 2012; 29: 455-466","DOI":"10.1111\/j.1525-1446.2012.01023.x"},{"key":"1095","doi-asserted-by":"crossref","unstructured":"1095) Pedersen C, Halvari H, Williams G: Worksite intervention effects on motivation, physical activity, and health: A cluster randomized controlled trial,. Psychol Sport Exerc, 2018; 35: 171-180","DOI":"10.1016\/j.psychsport.2017.11.004"},{"key":"1096","doi-asserted-by":"crossref","unstructured":"1096) Murray DM, Kurth C, Mullis R, Jeffery RW: Cholesterol reduction through low-intensity interventions: results from the Minnesota Heart Health Program. Prev Med, 1990; 19: 181-189","DOI":"10.1016\/0091-7435(90)90019-G"},{"key":"1097","doi-asserted-by":"crossref","unstructured":"1097) Perkins DD, Zimmerman MA: Empowerment theory, research, and application. Am J Community Psychol, 1995; 23: 569-579","DOI":"10.1007\/BF02506982"},{"key":"1098","doi-asserted-by":"crossref","unstructured":"1098) Ok Ham K, Jeong Kim B: Evaluation of a cardiovascular health promotion programme offered to low-income women in Korea. J Clin Nurs, 2011; 20: 1245-1254","DOI":"10.1111\/j.1365-2702.2010.03580.x"},{"key":"1099","unstructured":"1099) Morton DP, Rankin P, Morey P, Kent L, Hurlow T, Chang E, Diehl H: The effectiveness of the Complete Health Improvement Program (CHIP) in Australasia for reducing selected chronic disease risk factors: a feasibility study. N Z Med J, 2013; 126: 43-54"},{"key":"1100","doi-asserted-by":"crossref","unstructured":"1100) Salinardi TC, Batra P, Roberts SB, Urban LE, Robinson LM, Pittas AG, Lichtenstein AH, Deckersbach T, Saltzman E, Das SK: Lifestyle intervention reduces body weight and improves cardiometabolic risk factors in worksites. Am J Clin Nutr, 2013; 97: 667-676","DOI":"10.3945\/ajcn.112.046995"},{"key":"1101","doi-asserted-by":"crossref","unstructured":"1101) Kendall P, Hollon S: Cognitive-behavioral interventions: Overview and current status, Cognitive-behavioral interventions: theory, research, and procedures., Academic Press, 1979","DOI":"10.1016\/B978-0-12-404480-7.50007-1"},{"key":"1102","doi-asserted-by":"crossref","unstructured":"1102) Dekkers JC, van Wier MF, Ari\u00ebns GA, Hendriksen IJ, Pronk NP, Smid T, van Mechelen W: Comparative effectiveness of lifestyle interventions on cardiovascular risk factors among a Dutch overweight working population: a randomized controlled trial. BMC Public Health, 2011; 11: 49","DOI":"10.1186\/1471-2458-11-49"},{"key":"1103","doi-asserted-by":"crossref","unstructured":"1103) Noguchi M, Kojima S, Sairenchi T, Kinuta M, Yamakawa M, Nishizawa H, Takahara M, Imano H, Kitamura A, Yoshida T, Shintani A, Saito I, Yokoyama T, Shimomura I, Iso H: Japan Trial in High-Risk Individuals to Enhance Their Referral to Physicians (J-HARP)-A Nurse-Led, Community-Based Prevention Program of Lifestyle-Related Disease. J Epidemiol, 2020; 30: 194-199","DOI":"10.2188\/jea.JE20180194"},{"key":"1104","doi-asserted-by":"crossref","unstructured":"1104) Iso H, Noguchi M, Yokoyama T, Yoshida T, Saito I, Shintani A, Sairenchi T, Nishizawa H, Imano H, Kitamura A, Shimomura I, for J-HARP Research Group. Effect of a Community-Based Program to Accelerate Referral to Physicians for Individuals at High-Risk of Lifestyle-Related Diseases: A Cluster Randomized Trial, J Atheroscler Thromb. 2023; 30: 1389-1406","DOI":"10.5551\/jat.64100"},{"key":"1105","doi-asserted-by":"crossref","unstructured":"1105) Itakura H, Kita T, Mabuchi H, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K: Relationship between coronary events and serum cholesterol during 10 years of low-dose simvastatin therapy: long-term efficacy and safety in Japanese patients with hypercholesterolemia in the Japan Lipid Intervention Trial (J-LIT) Extension 10 Study, a prospective large-scale observational cohort study. Circ J, 2008; 72: 1218-1224","DOI":"10.1253\/circj.72.1218"},{"key":"1106","doi-asserted-by":"crossref","unstructured":"1106) Itoh H, Komuro I, Takeuchi M, Akasaka T, Daida H, Egashira Y, Fujita H, Higaki J, Hirata KI, Ishibashi S, Isshiki T, Ito S, Kashiwagi A, Kato S, Kitagawa K, Kitakaze M, Kitazono T, Kurabayashi M, Miyauchi K, Murakami T, Murohara T, Node K, Ogawa S, Saito Y, Seino Y, Shigeeda T, Shindo S, Sugawara M, Sugiyama S, Terauchi Y, Tsutsui H, Ueshima K, Utsunomiya K, Yamagishi M, Yamazaki T, Yo S, Yokote K, Yoshida K, Yoshimura M, Yoshimura N, Nakao K, Nagai R: Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. Diabetes Care, 2018; 41: 1275-1284","DOI":"10.2337\/dc17-2224"},{"key":"1107","doi-asserted-by":"crossref","unstructured":"1107) Itoh H, Komuro I, Takeuchi M, Akasaka T, Daida H, Egashira Y, Fujita H, Higaki J, Hirata KI, Ishibashi S, Isshiki T, Ito S, Kashiwagi A, Kato S, Kitagawa K, Kitakaze M, Kitazono T, Kurabayashi M, Miyauchi K, Murakami T, Murohara T, Node K, Ogawa S, Saito Y, Seino Y, Shigeeda T, Shindo S, Sugawara M, Sugiyama S, Terauchi Y, Tsutsui H, Ueshima K, Utsunomiya K, Yamagishi M, Yamazaki T, Yo S, Yokote K, Yoshida K, Yoshimura M, Yoshimura N, Nakao K, Nagai R: Achieving LDL cholesterol target levels &lt;1.81 mmol\/L may provide extra cardiovascular protection in patients at high risk: Exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients with Hypercholesterolaemia and Diabetic Retinopathy study. Diabetes Obes Metab, 2019; 21: 791-800","DOI":"10.1111\/dom.13575"},{"key":"1108","doi-asserted-by":"crossref","unstructured":"1108) Ouchi Y, Sasaki J, Arai H, Yokote K, Harada K, Katayama Y, Urabe T, Uchida Y, Hayashi M, Yokota N, Nishida H, Otonari T, Arai T, Sakuma I, Sakabe K, Yamamoto M, Kobayashi T, Oikawa S, Yamashita S, Rakugi H, Imai T, Tanaka S, Ohashi Y, Kuwabara M, Ito H: Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial. Circulation, 2019; 140: 992-1003","DOI":"10.1161\/CIRCULATIONAHA.118.039415"},{"key":"1109","doi-asserted-by":"crossref","unstructured":"1109) Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, Daida H: Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation, 2004; 110: 1061-1068","DOI":"10.1161\/01.CIR.0000140261.58966.A4"},{"key":"1110","doi-asserted-by":"crossref","unstructured":"1110) Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M: Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol, 2009; 54: 293-302","DOI":"10.1161\/circ.118.suppl_18.S_657-c"},{"key":"1111","doi-asserted-by":"crossref","unstructured":"1111) Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M: Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J, 2009; 73: 2110-2117","DOI":"10.1253\/circj.CJ-09-0358"},{"key":"1112","doi-asserted-by":"crossref","unstructured":"1112) Nakajima N, Miyauchi K, Yokoyama T, Manabu O, Tadashi M, Hiroshi T, Akihisa N, Ken Y, Sinya O, Takeshi K, Satoru S, Hiroyuki D: Effect of combination of ezetimibe and a statin on coronary plaque regression in patients with acute coronary syndrome: ZEUS trial (eZEtimibe Ultrasound Study),. IJC Metabolic &amp; Endocrine, 2014; 3: 8-13","DOI":"10.1016\/j.ijcme.2014.03.001"},{"key":"1113","doi-asserted-by":"crossref","unstructured":"1113) Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, Komura N, Sakamoto K, Oka H, Nakao K, Nakamura S, Ishihara M, Matsui K, Sakaino N, Nakamura N, Yamamoto N, Koide S, Matsumura T, Fujimoto K, Tsunoda R, Morikami Y, Matsuyama K, Oshima S, Kaikita K, Hokimoto S, Ogawa H: Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial. J Am Coll Cardiol, 2015; 66: 495-507","DOI":"10.1016\/j.jacc.2015.05.065"},{"key":"1114","doi-asserted-by":"crossref","unstructured":"1114) Nicholls SJ, Hsu A, Wolski K, Hu B, Bayturan O, Lavoie A, Uno K, Tuzcu EM, Nissen SE: Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol, 2010; 55: 2399-2407","DOI":"10.1016\/j.jacc.2010.02.026"},{"key":"1115","doi-asserted-by":"crossref","unstructured":"1115) Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, Ogawa T, Ozaki Y, Sakuma I, Nakagawa Y, Hibi K, Hiro T, Fukumoto Y, Hokimoto S, Miyauchi K, Yamazaki T, Ito H, Otsuji Y, Kimura K, Takahashi J, Hirayama A, Yokoi H, Kitagawa K, Urabe T, Okada Y, Terayama Y, Toyoda K, Nagao T, Matsumoto M, Ohashi Y, Kaneko T, Fujita R, Ohtsu H, Ogawa H, Daida H, Shimokawa H, Saito Y, Kimura T, Inoue T, Matsuzaki M, Nagai R: High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial. Circulation, 2018; 137: 1997-2009","DOI":"10.1161\/CIRCULATIONAHA.117.032615"},{"key":"1116","doi-asserted-by":"crossref","unstructured":"1116) Amarenco P, Labreuche J: Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol, 2009; 8: 453-463","DOI":"10.1016\/S1474-4422(09)70058-4"},{"key":"1117","doi-asserted-by":"crossref","unstructured":"1117) McKinney JS, Kostis WJ: Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke, 2012; 43: 2149-2156","DOI":"10.1161\/STROKEAHA.112.655894"},{"key":"1118","doi-asserted-by":"crossref","unstructured":"1118) Salvatore T, Morganti R, Marchioli R, De Caterina R: Cholesterol Lowering and Stroke: No Longer Room for Pleiotropic Effects of Statins - Confirmation from PCSK9 Inhibitor Studies. Am J Med, 2020; 133: 95-99.e96","DOI":"10.1016\/j.amjmed.2019.06.029"},{"key":"1119","doi-asserted-by":"crossref","unstructured":"1119) Pandit AK, Kumar P, Kumar A, Chakravarty K, Misra S, Prasad K: High-dose statin therapy and risk of intracerebral hemorrhage: a meta-analysis. Acta Neurol Scand, 2016; 134: 22-28","DOI":"10.1111\/ane.12540"},{"key":"1120","doi-asserted-by":"crossref","unstructured":"1120) Judge C, Ruttledge S, Costello M, Murphy R, Loughlin E, Alvarez-Iglesias A, Ferguson J, Gorey S, Nolan A, Canavan M, O&apos;Halloran M, O&apos;Donnell MJ: Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage - A Meta-Analysis. J Stroke Cerebrovasc Dis, 2019; 28: 1703-1709","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.02.018"},{"key":"1121","unstructured":"1121) Cheng Y, Qiao L, Jiang Z, Dong X, Feng H, Gui Q, Lu Y, Liang Y: Significant reduction in the LDL cholesterol increases the risk of intracerebral hemorrhage: a systematic review and meta-analysis of 33 randomized controlled trials. Am J Transl Res, 2020; 12: 463-477"},{"key":"1122","doi-asserted-by":"crossref","unstructured":"1122) Uchiyama S, Nakaya N, Mizuno K, Ohashi Y, Tajima N, Kushiro T, Teramoto T, Nakamura H: Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial. J Neurol Sci, 2009; 284: 72-76","DOI":"10.1016\/j.jns.2009.04.002"},{"key":"1123","doi-asserted-by":"crossref","unstructured":"1123) Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Jr., Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM: Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med, 2019; 380: 11-22","DOI":"10.1056\/NEJMoa1812792"},{"key":"1124","doi-asserted-by":"crossref","unstructured":"1124) Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K: Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis, 2008; 200: 135-140","DOI":"10.1016\/j.atherosclerosis.2008.06.003"},{"key":"1125","doi-asserted-by":"crossref","unstructured":"1125) Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Ridker PM, Ray KK, Katona BG, Himmelmann A, Loss LE, Rensfeldt M, Lundstr\u00f6m T, Agrawal R, Menon V, Wolski K, Nissen SE: Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA, 2020; 324: 2268-2280","DOI":"10.1001\/jama.2020.22258"},{"key":"1126","doi-asserted-by":"crossref","unstructured":"1126) Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kes\u00e4niemi YA, Sullivan D, Hunt D, Colman P, d&apos;Emden M, Whiting M, Ehnholm C, Laakso M: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet, 2005; 366: 1849-1861","DOI":"10.1016\/S0140-6736(05)67667-2"},{"key":"1127","doi-asserted-by":"crossref","unstructured":"1127) Ginsberg HN, Elam MB, Lovato LC, Crouse JR, 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC, Jr., Cushman WC, Simons-Morton DG, Byington RP: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med, 2010; 362: 1563-1574","DOI":"10.1056\/NEJMoa1001282"},{"key":"1128","doi-asserted-by":"crossref","unstructured":"1128) Scott R, O&apos;Brien R, Fulcher G, Pardy C, D&apos;Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A: Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care, 2009; 32: 493-498","DOI":"10.2337\/dc08-1543"},{"key":"1129","doi-asserted-by":"crossref","unstructured":"1129) Jakob T, Nordmann AJ, Schandelmaier S, Ferreira-Gonz\u00e1lez I, Briel M: Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev, 2016; 11: Cd009753","DOI":"10.1002\/14651858.CD009753.pub2"},{"key":"1130","doi-asserted-by":"crossref","unstructured":"1130) Wang D, Liu B, Tao W, Hao Z, Liu M: Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev, 2015; 2015: Cd009580","DOI":"10.1002\/14651858.CD009580.pub2"},{"key":"1131","doi-asserted-by":"crossref","unstructured":"1131) Maki KC, Guyton JR, Orringer CE, Hamilton-Craig I, Alexander DD, Davidson MH: Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. J Clin Lipidol, 2016; 10: 905-914","DOI":"10.1016\/j.jacl.2016.03.008"},{"key":"1132","doi-asserted-by":"crossref","unstructured":"1132) Marston NA, Giugliano RP, Im K, Silverman MG, O&apos;Donoghue ML, Wiviott SD, Ference BA, Sabatine MS: Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Circulation, 2019; 140: 1308-1317","DOI":"10.1161\/CIRCULATIONAHA.119.041998"},{"key":"1133","doi-asserted-by":"crossref","unstructured":"1133) Hulten E, Jackson JL, Douglas K, George S, Villines TC: The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med, 2006; 166: 1814-1821","DOI":"10.1001\/archinte.166.17.1814"},{"key":"1134","doi-asserted-by":"crossref","unstructured":"1134) Dohi T, Miyauchi K, Okazaki S, Yokoyama T, Yanagisawa N, Tamura H, Kojima T, Yokoyama K, Kurata T, Daida H: Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): a follow-up study. Atherosclerosis, 2010; 210: 497-502","DOI":"10.1016\/j.atherosclerosis.2009.12.001"},{"key":"1135","doi-asserted-by":"crossref","unstructured":"1135) Soran H, Kwok S, Adam S, Ho JH, Durrington PN: Evidence for more intensive cholesterol lowering. Curr Opin Lipidol, 2017; 28: 291-299","DOI":"10.1097\/MOL.0000000000000433"},{"key":"1136","doi-asserted-by":"crossref","unstructured":"1136) Natsuaki M, Furukawa Y, Morimoto T, Nakagawa Y, Ono K, Kaburagi S, Inada T, Mitsuoka H, Taniguchi R, Nakano A, Kita T, Sakata R, Kimura T: Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2. Circ J, 2012; 76: 1369-1379","DOI":"10.1253\/circj.CJ-11-1356"},{"key":"1137","doi-asserted-by":"crossref","unstructured":"1137) Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS: Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA, 2016; 316: 1289-1297","DOI":"10.1001\/jama.2016.13985"},{"key":"1138","doi-asserted-by":"crossref","unstructured":"1138) Puymirat E, Bonaca M, Fumery M, Tea V, Aissaoui N, Lemesles G, Bonello L, Ducrocq G, Cayla G, Ferri\u00e8res J, Schiele F, Simon T, Danchin N: Atherothrombotic risk stratification after acute myocardial infarction: The Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention in the light of the French Registry of Acute ST Elevation or non-ST Elevation Myocardial Infarction registries. Clin Cardiol, 2019; 42: 227-234","DOI":"10.1002\/clc.23131"},{"key":"1139","doi-asserted-by":"crossref","unstructured":"1139) Bohula EA, Morrow DA, Giugliano RP, Blazing MA, He P, Park JG, Murphy SA, White JA, Kesaniemi YA, Pedersen TR, Brady AJ, Mitchel Y, Cannon CP, Braunwald E: Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. J Am Coll Cardiol, 2017; 69: 911-921","DOI":"10.1016\/j.jacc.2016.11.070"},{"key":"1140","doi-asserted-by":"crossref","unstructured":"1140) Sabatine MS, De Ferrari GM, Giugliano RP, Huber K, Lewis BS, Ferreira J, Kuder JF, Murphy SA, Wiviott SD, Kurtz CE, Honarpour N, Keech AC, Sever PS, Pedersen TR: Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER. Circulation, 2018; 138: 756-766","DOI":"10.1161\/CIRCULATIONAHA.118.034309"},{"key":"1141","doi-asserted-by":"crossref","unstructured":"1141) Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM: Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med, 2015; 372: 2387-2397","DOI":"10.1056\/NEJMoa1410489"},{"key":"1142","doi-asserted-by":"crossref","unstructured":"1142) Zhan S, Tang M, Liu F, Xia P, Shu M, Wu X: Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst Rev, 2018; 11: Cd012502","DOI":"10.1002\/14651858.CD012502.pub2"},{"key":"1143","doi-asserted-by":"crossref","unstructured":"1143) Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med, 2017; 376: 1713-1722","DOI":"10.1056\/NEJMoa1615664"},{"key":"1144","doi-asserted-by":"crossref","unstructured":"1144) Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM: Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med, 2018; 379: 2097-2107","DOI":"10.1056\/NEJMoa1801174"},{"key":"1145","doi-asserted-by":"crossref","unstructured":"1145) Schmidt AF, Carter JL, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev, 2020; 10: Cd011748","DOI":"10.1002\/14651858.CD011748.pub3"},{"key":"1146","doi-asserted-by":"crossref","unstructured":"1146) Koskinas KC, Siontis GCM, Piccolo R, Mavridis D, R\u00e4ber L, Mach F, Windecker S: Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J, 2018; 39: 1172-1180","DOI":"10.1093\/eurheartj\/ehx566"},{"key":"1147","doi-asserted-by":"crossref","unstructured":"1147) Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J: Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med, 2014; 371: 203-212","DOI":"10.1056\/NEJMoa1300955"},{"key":"1148","doi-asserted-by":"crossref","unstructured":"1148) HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J, 2013; 34: 1279-1291","DOI":"10.1093\/eurheartj\/eht055"},{"key":"1149","doi-asserted-by":"crossref","unstructured":"1149) Schandelmaier S, Briel M, Saccilotto R, Olu KK, Arpagaus A, Hemkens LG, Nordmann AJ: Niacin for primary and secondary prevention of cardiovascular events. Cochrane Database Syst Rev, 2017; 6: Cd009744","DOI":"10.1002\/14651858.CD009744.pub2"},{"key":"1150","doi-asserted-by":"crossref","unstructured":"1150) D&apos;Andrea E, Hey SP, Ramirez CL, Kesselheim AS: Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis. JAMA Netw Open, 2019; 2: e192224","DOI":"10.1001\/jamanetworkopen.2019.2224"},{"key":"1151","doi-asserted-by":"crossref","unstructured":"1151) Keene D, Price C, Shun-Shin MJ, Francis DP: Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ, 2014; 349: g4379","DOI":"10.1136\/bmj.g4379"},{"key":"1152","doi-asserted-by":"crossref","unstructured":"1152) Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B: Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis, 2011; 217: 492-498","DOI":"10.1016\/j.atherosclerosis.2011.04.020"},{"key":"1153","unstructured":"1153) Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ: Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med, 2017; 377: 1217-1227"},{"key":"1154","doi-asserted-by":"crossref","unstructured":"1154) Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med, 2007; 357: 2109-2122","DOI":"10.1056\/NEJMoa0706628"},{"key":"1155","doi-asserted-by":"crossref","unstructured":"1155) Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P: Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med, 2010; 363: 2406-2415","DOI":"10.1056\/NEJMoa1009744"},{"key":"1156","doi-asserted-by":"crossref","unstructured":"1156) Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS: Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med, 2012; 367: 2089-2099","DOI":"10.1056\/NEJMoa1206797"},{"key":"1157","doi-asserted-by":"crossref","unstructured":"1157) Mabuchi H, Haba T, Tatami R, Miyamoto S, Sakai Y, Wakasugi T, Watanabe A, Koizumi J, Takeda R: Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N Engl J Med, 1981; 305: 478-482","DOI":"10.1056\/NEJM198108273050902"},{"key":"1158","doi-asserted-by":"crossref","unstructured":"1158) Endo A: The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res, 1992; 33: 1569-1582","DOI":"10.1016\/S0022-2275(20)41379-3"},{"key":"1159","doi-asserted-by":"crossref","unstructured":"1159) Bilheimer DW, Grundy SM, Brown MS, Goldstein JL: Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci U S A, 1983; 80: 4124-4128","DOI":"10.1073\/pnas.80.13.4124"},{"key":"1160","doi-asserted-by":"crossref","unstructured":"1160) Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM: Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA, 1996; 275: 128-133","DOI":"10.1001\/jama.275.2.128"},{"key":"1161","doi-asserted-by":"crossref","unstructured":"1161) Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA, 2011; 305: 2556-2564","DOI":"10.1001\/jama.2011.860"},{"key":"1162","doi-asserted-by":"crossref","unstructured":"1162) Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL, 2nd, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK: Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol, 2019; 39: e38-e81","DOI":"10.1161\/ATV.0000000000000073"},{"key":"1163","unstructured":"1163) Phamaceuticals and Medical Devices Agency: Revision of &quot;Precautions&quot; for preparations containing HMG-CoA reductase inhibitors. https:\/\/www.pmda.go.jp\/files\/000214541.pdf, 2016 (in Japanese)"},{"key":"1164","doi-asserted-by":"crossref","unstructured":"1164) Mammen AL: Statin-Associated Autoimmune Myopathy. N Engl J Med, 2016; 374: 664-669","DOI":"10.1056\/NEJMra1515161"},{"key":"1165","doi-asserted-by":"crossref","unstructured":"1165) Kajinami K, Tsukamoto K, Koba S, Inoue I, Yamakawa M, Suzuki S, Hamano T, Saito H, Saito Y, Masuda S, Nakayama T, Okamura T, Yamashita S, Kagawa T, Kaneyama J, Kuriyama A, Tanaka R, Hirata A: Statin Intolerance Clinical Guide 2018. J Atheroscler Thromb, 2020; 27: 375-396","DOI":"10.5551\/jat.50948"},{"key":"1166","doi-asserted-by":"crossref","unstructured":"1166) Edison RJ, Muenke M: Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med, 2004; 350: 1579-1582","DOI":"10.1056\/NEJM200404083501524"},{"key":"1167","doi-asserted-by":"crossref","unstructured":"1167) Gagn\u00e9 C, Gaudet D, Bruckert E: Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation, 2002; 105: 2469-2475","DOI":"10.1161\/01.CIR.0000018744.58460.62"},{"key":"1168","doi-asserted-by":"crossref","unstructured":"1168) Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med, 1990; 323: 1289-1298","DOI":"10.1056\/NEJM199011083231901"},{"key":"1169","unstructured":"1169) Mabuchi H, Kobayashi J, Kajinami K: Effect of MCI-196 in combination with pravastatin on hypercholesterolemia (I) - a study in patients with familial hypercholesterolemia (FH), Rinsho Iyaku Inc., 1996 (in Japanese)"},{"key":"1170","doi-asserted-by":"crossref","unstructured":"1170) Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation, 2003; 107: 2409-2415","DOI":"10.1161\/01.CIR.0000068312.21969.C8"},{"key":"1171","doi-asserted-by":"crossref","unstructured":"1171) Thomopoulos C, Skalis G, Michalopoulou H, Tsioufis C, Makris T: Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe\/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials. Clin Cardiol, 2015; 38: 763-769","DOI":"10.1002\/clc.22441"},{"key":"1172","doi-asserted-by":"crossref","unstructured":"1172) Takada T, Yamanashi Y, Konishi K, Yamamoto T, Toyoda Y, Masuo Y, Yamamoto H, Suzuki H: NPC1L1 is a key regulator of intestinal vitamin K absorption and a modulator of warfarin therapy. Sci Transl Med, 2015; 7: 275ra223","DOI":"10.1126\/scitranslmed.3010329"},{"key":"1173","doi-asserted-by":"crossref","unstructured":"1173) The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA, 1984; 251: 351-364","DOI":"10.1001\/jama.251.3.351"},{"key":"1174","doi-asserted-by":"crossref","unstructured":"1174) The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA, 1984; 251: 365-374","DOI":"10.1001\/jama.251.3.365"},{"key":"1175","doi-asserted-by":"crossref","unstructured":"1175) Rudling MJ, Reihn\u00e9r E, Einarsson K, Ewerth S, Angelin B: Low density lipoprotein receptor-binding activity in human tissues: quantitative importance of hepatic receptors and evidence for regulation of their expression in vivo. Proc Natl Acad Sci U S A, 1990; 87: 3469-3473","DOI":"10.1073\/pnas.87.9.3469"},{"key":"1176","doi-asserted-by":"crossref","unstructured":"1176) Kodama T, Reddy P, Kishimoto C, Krieger M: Purification and characterization of a bovine acetyl low density lipoprotein receptor. Proc Natl Acad Sci U S A, 1988; 85: 9238-9242","DOI":"10.1073\/pnas.85.23.9238"},{"key":"1177","doi-asserted-by":"crossref","unstructured":"1177) Kita T, Ishii K, Yokode M, Kume N, Nagano Y, Arai H, Kawai C: The role of oxidized low density lipoprotein in the pathogenesis of atherosclerosis. Eur Heart J, 1990; 11 Suppl E: 122-127","DOI":"10.1093\/eurheartj\/11.suppl_E.122"},{"key":"1178","doi-asserted-by":"crossref","unstructured":"1178) Itabe H, Takeshima E, Iwasaki H, Kimura J, Yoshida Y, Imanaka T, Takano T: A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. J Biol Chem, 1994; 269: 15274-15279","DOI":"10.1016\/S0021-9258(17)36602-4"},{"key":"1179","doi-asserted-by":"crossref","unstructured":"1179) Itabe H, Yamamoto H, Suzuki M, Kawai Y, Nakagawa Y, Suzuki A, Imanaka T, Takano T: Oxidized phosphatidylcholines that modify proteins. Analysis by monoclonal antibody against oxidized low density lipoprotein. J Biol Chem, 1996; 271: 33208-33217","DOI":"10.1074\/jbc.271.52.33208"},{"key":"1180","doi-asserted-by":"crossref","unstructured":"1180) Yamashita S, Bujo H, Arai H, Harada-Shiba M, Matsui S, Fukushima M, Saito Y, Kita T, Matsuzawa Y: Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb, 2008; 15: 292-303","DOI":"10.5551\/jat.E610"},{"key":"1181","doi-asserted-by":"crossref","unstructured":"1181) Tardif JC, C\u00f6t\u00e9 G, Lesp\u00e9rance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, de Guise P: Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med, 1997; 337: 365-372","DOI":"10.1056\/NEJM199708073370601"},{"key":"1182","doi-asserted-by":"crossref","unstructured":"1182) Yokoi H, Daida H, Kuwabara Y, Nishikawa H, Takatsu F, Tomihara H, Nakata Y, Kutsumi Y, Ohshima S, Nishiyama S, Seki A, Kato K, Nishimura S, Kanoh T, Yamaguchi H: Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol, 1997; 30: 855-862","DOI":"10.1016\/S0735-1097(97)00270-2"},{"key":"1183","doi-asserted-by":"crossref","unstructured":"1183) Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S, Kashiwagi S, Hayashi J: Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol, 2002; 39: 610-616","DOI":"10.1016\/S0735-1097(01)01783-1"},{"key":"1184","doi-asserted-by":"crossref","unstructured":"1184) Walldius G, Erikson U, Olsson AG, Bergstrand L, H\u00e5dell K, Johansson J, Kaijser L, Lassvik C, M\u00f6lgaard J, Nilsson S, et al.: The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol, 1994; 74: 875-883","DOI":"10.1016\/0002-9149(94)90579-7"},{"key":"1185","doi-asserted-by":"crossref","unstructured":"1185) Yamashita S, Arai H, Bujo H, Masuda D, Ohama T, Ishibashi T, Yanagi K, Doi Y, Nakagawa S, Yamashiro K, Tanabe K, Kita T, Matsuzaki M, Saito Y, Fukushima M, Matsuzawa Y: Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE). J Atheroscler Thromb, 2021; 28: 103-123","DOI":"10.5551\/jat.55327"},{"key":"1186","doi-asserted-by":"crossref","unstructured":"1186) Arai H, Bujo H, Masuda D, Ishibashi T, Nakagawa S, Tanabe K, Kagimura T, Kang HJ, Kim MH, Sung J, Kim SH, Kim CH, Park JE, Ge J, Oh BH, Kita T, Saito Y, Fukushima M, Matsuzawa Y, Yamashita S: Integrated Analysis of Two Probucol Trials for the Secondary Prevention of Atherosclerotic Cardiovascular Events: PROSPECTIVE and IMPACT. J Atheroscler Thromb, 2022; 29: 850-865","DOI":"10.5551\/jat.62821"},{"key":"1187","doi-asserted-by":"crossref","unstructured":"1187) Schoonjans K, Staels B, Auwerx J: Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res, 1996; 37: 907-925","DOI":"10.1016\/S0022-2275(20)42003-6"},{"key":"1188","unstructured":"1188) Fruchart JC, Brewer HB, Jr., Leitersdorf E: Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. Am J Cardiol, 1998; 81: 912-917"},{"key":"1189","doi-asserted-by":"crossref","unstructured":"1189) Ishibashi S, Yamashita S, Arai H, Araki E, Yokote K, Suganami H, Fruchart JC, Kodama T: Effects of K-877, a novel selective PPAR\u03b1 modulator (SPPARM\u03b1), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis, 2016; 249: 36-43","DOI":"10.1016\/j.atherosclerosis.2016.02.029"},{"key":"1190","doi-asserted-by":"crossref","unstructured":"1190) Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet, 2007; 369: 1090-1098","DOI":"10.1016\/S0140-6736(07)60527-3"},{"key":"1191","doi-asserted-by":"crossref","unstructured":"1191) Tanaka K, Ishikawa Y, Yokoyama M, Origasa H, Matsuzaki M, Saito Y, Matsuzawa Y, Sasaki J, Oikawa S, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K: Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke, 2008; 39: 2052-2058","DOI":"10.1161\/STROKEAHA.107.509455"},{"key":"1192","unstructured":"1192) Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, Murawska A, Young A, Lay M, Chen F, Sammons E, Waters E, Adler A, Bodansky J, Farmer A, McPherson R, Neil A, Simpson D, Peto R, Baigent C, Collins R, Parish S, Armitage J: Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. N Engl J Med, 2018; 379: 1540-1550"},{"key":"1193","doi-asserted-by":"crossref","unstructured":"1193) Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Albert CM, Gordon D, Copeland T, D&apos;Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE: Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med, 2019; 380: 23-32","DOI":"10.1056\/NEJMoa1811403"},{"key":"1194","doi-asserted-by":"crossref","unstructured":"1194) Lombardi M, Chiabrando JG, Vescovo GM, Bressi E, Del Buono MG, Carbone S, Koenig RA, Van Tassell BW, Abbate A, Biondi-Zoccai G, Dixon DL: Impact of Different Doses of Omega-3 Fatty Acids on Cardiovascular Outcomes: a Pairwise and Network Meta-analysis. Curr Atheroscler Rep, 2020; 22: 45","DOI":"10.1007\/s11883-020-00865-5"},{"key":"1195","doi-asserted-by":"crossref","unstructured":"1195) Alderman JD, Pasternak RC, Sacks FM, Smith HS, Monrad ES, Grossman W: Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio. Am J Cardiol, 1989; 64: 725-729","DOI":"10.1016\/0002-9149(89)90754-6"},{"key":"1196","doi-asserted-by":"crossref","unstructured":"1196) Teramoto T, Yamada N, Shimano H, Oka Y, Itakura H, Saito Y, Morisaki N, Shirai K, Ishikawa T, Tada N, Ito H, Yamanouchi T, Matsushima T, Kawakami M, Murase T, Okubo M, Totsuka Y, Kikuchi M: Dose-dependent effect of niceritrol on plasma lipoprotein-a. Scand J Clin Lab Invest, 1996; 56: 359-365","DOI":"10.3109\/00365519609090588"},{"key":"1197","doi-asserted-by":"crossref","unstructured":"1197) Carlson LA, Hamsten A, Asplund A: Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med, 1989; 226: 271-276","DOI":"10.1111\/j.1365-2796.1989.tb01393.x"},{"key":"1198","doi-asserted-by":"crossref","unstructured":"1198) Matsunaga A, Handa K, Mori T, Moriyama K, Hidaka K, Yuki M, Sasaki J, Arakawa K: Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia. Atherosclerosis, 1992; 94: 241-248","DOI":"10.1016\/0021-9150(92)90249-G"},{"key":"1199","doi-asserted-by":"crossref","unstructured":"1199) Ni YG, Condra JH, Orsatti L, Shen X, Di Marco S, Pandit S, Bottomley MJ, Ruggeri L, Cummings RT, Cubbon RM, Santoro JC, Ehrhardt A, Lewis D, Fisher TS, Ha S, Njimoluh L, Wood DD, Hammond HA, Wisniewski D, Volpari C, Noto A, Lo Surdo P, Hubbard B, Carf\u00ed A, Sitlani A: A proprotein convertase subtilisin-like\/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J Biol Chem, 2010; 285: 12882-12891","DOI":"10.1074\/jbc.M110.113035"},{"key":"1200","doi-asserted-by":"crossref","unstructured":"1200) Kiyosue A, Honarpour N, Kurtz C, Xue A, Wasserman SM, Hirayama A: A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk. Am J Cardiol, 2016; 117: 40-47","DOI":"10.1016\/j.amjcard.2015.10.021"},{"key":"1201","doi-asserted-by":"crossref","unstructured":"1201) Teramoto T, Kobayashi M, Tasaki H, Yagyu H, Higashikata T, Takagi Y, Uno K, Baccara-Dinet MT, Nohara A: Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins - ODYSSEY JAPAN Randomized Controlled Trial. Circ J, 2016; 80: 1980-1987","DOI":"10.1253\/circj.CJ-16-0387"},{"key":"1202","doi-asserted-by":"crossref","unstructured":"1202) Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, Millar JS, Ikewaki K, Siegelman ES, Gregg RE, Rader DJ: Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med, 2007; 356: 148-156","DOI":"10.1056\/NEJMoa061189"},{"key":"1203","doi-asserted-by":"crossref","unstructured":"1203) Samaha FF, McKenney J, Bloedon LT, Sasiela WJ, Rader DJ: Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med, 2008; 5: 497-505","DOI":"10.1038\/ncpcardio1250"},{"key":"1204","doi-asserted-by":"crossref","unstructured":"1204) Bosch J, Gerstein HC, Dagenais GR, D\u00edaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Ryd\u00e9n LE, Yusuf S: n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med, 2012; 367: 309-318","DOI":"10.1056\/NEJMoa1203859"},{"key":"1205","doi-asserted-by":"crossref","unstructured":"1205) Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W: Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med, 2011; 365: 2255-2267","DOI":"10.1056\/NEJMoa1107579"},{"key":"1206","doi-asserted-by":"crossref","unstructured":"1206) Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Pall D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM, for the PROMINENT Investigator: Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med, 2022; 387: 1923-1934","DOI":"10.1056\/NEJMoa2210645"},{"key":"1207","doi-asserted-by":"crossref","unstructured":"1207) Wiklund O, Pirazzi C, Romeo S: Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy. Curr Cardiol Rep, 2013; 15: 397","DOI":"10.1007\/s11886-013-0397-8"},{"key":"1208","doi-asserted-by":"crossref","unstructured":"1208) Hedrington MS, Davis SN: Peroxisome proliferator-activated receptor alpha-mediated drug toxicity in the liver. Expert Opin Drug Metab Toxicol, 2018; 14: 671-677","DOI":"10.1080\/17425255.2018.1483337"},{"key":"1209","doi-asserted-by":"crossref","unstructured":"1209) Law M, Rudnicka AR: Statin safety: a systematic review. Am J Cardiol, 2006; 97: 52c-60c","DOI":"10.1016\/j.amjcard.2005.12.010"},{"key":"1210","doi-asserted-by":"crossref","unstructured":"1210) Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, Krumholz HM: Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation, 2006; 114: 2788-2797","DOI":"10.1161\/CIRCULATIONAHA.106.624890"},{"key":"1211","doi-asserted-by":"crossref","unstructured":"1211) Thompson PD, Clarkson P, Karas RH: Statin-associated myopathy. JAMA, 2003; 289: 1681-1690","DOI":"10.1001\/jama.289.13.1681"},{"key":"1212","doi-asserted-by":"crossref","unstructured":"1212) Bays H: Statin safety: an overview and assessment of the data--2005. Am J Cardiol, 2006; 97: 6c-26c","DOI":"10.1016\/j.amjcard.2005.12.006"},{"key":"1213","doi-asserted-by":"crossref","unstructured":"1213) Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R: SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med, 2008; 359: 789-799","DOI":"10.1056\/NEJMoa0801936"},{"key":"1214","doi-asserted-by":"crossref","unstructured":"1214) Joy TR, Hegele RA: Narrative review: statin-related myopathy. Ann Intern Med, 2009; 150: 858-868","DOI":"10.7326\/0003-4819-150-12-200906160-00009"},{"key":"1215","doi-asserted-by":"crossref","unstructured":"1215) Katz DH, Intwala SS, Stone NJ: Addressing statin adverse effects in the clinic: the 5 Ms. J Cardiovasc Pharmacol Ther, 2014; 19: 533-542","DOI":"10.1177\/1074248414529622"},{"key":"1216","doi-asserted-by":"crossref","unstructured":"1216) Yu S, Jin J, Chen Z, Luo X: High-intensity statin therapy yields better outcomes in acute coronary syndrome patients: a meta-analysis involving 26,497 patients. Lipids Health Dis, 2020; 19: 194","DOI":"10.1186\/s12944-020-01369-6"},{"key":"1217","doi-asserted-by":"crossref","unstructured":"1217) Charles EC, Olson KL, Sandhoff BG, McClure DL, Merenich JA: Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med, 2005; 118: 618-624","DOI":"10.1016\/j.amjmed.2005.02.008"},{"key":"1218","doi-asserted-by":"crossref","unstructured":"1218) Jacobson TA: Toward &quot;pain-free&quot; statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc, 2008; 83: 687-700","DOI":"10.4065\/83.6.687"},{"key":"1219","doi-asserted-by":"crossref","unstructured":"1219) Bitzur R, Cohen H, Kamari Y, Harats D: Intolerance to statins: mechanisms and management. Diabetes Care, 2013; 36 Suppl 2: S325-330","DOI":"10.2337\/dcS13-2038"},{"key":"1220","doi-asserted-by":"crossref","unstructured":"1220) Azemawah V, Movahed MR, Centuori P, Penaflor R, Riel PL, Situ S, Shadmehr M, Hashemzadeh M: State of the Art Comprehensive Review of Individual Statins, Their Differences, Pharmacology, and Clinical Implications. Cardiovasc Drugs Ther, 2019; 33: 625-639","DOI":"10.1007\/s10557-019-06904-x"},{"key":"1221","doi-asserted-by":"crossref","unstructured":"1221) Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM: Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care, 2009; 32: 1924-1929","DOI":"10.2337\/dc09-0738"},{"key":"1222","doi-asserted-by":"crossref","unstructured":"1222) Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, 2010; 375: 735-742","DOI":"10.1016\/S0140-6736(09)61965-6"},{"key":"1223","doi-asserted-by":"crossref","unstructured":"1223) Casula M, Mozzanica F, Scotti L, Tragni E, Pirillo A, Corrao G, Catapano AL: Statin use and risk of new-onset diabetes: A meta-analysis of observational studies. Nutr Metab Cardiovasc Dis, 2017; 27: 396-406","DOI":"10.1016\/j.numecd.2017.03.001"},{"key":"1224","doi-asserted-by":"crossref","unstructured":"1224) Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ: Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet, 2012; 380: 565-571","DOI":"10.1016\/S0140-6736(12)61190-8"},{"key":"1225","doi-asserted-by":"crossref","unstructured":"1225) Cybulska B, K\u0142osiewicz-Latoszek L: How do we know that statins are diabetogenic, and why? Is it an important issue in the clinical practice? Kardiol Pol, 2018; 76: 1217-1223","DOI":"10.5603\/KP.a2018.0150"},{"key":"1226","doi-asserted-by":"crossref","unstructured":"1226) Davis KA, Miyares MA: Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia. Am J Health Syst Pharm, 2014; 71: 1001-1008","DOI":"10.2146\/ajhp130592"},{"key":"1227","doi-asserted-by":"crossref","unstructured":"1227) Sacks FM, Stanesa M, Hegele RA: Severe hypertriglyceridemia with pancreatitis: thirteen years&apos; treatment with lomitapide. JAMA Intern Med, 2014; 174: 443-447","DOI":"10.1001\/jamainternmed.2013.13309"},{"key":"1228","doi-asserted-by":"crossref","unstructured":"1228) France M, Rees A, Datta D, Thompson G, Capps N, Ferns G, Ramaswami U, Seed M, Neely D, Cramb R, Shoulders C, Barbir M, Pottle A, Eatough R, Martin S, Bayly G, Simpson B, Halcox J, Edwards R, Main L, Payne J, Soran H: HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. Atherosclerosis, 2016; 255: 128-139","DOI":"10.1016\/j.atherosclerosis.2016.10.017"},{"key":"1229","doi-asserted-by":"crossref","unstructured":"1229) Blom DJ, Raal FJ, Santos RD, Marais AD: Lomitapide and Mipomersen-Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis. Curr Atheroscler Rep, 2019; 21: 48","DOI":"10.1007\/s11883-019-0809-3"},{"key":"1230","doi-asserted-by":"crossref","unstructured":"1230) Harada-Shiba M, Ikewaki K, Nohara A, Otsubo Y, Yanagi K, Yoshida M, Chang Q, Foulds P: Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia. J Atheroscler Thromb, 2017; 24: 402-411","DOI":"10.5551\/jat.38216"},{"key":"1231","doi-asserted-by":"crossref","unstructured":"1231) Nohara A, Otsubo Y, Yanagi K, Yoshida M, Ikewaki K, Harada-Shiba M, Jurecka A: Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study. J Atheroscler Thromb, 2019; 26: 368-377","DOI":"10.5551\/jat.45708"},{"key":"1232","doi-asserted-by":"crossref","unstructured":"1232) Hirota T, Ieiri I: Drug-drug interactions that interfere with statin metabolism. Expert Opin Drug Metab Toxicol, 2015; 11: 1435-1447","DOI":"10.1517\/17425255.2015.1056149"},{"key":"1233","doi-asserted-by":"crossref","unstructured":"1233) Omar MA, Wilson JP, Cox TS: Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother, 2001; 35: 1096-1107","DOI":"10.1345\/1542-6270(2001)035<1096:RAHCRI>2.0.CO;2"},{"key":"1234","doi-asserted-by":"crossref","unstructured":"1234) Enajat M, Teerenstra S, van Kuilenburg JT, van Sorge-Greve AH, Albers-Akkers MT, Verheugt FW, Pop GA: Safety of the combination of intensive cholesterol-lowering therapy with oral anticoagulation medication in elderly patients with atrial fibrillation: a randomized, double-blind, placebo-controlled study. Drugs Aging, 2009; 26: 585-593","DOI":"10.2165\/10558450-000000000-00000"},{"key":"1235","unstructured":"1235) Patel BV, Leslie RS, Thiebaud P, Nichol MB, Tang SS, Solomon H, Honda D, Foody JM: Adherence with single-pill amlodipine\/atorvastatin vs a two-pill regimen. Vasc Health Risk Manag, 2008; 4: 673-681"},{"key":"1236","doi-asserted-by":"crossref","unstructured":"1236) Weisser B, Predel HG, Gillessen A, Hacke C, Vor dem Esche J, Rippin G, Noetel A, Randerath O: Single Pill Regimen Leads to Better Adherence and Clinical Outcome in Daily Practice in Patients Suffering from Hypertension and\/or Dyslipidemia: Results of a Meta-Analysis. High Blood Press Cardiovasc Prev, 2020; 27: 157-164","DOI":"10.1007\/s40292-020-00370-5"},{"key":"1237","doi-asserted-by":"crossref","unstructured":"1237) Hussein MA, Chapman RH, Benner JS, Tang SS, Solomon HA, Joyce A, Foody JM: Does a single-pill antihypertensive\/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study. Am J Cardiovasc Drugs, 2010; 10: 193-202","DOI":"10.2165\/11530680-000000000-00000"},{"key":"1238","doi-asserted-by":"crossref","unstructured":"1238) Neutel JM, Bestermann WH, Dyess EM, Graff A, Kursun A, Sutradhar S, Yunis C: The use of a single-pill calcium channel blocker\/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study. J Clin Hypertens (Greenwich), 2009; 11: 22-30","DOI":"10.1111\/j.1751-7176.2008.00058.x"},{"key":"1239","doi-asserted-by":"crossref","unstructured":"1239) Yusuf S, Joseph P, Dans A, Gao P, Teo K, Xavier D, L\u00f3pez-Jaramillo P, Yusoff K, Santoso A, Gamra H, Talukder S, Christou C, Girish P, Yeates K, Xavier F, Dagenais G, Rocha C, McCready T, Tyrwhitt J, Bosch J, Pais P: Polypill with or without Aspirin in Persons without Cardiovascular Disease. N Engl J Med, 2021; 384: 216-228","DOI":"10.1056\/NEJMoa2028220"},{"key":"1240","doi-asserted-by":"crossref","unstructured":"1240) Shalev V, Chodick G, Silber H, Kokia E, Jan J, Heymann AD: Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med, 2009; 169: 260-268","DOI":"10.1001\/archinternmed.2008.552"},{"key":"1241","doi-asserted-by":"crossref","unstructured":"1241) Origasa H, Yokoyama M, Matsuzaki M, Saito Y, Matsuzawa Y: Clinical importance of adherence to treatment with eicosapentaenoic acid by patients with hypercholesterolemia. Circ J, 2010; 74: 510-517","DOI":"10.1253\/circj.CJ-09-0746"},{"key":"1242","doi-asserted-by":"crossref","unstructured":"1242) van Driel ML, Morledge MD, Ulep R, Shaffer JP, Davies P, Deichmann R: Interventions to improve adherence to lipid-lowering medication. Cochrane Database Syst Rev, 2016; 12: Cd004371","DOI":"10.1002\/14651858.CD004371.pub4"},{"key":"1243","doi-asserted-by":"crossref","unstructured":"1243) Parris ES, Lawrence DB, Mohn LA, Long LB: Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care, 2005; 28: 595-599","DOI":"10.2337\/diacare.28.3.595"},{"key":"1244","doi-asserted-by":"crossref","unstructured":"1244) Herttua K, Martikainen P, Batty GD, Kivim\u00e4ki M: Poor Adherence to Statin and Antihypertensive Therapies as Risk Factors for Fatal Stroke. J Am Coll Cardiol, 2016; 67: 1507-1515","DOI":"10.1016\/j.jacc.2016.01.044"},{"key":"1245","doi-asserted-by":"crossref","unstructured":"1245) Deshpande S, Quek RG, Forbes CA, de Kock S, Kleijnen J, Gandra SR, Simpson RJ, Jr.: A systematic review to assess adherence and persistence with statins. Curr Med Res Opin, 2017; 33: 769-778","DOI":"10.1080\/03007995.2017.1281109"},{"key":"1246","doi-asserted-by":"crossref","unstructured":"1246) Mann DM, Woodward M, Muntner P, Falzon L, Kronish I: Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother, 2010; 44: 1410-1421","DOI":"10.1345\/aph.1P150"},{"key":"1247","unstructured":"1247) Wiegand P, McCombs JS, Wang JJ: Factors of hyperlipidemia medication adherence in a nationwide health plan. Am J Manag Care, 2012; 18: 193-199"},{"key":"1248","doi-asserted-by":"crossref","unstructured":"1248) Helin-Salmivaara A, Lavikainen P, Korhonen MJ, Halava H, Junnila SY, Kettunen R, Neuvonen PJ, Martikainen JE, Ruokoniemi P, Saastamoinen LK, Virta L, Huupponen R: Long-term persistence with statin therapy: a nationwide register study in Finland. Clin Ther, 2008; 30 Pt 2: 2228-2240","DOI":"10.1016\/j.clinthera.2008.12.003"},{"key":"1249","doi-asserted-by":"crossref","unstructured":"1249) Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J: Long-term persistence in use of statin therapy in elderly patients. JAMA, 2002; 288: 455-461","DOI":"10.1001\/jama.288.4.455"},{"key":"1250","doi-asserted-by":"crossref","unstructured":"1250) Navar AM, Roe MT, White JA, Cannon CP, Lokhnygina Y, Newby LK, Giugliano RP, Tershakovec AM, Braunwald E, Califf RM, Blazing MA: Medication Discontinuation in the IMPROVE-IT Trial. Circ Cardiovasc Qual Outcomes, 2019; 12: e005041","DOI":"10.1161\/CIRCOUTCOMES.118.005041"},{"key":"1251","doi-asserted-by":"crossref","unstructured":"1251) Barker-Collo S, Krishnamurthi R, Witt E, Feigin V, Jones A, McPherson K, Starkey N, Parag V, Jiang Y, Barber PA, Rush E, Bennett D, Aroll B: Improving Adherence to Secondary Stroke Prevention Strategies Through Motivational Interviewing: Randomized Controlled Trial. Stroke, 2015; 46: 3451-3458","DOI":"10.1161\/STROKEAHA.115.011003"},{"key":"1252","doi-asserted-by":"crossref","unstructured":"1252) Lyons I, Barber N, Raynor DK, Wei L: The Medicines Advice Service Evaluation (MASE): a randomised controlled trial of a pharmacist-led telephone based intervention designed to improve medication adherence. BMJ Qual Saf, 2016; 25: 759-769","DOI":"10.1136\/bmjqs-2015-004670"},{"key":"1253","doi-asserted-by":"crossref","unstructured":"1253) Santo K, Singleton A, Rogers K, Thiagalingam A, Chalmers J, Chow CK, Redfern J: Medication reminder applications to improve adherence in coronary heart disease: a randomised clinical trial. Heart, 2019; 105: 323-329","DOI":"10.1136\/heartjnl-2018-313479"},{"key":"1254","doi-asserted-by":"crossref","unstructured":"1254) Wu Z, Camargo CA, Jr., Khaw KT, Waayer D, Lawes CMM, Toop L, Scragg R: Effects of vitamin D supplementation on adherence to and persistence with long-term statin therapy: Secondary analysis from the randomized, double-blind, placebo-controlled ViDA study. Atherosclerosis, 2018; 273: 59-66","DOI":"10.1016\/j.atherosclerosis.2018.04.009"},{"key":"1255","doi-asserted-by":"crossref","unstructured":"1255) Daniel H, Christian W, Robin H, Lars S, Thomas M: Statin treatment after acute coronary syndrome: Adherence and reasons for non-adherence in a randomized controlled intervention trial. Sci Rep, 2019; 9: 12079","DOI":"10.1038\/s41598-019-48540-3"},{"key":"1256","doi-asserted-by":"crossref","unstructured":"1256) O\u00f1atibia-Astibia A, Malet-Larrea A, Larra\u00f1aga B, Gastelurrutia M, Calvo B, Ram\u00edrez D, Cantero I, Garay \u00c1, Goyenechea E: Tailored interventions by community pharmacists and general practitioners improve adherence to statins in a Spanish randomized controlled trial. Health Serv Res, 2019; 54: 658-668","DOI":"10.1111\/1475-6773.13152"},{"key":"1257","doi-asserted-by":"crossref","unstructured":"1257) Gagne JJ, Choudhry NK, Kesselheim AS, Polinski JM, Hutchins D, Matlin OS, Brennan TA, Avorn J, Shrank WH: Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study. Ann Intern Med, 2014; 161: 400-407","DOI":"10.7326\/M13-2942"},{"key":"1258","doi-asserted-by":"crossref","unstructured":"1258) Smith SC, Jr., Grundy SM: 2013 ACC\/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol. J Am Coll Cardiol, 2014; 64: 601-612","DOI":"10.1016\/j.jacc.2014.06.1159"},{"key":"1259","doi-asserted-by":"crossref","unstructured":"1259) Bangalore S, Fayyad R, Kastelein JJ, Laskey R, Amarenco P, DeMicco DA, Waters DD: 2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis? Am J Med, 2016; 129: 384-391","DOI":"10.1016\/j.amjmed.2015.10.024"},{"key":"1260","doi-asserted-by":"crossref","unstructured":"1260) Bacquer D, Smedt D, Reiner \u017d, Tokg\u00f6zo\u011flu L, Clays E, Kotseva K, Ryd\u00e9n L, Wood D, Backer G: Percentage low-density lipoprotein-cholesterol response to a given statin dose is not fixed across the pre-treatment range: Real world evidence from clinical practice: Data from the ESC-EORP EUROASPIRE V Study. Eur J Prev Cardiol, 2020; 27: 1630-1636","DOI":"10.1177\/2047487319874898"},{"key":"1261","doi-asserted-by":"crossref","unstructured":"1261) Hayward RA, Krumholz HM: Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health. Circ Cardiovasc Qual Outcomes, 2012; 5: 2-5","DOI":"10.1161\/CIRCOUTCOMES.111.964676"},{"key":"1262","doi-asserted-by":"crossref","unstructured":"1262) Hosomi N, Kitagawa K, Nagai Y, Nakagawa Y, Aoki S, Nezu T, Kagimura T, Maruyama H, Origasa H, Minematsu K, Uchiyama S, Matsumoto M: Desirable Low-Density Lipoprotein Cholesterol Levels for Preventing Stroke Recurrence: A Post Hoc Analysis of the J-STARS Study (Japan Statin Treatment Against Recurrent Stroke). Stroke, 2018; 49: 865-871","DOI":"10.1161\/STROKEAHA.117.018870"},{"key":"1263","doi-asserted-by":"crossref","unstructured":"1263) Wang N, Fulcher J, Abeysuriya N, Park L, Kumar S, Di Tanna GL, Wilcox I, Keech A, Rodgers A, Lal S: Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants. Lancet Diabetes Endocrinol, 2020; 8: 36-49","DOI":"10.1016\/S2213-8587(19)30388-2"},{"key":"1264","doi-asserted-by":"crossref","unstructured":"1264) Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D, Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto AM, Jr., Ridker PM, Grundy SM, Kastelein JJ: Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol, 2014; 64: 485-494","DOI":"10.1016\/j.jacc.2014.02.615"},{"key":"1265","doi-asserted-by":"crossref","unstructured":"1265) Ota T, Ishii H, Suzuki S, Shibata Y, Tatami Y, Harata S, Shimbo Y, Takayama Y, Tanaka A, Kawamura Y, Osugi N, Maeda K, Kondo T, Murohara T: Impact of the statin escape phenomenon on long-term clinical outcomes in patients with acute myocardial infarction: Subgroup analysis of the Nagoya Acute Myocardial Infarction Study (NAMIS). Atherosclerosis, 2015; 242: 155-160","DOI":"10.1016\/j.atherosclerosis.2015.07.012"},{"key":"1266","doi-asserted-by":"crossref","unstructured":"1266) Tanaka S, Ikari Y, Ijichi T, Nakazawa G: Treat-to-target lipid control is effective but highlighted poor prognosis without indication of statin following percutaneous coronary intervention. Cardiovasc Interv Ther, 2017; 32: 358-364","DOI":"10.1007\/s12928-016-0419-8"},{"key":"1267","doi-asserted-by":"crossref","unstructured":"1267) Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA, 2001; 285: 1711-1718","DOI":"10.1001\/jama.285.13.1711"},{"key":"1268","doi-asserted-by":"crossref","unstructured":"1268) Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004; 350: 1495-1504","DOI":"10.1056\/NEJMoa040583"},{"key":"1269","doi-asserted-by":"crossref","unstructured":"1269) Briel M, Schwartz GG, Thompson PL, de Lemos JA, Blazing MA, van Es GA, Kayik\u00e7ioglu M, Arntz HR, den Hartog FR, Veeger NJ, Colivicchi F, Dupuis J, Okazaki S, Wright RS, Bucher HC, Nordmann AJ: Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA, 2006; 295: 2046-2056","DOI":"10.1001\/jama.295.17.2046"},{"key":"1270","doi-asserted-by":"crossref","unstructured":"1270) Steg PG, Szarek M, Bhatt DL, Bittner VA, Br\u00e9geault MF, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Ostadal P, Parkhomenko A, Pordy R, Roe MT, Tricoci P, Vogel R, White HD, Zeiher AM, Schwartz GG: Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation, 2019; 140: 103-112","DOI":"10.1161\/CIRCULATIONAHA.118.038840"},{"key":"1271","doi-asserted-by":"crossref","unstructured":"1271) Harada-Shiba M, Ako J, Arai H, Hirayama A, Murakami Y, Nohara A, Ozaki A, Uno K, Nakamura M: Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: Results of the EXPLORE-J study. Atherosclerosis, 2018; 277: 362-368","DOI":"10.1016\/j.atherosclerosis.2018.06.856"},{"key":"1272","doi-asserted-by":"crossref","unstructured":"1272) Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Bor\u00e9n J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybj\u00e6rg-Hansen A: Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J, 2013; 34: 3478-3490a","DOI":"10.1093\/eurheartj\/eht273"},{"key":"1273","doi-asserted-by":"crossref","unstructured":"1273) Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, Seed M, Humphries SE: Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J, 2008; 29: 2625-2633","DOI":"10.1093\/eurheartj\/ehn422"},{"key":"1274","doi-asserted-by":"crossref","unstructured":"1274) Harada-Shiba M, Sugisawa T, Makino H, Abe M, Tsushima M, Yoshimasa Y, Yamashita T, Miyamoto Y, Yamamoto A, Tomoike H, Yokoyama S: Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia. J Atheroscler Thromb, 2010; 17: 667-674","DOI":"10.5551\/jat.4143"},{"key":"1275","doi-asserted-by":"crossref","unstructured":"1275) Luirink IK, Wiegman A, Kusters DM, Hof MH, Groothoff JW, de Groot E, Kastelein JJP, Hutten BA: 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. N Engl J Med, 2019; 381: 1547-1556","DOI":"10.1056\/NEJMoa1816454"},{"key":"1276","doi-asserted-by":"crossref","unstructured":"1276) Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, Blom D, Civeira F, Krempf M, Lorenzato C, Zhao J, Pordy R, Baccara-Dinet MT, Gipe DA, Geiger MJ, Farnier M: ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J, 2015; 36: 2996-3003","DOI":"10.1093\/eurheartj\/ehv370"},{"key":"1277","doi-asserted-by":"crossref","unstructured":"1277) Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Scott R, Wasserman SM, Gaudet D: PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet, 2015; 385: 331-340","DOI":"10.1016\/S0140-6736(14)61399-4"},{"key":"1278","doi-asserted-by":"crossref","unstructured":"1278) Levantesi G, Macchia A, Marfisi R, Franzosi MG, Maggioni AP, Nicolosi GL, Schweiger C, Tavazzi L, Tognoni G, Valagussa F, Marchioli R: Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol, 2005; 46: 277-283","DOI":"10.1016\/j.jacc.2005.03.062"},{"key":"1279","doi-asserted-by":"crossref","unstructured":"1279) Costa J, Borges M, David C, Vaz Carneiro A: Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ, 2006; 332: 1115-1124","DOI":"10.1136\/bmj.38793.468449.AE"},{"key":"1280","doi-asserted-by":"crossref","unstructured":"1280) Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet, 2008; 371: 117-125","DOI":"10.1016\/S0140-6736(08)60104-X"},{"key":"1281","doi-asserted-by":"crossref","unstructured":"1281) Kohsaka S, Kimura T, Goto M, Lee VV, Elayda M, Furukawa Y, Fukushima M, Komeda M, Sakata R, Willerson JT, Wilson JM, Kita T: Difference in patient profiles and outcomes in Japanese versus American patients undergoing coronary revascularization (collaborative study by CREDO-Kyoto and the Texas Heart Institute Research Database). Am J Cardiol, 2010; 105: 1698-1704","DOI":"10.1016\/j.amjcard.2010.01.349"},{"key":"1282","doi-asserted-by":"crossref","unstructured":"1282) Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D: Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care, 2006; 29: 1220-1226","DOI":"10.2337\/dc05-2465"},{"key":"1283","doi-asserted-by":"crossref","unstructured":"1283) Bayturan O, Kapadia S, Nicholls SJ, Tuzcu EM, Shao M, Uno K, Shreevatsa A, Lavoie AJ, Wolski K, Schoenhagen P, Nissen SE: Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol, 2010; 55: 2736-2742","DOI":"10.1016\/j.jacc.2010.01.050"},{"key":"1284","doi-asserted-by":"crossref","unstructured":"1284) Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M: Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome--serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome Trial (the JAPAN-ACS Trial). Circ J, 2010; 74: 1165-1174","DOI":"10.1253\/circj.CJ-09-0766"},{"key":"1285","doi-asserted-by":"crossref","unstructured":"1285) Arai H, Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M: More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome--sub-analysis of JAPAN-ACS study. J Atheroscler Thromb, 2010; 17: 1096-1107","DOI":"10.5551\/jat.5660"},{"key":"1286","doi-asserted-by":"crossref","unstructured":"1286) Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbal\u00e1n R, \u0160pinar J, Park JG, White JA, Bohula EA, Braunwald E: Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, 2018; 137: 1571-1582","DOI":"10.1161\/CIRCULATIONAHA.117.030950"},{"key":"1287","doi-asserted-by":"crossref","unstructured":"1287) Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, R\u00f6ther J, Wilson PW: International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA, 2006; 295: 180-189","DOI":"10.1001\/jama.295.2.180"},{"key":"1288","doi-asserted-by":"crossref","unstructured":"1288) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994; 344: 1383-1389","DOI":"10.1016\/S0140-6736(94)90566-5"},{"key":"1289","doi-asserted-by":"crossref","unstructured":"1289) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med, 1998; 339: 1349-1357","DOI":"10.1056\/NEJM199811053391902"},{"key":"1290","doi-asserted-by":"crossref","unstructured":"1290) Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Moy\u00e9 LA, Piller LB, Rutherford J, Simpson LM, Braunwald E: Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation, 1999; 99: 216-223","DOI":"10.1161\/01.CIR.99.2.216"},{"key":"1291","doi-asserted-by":"crossref","unstructured":"1291) Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ, 1998; 316: 823-828","DOI":"10.1136\/bmj.316.7134.823"},{"key":"1292","doi-asserted-by":"crossref","unstructured":"1292) Murakami K, Ishibashi S, Yoshida Y, Yamada N, Akanuma Y: Lipoprotein(a) as a coronary risk factor in Japanese patients with Type II (non-insulin-dependent) diabetes mellitus. Relation with apolipoprotein(a) phenotypes. Diabetologia, 1998; 41: 1397-1398","DOI":"10.1007\/s001250051083"},{"key":"1293","doi-asserted-by":"crossref","unstructured":"1293) Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N: Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet, 2009; 373: 1765-1772","DOI":"10.1016\/S0140-6736(09)60697-8"},{"key":"1294","doi-asserted-by":"crossref","unstructured":"1294) Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassa\u00ef B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C: Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ, 2011; 343: d4169","DOI":"10.1136\/bmj.d4169"},{"key":"1295","doi-asserted-by":"crossref","unstructured":"1295) Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008; 359: 1577-1589","DOI":"10.1056\/NEJMoa0806470"},{"key":"1296","doi-asserted-by":"crossref","unstructured":"1296) Orchard TJ, Nathan DM, Zinman B, Cleary P, Brillon D, Backlund JY, Lachin JM: Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA, 2015; 313: 45-53","DOI":"10.1001\/jama.2014.16107"},{"key":"1297","doi-asserted-by":"crossref","unstructured":"1297) Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY, Smithline Kinder L, Ellis D, Becker DJ: Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care, 2003; 26: 1374-1379","DOI":"10.2337\/diacare.26.5.1374"},{"key":"1298","doi-asserted-by":"crossref","unstructured":"1298) Goto A, Goto M, Terauchi Y, Yamaguchi N, Noda M: Association Between Severe Hypoglycemia and Cardiovascular Disease Risk in Japanese Patients With Type 2 Diabetes. J Am Heart Assoc, 2016; 5: e002875","DOI":"10.1161\/JAHA.115.002875"},{"key":"1299","doi-asserted-by":"crossref","unstructured":"1299) Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, Bigger T, Cushman W, Goff D, Soliman EZ, Thomas A, Papademetriou V: Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). Am J Cardiol, 2014; 114: 1217-1222","DOI":"10.1016\/j.amjcard.2014.07.045"},{"key":"1300","doi-asserted-by":"crossref","unstructured":"1300) Miller ME, Williamson JD, Gerstein HC, Byington RP, Cushman WC, Ginsberg HN, Ambrosius WT, Lovato L, Applegate WB: Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care, 2014; 37: 634-643","DOI":"10.2337\/dc13-1545"},{"key":"1301","doi-asserted-by":"crossref","unstructured":"1301) Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE: Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med, 2015; 373: 2117-2128","DOI":"10.1056\/NEJMoa1504720"},{"key":"1302","doi-asserted-by":"crossref","unstructured":"1302) Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR: Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med, 2017; 377: 644-657","DOI":"10.1056\/NEJMoa1611925"},{"key":"1303","doi-asserted-by":"crossref","unstructured":"1303) Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB: Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med, 2016; 375: 311-322","DOI":"10.1056\/NEJMoa1603827"},{"key":"1304","doi-asserted-by":"crossref","unstructured":"1304) Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsb\u00f8ll T: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med, 2016; 375: 1834-1844","DOI":"10.1056\/NEJMoa1607141"},{"key":"1305","unstructured":"1305) Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Ryd\u00e9n L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T: Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet, 2019; 394: 131-138"},{"key":"1306","doi-asserted-by":"crossref","unstructured":"1306) Araki A, Iimuro S, Sakurai T, Umegaki H, Iijima K, Nakano H, Oba K, Yokono K, Sone H, Yamada N, Ako J, Kozaki K, Miura H, Kashiwagi A, Kikkawa R, Yoshimura Y, Nakano T, Ohashi Y, Ito H: Non-high-density lipoprotein cholesterol: an important predictor of stroke and diabetes-related mortality in Japanese elderly diabetic patients. Geriatr Gerontol Int, 2012; 12 Suppl 1: 18-28","DOI":"10.1111\/j.1447-0594.2011.00809.x"},{"key":"1307","doi-asserted-by":"crossref","unstructured":"1307) Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004; 364: 685-696","DOI":"10.1016\/S0140-6736(04)16895-5"},{"key":"1308","doi-asserted-by":"crossref","unstructured":"1308) Kengne AP, Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Gu DF, Suh I, Woodward M: Systolic blood pressure, diabetes and the risk of cardiovascular diseases in the Asia-Pacific region. J Hypertens, 2007; 25: 1205-1213","DOI":"10.1097\/HJH.0b013e3280dce59e"},{"key":"1309","doi-asserted-by":"crossref","unstructured":"1309) Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A: Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA, 2015; 313: 603-615","DOI":"10.1001\/jama.2014.18574"},{"key":"1310","doi-asserted-by":"crossref","unstructured":"1310) McBrien K, Rabi DM, Campbell N, Barnieh L, Clement F, Hemmelgarn BR, Tonelli M, Leiter LA, Klarenbach SW, Manns BJ: Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis. Arch Intern Med, 2012; 172: 1296-1303","DOI":"10.1001\/archinternmed.2012.3147"},{"key":"1311","doi-asserted-by":"crossref","unstructured":"1311) Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 2003; 348: 383-393","DOI":"10.1056\/NEJMoa021778"},{"key":"1312","doi-asserted-by":"crossref","unstructured":"1312) Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med, 2008; 358: 580-591","DOI":"10.1056\/NEJMoa0706245"},{"key":"1313","doi-asserted-by":"crossref","unstructured":"1313) Manson JE, Greenland P, LaCroix AZ, Stefanick ML, Mouton CP, Oberman A, Perri MG, Sheps DS, Pettinger MB, Siscovick DS: Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med, 2002; 347: 716-725","DOI":"10.1056\/NEJMoa021067"},{"key":"1314","unstructured":"1314) Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A, Nathan DM, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Reboussin D, Regensteiner JG, Rickman AD, Ryan DH, Safford M, Wadden TA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ: Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med, 2013; 369: 145-154"},{"key":"1315","doi-asserted-by":"crossref","unstructured":"1315) Schellenberg ES, Dryden DM, Vandermeer B, Ha C, Korownyk C: Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med, 2013; 159: 543-551","DOI":"10.7326\/0003-4819-159-8-201310150-00007"},{"key":"1316","unstructured":"1316) Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, Haraguchi M, Morita A, Ohashi K, Hara K, Morise A, Izumi K, Ishizuka N, Ohashi Y, Noda M, Kadowaki T: Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol, 2017; 5: 951-964"},{"key":"1317","doi-asserted-by":"crossref","unstructured":"1317) Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Mu\u00f1oz D, Smith SC, Jr., Virani SS, Williams KA, Sr., Yeboah J, Ziaeian B: 2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019; 140: e563-e595","DOI":"10.1161\/CIR.0000000000000677"},{"key":"1318","doi-asserted-by":"crossref","unstructured":"1318) Collins R, Armitage J, Parish S, Sleigh P, Peto R: MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet, 2003; 361: 2005-2016","DOI":"10.1016\/S0140-6736(03)13636-7"},{"key":"1319","unstructured":"1319) Amarenco P, Bogousslavsky J, Callahan A, 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med, 2006; 355: 549-559"},{"key":"1320","doi-asserted-by":"crossref","unstructured":"1320) Callahan A, Amarenco P, Goldstein LB, Sillesen H, Messig M, Samsa GP, Altafullah I, Ledbetter LY, MacLeod MJ, Scott R, Hennerici M, Zivin JA, Welch KM: Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Arch Neurol, 2011; 68: 1245-1251","DOI":"10.1001\/archneurol.2011.146"},{"key":"1321","unstructured":"1321) National Cerebral and Cardiovascular Center, Stroke Data Bank Editorial Committee: Stroke Treatment Data Bank,2021, Nakayama Shoten Co,.Ltd,2021 (in Japanese)"},{"key":"1322","unstructured":"1322) Tanaka H, Iso H, Yokoyama T, et al.: Cerebrovasculardisease.In: Cerebrovasculardisease, pp1193-1226, OxfordPress, 2001"},{"key":"1323","doi-asserted-by":"crossref","unstructured":"1323) Kimura K, Kazui S, Minematsu K, Yamaguchi T: Analysis of 16,922 patients with acute ischemic stroke and transient ischemic attack in Japan. A hospital-based prospective registration study. Cerebrovasc Dis, 2004; 18: 47-56","DOI":"10.1159\/000078749"},{"key":"1324","doi-asserted-by":"crossref","unstructured":"1324) Takashima N, Arima H, Kita Y, Fujii T, Miyamatsu N, Komori M, Sugimoto Y, Nagata S, Miura K, Nozaki K: Incidence, Management and Short-Term Outcome of Stroke in a General Population of 1.4 Million Japanese - Shiga Stroke Registry. Circ J, 2017; 81: 1636-1646","DOI":"10.1253\/circj.CJ-17-0177"},{"key":"1325","doi-asserted-by":"crossref","unstructured":"1325) Petty GW, Brown RD, Jr., Whisnant JP, Sicks JD, O&apos;Fallon WM, Wiebers DO: Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke, 1999; 30: 2513-2516","DOI":"10.1161\/01.STR.30.12.2513"},{"key":"1326","doi-asserted-by":"crossref","unstructured":"1326) Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R: Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet, 2007; 370: 1829-1839","DOI":"10.1016\/S0140-6736(07)61778-4"},{"key":"1327","doi-asserted-by":"crossref","unstructured":"1327) Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Lancet, 1998; 352: 1801-1807","DOI":"10.1016\/S0140-6736(98)03454-0"},{"key":"1328","doi-asserted-by":"crossref","unstructured":"1328) Schneider AT, Kissela B, Woo D, Kleindorfer D, Alwell K, Miller R, Szaflarski J, Gebel J, Khoury J, Shukla R, Moomaw C, Pancioli A, Jauch E, Broderick J: Ischemic stroke subtypes: a population-based study of incidence rates among blacks and whites. Stroke, 2004; 35: 1552-1556","DOI":"10.1161\/01.STR.0000129335.28301.f5"},{"key":"1329","doi-asserted-by":"crossref","unstructured":"1329) Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU: Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke, 2001; 32: 2735-2740","DOI":"10.1161\/hs1201.100209"},{"key":"1330","doi-asserted-by":"crossref","unstructured":"1330) Gu X, Li Y, Chen S, Yang X, Liu F, Li Y, Li J, Cao J, Liu X, Chen J, Shen C, Yu L, Huang J, Lam TH, Fang X, He Y, Zhang X, Lu X, Wu S, Gu D: Association of Lipids With Ischemic and Hemorrhagic Stroke: A Prospective Cohort Study Among 267 500 Chinese. Stroke, 2019; 50: 3376-3384","DOI":"10.1161\/STROKEAHA.119.026402"},{"key":"1331","doi-asserted-by":"crossref","unstructured":"1331) Iso H, Jacobs DR, Jr., Wentworth D, Neaton JD, Cohen JD: Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med, 1989; 320: 904-910","DOI":"10.1056\/NEJM198904063201405"},{"key":"1332","doi-asserted-by":"crossref","unstructured":"1332) Lepp\u00e4l\u00e4 JM, Virtamo J, Fogelholm R, Albanes D, Heinonen OP: Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants. Stroke, 1999; 30: 2535-2540","DOI":"10.1161\/01.STR.30.12.2535"},{"key":"1333","unstructured":"1333) Zhang X, Patel A, Horibe H, Wu Z, Barzi F, Rodgers A, MacMahon S, Woodward M: Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol, 2003; 32: 563-572"},{"key":"1334","doi-asserted-by":"crossref","unstructured":"1334) Law MR, Wald NJ, Rudnicka AR: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ, 2003; 326: 1423","DOI":"10.1136\/bmj.326.7404.1423"},{"key":"1335","doi-asserted-by":"crossref","unstructured":"1335) Bots ML, Elwood PC, Nikitin Y, Salonen JT, Freire de Concalves A, Inzitari D, Sivenius J, Benetou V, Tuomilehto J, Koudstaal PJ, Grobbee DE: Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Community Health, 2002; 56 Suppl 1: i19-24","DOI":"10.1136\/jech.56.suppl_1.i19"},{"key":"1336","doi-asserted-by":"crossref","unstructured":"1336) Shahar E, Chambless LE, Rosamond WD, Boland LL, Ballantyne CM, McGovern PG, Sharrett AR: Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke, 2003; 34: 623-631","DOI":"10.1161\/01.STR.0000057812.51734.FF"},{"key":"1337","doi-asserted-by":"crossref","unstructured":"1337) Sturgeon JD, Folsom AR, Longstreth WT, Jr., Shahar E, Rosamond WD, Cushman M: Risk factors for intracerebral hemorrhage in a pooled prospective study. Stroke, 2007; 38: 2718-2725","DOI":"10.1161\/STROKEAHA.107.487090"},{"key":"1338","doi-asserted-by":"crossref","unstructured":"1338) Lindenstr\u00f8m E, Boysen G, Nyboe J: Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ, 1994; 309: 11-15","DOI":"10.1136\/bmj.309.6946.11"},{"key":"1339","doi-asserted-by":"crossref","unstructured":"1339) Wannamethee SG, Shaper AG, Ebrahim S: HDL-Cholesterol, total cholesterol, and the risk of stroke in middle-aged British men. Stroke, 2000; 31: 1882-1888","DOI":"10.1161\/01.STR.31.8.1882"},{"key":"1340","doi-asserted-by":"crossref","unstructured":"1340) Bowman TS, Sesso HD, Ma J, Kurth T, Kase CS, Stampfer MJ, Gaziano JM: Cholesterol and the risk of ischemic stroke. Stroke, 2003; 34: 2930-2934","DOI":"10.1161\/01.STR.0000102171.91292.DC"},{"key":"1341","doi-asserted-by":"crossref","unstructured":"1341) H\u00e5heim LL, Holme I, Hjermann I, Leren P: Risk factors of stroke incidence and mortality. A 12-year follow-up of the Oslo Study. Stroke, 1993; 24: 1484-1489","DOI":"10.1161\/01.STR.24.10.1484"},{"key":"1342","doi-asserted-by":"crossref","unstructured":"1342) Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG: Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA, 2008; 300: 2142-2152","DOI":"10.1001\/jama.2008.621"},{"key":"1343","doi-asserted-by":"crossref","unstructured":"1343) Mizuno K, Nakaya N, Ohashi Y, Tajima N, Kushiro T, Teramoto T, Uchiyama S, Nakamura H: Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation, 2008; 117: 494-502","DOI":"10.1161\/CIRCULATIONAHA.106.671826"},{"key":"1344","doi-asserted-by":"crossref","unstructured":"1344) Goldstein LB, Amarenco P, Szarek M, Callahan A, 3rd, Hennerici M, Sillesen H, Zivin JA, Welch KM: Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology, 2008; 70: 2364-2370","DOI":"10.1212\/01.wnl.0000296277.63350.77"},{"key":"1345","doi-asserted-by":"crossref","unstructured":"1345) Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A, 3rd, Hennerici M, Simunovic L, Zivin JA, Welch KM: Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke, 2007; 38: 3198-3204","DOI":"10.1161\/STROKEAHA.107.493106"},{"key":"1346","doi-asserted-by":"crossref","unstructured":"1346) Sillesen H, Amarenco P, Hennerici MG, Callahan A, Goldstein LB, Zivin J, Messig M, Welch KM: Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke, 2008; 39: 3297-3302","DOI":"10.1161\/STROKEAHA.108.516450"},{"key":"1347","doi-asserted-by":"crossref","unstructured":"1347) Amarenco P, Benavente O, Goldstein LB, Callahan A, 3rd, Sillesen H, Hennerici MG, Gilbert S, Rudolph AE, Simunovic L, Zivin JA, Welch KM: Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke, 2009; 40: 1405-1409","DOI":"10.1161\/STROKEAHA.108.534107"},{"key":"1348","doi-asserted-by":"crossref","unstructured":"1348) Mart\u00ed-F\u00e0bregas J, Gomis M, Arboix A, Aleu A, Pagonabarraga J, Belv\u00eds R, Cocho D, Roquer J, Rodr\u00edguez A, Garc\u00eda MD, Molina-Porcel L, D\u00edaz-Manera J, Mart\u00ed-Vilalta JL: Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke, 2004; 35: 1117-1121","DOI":"10.1161\/01.STR.0000125863.93921.3f"},{"key":"1349","doi-asserted-by":"crossref","unstructured":"1349) Colivicchi F, Bassi A, Santini M, Caltagirone C: Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke, 2007; 38: 2652-2657","DOI":"10.1161\/STROKEAHA.107.487017"},{"key":"1350","doi-asserted-by":"crossref","unstructured":"1350) Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B: Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med, 2016; 375: 323-334","DOI":"10.1056\/NEJMoa1515920"},{"key":"1351","doi-asserted-by":"crossref","unstructured":"1351) Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med, 2019; 380: 2295-2306","DOI":"10.1056\/NEJMoa1811744"},{"key":"1352","doi-asserted-by":"crossref","unstructured":"1352) Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sj\u00f6str\u00f6m CD, Toto RD, Langkilde AM, Wheeler DC: Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med, 2020; 383: 1436-1446","DOI":"10.1056\/NEJMoa2024816"},{"key":"1353","doi-asserted-by":"crossref","unstructured":"1353) McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, B\u011blohl\u00e1vek J, B\u00f6hm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Duk\u00e1t A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O&apos;Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sj\u00f6strand M, Langkilde AM: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med, 2019; 381: 1995-2008","DOI":"10.1056\/NEJMoa1911303"},{"key":"1354","doi-asserted-by":"crossref","unstructured":"1354) Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med, 2019; 380: 347-357","DOI":"10.1056\/NEJMoa1812389"},{"key":"1355","doi-asserted-by":"crossref","unstructured":"1355) Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellstr\u00f6m B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Gr\u00f6nhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet, 2011; 377: 2181-2192","DOI":"10.1016\/S0140-6736(11)60739-3"},{"key":"1356","doi-asserted-by":"crossref","unstructured":"1356) Nakamura H, Mizuno K, Ohashi Y, Yoshida T, Hirao K, Uchida Y: Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis, 2009; 206: 512-517","DOI":"10.1016\/j.atherosclerosis.2009.03.031"},{"key":"1357","doi-asserted-by":"crossref","unstructured":"1357) Yokote K, Yamashita S, Arai H, Araki E, Suganami H, Ishibashi S, Of The KSGOB: Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-\u03b1 Modulator (SPPARM\u03b1), in Dyslipidemic Patients with Renal Impairment. Int J Mol Sci, 2019; 20","DOI":"10.3390\/ijms20030706"},{"key":"1358","doi-asserted-by":"crossref","unstructured":"1358) Lamprea-Montealegre JA, Staplin N, Herrington WG, Haynes R, Emberson J, Baigent C, de Boer IH: Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD. Clin J Am Soc Nephrol, 2020; 15: 47-60","DOI":"10.2215\/CJN.07320619"},{"key":"1359","doi-asserted-by":"crossref","unstructured":"1359) Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner \u017d, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL: 2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention &amp; Rehabilitation (EACPR). Atherosclerosis, 2016; 253: 281-344","DOI":"10.1016\/j.atherosclerosis.2016.08.018"},{"key":"1360","doi-asserted-by":"crossref","unstructured":"1360) Mabuchi H, Nohara A, Noguchi T, Kobayashi J, Kawashiri MA, Tada H, Nakanishi C, Mori M, Yamagishi M, Inazu A, Koizumi J: Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan. Atherosclerosis, 2011; 214: 404-407","DOI":"10.1016\/j.atherosclerosis.2010.11.005"},{"key":"1361","doi-asserted-by":"crossref","unstructured":"1361) Akioyamen LE, Genest J, Shan SD, Reel RL, Albaum JM, Chu A, Tu JV: Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open, 2017; 7: e016461","DOI":"10.1136\/bmjopen-2017-016461"},{"key":"1362","doi-asserted-by":"crossref","unstructured":"1362) Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG: Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects. J Am Coll Cardiol, 2020; 75: 2553-2566","DOI":"10.1016\/j.jacc.2020.03.057"},{"key":"1363","doi-asserted-by":"crossref","unstructured":"1363) Hu P, Dharmayat KI, Stevens CAT, Sharabiani MTA, Jones RS, Watts GF, Genest J, Ray KK, Vallejo-Vaz AJ: Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis. Circulation, 2020; 141: 1742-1759","DOI":"10.1161\/CIRCULATIONAHA.119.044795"},{"key":"1364","doi-asserted-by":"crossref","unstructured":"1364) Austin MA, Hutter CM, Zimmern RL, Humphries SE: Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol, 2004; 160: 421-429","DOI":"10.1093\/aje\/kwh237"},{"key":"1365","doi-asserted-by":"crossref","unstructured":"1365) Hutter CM, Austin MA, Humphries SE: Familial hypercholesterolemia, peripheral arterial disease, and stroke: a HuGE minireview. Am J Epidemiol, 2004; 160: 430-435","DOI":"10.1093\/aje\/kwh238"},{"key":"1366","doi-asserted-by":"crossref","unstructured":"1366) Akioyamen LE, Tu JV, Genest J, Ko DT, Coutin AJS, Shan SD, Chu A: Risk of Ischemic Stroke and Peripheral Arterial Disease in Heterozygous Familial Hypercholesterolemia: A Meta-Analysis. Angiology, 2019; 70: 726-736","DOI":"10.1177\/0003319719835433"},{"key":"1367","doi-asserted-by":"crossref","unstructured":"1367) Mabuchi H: Half a Century Tales of Familial Hypercholesterolemia (FH) in Japan. J Atheroscler Thromb, 2017; 24: 189-207","DOI":"10.5551\/jat.RV16008"},{"key":"1368","doi-asserted-by":"crossref","unstructured":"1368) Betteridge DJ, Bhatnager D, Bing RF, Durrington PN, Evans GR, Flax H, Jay RH, Lewis-Barned N, Mann J, Matthews DR, et al.: Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine. BMJ, 1992; 304: 1335-1338","DOI":"10.1136\/bmj.304.6838.1335"},{"key":"1369","doi-asserted-by":"crossref","unstructured":"1369) Hoogerbrugge N, Mol MJ, Van Dormaal JJ, Rustemeijer C, Muls E, Stalenhoef AF, Birkenh\u00e4ger JC: The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia. J Intern Med, 1990; 228: 261-266","DOI":"10.1111\/j.1365-2796.1990.tb00229.x"},{"key":"1370","doi-asserted-by":"crossref","unstructured":"1370) Wiklund O, Angelin B, Fager G, Eriksson M, Olofsson SO, Berglund L, Lind\u00e9n T, Sj\u00f6berg A, Bondjers G: Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels. J Intern Med, 1990; 228: 241-247","DOI":"10.1111\/j.1365-2796.1990.tb00225.x"},{"key":"1371","doi-asserted-by":"crossref","unstructured":"1371) Avis HJ, Hutten BA, Gagn\u00e9 C, Langslet G, McCrindle BW, Wiegman A, Hsia J, Kastelein JJ, Stein EA: Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol, 2010; 55: 1121-1126","DOI":"10.1016\/j.jacc.2009.10.042"},{"key":"1372","doi-asserted-by":"crossref","unstructured":"1372) Clauss SB, Holmes KW, Hopkins P, Stein E, Cho M, Tate A, Johnson-Levonas AO, Kwiterovich PO: Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics, 2005; 116: 682-688","DOI":"10.1542\/peds.2004-2090"},{"key":"1373","doi-asserted-by":"crossref","unstructured":"1373) de Jongh S, Ose L, Szamosi T, Gagn\u00e9 C, Lambert M, Scott R, Perron P, Dobbelaere D, Saborio M, Tuohy MB, Stepanavage M, Sapre A, Gumbiner B, Mercuri M, van Trotsenburg AS, Bakker HD, Kastelein JJ: Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation, 2002; 106: 2231-2237","DOI":"10.1161\/01.CIR.0000035247.42888.82"},{"key":"1374","doi-asserted-by":"crossref","unstructured":"1374) Knipscheer HC, Boelen CC, Kastelein JJ, van Diermen DE, Groenemeijer BE, van den Ende A, B\u00fcller HR, Bakker HD: Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res, 1996; 39: 867-871","DOI":"10.1203\/00006450-199605000-00021"},{"key":"1375","doi-asserted-by":"crossref","unstructured":"1375) Stein EA, Illingworth DR, Kwiterovich PO, Jr., Liacouras CA, Siimes MA, Jacobson MS, Brewster TG, Hopkins P, Davidson M, Graham K, Arensman F, Knopp RH, DuJovne C, Williams CL, Isaacsohn JL, Jacobsen CA, Laskarzewski PM, Ames S, Gormley GJ: Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA, 1999; 281: 137-144","DOI":"10.1001\/jama.281.2.137"},{"key":"1376","doi-asserted-by":"crossref","unstructured":"1376) Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, B\u00fcller HR, Sijbrands EJ, Kastelein JJ: Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA, 2004; 292: 331-337","DOI":"10.1001\/jama.292.3.331"},{"key":"1377","doi-asserted-by":"crossref","unstructured":"1377) Stein EA, Dann EJ, Wiegman A, Skovby F, Gaudet D, Sokal E, Charng MJ, Mohamed M, Luirink I, Raichlen JS, Sund\u00e9n M, Carlsson SC, Raal FJ, Kastelein JJP: Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations. J Am Coll Cardiol, 2017; 70: 1162-1170","DOI":"10.1016\/j.jacc.2017.06.058"},{"key":"1378","doi-asserted-by":"crossref","unstructured":"1378) Lambert M, Lupien PJ, Gagn\u00e9 C, L\u00e9vy E, Blaichman S, Langlois S, Hayden M, Rose V, Clarke JT, Wolfe BM, Clarson C, Parsons H, Stephure DK, Potvin D, Lambert J: Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. Pediatrics, 1996; 97: 619-628","DOI":"10.1542\/peds.97.5.619"},{"key":"1379","doi-asserted-by":"crossref","unstructured":"1379) Harada-Shiba M, Arisaka O, Ohtake A, Okada T, Suganami H: Efficacy and Safety of Pitavastatin in Japanese Male Children with Familial Hypercholesterolemia. J Atheroscler Thromb, 2016; 23: 48-55","DOI":"10.5551\/jat.28753"},{"key":"1380","doi-asserted-by":"crossref","unstructured":"1380) Nozue T, Michishita I, Ito Y, Hirano T: Effects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemia. J Atheroscler Thromb, 2008; 15: 146-153","DOI":"10.5551\/jat.E552"},{"key":"1381","doi-asserted-by":"crossref","unstructured":"1381) Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet, 2001; 357: 577-581","DOI":"10.1016\/S0140-6736(00)04053-8"},{"key":"1382","doi-asserted-by":"crossref","unstructured":"1382) Rodenburg J, Vissers MN, Wiegman A, van Trotsenburg AS, van der Graaf A, de Groot E, Wijburg FA, Kastelein JJ, Hutten BA: Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation, 2007; 116: 664-668","DOI":"10.1161\/CIRCULATIONAHA.106.671016"},{"key":"1383","doi-asserted-by":"crossref","unstructured":"1383) Besseling J, Hovingh GK, Huijgen R, Kastelein JJP, Hutten BA: Statins in Familial Hypercholesterolemia: Consequences for Coronary Artery Disease and All-Cause Mortality. J Am Coll Cardiol, 2016; 68: 252-260","DOI":"10.1016\/j.jacc.2016.04.054"},{"key":"1384","doi-asserted-by":"crossref","unstructured":"1384) Jay RH, Sturley RH, Stirling C, McGarrigle HH, Katz M, Reckless JP, Betteridge DJ: Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia. Br J Clin Pharmacol, 1991; 32: 417-422","DOI":"10.1111\/j.1365-2125.1991.tb03924.x"},{"key":"1385","doi-asserted-by":"crossref","unstructured":"1385) Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman SM, Stein EA: Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet, 2015; 385: 341-350","DOI":"10.1016\/S0140-6736(14)61374-X"},{"key":"1386","doi-asserted-by":"crossref","unstructured":"1386) Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med, 2008; 358: 1431-1443","DOI":"10.1056\/NEJMoa0800742"},{"key":"1387","doi-asserted-by":"crossref","unstructured":"1387) Authors\/Task Force Members, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis 2019; 290: 140-205","DOI":"10.1016\/j.atherosclerosis.2019.08.014"},{"key":"1388","doi-asserted-by":"crossref","unstructured":"1388) Wang A, Richhariya A, Gandra SR, Calimlim B, Kim L, Quek RG, Nordyke RJ, Toth PP: Systematic Review of Low-Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia. J Am Heart Assoc, 2016; 5","DOI":"10.1161\/JAHA.116.003294"},{"key":"1389","doi-asserted-by":"crossref","unstructured":"1389) Luirink IK, Determeijer J, Hutten BA, Wiegman A, Bruckert E, Schmitt CP, Groothoff JW: Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review. J Clin Lipidol, 2019; 13: 31-39","DOI":"10.1016\/j.jacl.2018.10.011"},{"key":"1390","doi-asserted-by":"crossref","unstructured":"1390) Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128 Suppl 5: S213-56","DOI":"10.1542\/peds.2009-2107C"},{"key":"1391","doi-asserted-by":"crossref","unstructured":"1391) Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, Drogari E, Ramaswami U: Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev, 2019; 2019","DOI":"10.1002\/14651858.CD006401.pub5"},{"key":"1392","doi-asserted-by":"crossref","unstructured":"1392) Tada H, Hori M, Matsuki K, Ogura M, Nohara A, Kawashiri MA, Harada-Shiba M: Achilles Tendon Thickness Assessed by X-ray Predicting a Pathogenic Mutation in Familial Hypercholesterolemia Gene. J Atheroscler Thromb, 2022; 29: 816-824","DOI":"10.5551\/jat.62869"},{"key":"1393","doi-asserted-by":"crossref","unstructured":"1393) Harada-Shiba M, Ohtake A, Sugiyama D, Tada H, Dobashi K, Matsuki K, Minamino T, Yamashita S, Yamamoto Y: Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022. J Atheroscler Thromb, 2023; 30: 531-557","DOI":"10.5551\/jat.CR006"},{"key":"1394","doi-asserted-by":"crossref","unstructured":"1394) Tada H, Nomura A, Ogura M, Ikewaki K, Ishigaki Y, Inagaki K, Tsukamoto K, Dobashi K, Nakamura K, Hori M, Matsuki K, Yamashita S, Yokoyama S, Kawashiri MA, Harada-Shiba M: Diagnosis and Management of Sitosterolemia 2021. J Atheroscler Thromb, 2021; 28: 791-801","DOI":"10.5551\/jat.RV17052"},{"key":"1395","doi-asserted-by":"crossref","unstructured":"1395) Koyama S, Sekijima Y, Ogura M, Hori M, Matsuki K, Miida T, Harada-Shiba M: Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments. J Atheroscler Thromb, 2021; 28: 905-925","DOI":"10.5551\/jat.RV17055"},{"key":"1396","doi-asserted-by":"crossref","unstructured":"1396) Qian LJ, Gao Y, Zhang YM, Chu M, Yao J, Xu D: Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials. Sci Rep, 2017; 7: 238","DOI":"10.1038\/s41598-017-00316-3"},{"key":"1397","doi-asserted-by":"crossref","unstructured":"1397) Uauy R, Vega GL, Grundy SM, Bilheimer DM: Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentrations or turnover. J Pediatr, 1988; 113: 387-392","DOI":"10.1016\/S0022-3476(88)80289-0"},{"key":"1398","doi-asserted-by":"crossref","unstructured":"1398) Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ: Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation, 2013; 128: 2113-2120","DOI":"10.1161\/CIRCULATIONAHA.113.004678"},{"key":"1399","doi-asserted-by":"crossref","unstructured":"1399) Raal FJ, Pilcher GJ, Panz VR, van Deventer HE, Brice BC, Blom DJ, Marais AD: Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation, 2011; 124: 2202-2207","DOI":"10.1161\/CIRCULATIONAHA.111.042523"},{"key":"1400","doi-asserted-by":"crossref","unstructured":"1400) Yamamoto A, Matsuzawa Y, Yokoyama S, Funahashi T, Yamamura T, Kishino B: Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol, 1986; 57: 29h-35h","DOI":"10.1016\/0002-9149(86)90434-0"},{"key":"1401","doi-asserted-by":"crossref","unstructured":"1401) Shirahata Y, Ohkohchi N, Kawagishi N, Syouji M, Tsukamoto S, Sekiguchi S, Koyamada N, Oikawa S, Satomi S: Living-donor liver transplantation for homozygous familial hypercholesterolemia from a donor with heterozygous hypercholesterolemia. Transpl Int, 2003; 16: 276-279","DOI":"10.1111\/j.1432-2277.2003.tb00299.x"},{"key":"1402","doi-asserted-by":"crossref","unstructured":"1402) Kawagishi N, Satoh K, Akamatsu Y, Sekiguchi S, Ishigaki Y, Oikawa S, Satomi S: Long-term outcome after living donor liver transplantation for two cases of homozygous familial hypercholesterolemia from a heterozygous donor. J Atheroscler Thromb, 2007; 14: 94-98","DOI":"10.5551\/jat.14.94"},{"key":"1403","doi-asserted-by":"crossref","unstructured":"1403) Bujo H, Takahashi K, Saito Y, Maruyama T, Yamashita S, Matsuzawa Y, Ishibashi S, Shionoiri F, Yamada N, Kita T: Clinical features of familial hypercholesterolemia in Japan in a database from 1996-1998 by the research committee of the ministry of health, labour and welfare of Japan. J Atheroscler Thromb, 2004; 11: 146-151","DOI":"10.5551\/jat.11.146"},{"key":"1404","doi-asserted-by":"crossref","unstructured":"1404) Maruyama T, Yamashita S, Matsuzawa Y, Bujo H, Takahashi K, Saito Y, Ishibashi S, Ohashi K, Shionoiri F, Gotoda T, Yamada N, Kita T: Mutations in Japanese subjects with primary hyperlipidemia--results from the Research Committee of the Ministry of Health and Welfare of Japan since 1996. J Atheroscler Thromb, 2004; 11: 131-145","DOI":"10.5551\/jat.11.131"},{"key":"1405","doi-asserted-by":"crossref","unstructured":"1405) Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG: Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest, 1973; 52: 1544-1568","DOI":"10.1172\/JCI107332"},{"key":"1406","doi-asserted-by":"crossref","unstructured":"1406) Brahm AJ, Hegele RA: Combined hyperlipidemia: familial but not (usually) monogenic. Curr Opin Lipidol, 2016; 27: 131-140","DOI":"10.1097\/MOL.0000000000000270"},{"key":"1407","doi-asserted-by":"crossref","unstructured":"1407) Gill PK, Dron JS, Berberich AJ, Wang J, McIntyre AD, Cao H, Hegele RA: Combined hyperlipidemia is genetically similar to isolated hypertriglyceridemia. J Clin Lipidol, 2021; 15: 79-87","DOI":"10.1016\/j.jacl.2020.11.006"},{"key":"1408","doi-asserted-by":"crossref","unstructured":"1408) Iwata F, Okada T, Kuromori Y, Hara M, Harada K: Screening for familial combined hyperlipidemia in children using lipid phenotypes. J Atheroscler Thromb, 2003; 10: 299-303","DOI":"10.5551\/jat.10.299"},{"key":"1409","doi-asserted-by":"crossref","unstructured":"1409) Austin MA, McKnight B, Edwards KL, Bradley CM, McNeely MJ, Psaty BM, Brunzell JD, Motulsky AG: Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. Circulation, 2000; 101: 2777-2782","DOI":"10.1161\/01.CIR.101.24.2777"},{"key":"1410","doi-asserted-by":"crossref","unstructured":"1410) Pitsavos C, Skoumas I, Masoura C, Aznaouridis K, Papadimitriou L, Chrysohoou C, Giotsas N, Toutouza M, Stefanadis C: Prevalence and determinants of coronary artery disease in males and females with familial combined hyperlipidaemia. Atherosclerosis, 2008; 199: 402-407","DOI":"10.1016\/j.atherosclerosis.2007.11.021"},{"key":"1411","unstructured":"1411) Mabuchi H, Koizumi J: Serum lipids and coronary atherosclerosis in familial combined hyperlipidemia diagnosed definitively by family survey, Ministry of Health and Welfare Primary Hyperlipidemia Research Group for Specific Diseases, 1998. (in Japanese)"},{"key":"1412","doi-asserted-by":"crossref","unstructured":"1412) Mahley RW, Huang Y, Rall SC, Jr.: Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res, 1999; 40: 1933-1949","DOI":"10.1016\/S0022-2275(20)32417-2"},{"key":"1413","doi-asserted-by":"crossref","unstructured":"1413) Hopkins PN, Brinton EA, Nanjee MN: Hyperlipoproteinemia type 3: the forgotten phenotype. Curr Atheroscler Rep, 2014; 16: 440","DOI":"10.1007\/s11883-014-0440-2"},{"key":"1414","unstructured":"1414) LaRosa JC, Chambless LE, Criqui MH, Frantz ID, Glueck CJ, Heiss G, Morrison JA: Patterns of dyslipoproteinemia in selected North American populations. The Lipid Research Clinics Program Prevalence Study. Circulation, 1986; 73: I12-29"},{"key":"1415","doi-asserted-by":"crossref","unstructured":"1415) Hopkins PN, Nanjee MN, Wu LL, McGinty MG, Brinton EA, Hunt SC, Anderson JL: Altered composition of triglyceride-rich lipoproteins and coronary artery disease in a large case-control study. Atherosclerosis, 2009; 207: 559-566","DOI":"10.1016\/j.atherosclerosis.2009.05.016"},{"key":"1416","doi-asserted-by":"crossref","unstructured":"1416) Eto M, Saito M, Nakata H, Iwashima Y, Watanabe K, Ikoda A, Kaku K: Type III hyperlipoproteinema with apolipoprotein E2\/2 genotype in Japan. Clin Genet, 2002; 61: 416-422","DOI":"10.1034\/j.1399-0004.2002.610604.x"},{"key":"1417","unstructured":"1417) Yamamura T: Familial type III hyperlipidemia. Nihon Naika Gakkai Zasshi, 1992 (in Japanese)"},{"key":"1418","doi-asserted-by":"crossref","unstructured":"1418) Sniderman A, Tremblay A, Bergeron J, Gagn\u00e9 C, Couture P: Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B. J Clin Lipidol, 2007; 1: 256-263","DOI":"10.1016\/j.jacl.2007.07.006"},{"key":"1419","doi-asserted-by":"crossref","unstructured":"1419) Murase T, Okubo M, Takeuchi I: Non-HDL-cholesterol\/apolipoprotein B ratio: a useful distinguishing feature in the screening for type III hyperlipoproteinemia. J Clin Lipidol, 2010; 4: 99-104","DOI":"10.1016\/j.jacl.2010.01.004"},{"key":"1420","doi-asserted-by":"crossref","unstructured":"1420) Yuasa-Kawase M, Masuda D, Kitazume-Taneike R, Yamashita T, Kawase R, Nakaoka H, Inagaki M, Nakatani K, Tsubakio-Yamamoto K, Ohama T, Toyama-Nakagawa Y, Nishida M, Ishigami M, Saito M, Eto M, Matsuyama A, Komuro I, Yamashita S: Apolipoprotein B-48 to triglyceride ratio is a novel and useful marker for detection of type III hyperlipidemia after antihyperlipidemic intervention. J Atheroscler Thromb, 2012; 19: 862-871","DOI":"10.5551\/jat.13052"},{"key":"1421","doi-asserted-by":"crossref","unstructured":"1421) Ossoli A, Simonelli S, Vitali C, Franceschini G, Calabresi L: Role of LCAT in Atherosclerosis. J Atheroscler Thromb, 2016; 23: 119-127","DOI":"10.5551\/jat.32854"},{"key":"1422","doi-asserted-by":"crossref","unstructured":"1422) Tietjen I, Hovingh GK, Singaraja R, Radomski C, McEwen J, Chan E, Mattice M, Legendre A, Kastelein JJ, Hayden MR: Increased risk of coronary artery disease in Caucasians with extremely low HDL cholesterol due to mutations in ABCA1, APOA1, and LCAT. Biochim Biophys Acta, 2012; 1821: 416-424","DOI":"10.1016\/j.bbalip.2011.08.006"},{"key":"1423","doi-asserted-by":"crossref","unstructured":"1423) Muratsu J, Koseki M, Masuda D, Yasuga Y, Tomoyama S, Ataka K, Yagi Y, Nakagawa A, Hamada H, Fujita S, Hattori H, Ohama T, Nishida M, Hiraoka H, Matsuzawa Y, Yamashita S: Accelerated Atherogenicity in Tangier Disease. J Atheroscler Thromb, 2018; 25: 1076-1085","DOI":"10.5551\/jat.43257"},{"key":"1424","doi-asserted-by":"crossref","unstructured":"1424) Zanoni P, von Eckardstein A: Inborn errors of apolipoprotein A-I metabolism: implications for disease, research and development. Curr Opin Lipidol, 2020; 31: 62-70","DOI":"10.1097\/MOL.0000000000000667"},{"key":"1425","doi-asserted-by":"crossref","unstructured":"1425) Vodnala D, Rubenfire M, Brook RD: Secondary causes of dyslipidemia. Am J Cardiol, 2012; 110: 823-825","DOI":"10.1016\/j.amjcard.2012.04.062"},{"key":"1426","doi-asserted-by":"crossref","unstructured":"1426) Yanai H, Yoshida H: Secondary dyslipidemia: its treatments and association with atherosclerosis. Glob Health Med, 2021; 3: 15-23","DOI":"10.35772\/ghm.2020.01078"},{"key":"1427","unstructured":"1427) Rader D, Hobbs H: Disorders of lipoprotein metabolism, 2015"},{"key":"1428","doi-asserted-by":"crossref","unstructured":"1428) Rodondi N, Aujesky D, Vittinghoff E, Cornuz J, Bauer DC: Subclinical hypothyroidism and the risk of coronary heart disease: a meta-analysis. Am J Med, 2006; 119: 541-551","DOI":"10.1016\/j.amjmed.2005.09.028"},{"key":"1429","doi-asserted-by":"crossref","unstructured":"1429) Pearce EN: Hypothyroidism and dyslipidemia: modern concepts and approaches. Curr Cardiol Rep, 2004; 6: 451-456","DOI":"10.1007\/s11886-004-0054-3"},{"key":"1430","doi-asserted-by":"crossref","unstructured":"1430) Duntas LH, Brenta G: Thyroid hormones: a potential ally to LDL-cholesterol-lowering agents. Hormones (Athens), 2016; 15: 500-510","DOI":"10.14310\/horm.2002.1707"},{"key":"1431","doi-asserted-by":"crossref","unstructured":"1431) Gao N, Zhang W, Zhang YZ, Yang Q, Chen SH: Carotid intima-media thickness in patients with subclinical hypothyroidism: a meta-analysis. Atherosclerosis, 2013; 227: 18-25","DOI":"10.1016\/j.atherosclerosis.2012.10.070"},{"key":"1432","doi-asserted-by":"crossref","unstructured":"1432) Li X, Wang Y, Guan Q, Zhao J, Gao L: The lipid-lowering effect of levothyroxine in patients with subclinical hypothyroidism: A systematic review and meta-analysis of randomized controlled trials. Clin Endocrinol (Oxf), 2017; 87: 1-9","DOI":"10.1111\/cen.13338"},{"key":"1433","doi-asserted-by":"crossref","unstructured":"1433) Aziz M, Kandimalla Y, Machavarapu A, Saxena A, Das S, Younus A, Nguyen M, Malik R, Anugula D, Latif MA, Humayun C, Khan IM, Adus A, Rasool A, Veledar E, Nasir K: Effect of Thyroxin Treatment on Carotid Intima-Media Thickness (CIMT) Reduction in Patients with Subclinical Hypothyroidism (SCH): a Meta-Analysis of Clinical Trials. J Atheroscler Thromb, 2017; 24: 643-659","DOI":"10.5551\/jat.39917"},{"key":"1434","doi-asserted-by":"crossref","unstructured":"1434) Zhao T, Chen B, Zhou Y, Wang X, Zhang Y, Wang H, Shan Z: Effect of levothyroxine on the progression of carotid intima-media thickness in subclinical hypothyroidism patients: a meta-analysis. BMJ Open, 2017; 7: e016053","DOI":"10.1136\/bmjopen-2017-016053"},{"key":"1435","doi-asserted-by":"crossref","unstructured":"1435) Andersen MN, Olsen AS, Madsen JC, Kristensen SL, Faber J, Torp-Pedersen C, Gislason GH, Selmer C: Long-Term Outcome in Levothyroxine Treated Patients With Subclinical Hypothyroidism and Concomitant Heart Disease. J Clin Endocrinol Metab, 2016; 101: 4170-4177","DOI":"10.1210\/jc.2016-2226"},{"key":"1436","unstructured":"1436) Ramkumar S, Raghunath A, Raghunath S: Statin Therapy: Review of Safety and Potential Side Effects. Acta Cardiol Sin, 2016; 32: 631-639"},{"key":"1437","doi-asserted-by":"crossref","unstructured":"1437) Wheeler DC, Bernard DB: Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am J Kidney Dis, 1994; 23: 331-346","DOI":"10.1016\/S0272-6386(12)80994-2"},{"key":"1438","doi-asserted-by":"crossref","unstructured":"1438) Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE: Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol, 2018; 14: 57-70","DOI":"10.1038\/nrneph.2017.155"},{"key":"1439","doi-asserted-by":"crossref","unstructured":"1439) Shen H, Feng S, Lu Y, Jiang L, Yang T, Wang Z: Correlation between plasma proprotein convertase subtilisin\/kexin type 9 and blood lipids in patients with newly diagnosed primary nephrotic syndrome. Ren Fail, 2020; 42: 405-412","DOI":"10.1080\/0886022X.2020.1756846"},{"key":"1440","doi-asserted-by":"crossref","unstructured":"1440) Ordo\u00f1ez JD, Hiatt RA, Killebrew EJ, Fireman BH: The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int, 1993; 44: 638-642","DOI":"10.1038\/ki.1993.292"},{"key":"1441","doi-asserted-by":"crossref","unstructured":"1441) D&apos;Amico G, Gentile MG, Manna G, Fellin G, Ciceri R, Cofano F, Petrini C, Lavarda F, Perolini S, Porrini M: Effect of vegetarian soy diet on hyperlipidaemia in nephrotic syndrome. Lancet, 1992; 339: 1131-1134","DOI":"10.1016\/0140-6736(92)90731-H"},{"key":"1442","unstructured":"1442) Gentile MG, Fellin G, Cofano F, Delle Fave A, Manna G, Ciceri R, Petrini C, Lavarda F, Pozzi F, D&apos;Amico G: Treatment of proteinuric patients with a vegetarian soy diet and fish oil. Clin Nephrol, 1993; 40: 315-320"},{"key":"1443","doi-asserted-by":"crossref","unstructured":"1443) Bell S, Cooney J, Packard CJ, Caslake MJ, Deighan CJ: The effect of omega-3 fatty acids on the atherogenic lipoprotein phenotype in patients with nephrotic range proteinuria. Clin Nephrol, 2012; 77: 445-453","DOI":"10.5414\/CN107450"},{"key":"1444","doi-asserted-by":"crossref","unstructured":"1444) Yanai H: Hyperlipidemia due to Nephrotic Syndrome: Its Effects and Effects of Interventions on Atherogenesis, Cardiovascular and Renal Outcomes. J Endocrinol Metab, 2020; 10: 63-73","DOI":"10.14740\/jem663"},{"key":"1445","doi-asserted-by":"crossref","unstructured":"1445) Zheng-Lin B, Ortiz A: Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. Drugs, 2018; 78: 215-229","DOI":"10.1007\/s40265-017-0858-2"},{"key":"1446","doi-asserted-by":"crossref","unstructured":"1446) Sjuls S, Jensen U, Littmann K, Bruchfeld A, Brinck J: Effective cholesterol lowering after myocardial infarction in patients with nephrotic syndrome may require a multi-pharmacological approach: a case report. Eur Heart J Case Rep, 2021; 5: ytab151","DOI":"10.1093\/ehjcr\/ytab151"},{"key":"1447","doi-asserted-by":"crossref","unstructured":"1447) Jatem E, Lima J, Montoro B, Torres-Bondia F, Segarra A: Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic Syndrome. Kidney Int Rep, 2021; 6: 101-109","DOI":"10.1016\/j.ekir.2020.09.046"},{"key":"1448","doi-asserted-by":"crossref","unstructured":"1448) Kong X, Yuan H, Fan J, Li Z, Wu T, Jiang L: Lipid-lowering agents for nephrotic syndrome. Cochrane Database Syst Rev, 2013: Cd005425","DOI":"10.1002\/14651858.CD005425.pub2"},{"key":"1449","doi-asserted-by":"crossref","unstructured":"1449) Alawami M, Wimalasena S, Ghashi R, Alnasrallah B: Acute arterial cardiovascular events risk in patients with primary membranous nephropathy. Intern Med J, 2019; 49: 855-858","DOI":"10.1111\/imj.14146"},{"key":"1450","doi-asserted-by":"crossref","unstructured":"1450) Xu H, Carrero JJ: Insulin resistance in chronic kidney disease. Nephrology (Carlton), 2017; 22 Suppl 4: 31-34","DOI":"10.1111\/nep.13147"},{"key":"1451","doi-asserted-by":"crossref","unstructured":"1451) Eto M, Saito M, Okada M, Kume Y, Kawasaki F, Matsuda M, Yoneda M, Matsuki M, Takigami S, Kaku K: Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients. Am J Kidney Dis, 2002; 40: 243-251","DOI":"10.1053\/ajkd.2002.34502"},{"key":"1452","doi-asserted-by":"crossref","unstructured":"1452) Rosenblit PD: Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition. Curr Diab Rep, 2019; 19: 61","DOI":"10.1007\/s11892-019-1178-6"},{"key":"1453","doi-asserted-by":"crossref","unstructured":"1453) Sorokin A, Brown JL, Thompson PD: Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis, 2007; 194: 293-299","DOI":"10.1016\/j.atherosclerosis.2006.11.036"},{"key":"1454","doi-asserted-by":"crossref","unstructured":"1454) Van Dam GM, Gips CH: Primary biliary cirrhosis in The Netherlands. An analysis of associated diseases, cardiovascular risk, and malignancies on the basis of mortality figures. Scand J Gastroenterol, 1997; 32: 77-83","DOI":"10.3109\/00365529709025067"},{"key":"1455","unstructured":"1455) Wang C, Zhao P, Liu W: Risk of incident coronary artery disease in patients with primary biliary cirrhosis. Int J Clin Exp Med, 2014; 7: 2921-2924"},{"key":"1456","doi-asserted-by":"crossref","unstructured":"1456) Miller JP: Dyslipoproteinaemia of liver disease. Baillieres Clin Endocrinol Metab, 1990; 4: 807-832","DOI":"10.1016\/S0950-351X(05)80080-1"},{"key":"1457","doi-asserted-by":"crossref","unstructured":"1457) Yanai H, Hirowatari Y, Yoshida H: Diabetic dyslipidemia: evaluation and mechanism. Glob Health Med, 2019; 1: 30-35","DOI":"10.35772\/ghm.2019.01007"},{"key":"1458","doi-asserted-by":"crossref","unstructured":"1458) Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, Colao A: Complications of Cushing&apos;s syndrome: state of the art. Lancet Diabetes Endocrinol, 2016; 4: 611-629","DOI":"10.1016\/S2213-8587(16)00086-3"},{"key":"1459","doi-asserted-by":"crossref","unstructured":"1459) Lupoli R, Ambrosino P, Tortora A, Barba L, Lupoli GA, Di Minno MN: Markers of atherosclerosis in patients with Cushing&apos;s syndrome: a meta-analysis of literature studies. Ann Med, 2017; 49: 206-216","DOI":"10.1080\/07853890.2016.1252055"},{"key":"1460","doi-asserted-by":"crossref","unstructured":"1460) Rofougaran R, Mooraki A, Bastani B: Insulin-requiring diabetes mellitus, hyperlipidemia, and anginal chest pains as prominent features of pheochromocytoma. Am J Nephrol, 1997; 17: 474-476","DOI":"10.1159\/000169145"},{"key":"1461","doi-asserted-by":"crossref","unstructured":"1461) Winocour PH, Masud T, Clark F, Cooper BG, Laker MF, Alberti KG: Lipid and lipoprotein metabolism in familial combined hyperlipidaemia during treatment of sporadic phaeochromocytoma: a case study. Postgrad Med J, 1992; 68: 371-375","DOI":"10.1136\/pgmj.68.799.371"},{"key":"1462","doi-asserted-by":"crossref","unstructured":"1462) Yamamoto M, Hosokawa T, Suehiro T, Numata S, Yamano T, Ono F: [A case of pheochromocytoma with hyper-HDL-cholesterolemia]. Nihon Naika Gakkai Zasshi, 1991; 80: 1678-1679","DOI":"10.2169\/naika.80.1678"},{"key":"1463","doi-asserted-by":"crossref","unstructured":"1463) Ueda S, Morimoto T, Ando S, Takishita S, Kawano Y, Shimamoto K, Ogihara T, Saruta T: A randomised controlled trial for the evaluation of risk for type 2 diabetes in hypertensive patients receiving thiazide diuretics: Diuretics In the Management of Essential hypertension (DIME) study. BMJ Open, 2014; 4: e004576","DOI":"10.1136\/bmjopen-2013-004576"},{"key":"1464","doi-asserted-by":"crossref","unstructured":"1464) Carlsen JE, K\u00f8ber L, Torp-Pedersen C, Johansen P: Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ, 1990; 300: 975-978","DOI":"10.1136\/bmj.300.6730.975"},{"key":"1465","unstructured":"1465) Basdevant A: Steroids and lipid metabolism: mechanism of action. Int J Fertil, 1992; 37 Suppl 2: 93-97"},{"key":"1466","doi-asserted-by":"crossref","unstructured":"1466) Lobo RA: Cardiovascular implications of estrogen replacement therapy. Obstet Gynecol, 1990; 75: 18S-25S; discussion 31S-35S","DOI":"10.1097\/00006250-199004001-00005"},{"key":"1467","doi-asserted-by":"crossref","unstructured":"1467) Arca M, Vega GL, Grundy SM: Hypercholesterolemia in postmenopausal women. Metabolic defects and response to low-dose lovastatin. JAMA, 1994; 271: 453-459","DOI":"10.1001\/jama.271.6.453"},{"key":"1468","doi-asserted-by":"crossref","unstructured":"1468) Donahoo WT, Kosmiski LA, Eckel RH: Drugs causing dyslipoproteinemia. Endocrinol Metab Clin North Am, 1998; 27: 677-697","DOI":"10.1016\/S0889-8529(05)70033-5"},{"key":"1469","doi-asserted-by":"crossref","unstructured":"1469) McDiarmid SV, Gornbein JA, Fortunat M, Saikali D, Vargas JH, Busuttil RW, Ament ME: Serum lipid abnormalities in pediatric liver transplant patients. Transplantation, 1992; 53: 109-115","DOI":"10.1097\/00007890-199201000-00021"},{"key":"1470","doi-asserted-by":"crossref","unstructured":"1470) Seymen P, Yildiz M, T\u00fcrkmen MF, Titiz MI, Seymen HO: Effects of cyclosporine-tacrolimus switching in posttransplantation hyperlipidemia on high-density lipoprotein 2\/3, lipoprotein a1\/b, and other lipid parameters. Transplant Proc, 2009; 41: 4181-4183","DOI":"10.1016\/j.transproceed.2009.09.069"},{"key":"1471","unstructured":"1471) Friis-M\u00f8ller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, Thi\u00e9baut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD: Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med, 2007; 356: 1723-1735"},{"key":"1472","doi-asserted-by":"crossref","unstructured":"1472) Ergin HE, Inga EE, Maung TZ, Javed M, Khan S: HIV, Antiretroviral Therapy and Metabolic Alterations: A Review. Cureus, 2020; 12: e8059","DOI":"10.7759\/cureus.8059"},{"key":"1473","doi-asserted-by":"crossref","unstructured":"1473) Lagathu C, B\u00e9r\u00e9ziat V, Gorwood J, Fellahi S, Bastard JP, Vigouroux C, Boccara F, Capeau J: Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment. Expert Opin Drug Saf, 2019; 18: 829-840","DOI":"10.1080\/14740338.2019.1644317"},{"key":"1474","doi-asserted-by":"crossref","unstructured":"1474) Maggi P, Di Biagio A, Rusconi S, Cicalini S, D&apos;Abbraccio M, d&apos;Ettorre G, Martinelli C, Nunnari G, Sighinolfi L, Spagnuolo V, Squillace N: Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis, 2017; 17: 551","DOI":"10.1186\/s12879-017-2626-z"},{"key":"1475","doi-asserted-by":"crossref","unstructured":"1475) Gon\u00e7alves P, Ara\u00fajo JR, Martel F: Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms. Eur Neuropsychopharmacol, 2015; 25: 1-16","DOI":"10.1016\/j.euroneuro.2014.11.008"},{"key":"1476","doi-asserted-by":"crossref","unstructured":"1476) Kang SH, Lee JI: Metabolic disturbances independent of body mass in patients with schizophrenia taking atypical antipsychotics. Psychiatry Investig, 2015; 12: 242-248","DOI":"10.4306\/pi.2015.12.2.242"},{"key":"1477","doi-asserted-by":"crossref","unstructured":"1477) Bershad S, Rubinstein A, Paterniti JR, Le NA, Poliak SC, Heller B, Ginsberg HN, Fleischmajer R, Brown WV: Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med, 1985; 313: 981-985","DOI":"10.1056\/NEJM198510173131604"},{"key":"1478","doi-asserted-by":"crossref","unstructured":"1478) Shenoy C, Shenoy MM, Rao GK: Dyslipidemia in Dermatological Disorders. N Am J Med Sci, 2015; 7: 421-428","DOI":"10.4103\/1947-2714.168657"},{"key":"1479","doi-asserted-by":"crossref","unstructured":"1479) Imhof A, Koenig W: Alcohol inflammation and coronary heart disease. Addict Biol, 2003; 8: 271-277","DOI":"10.1080\/13556210310001602176"},{"key":"1480","doi-asserted-by":"crossref","unstructured":"1480) Gonz\u00e1lez-Reimers E, Santolaria-Fern\u00e1ndez F, Mart\u00edn-Gonz\u00e1lez MC, Fern\u00e1ndez-Rodr\u00edguez CM, Quintero-Platt G: Alcoholism: a systemic proinflammatory condition. World J Gastroenterol, 2014; 20: 14660-14671","DOI":"10.3748\/wjg.v20.i40.14660"},{"key":"1481","doi-asserted-by":"crossref","unstructured":"1481) Quintana HK, Janszky I, Kanar A, Gigante B, Druid H, Ahlbom A, de Faire U, Hallqvist J, Leander K: Comorbidities in relation to fatality of first myocardial infarction. Cardiovasc Pathol, 2018; 32: 32-37","DOI":"10.1016\/j.carpath.2017.11.002"},{"key":"1482","doi-asserted-by":"crossref","unstructured":"1482) Allen CL, Bayraktutan U: Risk factors for ischaemic stroke. Int J Stroke, 2008; 3: 105-116","DOI":"10.1111\/j.1747-4949.2008.00187.x"},{"key":"1483","doi-asserted-by":"crossref","unstructured":"1483) Arai H, Mortaki K, Rane P, Quinn C, Zhao Z, Qian Y: Estimating Years of Life Lost Due to Cardiovascular Disease in Japan. Circ J, 2019; 83: 1006-1010","DOI":"10.1253\/circj.CJ-18-1216"},{"key":"1484","doi-asserted-by":"crossref","unstructured":"1484) Uchikado Y, Ikeda Y, Ohishi M: Current Understanding of the Role of Frailty in Cardiovascular Disease. Circ J, 2020; 84: 1903-1908","DOI":"10.1253\/circj.CJ-20-0594"},{"key":"1485","doi-asserted-by":"crossref","unstructured":"1485) Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA: Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci, 2001; 56: M146-156","DOI":"10.1093\/gerona\/56.3.M146"},{"key":"1486","doi-asserted-by":"crossref","unstructured":"1486) Satake S, Arai H: The revised Japanese version of the Cardiovascular Health Study criteria (revised J-CHS criteria). Geriatr Gerontol Int, 2020; 20: 992-993","DOI":"10.1111\/ggi.14005"},{"key":"1487","doi-asserted-by":"crossref","unstructured":"1487) Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, Jang HC, Kang L, Kim M, Kim S, Kojima T, Kuzuya M, Lee JSW, Lee SY, Lee WJ, Lee Y, Liang CK, Lim JY, Lim WS, Peng LN, Sugimoto K, Tanaka T, Won CW, Yamada M, Zhang T, Akishita M, Arai H: Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc, 2020; 21: 300-307.e302","DOI":"10.1016\/j.jamda.2019.12.012"},{"key":"1488","doi-asserted-by":"crossref","unstructured":"1488) Akishita M, Kozaki K, Iijima K, Tanaka T, Shibasaki K, Ogawa S, Arai H: Chapter 1 Definitions and diagnosis of sarcopenia. Geriatr Gerontol Int, 2018; 18 Suppl 1: 7-12","DOI":"10.1111\/ggi.13311"},{"key":"1489","doi-asserted-by":"crossref","unstructured":"1489) Woods NF, LaCroix AZ, Gray SL, Aragaki A, Cochrane BB, Brunner RL, Masaki K, Murray A, Newman AB: Frailty: emergence and consequences in women aged 65 and older in the Women&apos;s Health Initiative Observational Study. J Am Geriatr Soc, 2005; 53: 1321-1330","DOI":"10.1111\/j.1532-5415.2005.53405.x"},{"key":"1490","doi-asserted-by":"crossref","unstructured":"1490) Newman AB, Simonsick EM, Naydeck BL, Boudreau RM, Kritchevsky SB, Nevitt MC, Pahor M, Satterfield S, Brach JS, Studenski SA, Harris TB: Association of long-distance corridor walk performance with mortality, cardiovascular disease, mobility limitation, and disability. JAMA, 2006; 295: 2018-2026","DOI":"10.1001\/jama.295.17.2018"},{"key":"1491","doi-asserted-by":"crossref","unstructured":"1491) Sergi G, Veronese N, Fontana L, De Rui M, Bolzetta F, Zambon S, Corti MC, Baggio G, Toffanello ED, Crepaldi G, Perissinotto E, Manzato E: Pre-frailty and risk of cardiovascular disease in elderly men and women: the Pro.V.A. study. J Am Coll Cardiol, 2015; 65: 976-983","DOI":"10.1016\/j.jacc.2014.12.040"},{"key":"1492","doi-asserted-by":"crossref","unstructured":"1492) F\u00fclster S, Tacke M, Sandek A, Ebner N, Tsch\u00f6pe C, Doehner W, Anker SD, von Haehling S: Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J, 2013; 34: 512-519","DOI":"10.1093\/eurheartj\/ehs381"},{"key":"1493","doi-asserted-by":"crossref","unstructured":"1493) Cacoub PP, Abola MT, Baumgartner I, Bhatt DL, Creager MA, Liau CS, Goto S, R\u00f6ther J, Steg PG, Hirsch AT: Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Atherosclerosis, 2009; 204: e86-92","DOI":"10.1016\/j.atherosclerosis.2008.10.023"},{"key":"1494","unstructured":"1494) Setacci C, de Donato G, Setacci F, Chisci E: Diabetic patients: epidemiology and global impact. J Cardiovasc Surg (Torino), 2009; 50: 263-273"},{"key":"1495","doi-asserted-by":"crossref","unstructured":"1495) Lin CH, Chou CY, Liu CS, Huang CY, Li TC, Lin CC: Association between frailty and subclinical peripheral vascular disease in a community-dwelling geriatric population: Taichung Community Health Study for Elders. Geriatr Gerontol Int, 2015; 15: 261-267","DOI":"10.1111\/ggi.12265"},{"key":"1496","doi-asserted-by":"crossref","unstructured":"1496) Fang ZB, Hu FY, Arya S, Gillespie TW, Rajani RR: Preoperative frailty is predictive of complications after major lower extremity amputation. J Vasc Surg, 2017; 65: 804-811","DOI":"10.1016\/j.jvs.2016.10.102"},{"key":"1497","doi-asserted-by":"crossref","unstructured":"1497) Ali TZ, Lehman EB, Aziz F: Modified Frailty Index Can Be Used to Predict Adverse Outcomes and Mortality after Lower Extremity Bypass Surgery. Ann Vasc Surg, 2018; 46: 168-177","DOI":"10.1016\/j.avsg.2017.07.007"},{"key":"1498","unstructured":"1498) Ministry of Health, Labour and Welfare: Vital Statistics in Japan, 2018, https: \/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/jinkou\/geppo\/nengai18\/dl\/gaikyou30-190626.pdf, 2019 (in Japanese)"},{"key":"1499","doi-asserted-by":"crossref","unstructured":"1499) Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A: Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation, 1994; 90: 583-612","DOI":"10.1161\/01.CIR.90.1.583"},{"key":"1500","doi-asserted-by":"crossref","unstructured":"1500) Ueshima H: Explanation for the Japanese paradox: prevention of increase in coronary heart disease and reduction in stroke. J Atheroscler Thromb, 2007; 14: 278-286","DOI":"10.5551\/jat.E529"},{"key":"1501","doi-asserted-by":"crossref","unstructured":"1501) Fukiyama K, Kimura Y, Wakugami K, Muratani H: Incidence and long-term prognosis of initial stroke and acute myocardial infarction in Okinawa, Japan. Hypertens Res, 2000; 23: 127-135","DOI":"10.1291\/hypres.23.127"},{"key":"1502","doi-asserted-by":"crossref","unstructured":"1502) Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, Nakamura H, Okubo K, Iida M: Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke, 2003; 34: 2349-2354","DOI":"10.1161\/01.STR.0000090348.52943.A2"},{"key":"1503","doi-asserted-by":"crossref","unstructured":"1503) Kudenchuk PJ, Maynard C, Martin JS, Wirkus M, Weaver WD: Comparison of presentation, treatment, and outcome of acute myocardial infarction in men versus women (the Myocardial Infarction Triage and Intervention Registry). Am J Cardiol, 1996; 78: 9-14","DOI":"10.1016\/S0002-9149(96)00218-4"},{"key":"1504","doi-asserted-by":"crossref","unstructured":"1504) Chandra NC, Ziegelstein RC, Rogers WJ, Tiefenbrunn AJ, Gore JM, French WJ, Rubison M: Observations of the treatment of women in the United States with myocardial infarction: a report from the National Registry of Myocardial Infarction-I. Arch Intern Med, 1998; 158: 981-988","DOI":"10.1001\/archinte.158.9.981"},{"key":"1505","doi-asserted-by":"crossref","unstructured":"1505) Vakili BA, Kaplan RC, Brown DL: Sex-based differences in early mortality of patients undergoing primary angioplasty for first acute myocardial infarction. Circulation, 2001; 104: 3034-3038","DOI":"10.1161\/hc5001.101060"},{"key":"1506","unstructured":"1506) Marso SP, Gowda M, O&apos;Keefe JH, Coen MM, McCallister BD, Giorgi LV, Huber KC, Laster SB, Johnson WL, Rutherford BD: Improving in-hospital mortality in the setting of an increasing risk profile among patients undergoing catheter-based reperfusion for an acute myocardial infarction without cardiogenic shock. J Invasive Cardiol, 2003; 15: 711-716"},{"key":"1507","doi-asserted-by":"crossref","unstructured":"1507) Kimura Y, Takishita S, Muratani H, Kinjo K, Shinzato Y, Muratani A, Fukiyama K: Demographic study of first-ever stroke and acute myocardial infarction in Okinawa, Japan. Intern Med, 1998; 37: 736-745","DOI":"10.2169\/internalmedicine.37.736"},{"key":"1508","doi-asserted-by":"crossref","unstructured":"1508) Kosuge M, Kimura K, Kojima S, Sakamoto T, Ishihara M, Asada Y, Tei C, Miyazaki S, Sonoda M, Tsuchihashi K, Yamagishi M, Ikeda Y, Shirai M, Hiraoka H, Inoue T, Saito F, Ogawa H: Sex differences in early mortality of patients undergoing primary stenting for acute myocardial infarction. Circ J, 2006; 70: 217-221","DOI":"10.1253\/circj.70.217"},{"key":"1509","doi-asserted-by":"crossref","unstructured":"1509) Turin TC, Kita Y, Rumana N, Nakamura Y, Takashima N, Ichikawa M, Sugihara H, Morita Y, Hirose K, Okayama A, Miura K, Ueshima H: Ischemic stroke subtypes in a Japanese population: Takashima Stroke Registry, 1988-2004. Stroke, 2010; 41: 1871-1876","DOI":"10.1161\/STROKEAHA.110.581033"},{"key":"1510","doi-asserted-by":"crossref","unstructured":"1510) Kita Y, Turin TC, Ichikawa M, Sugihara H, Morita Y, Tomioka N, Rumana N, Okayama A, Nakamura Y, Abbott RD, Ueshima H: Trend of stroke incidence in a Japanese population: Takashima stroke registry, 1990-2001. Int J Stroke, 2009; 4: 241-249","DOI":"10.1111\/j.1747-4949.2009.00293.x"},{"key":"1511","doi-asserted-by":"crossref","unstructured":"1511) Maeda K, Toyoda K, Minematsu K, Kobayashi S: Effects of sex difference on clinical features of acute ischemic stroke in Japan. J Stroke Cerebrovasc Dis, 2013; 22: 1070-1075","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.07.006"},{"key":"1512","doi-asserted-by":"crossref","unstructured":"1512) Baba S, Iso H, Mannami T, Sasaki S, Okada K, Konishi M: Cigarette smoking and risk of coronary heart disease incidence among middle-aged Japanese men and women: the JPHC Study Cohort I. Eur J Cardiovasc Prev Rehabil, 2006; 13: 207-213","DOI":"10.1097\/01.hjr.0000194417.16638.3d"},{"key":"1513","doi-asserted-by":"crossref","unstructured":"1513) Honjo K, Iso H, Tsugane S, Tamakoshi A, Satoh H, Tajima K, Suzuki T, Sobue T: The effects of smoking and smoking cessation on mortality from cardiovascular disease among Japanese: pooled analysis of three large-scale cohort studies in Japan. Tob Control, 2010; 19: 50-57","DOI":"10.1136\/tc.2009.029751"},{"key":"1514","doi-asserted-by":"crossref","unstructured":"1514) Nakamura K, Nakagawa H, Sakurai M, Murakami Y, Irie F, Fujiyoshi A, Okamura T, Miura K, Ueshima H: Influence of smoking combined with another risk factor on the risk of mortality from coronary heart disease and stroke: pooled analysis of 10 Japanese cohort studies. Cerebrovasc Dis, 2012; 33: 480-491","DOI":"10.1159\/000336764"},{"key":"1515","doi-asserted-by":"crossref","unstructured":"1515) Huxley RR, Woodward M: Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet, 2011; 378: 1297-1305","DOI":"10.1016\/S0140-6736(11)60781-2"},{"key":"1516","doi-asserted-by":"crossref","unstructured":"1516) Kawano H, Soejima H, Kojima S, Kitagawa A, Ogawa H: Sex differences of risk factors for acute myocardial infarction in Japanese patients. Circ J, 2006; 70: 513-517","DOI":"10.1253\/circj.70.513"},{"key":"1517","doi-asserted-by":"crossref","unstructured":"1517) Nishino Y, Tsuji I, Tanaka H, Nakayama T, Nakatsuka H, Ito H, Suzuki T, Katanoda K, Sobue T, Tominaga S: Stroke mortality associated with environmental tobacco smoke among never-smoking Japanese women: a prospective cohort study. Prev Med, 2014; 67: 41-45","DOI":"10.1016\/j.ypmed.2014.06.029"},{"key":"1518","doi-asserted-by":"crossref","unstructured":"1518) Miura K, Nakagawa H, Ohashi Y, Harada A, Taguri M, Kushiro T, Takahashi A, Nishinaga M, Soejima H, Ueshima H: Four blood pressure indexes and the risk of stroke and myocardial infarction in Japanese men and women: a meta-analysis of 16 cohort studies. Circulation, 2009; 119: 1892-1898","DOI":"10.1161\/CIRCULATIONAHA.108.823112"},{"key":"1519","doi-asserted-by":"crossref","unstructured":"1519) Ikeda A, Iso H, Yamagishi K, Inoue M, Tsugane S: Blood pressure and the risk of stroke, cardiovascular disease, and all-cause mortality among Japanese: the JPHC Study. Am J Hypertens, 2009; 22: 273-280","DOI":"10.1038\/ajh.2008.356"},{"key":"1520","doi-asserted-by":"crossref","unstructured":"1520) Arima H, Tanizaki Y, Yonemoto K, Doi Y, Ninomiya T, Hata J, Fukuhara M, Matsumura K, Iida M, Kiyohara Y: Impact of blood pressure levels on different types of stroke: the Hisayama study. J Hypertens, 2009; 27: 2437-2443","DOI":"10.1097\/HJH.0b013e328330e882"},{"key":"1521","doi-asserted-by":"crossref","unstructured":"1521) Takashima N, Ohkubo T, Miura K, Okamura T, Murakami Y, Fujiyoshi A, Nagasawa SY, Kadota A, Kita Y, Miyagawa N, Hisamatsu T, Hayakawa T, Okayama A, Ueshima H: Long-term risk of BP values above normal for cardiovascular mortality: a 24-year observation of Japanese aged 30 to 92 years. J Hypertens, 2012; 30: 2299-2306","DOI":"10.1097\/HJH.0b013e328359a9f7"},{"key":"1522","doi-asserted-by":"crossref","unstructured":"1522) Saito I, Kokubo Y, Yamagishi K, Iso H, Inoue M, Tsugane S: Diabetes and the risk of coronary heart disease in the general Japanese population: the Japan Public Health Center-based prospective (JPHC) study. Atherosclerosis, 2011; 216: 187-191","DOI":"10.1016\/j.atherosclerosis.2011.01.021"},{"key":"1523","doi-asserted-by":"crossref","unstructured":"1523) Kato M, Noda M, Mizoue T, Goto A, Takahashi Y, Matsushita Y, Nanri A, Iso H, Inoue M, Sawada N, Tsugane S: Diagnosed diabetes and premature death among middle-aged Japanese: results from a large-scale population-based cohort study in Japan (JPHC study). BMJ Open, 2015; 5: e007736","DOI":"10.1136\/bmjopen-2015-007736"},{"key":"1524","doi-asserted-by":"crossref","unstructured":"1524) Peters SA, Huxley RR, Woodward M: Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia, 2014; 57: 1542-1551","DOI":"10.1007\/s00125-014-3260-6"},{"key":"1525","doi-asserted-by":"crossref","unstructured":"1525) Peters SA, Huxley RR, Woodward M: Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet, 2014; 383: 1973-1980","DOI":"10.1016\/S0140-6736(14)60040-4"},{"key":"1526","doi-asserted-by":"crossref","unstructured":"1526) Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC: Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med, 2000; 343: 16-22","DOI":"10.1056\/NEJM200007063430103"},{"key":"1527","doi-asserted-by":"crossref","unstructured":"1527) Chiuve SE, Fung TT, Rexrode KM, Spiegelman D, Manson JE, Stampfer MJ, Albert CM: Adherence to a low-risk, healthy lifestyle and risk of sudden cardiac death among women. JAMA, 2011; 306: 62-69","DOI":"10.1001\/jama.2011.907"},{"key":"1528","doi-asserted-by":"crossref","unstructured":"1528) Chiuve SE, Rexrode KM, Spiegelman D, Logroscino G, Manson JE, Rimm EB: Primary prevention of stroke by healthy lifestyle. Circulation, 2008; 118: 947-954","DOI":"10.1161\/CIRCULATIONAHA.108.781062"},{"key":"1529","doi-asserted-by":"crossref","unstructured":"1529) Chomistek AK, Chiuve SE, Eliassen AH, Mukamal KJ, Willett WC, Rimm EB: Healthy lifestyle in the primordial prevention of cardiovascular disease among young women. J Am Coll Cardiol, 2015; 65: 43-51","DOI":"10.1016\/j.jacc.2014.10.024"},{"key":"1530","doi-asserted-by":"crossref","unstructured":"1530) Hackshaw A, Rodeck C, Boniface S: Maternal smoking in pregnancy and birth defects: a systematic review based on 173 687 malformed cases and 11.7 million controls. Hum Reprod Update, 2011; 17: 589-604","DOI":"10.1093\/humupd\/dmr022"},{"key":"1531","doi-asserted-by":"crossref","unstructured":"1531) Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM: Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation, 2010; 121: 1069-1077","DOI":"10.1161\/CIRCULATIONAHA.109.906479"},{"key":"1532","doi-asserted-by":"crossref","unstructured":"1532) Edison RJ, Muenke M: Gestational exposure to lovastatin followed by cardiac malformation misclassified as holoprosencephaly. N Engl J Med, 2005; 352: 2759","DOI":"10.1056\/NEJM200506303522622"},{"key":"1533","doi-asserted-by":"crossref","unstructured":"1533) Bateman BT, Hernandez-Diaz S, Fischer MA, Seely EW, Ecker JL, Franklin JM, Desai RJ, Allen-Coleman C, Mogun H, Avorn J, Huybrechts KF: Statins and congenital malformations: cohort study. BMJ, 2015; 350: h1035","DOI":"10.1136\/bmj.h1035"},{"key":"1534","doi-asserted-by":"crossref","unstructured":"1534) Gutierrez J, Ramirez G, Rundek T, Sacco RL: Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med, 2012; 172: 909-919","DOI":"10.1001\/archinternmed.2012.2145"},{"key":"1535","doi-asserted-by":"crossref","unstructured":"1535) Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, Wetterslev J: Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ, 2011; 343: d6898","DOI":"10.1136\/bmj.d6898"},{"key":"1536","doi-asserted-by":"crossref","unstructured":"1536) Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med, 2005; 353: 2643-2653","DOI":"10.1056\/NEJMoa052187"},{"key":"1537","doi-asserted-by":"crossref","unstructured":"1537) Fox CS, Golden SH, Anderson C, Bray GA, Burke LE, de Boer IH, Deedwania P, Eckel RH, Ershow AG, Fradkin J, Inzucchi SE, Kosiborod M, Nelson RG, Patel MJ, Pignone M, Quinn L, Schauer PR, Selvin E, Vafiadis DK: Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care, 2015; 38: 1777-1803","DOI":"10.2337\/dci15-0012"},{"key":"1538","doi-asserted-by":"crossref","unstructured":"1538) Miura K, Nagai M, Ohkubo T: Epidemiology of hypertension in Japan: where are we now? Circ J, 2013; 77: 2226-2231","DOI":"10.1253\/circj.CJ-13-0847"},{"key":"1539","doi-asserted-by":"crossref","unstructured":"1539) Turnbull F, Woodward M, Neal B, Barzi F, Ninomiya T, Chalmers J, Perkovic V, Li N, MacMahon S: Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J, 2008; 29: 2669-2680","DOI":"10.1093\/eurheartj\/ehn427"},{"key":"1540","doi-asserted-by":"crossref","unstructured":"1540) Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen\/progestin Replacement Study (HERS) Research Group. JAMA, 1998; 280: 605-613","DOI":"10.1001\/jama.280.7.605"},{"key":"1541","doi-asserted-by":"crossref","unstructured":"1541) Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N: Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen\/progestin Replacement Study follow-up (HERS II). JAMA, 2002; 288: 49-57","DOI":"10.1001\/jama.288.1.49"},{"key":"1542","doi-asserted-by":"crossref","unstructured":"1542) Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ: Effect of estrogen plus progestin on stroke in postmenopausal women: the Women&apos;s Health Initiative: a randomized trial. JAMA, 2003; 289: 2673-2684","DOI":"10.1001\/jama.289.20.2673"},{"key":"1543","doi-asserted-by":"crossref","unstructured":"1543) Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M: Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med, 2003; 349: 523-534","DOI":"10.1056\/NEJMoa030808"},{"key":"1544","doi-asserted-by":"crossref","unstructured":"1544) Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, Trevisan M, Aragaki A, Baird AE, Bray PF, Buring JE, Criqui MH, Herrington D, Lynch JK, Rapp SR, Torner J: Effects of conjugated equine estrogen on stroke in the Women&apos;s Health Initiative. Circulation, 2006; 113: 2425-2434","DOI":"10.1161\/CIRCULATIONAHA.105.594077"},{"key":"1545","doi-asserted-by":"crossref","unstructured":"1545) Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML: Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA, 2007; 297: 1465-1477","DOI":"10.1001\/jama.297.13.1465"},{"key":"1546","unstructured":"1546) The Japan Society of Obstetrics and Gynecology and the Japan Society for Menopause and Women&apos;s Health: Hormone Replacement Therapy Guidelines 2017. Japan Society of Obstetrics and Gynecology, 2017 (in Japanese)"},{"key":"1547","doi-asserted-by":"crossref","unstructured":"1547) L\u00f8kkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard \u00d8: Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J, 2008; 29: 2660-2668","DOI":"10.1093\/eurheartj\/ehn408"},{"key":"1548","unstructured":"1548) Committee for the Preparation of the Management for Primary Prevention of Atherosclerotic Cardiovascular Diseases in Women 2018\uff1aManagement for Primary Prevention of Atherosclerotic Cardiovascular Diseases in Women 2018, The Japan Society for Menopause and Women&apos;s Health, Shindan to Chiryo sha Inc., 2018 (in Japanese)"},{"key":"1549","doi-asserted-by":"crossref","unstructured":"1549) Okada T, Murata M, Yamauchi K, Harada K: New criteria of normal serum lipid levels in Japanese children: the nationwide study. Pediatr Int, 2002; 44: 596-601","DOI":"10.1046\/j.1442-200X.2002.01634.x"},{"key":"1550","doi-asserted-by":"crossref","unstructured":"1550) Abe Y, Okada T, Sugiura R, Yamauchi K, Murata M: Reference Ranges for the Non-High-Density Lipoprotein Cholesterol Levels in Japanese Children and Adolescents. J Atheroscler Thromb, 2015; 22: 669-675","DOI":"10.5551\/jat.28100"},{"key":"1551","unstructured":"1551) Japan Society for the Study of Obesity: Guidelines for the management of obesity disease in children and adolescents 2017, Life Science Publishing, 2017"},{"key":"1552","unstructured":"1552) Kobayashi Y, Sugihara S, Tanaka Y, Ishihara H, Ohno K, Fujita H, Takizawa N, Tsuchihashi M: A consideration on criteria for blood collection after a meal in medical examinations of life-style related diseases in children. The Journal of the Japan Peiatric Society, 2011; 115: 1255-1264 (in Japanese)"},{"key":"1553","doi-asserted-by":"crossref","unstructured":"1553) Dobashi K: Changes in Serum Cholesterol in Childhood and its Tracking to Adulthood. J Atheroscler Thromb, 2022; 29: 5-7","DOI":"10.5551\/jat.ED163"},{"key":"1554","doi-asserted-by":"crossref","unstructured":"1554) Zeitler P, Fu J, Tandon N, Nadeau K, Urakami T, Barrett T, Maahs D: ISPAD Clinical Practice Consensus Guidelines 2014. Type 2 diabetes in the child and adolescent. Pediatr Diabetes, 2014; 15 Suppl 20: 26-46","DOI":"10.1111\/pedi.12179"},{"key":"1555","unstructured":"1555) Japan Diabetes Society and Japanese Society for Pediatric Endocrinology: Consensus Guidelines for Diabetes Mellitus in Children and Adolescents, Nankodo, 2015 (in Japanese)"},{"key":"1556","doi-asserted-by":"crossref","unstructured":"1556) Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA, 1990; 264: 3018-3024","DOI":"10.1001\/jama.264.23.3018"},{"key":"1557","doi-asserted-by":"crossref","unstructured":"1557) Newman WP, 3rd, Freedman DS, Voors AW, Gard PD, Srinivasan SR, Cresanta JL, Williamson GD, Webber LS, Berenson GS: Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. N Engl J Med, 1986; 314: 138-144","DOI":"10.1056\/NEJM198601163140302"},{"key":"1558","doi-asserted-by":"crossref","unstructured":"1558) Dobashi K: Evaluation of Obesity in School-Age Children. J Atheroscler Thromb, 2016; 23: 32-38","DOI":"10.5551\/jat.29397"},{"key":"1559","unstructured":"1559) Information Center for Specific Pediatric Chronic Diseases, Japan https: \/\/www.shouman.jp\/disease\/details\/08_12_130\/ (in Japanese)"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/31\/6\/31_GL2022\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T03:21:20Z","timestamp":1730863280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/31\/6\/31_GL2022\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":1559,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.gl2022","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,1]]},"article-number":"GL2022"}}